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Abstract 
 
Introduction 
The amino acid homocysteine has been identified as a risk factor for cardiovascular 
disease (CVD), as elevated levels induce atherosclerosis, through a direct effect on 
arterial tissue.   In alcohol dependent individuals an association between plasma 
homocysteine levels and alcohol consumption has been found (Bleich et al. 2000d).  
However this link has not been explored in individuals who have a range of non-
dependent alcohol drinking patterns.  This fact has informed the design of the 
present work.  
 
Material and Methods 
A convenience sample of abstainers (N=7), non-dependent drinkers (N=28) and 
alcohol dependent individuals (N=18) was recruited. Alcohol consumption was 
recorded using questionnaires and diaries.   All study participants’ biological 
samples were analysed for the following biomarkers: plasma homocysteine (HPLC); 
serum folate and vitamin B12 (competitive immunoassay); serum Carbohydrate 
Deficient Transferrin (N-Latex immunoassay); urinary creatinine (colorimetric assay) 
and the methylenetetrahydrofolate (MTHFRC677T) polymorphism (Real-Time 
Polymerase Chain Reaction (PCR)).   
 
Results 
There was no association between alcohol consumption during drinking days and 
plasma homocysteine levels in non-dependent drinkers. However when this group 
was categorised according to pattern of consumption, plasma homocysteine levels 
were found to be lower in abstainers (median 5.60 µmol/l), but higher in sessional 
drinkers (median 7.15 µmol/l) and alcohol-dependent individuals (median 7.89 
µmol/). The mutant MTHFR(C677T) polymorphism when present was associated with 
an increase in plasma homocysteine levels, which correlated with alcohol 
consumption (R=0.975).       CDT levels were found to be elevated in both sessional 
and alcohol-dependent individuals at baseline (median 2.68% and 5.95% 
respectively) compared with abstainers (2.16%).  Additionally there was a linear 
relationship between the number of drinking days in a week and a positive CDT 
result, in a sample of sessional drinkers (R=0.98).   
 
xxviii 
Discussion 
The work undertaken has shown that sessional drinking and alcohol dependence 
does increase homocysteine levels in comparison to abstainers.  This may have 
important implications in relation to CVD risk.  Additionally new evidence of the 
utility of CDT as a biomarker of alcohol consumption within a sample of sessional 
drinkers, has been identified.   
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CHAPTER 1: LITERATURE REVIEW 
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1.1 INTRODUCTION 
 
The misuse of alcohol remains a major public health issue within the UK, being 
linked to a wide range of medical conditions including increased risk of 
cardiovascular disease (CVD) (Agarwal 2002; Lakshman et al. 2009).  A review by 
(Anderson et al. 2009), further highlights the effect of alcohol as a casual factor on 
the following: intentional, unintentional injuries and harm to people other than the 
drinker (Rehm et al. 2004), reduced job performance (Manigone et al. 1999), 
absenteeism (Roche et al. 2008), family deprivation (Gururaj et al. 2006), 
interpersonal violence (Gil-González et al. 2006), suicide (Cargiulo 2007), murder 
(Rehm et al. 2006), crime (Richardson and Budd 2003) and fatalities caused by 
driving while under the influence of alcohol (drink driving) (Cherpitel et al. 2003).  
Furthermore alcohol has also been shown to be a contributing factor to undertaking 
risky sexual behaviour (Kalichman et al. 2007), sexually transmitted infections (STIs) 
(Cook and Clark 2005) and Human Immunodeficiency Virus (HIV) infection (Fisher 
et al. 2007).    The consumption of alcohol, especially in specific drinking patterns, 
requires further investigation as to its impact on health.  Within the literature there 
are a number of studies which identify the costs of alcohol misuse, which are useful  
in identifying the greatest economic costs caused by alcohol misuse and the specific 
problems generated by alcohol misuse and in which geographical regions 
(Mohapatra et al. 2010; Rehm et al. 2009).      
 
Alcohol is a risk factor for global burden of disease (GBD) and is ranked fifth, behind 
tobacco (Ezzati et al. 2004).   New data has been published in 2010, by a key group 
of UK alcohol and drug researchers and have categorised alcohol as the number 
one drug, for causing harm, above the illegal drugs such as heroin, crack cocaine 
and metamfetamine (Nutt et al. 2010).  European regions have the highest 
proportion of alcohol attributable deaths with more than one in every ten deaths 
seen in European men.  Within Europe, the highest proportion was for the countries 
of the former Soviet Union (Rehm et al. 2009).  Scotland is ranked eighth in the 
world for the highest pure alcohol consumption (The Scottish Government 2009b).  
The per capita pure alcohol consumption in Scotland is 11.8 litres, which is higher in 
comparison to England and Wales which is 10.3 litres (The Scottish Government 
2009b).  There is a close link between a country’s total alcohol per head 
consumption and the prevalence of alcohol-related harm and alcohol dependence; 
3 
when alcohol consumption increases so does alcohol-related harm and the 
proportion of people with alcohol dependence.  Furthermore there appears to be an 
association between the prevalence of alcohol dependence and alcohol related 
harm.  The death of 1 in 20 Scots has been linked to alcohol related causes (The 
Scottish Government 2009a). 
 
The effect of alcohol consumption on health is estimated at 3.8% of all global deaths 
and 4.6% of global disability-adjusted life years (DALYs) are directly attributable to 
alcohol (Rehm et al. 2009). The costs associated with alcohol amount to more than 
1% of the gross national product in high-income and middle-income countries and 
the costs of social harm constitute a major proportion in additional health costs 
(Rehm et al. 2009). Alcohol misuse costs the UK economy £6.4 billion, through 
alcohol related sickness, absence from work and death (Ward et al. 2010). Table 1.1 
illustrates the cost burden of alcohol misuse in Scotland, compared with other 
countries around the world, and all are classified as high income countries.   
 
It is clear from table 1.1 that Scotland incurs similar healthcare costs as a 
percentage of total social costs, to that of the USA, however these costs are for 
populations which are 54 times smaller than the total USA population.  The high 
level of alcohol induced costs to law enforcement in Scotland, are shown to be 
higher than the largest sample country, the USA.  Both these statistics are worrying 
and highlight the detrimental problem alcohol misuse is having on societal costs 
within Scotland.  Further highlighted in table 1.1, Scotland and the USA have the 
highest total alcohol costs as a percentage of the gross domestic product (GDP) 
(purchasing power parity (PPP)), in comparison to other high income countries, 
including Australia, Canada and France.  Italy has the lowest alcohol costs as a 
percentage of their GDP.   
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Table 1.1: Overview of social costs attributable to alcohol in 7 developed countries (Mohapatra et al. 2010) 
Indicators Australia Canada France Italy UK (Scotland) USA 
Reference (Collins and 
Lapsley 2002) 
(Rehm et al. 
2006) 
(Fenoglio et al. 
2003) 
(Collicelli 
1996) 
(Varney and Guest 
2002) 
(US Department of 
Health and Human 
Services 2000) 
Population in study 
year (millions) 
18.8 31.3 58.7 56.8 5.1 278.4 
GDP (PPP) IN 
2006 million USD 
674,600 1,181,000 1,902,000 1,756,000 165,808 13,060,000 
Total social costs 
of alcohol 
5,227.6 13,957.9 25,347.4 11,573.5 3555.7 216,154.5 
Healthcare costs 
as % of total social 
cost 
4.1 22.7 16.0 19.9 8.9 13.3 
Law enforcement 
costs as % of total 
social costs 
15.5 21.1 0.3 1.3 25.0 3.4 
TOTAL alcohol 
costs as % GDP 
(PPP) 
0.77 1.18 1.33 0.66 1.36 1.66 
HEALTHCARE 
alcohol costs as % 
GDP (PP) 
0.03 0.27 0.21 0.13 0.12 0.22 
LAW alcohol costs 
as % GDP (PPP) 
0.12 0.25 0.00 0.01 0.34 0.06 
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A more recent report by the Scottish Government has shown the estimated societal 
costs of alcohol misuse in Scotland from 2007 is approximately £3.55 billion per 
year,  which equates to approximately £500 for every adult in Scotland (The Scottish 
Government 2010b).  The prevalence of harmful and hazardous alcohol use 
(defined in table 1.3), in Scotland, as stated in the 2003 Scottish Health Survey was 
27.9% (Drummond et al. 2009).  The prevalence of alcohol dependence in Scotland 
was 4.9% in adults over the age of 16 years (Drummond et al. 2009).  These 
percentages indicate that approximately 1,172,200 people were drinking either 
harmfully or hazardously and approximately 206,000 were dependent on alcohol 
(Drummond et al. 2009).  Table 1.2 illustrates the estimated costs of alcohol misuse 
within major social resources, up to 2007. 
 
Table 1.2: Estimated annual societal costs of alcohol misuse in Scotland for 2007 
(The Scottish Government 2010b) 
Resource  Range 
(£million) 
Mid-point 
(£million) 
Health Service 143.6-392.8 267.8 
Social Care 114.2-346.8 230.5 
Crime 462.5-991.7 727.1 
Productive Capacity of The Scottish 
Economy 
725.2-1006.1 865.7 
Wider Social Costs  1031.1-1898.0 1464.6 
Total  2476.6-4635.4 3555.7 
 
Table 1.2 clearly shows the effect of alcohol misuse is increasing the burden on 
NHS Scotland and the other core social resources.  An approximate total cost of 
alcohol misuse on the UK NHS system has been estimated at £3 billion, by the 
leading alcohol charity, Alcohol Concern (Ward et al. 2010).   This figure 
encompasses the approximate cost of treating alcohol dependency, which is 
estimated to cost the UK NHS £217 million (Drummond 2005).  This figure refers to 
the treating of just 6% of alcohol dependent patients.  In comparison it costs the UK 
NHS £436 million (Department of Health 2009) to treat 58% of drug dependent 
patients.  If 50% of all alcohol dependent patients were treated for their dependency 
problem; this would cost the NHS billions of pounds. Furthermore it is clear from the 
6 
figures generated from the report by Alcohol Concern that alcohol dependency is 
more expensive to treat in comparison to drug dependency (Ward et al. 2010).    
 
Recent figures have shown that within the last ten years, UK hospital admissions 
due to alcohol attributed conditions have doubled (Song 2009; The NHS Information 
Centre 2008)  This statistic highlights the detrimental effects acute and chronic 
alcohol consumption have on the health of the Scottish population.  In 2007/2008 
there were 42,430 alcohol related discharges from general hospitals in Scotland, 
this is equal to 777 per 100,000 of the population (The Scottish Government 2010a).  
Of the 42,430 total, 28,586 patients were discharged with an alcohol-related 
diagnosis for their admission to hospital, which included 6817 discharges for 
alcoholic liver disease (NHS Scotland 2009).  
 
The impact of alcohol misuse, does not only effect the NHS, but also has a cost 
burden on the other societal resources, including the criminal justice system and 
social services (Department for Work and Pensions 2010).  The effect of alcohol 
misuse on the family unit can cause a great impact, for example: increased family 
tension, increased levels of quarrelling and violence; destabilising relationships, 
family members becoming anxious, depressed, socially withdrawn or developing 
their own alcohol misuse problems; furthermore children can develop behavioural 
problems and underperform at school (Department for Work and Pensions 2010).   
Alcohol misuse has also be linked to increasing rates of marriage separation and 
divorce (Department for Work and Pensions 2010).  The burden of alcohol misuse 
on the family unit can also overflow into the affected individual’s workplace, whereby 
deterioration in performance, conflict with colleagues, an increase in workplace 
accidents and poor attendance, could lead to dismissal and lack of employability 
(Department for Work and Pensions 2010).  There is also potential for these 
outcomes to affect an individual, who is not misusing alcohol, but lives with a family 
member who has an alcohol problem.  Another major burden of alcohol misuse is on 
the criminal justice system, where heavy drinking is associated with crimes 
including: petty theft, driving offences, fraud, sexual offences and violent crime 
(Department for Work and Pensions 2010).  A report by the Scottish Government 
has shown the increasing costs of alcohol misuse on the criminal justice and 
emergency services and social work services from, 2001 to 2007, where there has 
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been a 69% and 50% increase in costs respectively since 2001 (The Scottish 
Government 2010b).    
 
In an effort to combat excessive alcohol consumption and alcohol misuse in 
Scotland, the Scottish Government has prepared a bill to tackle the effect alcohol 
misuse has on society across Scotland (The Scottish Government 2010a).  The 
“Alcohol Bill” has several key proposals which include: minimum pricing of alcohol; 
bans on irresponsible marketing and promotions in bars and clubs; ensuring the 
availability of small measures of wine in licensed premises; increasing the purchase 
age of alcohol off sales to 21 years and potentially charging alcohol retailers a social 
responsibility fee (The Scottish Government 2010a).  The Alcohol Bill has been 
presented to the Scottish Parliament in early 2010 and as of October 2010 the bill is 
at the second stage of development, with a view of being made law in 2011.  
Furthermore the National Institute for Health and Clinical Excellence (NICE) has 
issued guidelines which aim to reduce alcohol related harm (National Institute for 
Health and Clinical Excellence (NICE) 2010).  The guidelines, published on the 2nd 
June 2010 state: 
• Alcohol should be made less affordable by introducing a minimum price per 
unit.  Prices should also be regularly reviewed. 
• Alcohol should be made less easy to buy, e.g. reducing the volume of 
imports, alcohol outlets within a given area and the hours in which alcohol 
can be purchased. 
• Applications for new licences to sell alcohol should be based on the number 
of outlets in a given area, taking into consideration the potential impacts on 
crime, disorder and alcohol related illnesses and deaths.   
• “Protection of the public’s health” should be added to the current licensing 
objectives, which are already the case in Scotland.  This would mean that 
premises would have a legal obligation to consider the health of their 
customers when selling them alcohol. 
• The current advertising regulations should be strengthened to minimise 
children and young people’s exposure to alcohol products.  A complete ban 
on alcohol advertising should also be considered to protect these high-risk 
groups, as in the case with tobacco products.   
The guidelines issued by NICE and the Scottish Governments Alcohol Bill, highlight 
the efforts to reduce alcohol related harm. 
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In 2004 most of the global alcohol-attributable burden of disease occurred in people 
age 15-29 years (33.6% of all alcohol-attributable DALYs) followed by those aged 
20-44 years (31.3%) and 45-59 years (22.0%) (Rehm et al. 2009).  In all these age 
groups, alcohol consumption was responsible for more than 10% of all burden of 
disease in men and for 2-3% in women (Rehm et al. 2009).  When compared with 
other traditional risk factors including tobacco, cholesterol or hypertension the age 
profile of alcohol-attributable disease burden is shifted towards younger populations 
(Rehm et al. 2009).      
 
Figures relating to 2005 suggests, 88% of Scottish men and women consume 
alcohol (Catto 2008).  More recent figures show that in Scotland it has been 
estimated that 40% of men and 33% of women consume more than the 
recommended daily alcohol drinking limits (guidelines explained in section 1.2) 
(British Heart Foundation Health Promotion Research Group 2008).  In relation to 
specific age groups, The Alcohol Statistics Scotland 2009 report stated than 60% of 
16-24 year old males and females exceed the Governments drinking guidelines at 
least once per week.  This statistic from 2009 shows a continuing trend from 2004, 
where alcohol attributable death is shifting from an older population to a younger 
population and highlights the need to investigate alcohol drinking patterns in 
younger age groups.   
 
A review published by Coghill et al. (2009) examined the levels of per capita alcohol 
consumption and alcohol-related mortality in the UK over the past 25 years and 
found that there was a significant correlation (which has increased from 1991 to 
2006) between per capita alcohol consumption and alcohol-related mortality per 
100,000 of the population (Coghill et al. 2009).  The report also showed that the 
correlation between alcohol consumption-related morbidity was highest in Scotland, 
and the full effects of consumption became apparent, approximately one year later 
(Coghill et al. 2009).   
 
Exceeding the recommended alcohol drinking guidelines increases the risk of 
coronary heart disease (CHD) and research has shown that 40% of young men and 
34% of young women exceed these guidelines at least once per week in Scotland 
(British Heart Foundation Health Promotion Research Group 2008), putting them at 
risk of developing CHD or another associated CVD.  A report by Rehm et al. (2009) 
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has highlighted that two different types of alcohol consumption affect health: 
average volume of alcohol consumption and patterns of drinking, especially 
episodes involving heavy drinking (Rehm et al. 2003; Rehm et al. 2004). Drinking 
patterns which are associated with heavy consumption (e.g. sessional drinking or 
heavy episodic drinking) are more common in countries with a lower GDP in 
comparison to countries with a higher GDP.  This can be illustrated through the 
different life expectancies between eastern and western Europe  (Anderson, 
Chisholm and Fuhr 2009; Zatonski 2008).   Scotland’s alcohol consumption 
behaviour, contradicts this trend as Scotland is classified by the World Health 
Organisation (WHO) as a high-income country, but has a high rate of alcohol 
consumption, especially in terms of sessional drinking (The Scottish Government 
2009b). 
 
A study conducted by Information Services Division (ISD) Scotland found that 1493 
deaths from heart disease could have been prevented by lower levels of alcohol 
consumption (The Scottish Government 2009a).  Scotland has the highest rates of 
CHD in the world and the second highest in the western world as reported in the 
Scottish Health Survey 2003 (Bromley et al. 2003).  Statistics generated from 
research conducted more recently by the British Heart Foundation (BHF) highlighted 
that there were 18,000 CVD deaths in Scotland in 2008/2009 (British Heart 
Foundation Health Promotion Research Group 2008).  The report by the British 
Heart Foundation also highlighted that within Scotland, 620,000 people have been 
diagnosed with heart and circulatory disease and there are approximately 12,000 
individuals who suffer a myocardial infarction (MI) every year.   
 
A known risk factor for CVD, has been identified as the amino acid homocysteine.  
Elevated levels of homocysteine induce atherosclerosis, through a direct effect on 
arterial tissue (McCully 2001).   It has been suggested that there is an association 
between plasma homocysteine levels and alcohol consumption in alcohol 
dependent individuals (Bleich et al. 2000d).  However this research has not been 
conducted in a population of healthy individuals who consume alcohol in a range of 
non-dependent patterns.   
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1.2 ALCOHOL CONSUMPTION GUIDELINES 
 
Guidelines for the consumption of alcohol have been outlined by the UK Department 
of Health (UK Department of Health 1995) and act as a public health message.  The 
consumption of alcohol above these recommended guidelines has been associated 
with detrimental health effects (Beaglehole and Bonita 2009).  Different patterns of 
alcohol consumption can be described in terms of the UK unit of alcohol (8 g of 
ethanol).   
1.2.1 Terminology and Definitions of Alcohol Drinking Patterns 
 
A range of terminology in common usage is, used to describe the consumption of 
alcohol.  A key report published by the British Medical Association (British Medical 
Association Board of Science 2008), has given specific definitions to alcohol 
terminology in common usage in conjunction with the World Health Organisation 
(WHO) International Classification of Diseases 10th revision (WHO ICD-10) (World 
Health Organisation 2007) report, and are described in table 1.3.   
 
The terminology described in table 1.3 is commonly used by clinicians to diagnose 
patients who exhibit problems with alcohol dependence and have exhibited social 
and health problems, caused by excessive alcohol consumption.  These terms 
should not be confused with alcohol drinking patterns which use specific numerical 
values to quantify the amount of alcohol being consumed. 
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Table 1.3: Terminologies commonly used to describe alcohol consumption (sourced from; British Medical Association Board of Science 2008; World Health 
Organisation 2007; World Health Organisation 2008; Drummond et al. 2009). 
Alcohol Consumption Terminology Definition 
Alcohol abuse A term in common usage, especially in the USA.  Is not included within the ICD-10.  The Diagnostic and 
Statistical Manual of Mental Disorder (DSM-IV, 4th Ed, 1994) defines psychoactive substance abuse as 
a maladaptive pattern of substance use leading to clinically significant impairment or distress, as 
manifested by one or more of the following occurring within a 12 month period: 
• Recurrent substance use resulting in a failure to fulfil major roles obligations at school, work or 
home. 
• Recurrent substance use in situations in which it is physically hazardous (e.g. driving a car) 
• Recurrent substance-related legal problems (e.g. arrests for being drunk and disorderly) 
• Continued substance use despite having persistent or recurrent social or interpersonal problems 
caused or exacerbated by the effects of the substance (e.g. arguments with spouse or physical 
fights).  
Alcohol misuse The use of alcohol for a purpose not consistent with legal or medical guidelines (World Health 
Organisation 2008). 
Alcoholism  A term in common usage which is generally taken to refer to chronic continual drinking or periodic 
consumption of alcohol which characterized by impaired control over drinking, frequent episodes of 
intoxication, preoccupation with alcohol and the use of alcohol despite adverse consequences.  
Alcoholism is not included as a diagnostic term within the ICD-10. 
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Alcohol Consumption Terminology Definition 
Alcohol Use Disorders (AUDs) AUDs are classified into three categories: hazardous alcohol use, harmful alcohol use and alcohol 
dependence.  
Hazardous Alcohol Use: A pattern of alcohol consumption that increases the risk of harmful 
consequences for the individual.  In contrast to harmful use, hazardous drinking refers to patterns of use 
that are of public health significance despite the absence of any current disorder in the individual user.  
Hazardous drinking is not included as a diagnostic term in the ICD-10.  For reference the current UK 
Government’s responsible drinking guidelines are adult men should not exceed four units per day or 21 
units per week and adult women should not exceed three units per day or 14 units per week (UK 
Department of Health 1995).    
Harmful Alcohol Use: A pattern of alcohol use that causes damage to physical and/or mental health 
and can include adverse social consequences.  Harmful drinking is included as a diagnostic term within 
the ICD-10.   
Alcohol Dependence Syndrome: Classified by the ICD-10 as a cluster of behavioural, cognitive, and 
physiological phenomena that develop after repeated alcohol use and that typically include a strong 
desire to consume alcohol, difficulties in controlling its use, persisting in its use despite harmful 
consequences, a higher priority given to its use than to other activities and obligations, increased 
tolerance and sometimes a physical withdrawal state.   
AUDs are included in the World Health Organisation’s International Classification of Mental and 
Behavioural Disorders (World Health Organisation 1992).  
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The use of the above terms to describe alcohol consumption does not allow for a 
quantitative measurement of the actual grams of alcohol consumed.  The use of the 
phrase ‘alcohol misuse’ or ‘alcohol abuse’ does not quantitatively define the exact 
amount of alcohol consumed.  The use of alcohol drinking pattern categories, which 
uses numerical values, such as grams of alcohol, within their definitions, allows for 
analysis of alcohol consumption to quantitatively determine if an individual is 
consuming alcohol in an unhealthy and potentially harmful pattern.  By using set 
guidelines, such as the UK Department of Health’s responsible daily drinking 
message of 16-24 g (female) and 24-32 g (male), allows the public to determine and 
monitor their consumption within a set range.   
 
The review of the literature within this thesis will focus on the alcohol consumption 
guidelines which use exact grams of alcohol, recommended by the UK Department 
of Health, to determine if alcohol consumption is above or below the recommended 
daily limit.  It is widely acknowledged in the literature that alcohol consumption 
definitions vary widely, however by using set definitions with numerical values this 
can reduce error, especially when comparing alcohol consumption to potential 
health risk by way of biological markers (e.g. plasma homocysteine).   
 
Published literature within the field of alcohol research, often described alcohol 
consumption as, light, moderate or heavy, however these terms are not quantitative 
in terms of actually describing alcohol consumption in terms of units or grams of 
pure ethanol (Agarwal 2002; Agarwal and Srivastava 2001; Berger et al. 1999).  The 
terms of light and moderate alcohol consumption have been widely used 
internationally and are unhelpful.  Table 1.4 describes the currently accepted 
description of light, moderate, heavy and sessional drinking (Agarwal 2002).   
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Table 1.4: Comparison of UK units/day and grams of pure alcohol/day in 
light/moderate/heavy drinking  
Descriptive words to 
describe alcohol 
consumption 
Grams (g) of pure 
alcohol/day 
UK Units*/day 
Heavy >80g >10 
Sessional 48-64g >6-8 
Moderate 30-80g 4-10 
Light <30 g <4 
* 1 unit = 8g of pure ethanol  
 
It could be suggested that within the UK, moderate drinking can be defined as 
responsible drinking, whereby the Government has identified units (which can be 
converted to grams) of alcohol which are within healthy limits for both males and 
females (UK Department of Health 1995).  However as the definitions of “light” and 
“moderate” drinking are not specific, but used within the literature frequently, without 
quantitative definition.  The UK Department of Health guidelines for alcohol 
consumption, allows for the definition and quantification of drinking patterns such as 
responsible and sessional, as they provide known and specific alcohol quantities 
(units) within each definition.  These pre-defined drinking patterns allows for alcohol 
consumption to be equated to potential health risks, including CVD. 
 
1.2.2 Responsible Drinking 
 
Within the UK, the Department of Health has put in place guidelines for the 
responsible consumption of alcohol (UK Department of Health 1995).  This report 
was in response to evidence which was published in the literature which suggested 
that moderate alcohol consumption could give protection from CHD (Agarwal 2002; 
Agarwal and Srivastava 2001; UK Department of Health 1995).  Before the report 
was published in 1995, the current sensible drinking message in the UK was that 
men should drink no more than 21 units (168 g) and women 14 units (112 g) per 
week (Department of Health 1992).  However this sensible drinking message was 
open to misinterpretation, as an individual could consume all of their units in a single 
day or session, and so greatly increase the harmful effects of acute alcohol 
15 
consumption.  Therefore the benefit of alcohol consumption preventing CHD would 
be lost.     
 
The responsible daily alcohol consumption guidelines allows for individuals to 
consume alcohol on a daily basis and if within the responsible drinking guidelines no 
alcohol free days are required (UK Department of Health 1995).  However the 
recommendation regarding alcohol free days has now changed, and within a report 
published by the Scottish Government, it is recommended that there are at least two 
alcohol free days within any week (Catto 2008).  
 
1.2.3 Sessional or “Binge” Drinking 
 
The definition of sessional drinking in the UK is “drinking more than double the 
recommended daily limit on any one day in the past week”, which would equate to 8 
UK units (64 g) for men and 6 units (48 g) for women (Catto 2008; Gill, Murdoch, 
and O'May 2009).  This type of drinking pattern is also known as “binge drinking”.  
Binge drinking is a popular term used in the UK media, for the purpose of this 
literature review and subsequent data analysis within this thesis, “binge drinking” will 
be referred to as sessional drinking.   
 
The quantitative definition of sessional drinking varies throughout the world, as does 
the definition of a standard “drink” (see Appendix 1A).   Within a standard drink in 
the UK there are 8 g of pure ethanol, whereas in the USA a standard drink contains 
12 g of pure ethanol.   The table in Appendix 1A details the variability in sessional 
drinking definitions throughout the world and also the difference in pure ethanol 
content within a “standard” drink. 
 
Sessional drinking is referred to as heavy drinking over an evening or similar time 
period, and is also referred to as heavy episodic drinking (HED) (DiGuarde 2009).  
HED is a popular term in the United States, but not so widely used in the UK.  The 
amount of alcohol consumed in a sessional drinking episode can be less than a 
bottle of wine, which is equal to 72 g of alcohol or 9 units of (12 %ABV) wine.   
 
Jayne et al. 2008 describes European countries including the UK as “dry”, where 
beer and spirits are drinks which are well established and alcohol consumed is lower 
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overall but is more likely to result in intoxication.  In comparison in “wet” countries, 
most commonly Mediterranean counties, where wine is a customary drink and 
alcohol consumption is high but does not lead to intoxication and is part of the social 
culture (Jayne et al. 2008).  It is also important to note that in “dry” countries beer is 
a more established drink in comparison to wine and the growth in new beverages, 
such as “alcopops” or designers drinks (RTDs) has become very popular.   The 
cultural and social problems associated with sessional drinking have been well 
documented in the media and by the UK Government (Catto 2008; NHS Scotland 
2009).  However the pathophysiological consequences of sessional drinking have 
not been well documented.  The consequences of the consumption of acute 
volumes of alcohol over short periods of time has not been fully investigated and 
compared to the known damaging health effects of chronic alcohol consumption.   
 
1.3 ALCOHOL METABOLISM 
 
1.3.1 Alcohol 
 
Alcohol is a depressant that is absorbed into the bloodstream and distributed to all 
organ systems in the body.  Alcohol in varying doses can cause: staggering, slurred 
speech, double vision, mood swings, unconsciousness, persistent impotence, loss 
of libido, hepatitis, oesophagitis and pancreatitis (Agarwal and Srivastava 2001).  
Heavy or sessional drinking can cause death by respiratory depression.  Long term 
alcohol use has been linked to increased liver disease, heart disease, peptic ulcers, 
cancers, complicated pregnancies, birth defects and brain damage (Patussi et al. 
2010). 
 
1.3.2 Alcohol Metabolism 
 
The metabolism of ethanol is performed by multiple forms of the enzyme alcohol 
dehydrogenase (ADH) (Lieber 2004).  The ADH enzyme exists in the cytosol and 
catalyzes the conversion of ethanol to acetaldehyde, while also reducing NAD+ to 
NADH (Lieber 1992; Lieber 1998).  In addition the metabolism of ethanol results in 
the formation of toxic free radicals and produces oxidative stress.    Figure 1.1 
17 
illustrates the metabolism of ethanol in vivo, by the enzyme alcohol dehydrogenase 
(ADH). 
 
 
 
CH3CH2OH + NAD+                                      CH3CHO+ + NADH + H+ 
 
Figure 1.1: Metabolism of ethanol adapted from Lieber (2004)  
 
ADH is a broad spectrum substrate specific enzyme, with the potential to bind to 
multiple substrates.  ADH is not only specific to xenobiotic (foreign substance) 
metabolism such as alcohol, but also physiological substrates which includes the 
dehydrogenation of steroids, oxidation of intermediary alcohols of the shunt pathway 
of mebalonate, metabolism and also ω-oxidation of fatty acids (Bjorkhem 1972).. 
 
Human liver ADH is a zinc metalloenzyme and occurs in multiple molecular forms.  
ADH has also been discovered in the stomach and upper gastrointestinal tract (GI).  
Polymorphisms have been identified at two locations within the gene which codes 
for ADH, these occur at two loci, ADH2 and ADH3, which encode the β and γ 
subunits of ADH (Bosron et al. 1993).  The latest ADH isoenzyme to be discovered 
is sigma-ADH; which is found in the upper GI and exhibits variability towards certain 
ethnic races, which includes the Japanese race.  Sigma ADH is less active in a large 
proportion of the Japanese population resulting in the poor metabolism of ethanol 
being evident in these individuals. 
 
Ethanol oxidation via the ADH pathway results in the production of large amounts of 
reduction species, which means that hepatocytes have the inability to maintain 
redox homeostasis (Lieber 1998).  The inability to maintain redox homeostasis 
contributes to metabolic disorders such as hypoglycaemia and hyperlactacidemia 
(Lieber 1998).  The elevated NADH levels promote fatty acid synthesis and blocks 
lipid oxidation in the mitochondria, which results in the accumulation of fat, resulting 
in the condition known as ‘fatty liver’.  An overview of the ethanol metabolic pathway 
is shown in figure 1.2.  
 
Ethanol  ADH Acetaldehyde 
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Also illustrated in figure 1.2, is the second metabolic pathway, by which alcohol can 
be metabolised, known as the microsomal ethanol oxidising system (MEOS).  The 
MEOS pathway, comes into effect when chronic alcohol consumption has been 
undertaken, whereby there is a 4-fold increase in the cytochrome P450 enzyme 2EI 
(CYP2EI) (Tsutsumi et al. 2089).  The induction of the CYP2EI enzyme contributes 
to the metabolic tolerance against ethanol that develops within individuals who are 
alcohol dependent.  This tolerance to alcohol by way of the MEOS pathway, can 
also induce tolerance to other types of drugs, including, meprobamate 
(benzodiazepine) and pentobarbital (barbiturate) (Misra et al. 1971).         
 
From the information illustrated in figure 1.2, alcohol has numerous effects on the 
body, when ingested.  The wide ranging consequences, when acetaldehyde has 
been produced; include the increase in ethanol metabolism and urine production, 
displacement of redox haemostasis, metabolic abnormalities within methionine 
synthesis and vitamin deficiency.   
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Figure 1.2: Hepatic, nutritional and metabolic abnormalities associated with ethanol 
consumption adapted from Lieber (2004)  
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MEOS= Microsomal Ethanol Oxidizing System 
ADH= Alcohol Dehydrogenase 
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The consumption of alcohol, as outlined in figure 1.2, highlights that alcohol 
consumption can lead to malnutrition.  The vitamins and amino acids most 
associated with alcohol-induced depletion are folate, vitamins B6 and B12 and the 
amino acid methionine (Mason and Choi 2005).  These vitamin and amino acids 
play a key role in the metabolism of homocysteine, which has been identified as a 
biomarker of CVD risk.   
 
Alcohol reduces the bioavailability of the enzyme methionine synthase, which is 
required for the remethylation of homocysteine to methionine (Lutz et al. 2006).  The 
vitamins folate and vitamin B12 are required as co-factors within this reaction.  The 
inhibition of this enzyme due to alcohol consumption inadvertently increases the 
circulating levels of homocysteine in plasma and serum, which is known to have a 
direct effect on the cells within the endothelium causing dysfunction and formation of 
atherogenic plaques (Lutz et al. 2006; Trabetti 2008).  Endothelial dysfunction and 
atherogenic plaques are known risk factors for CVD (Trabetti 2008).  
 
To equate alcohol consumption to potential health risks including risk of CVD, it is 
important that alcohol consumption is determined accurately and quantitatively.   
There are various ways to analyse and record alcohol consumption, which include; 
questionnaires, diaries and biomarkers.   
 
1.4 ALCOHOL CONSUMPTION MEASUREMENT METHODS 
 
The quantitative estimation of alcohol consumption may be performed using a 
number of methods and/or tools; e.g. alcohol diaries, questionnaires and biological 
measurement.  The most accurate method of estimating alcohol consumption is by 
measuring the volume of ethanol within breath, blood or urine or by a known 
biomarker which increases in concentration in the presence of alcohol consumption, 
such as Carbohydrate-Deficient Transferrin (CDT).  This section will describe the 
different methods for measuring alcohol consumption. 
 
The self-reporting methods used to assess alcohol use, can include: face to face 
interviews; telephone interviews, diaries and questionnaires (MacDonald 1999).  
These methods are commonly used within research investigating alcohol 
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consumption and are a less intrusive way to access alcohol consumption, within a 
sample of the general population.  However these methods listed above do require 
honesty and accurate memory recall by individuals.  Table 1.5 details the different 
types of questionnaires and diaries which can be used to ascertain self-reporting 
alcohol use. 
 
Table 1.5: Types of self-reporting methods used for determining alcohol 
consumption, adapted from MacDonald (1999). 
Summary of Drinking Actual Drinking 
Quantity-frequency method Prospective diaries 
Extended quantity-frequency method Retrospective diaries 
Graduated-frequency method Recall method 
Periodic-specific normal week  
Lifetime drinking history  
 
1.4.1 Questionnaire 
 
A questionnaire is a valuable tool for determining an individual’s view point or 
lifestyle within a particular topic (Boynton and Greenhalgh 2004).  The main 
disadvantages of questionnaires are the reliability of an individual to tell the truth 
regarding their view point on a chosen subject, this is very relevant when it comes to 
stating alcohol consumption.   A report published recently, has stated that 
questionnaires and surveys relating to alcohol consumption are known to 
underestimate the true total consumption, by potentially up to 50% (Catto 2008).   
 
There are a number of different types of questionnaires which can be utilised to 
measure self-reported alcohol consumption and are listed in table 1.6.   The 
advantages and disadvantages of each type of self reporting questionnaire are also 
presented in table 1.6.  
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Table 1.6: Advantages and disadvantages of self-report alcohol use questionnaires. 
Questionnaire Use Advantage Disadvantage 
Quantity-frequency Reporting of usual daily consumption of 
any type of alcohol drink e.g. how often 
do you drink? 
Allows determination of alcohol 
consumption daily, which can be 
compared to the UK guidelines. 
Does not give alcohol 
consumption frequency on more 
than one day. 
Extended quantity-frequency More detailed questions relating to daily 
alcohol consumption and includes 
weekends.  
More detailed than quantity 
frequency and takes into account the 
variability of drinking patterns i.e. is 
sessional drinking more likely on 
weekends.    
Does not ask questions relating to 
volume of alcohol consumed. 
Graduated frequency Questions asked in relation to quantity 
and volume of alcohol consumed.  
Frequency of alcohol consumption is 
estimated in the quantity of alcohol 
consumed, beginning with largest 
and scaling down to smallest 
Memory recalls potentially a 
problem, especially if heavy 
alcohol consumption is being 
described.   
Period-specific normal week Questions asked in relation to a normal 
week.  
This method allows for consumption 
to be compared between work days 
and weekends. 
A normal week can vary 
considerably for certain 
individuals.   
Lifetime drinking history Asks questions in relation to lifetime of 
drinking.  Can be asked via face-face 
interview or self-administered 
questionnaires.    
Gives a large amount of data on 
alcohol consumption over a lifetime 
period, thus detailed drinking 
patterns variability during a lifetime.   
Memory recall would be a major 
problem.  
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Another major group of questionnaires are those employed as screening tools by 
healthcare professionals. 
 
The AUDIT (Alcohol Use Disorders Identification Test) screening tool emerged from 
a multicentre WHO collaborative project within six countries and was originally 
developed to be used within primary healthcare settings (e.g. GP surgeries) 
(Saunders et al. 1993).   It was designed to detect Alcohol Use Disorders (AUDs) 
(as defined in table 1.3) (Babor et al. 2001).  As noted, the AUD categories 
(hazardous, harmful and alcohol dependence) are associated with increasing levels 
of risk and harm due to alcohol consumption.  An overview of the AUDIT and the 
associated reliability and validity are summarised in table 1.7.   
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Table 1.7: Summary of alcohol screening questionnaires, adapted from Burns et al. (2009). 
Questionnaire Reference No. of 
Questions 
Completion 
Time 
Strength and Limitations Reliability 
(Cronbach’s α) 
AUDIT-C  
(Alcohol Use 
Disorders 
Identification Test 
– Consumption) 
(Bush et 
al. 1998) 
3 < 1 minute  Shortened version of the AUDIT questionnaire and therefore designed to be 
quicker to administer (e.g. advantageous in emergency departments).  
Designed to detect AUDs and risk drinking.  Has been validated in the primary 
care setting, emergency settings, general population, university student 
populations and adolescents (Dawson et al. 2005; Harris et al. 2010).  
Dawson et al. 2005 has suggested different cut-off values for males and 
females as this has been shown to improve the sensitive and specificity of the 
AUDIT-C.  This has also been suggested within the Bradley et al. (2009) 
review (Bradley et al. 2009). 
0.74-0.94 
(Meneses-Gaya 
et al. 2010; 
Reinert and 
Allen 2007) 
AUDIT  
(Alcohol Use 
Disorders 
Identification 
Test) 
(Saunders 
et al. 
1993) 
10 2 minutes  Originally developed by the WHO to detect alcohol dependency in men but 
has been evaluated in a variety of settings, populations and cultural groups.   
Original AUDIT development was evaluated in: Australia, Bulgaria, Kenya, 
Mexico, Norway and the USA (Saunders et al. 1993).  AUDIT has established 
reliability and validity within primary care patients (rural and urban) and 
subgroups including: women, unemployed, university/college students,  
adolescents, and different ethnic groups (Dawe et al. 2002; Daeppen et al. 
2000).  There is a large body of evidence showing high sensitivity and 
specificity in the aforementioned groups (Reinert and Allen 2007).  
Median: 0.83, 
range: 0.75-0.97 
(Reinert and 
Allen 2007) 
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Questionnaire Reference No. of 
Questions 
Completion 
Time 
Strength and Limitations Reliability 
(Cronbach’s α) 
NET 
(Normal drinker, 
Eye-opener, 
Tolerance) 
(Bottoms 
et al. 
1989) 
3 1 minute  Developed for use in an obstetric population (pre-pregnancy and pregnancy).  
Shown to be more reliable than CAGE within this population group, but has 
exhibited lower sensitivity than both the T-ACE and TWEAK.  Has not been 
validated outwith the USA as an independent screening instrument (Burns et 
al. 2009).  Furthermore the literature suggests this questionnaire has only 
been utilised in one study (Bottoms et al. 1979), therefore explaining the lack 
of reliability and validity evidence. 
 
Not reported in 
the literature.    
T-ACE 
(Take (number of 
drinks), Annoyed, 
Cut-down, Eye-
opener) 
(Sokol et 
al. 1989) 
4 1 minute Derivative of the MAST and CAGE questionnaire.  Designed for detecting 
excessive alcohol use in pregnant women.  Has an excellent correlation 
agreement with structured interview in pregnant women for identifying alcohol 
abuse (Burns et al. 2009).  Furthermore, this questionnaire is more reliable in 
detecting the consumption of high-risk drinking (defined as five or more drinks 
on one occasion), during pregnancy, compared to CAGE (Burns et al. 2009).    
Like the NET questionnaire, T-ACE has not been validated outwith the USA as 
an independent screening instrument (Burns et al. 2009).  A recent systematic 
review by Burns and co-workers has identified only 4 studies (Chang et al. 
1998; Russell et al. 1994; Russell et al. 1996; Sokol et al. 1989) where T-ACE 
has been used as an alcohol screening questionnaire (Burns et al. 2009) 
Not reported in 
the literature. 
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Questionnaire Reference No. of 
Questions 
Completion 
Time 
Strength and Limitations Reliability 
(Cronbach’s α) 
TWEAK 
(Tolerance, 
Worried, Eye-
opener, Amnesia, 
Kut-down) 
(Russell 
and Bigler 
1979) 
5 1 minute Derivative of the MAST and CAGE questionnaire.  Designed for detecting 
excessive alcohol use in pregnant women.  Shown to exhibit sensitivity of 75% 
and 90% within this population (Fiellin et al. 2000).  Similar to NET and T-
ACE, the TWEAK questionnaire has not been validated outwith the USA as an 
independent screening instrument (Burns et al. 2009).  A recent systematic 
review by Burns and co-workers has identified only 3 studies (Dawson et al. 
2001; Russell et al. 1994; Russell et al. 1996) where TWEAK has been used 
as an alcohol screening questionnaire (Burns et al. 2009) 
 
 0.71  
(Coker et al. 
2004; Russell 
and Bigler 1979) 
CAGE  
(Cut-down, 
Annoyed, Guilt, 
Eye-opener) 
(Mayfield 
et al. 
1974) 
4 1 minute Short questions with yes or no answers.  Developed for use in men and not 
considered to be accurate for identifying alcohol abuse in women and different 
ethnic groups (Bradley et al. 1998).  Has exhibited a stronger reliability and 
accuracy in the in-patient population (medical, surgery and psychiatry) (Dhalla 
and Kopex 2007).   Recent review by Dhalla and Kopex has highlighted  the 
high retest reliability of 0.80-0.95 for CAGE and correlations of 0.48-0.70 with 
other screening questionnaires (Dhalla and Kopex 2007)   However CAGE is 
of limited value in the primary care population, with the suggested cut off score 
of ≥2 (Burns et al. 2009).   
 
0.70-0.85 
(Dhalla and 
Kopex 2007) 
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Questionnaire Reference No. of 
Questions 
Completion 
Time 
Strength and Limitations Reliability 
(Cronbach’s α) 
SMAST 
(Short Michigan 
Alcohol 
Screening Test) 
(Selzer, 
Vinoku, 
and van 
Rooijen 
1975) 
13 1-2 minutes Yes or no questionnaires relating to the previous 12 months of alcohol 
consumption.  The shortened version of the MAST questionnaire and 
therefore is quicker to administer to patients or participants.  SMAST has been 
examined in a primary care setting; however reliability and validity data 
suggest that the SMAST questionnaire is a better measure of lifetime or past 
problem drinking in a clinical population (Barry and Fleming 1993).   
 
0.60-0.81  
(Gibbs 1983) 
MAST 
(Michigan Alcohol 
Screening Test) 
(Selzer 
1971) 
24 10-15 
minutes 
Questions with yes or no answers that relate to alcohol consumption within 
previous 12 months. The first study to determine the reliability of MAST was 
conducted in 1975 by Selzer and colleagues, which determined that MAST 
showed a high internal consistency (Selzer et al. 1975).  However a study by 
Crook and colleagues contradicted the coefficients stated in the original 
reliability study (Crook et al. 1994) and suggested that the MAST 
questionnaire score be calculated using sub-scales.  This would provide more 
information in terms of alcohol dependence than a single overarching total 
score.  Reliability and validity evidence has shown MAST is more useful in 
detecting alcohol abuse and dependence in clinical populations, as opposed 
to the general population (Dawe et al. 2002).   
 
0.83-0.95 
(Gibbs 1983; 
Selzer 1971) 
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Currently the WHO, NIAAA (National Institute of Alcohol Abuse and Alcoholism), 
UPSTF (US Preventive Services Task Force) and NICE have repeated the 
recommendation that the AUDIT is used to screen for alcohol misuse in primary 
care.  Furthermore, they suggest that the AUDIT is more reliable than other 
screening tools within this setting (National Institute for Health and Clinical 
Excellence 2010; Rubinsky et al. 2010).   
 
The questions stated within the AUDIT relate to alcohol consumption, drinking 
behaviour and alcohol-related problems and score an individual out of a total of 40.  
The higher the total score the more severe the alcohol problem and the likelihood for 
an individual to develop dependency.  The AUDIT scoring criteria are: 1-7 
represents low risk drinking; 8-15 is indicative of hazardous drinking (and is 
appropriate for simple advice focused on reducing consumption); 16-19 is 
suggestive of harmful drinking (brief counselling and continued monitoring is seen 
as appropriate) and above 20 is potential dependency (further diagnostic evaluation 
is warranted) (Babor et al. 2001; National Institute for Health and Clinical Excellence 
2010).  Babor et al (2001) have reported that a cut-off score of 10 will provide 
greater specificity, but this will therefore reduce sensitivity and is currently not 
recommended (National Institute for Health and Clinical Excellence 2010).   
 
There has been a strong body of evidence published in the literature indicating the 
high sensitivity and specificity demonstrated in the scoring system used within the 
AUDIT, to detect the criteria of hazardous and harmful alcohol use (Hodgson et al. 
2002).  For harmful and hazardous alcohol use, 92% of those identified using AUDIT 
have a score of 8 or above.  For those individuals consuming alcohol in a non-
hazardous pattern, 94% scored less than 8 (National Institute for Health and Clinical 
Excellence 2010; Saunders et al. 1993).  Since the development of the AUDIT, 
numerous independent studies have reported that it is a valid and reliable screening 
questionnaire and is considered to be the gold standard (Hodgson et al. 2002; 
National Institute for Health and Clinical Excellence 2010; Rubinsky et al. 2010). 
 
Recent findings have suggested that the effectiveness of alcohol screening 
questionnaires should take into consideration the fact that the diagnostic AUDIT 
scores for males and females may be different (Aalton et al. 2009).  Data published 
by Aalto and co-workers suggests that the AUDIT cut off score of 8 and above is 
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suitable for males, but should be lower for females (Aalton et al. 2009).  Further 
work is needed to clarify whether or not the interpretation of AUDIT scores should 
take into account gender.      
 
The psychometric properties of the AUDIT have been examined within a number of 
different population samples (Dawe et al. 2002).  This has revealed, that with the 
exception of the geriatric population, the AUDIT has a good internal reliability in all 
validated population samples.  The performance of AUDIT has also been 
investigated in comparison to other screening questionnaires.  For example a 
comparison with MAST and CAGE showed convergent validity with moderate to 
high correlations (Dawe et al. 2002).  The AUDIT questionnaire has been shown to 
be consistent in terms of sensitivity in detection of less severe cases of alcohol 
misuse, in comparison to CAGE and MAST, therefore demonstrating a high 
sensitivity to detecting non-dependent alcohol misuse (Dawe et al. 2002).    
 
The original AUDIT questionnaire has been shortened to evaluate only alcohol 
consumption, using three questions and is known as the AUDIT–C (AUDIT-
Consumption).  It has shown good reliability in detecting heavy drinking and 
dependency, however the sensitivity and specificity are still lower than the full 
AUDIT (Bush et al. 1998).  Data pertaining to the reliability and validity of the 
AUDIT-C is highlighted in table 1.7.  One major benefit of the AUDIT-C is its 
appropriate use where time restrictions are in place and under this condition, 
AUDIT-C has been shown to be reliable (Bush et al. 1998).   
   
The CAGE questionnaire was developed in the USA from a clinical study of medical 
and surgical patients (Mayfield et al. 1974).  CAGE can be administered as a self-
reported questionnaire or can be used within an interview, and either mode of 
administration is reported to have no effect on the patient’s response.  The reliability 
and validity of the CAGE questionnaire is summarised in table 1.7.  The four 
questions that form the CAGE questionnaire have exhibited good internal reliability, 
with all four questions correlating with the other, indicating that the CAGE 
questionnaire is measuring a single homogeneous construct (Watson et al. 1995).   
Evidence showing the comparability of CAGE and MAST have shown that CAGE is 
a better identifier of recent alcohol misuse problems and dependency compared to 
MAST which has a higher reliability of determining alcohol dependency over an 
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individual’s life time (Dawe et al. 2002).  There have been suggestions in the 
literature that the CAGE should be incorporated into medical history questionnaires, 
using the question “do you ever drink alcohol?”  However if the aim is to detect 
hazardous or harmful drinking the AUDIT should be used as it is more sensitive 
(Dawe et al. 2002).   
 
The Michigan Alcohol Screening Test (MAST) was developed for use as a 
structured questionnaire to detect alcoholism that could be used by a range of 
clinicians, within different fields (Selzer 1971).  The MAST questionnaire has also 
been developed into a shortened version, which includes 13 questions, compared to 
the full 24 questionnaire version, known as SMAST (Short Michigan Alcohol 
Screening Test).  The MAST questionnaire was originally developed using a small 
sample of males who were alcohol dependent alongside a control group.  The lack 
of a range in individuals within the original group used to develop the MAST 
questionnaire, has not prevented the questionnaire being widely used and showing 
good reliability and validity.  The validity and reliability of both the MAST and 
SMAST are reviewed in tale 1.7.  The cut-off score for MAST is 13, which will detect 
the presence of the DSM defined alcohol abuse and dependency (Selzer 1971).  
Using this score MAST has a sensitivity of 0.91 and specificity of 0.76, when 
detecting alcohol dependency (Ross et al. 1990).  Within the original reliability study 
the author also suggests the score of 5 can reliably determine hazardous and 
harmful dependency using MAST (Selzer 1971).   However more recent evidence 
has shown the AUDIT is more reliable for the detection of hazardous and harmful 
drinking (National Institute for Health and Clinical Excellence 2010).   
 
The NET, TWEAK and T-ACE questionnaires have been developed for the use 
within a specific population: pregnant women.  The reliability and validity of NET, 
TWEAK AND T-ACE are reviewed in table 1.7.  Literature evidence suggested that 
the MAST and CAGE questionnaire did not provide suitable sensitivity within 
samples of pregnant women, requiring the need to develop screening tools 
specifically for that sample group (Dawe et al. 2002).  The T-ACE questionnaire has 
been derived from the CAGE questionnaire, where the questions have been 
reduced from four to three, where the question about guilt has been replaced with a 
tolerance question (Bradley et al. 1998).  Furthermore the NET questionnaire is 
similar to the T-ACE questionnaire, but replaces the ‘cut-down’ and ‘annoyed’ 
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questions with a question asking if the patient is a normal drinker (Bradley et al. 
1998).  The TWEAK questionnaire is similar to T-ACE where it merges questions 
from both the MAST and CAGE questionnaires (Bradley et al. 1998).  In a recently 
published systematic review (Burns et al. 2009) the T-ACE and TWEAK exhibited 
higher sensitivity (90-92%) and specificity (94-97%) in comparison to NET 
(sensitivity 71% and specificity 86%).  The recently published systematic review by 
Burns and co-workers suggests that TWEAK and T-ACE, along with AUDIT-C are 
valid tools for determining at risk drinking in pregnant women, however more work is 
required to fully validate these tools within this sample and determine the test-retest 
reliability.       
 
The validity and reliability of alcohol screening questionnaires, as reported in the 
literature, clearly highlight their ability to detect hazardous and harmful alcohol 
consumption and dependency (National Institute for Health and Clinical Excellence 
2010; Rumpf et al. 202; Saunders et al. 1993).  However evidence suggests that 
their reported reliability and validity (reviewed in table 1.7), may be specific to certain 
healthcare settings, ages, ethnic and gender groups and this should be taken into 
consideration before implementing their use (Fiellin et al. 2000).   
 
All the aforementioned screening questionnaires do not ask for grams or units of 
alcohol consumed when drinking and these questionnaires have been primarily 
designed to detect alcohol misuse and/or dependency.  The AUDIT questionnaire 
does ask a patient how many drinks they consume in a typical drinking day, 
however no standard measure of a “drink” is given and as an example, the grams of 
alcohol found in a large glass of wine (24 g) compared to a measure of spirit (8 g) 
are very different, but both are defined as a “drink”.  Therefore the ability of these 
questionnaires to over or underestimate alcohol consumption is clear.   
 
Alcohol screening questionnaires, including AUDIT and CAGE have been compared 
to alcohol biomarkers (e.g. CDT), with aim to compare their reliability and determine 
the efficiency of both tools in identifying alcohol dependence and/or misuse.  A 
search of the literature has identified several publications which compare alcohol 
screening questionnaires to biological markers (Comasco et al. 2009; Couture et al. 
2010; Hermansson et al. 2003; Miller et al. 2004; Neumann et al. 2009).  A study by 
Couture et al. (2010) compared AUDIT and MAST to a range of alcohol biomarkers, 
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including CDT, GGT, AST, ALT and MCV in a sample of drink-drive offenders in 
Canada.  The aim of the study was to predict if either tool could determine if the 
individual was likely to reoffend.  Within the sample (N=154), MAST and AUDIT 
identified 97.9% and 66.0% prevalence of alcohol misuse.    However the use of the 
various alcohol biomarkers did not identify a high prevalence of alcohol misuse 
within the sample.  This could be explained, by the time of blood sampling as the 
study authors did not take into consideration the half-life of the alcohol biomarkers 
and depending on the timing of blood sampling the levels of the biomarker could 
have declined to that of a level below the positive threshold.  Therefore not reflecting 
the drinking time-frame captured by the questionnaire.  This would be especially 
important if a study participant was a sessional drinker, with periods of high alcohol 
consumption and alcohol free days. 
 
Furthermore a number of studies have shown that both alcohol screening 
questionnaires (e.g. AUDIT and CAGE), used in conjunction with biomarkers (e.g. 
CDT) have been successful in determining alcohol dependence (Comasco et al. 
2009; Hermansson et al. 2003; Neumann et al. 2009).  The study by Hermansson et 
al. (2003) showed a 20% prevalence of alcohol dependence in the study sample 
(N=990), detected using either CDT or AUDIT.  However no correlation between 
AUDIT and CDT was demonstrated by Hermansson et al. (2003), when both tools 
were used together, and this was further demonstrated by Neumann et al. (2009).  A 
mechanism of explanation for no correlation between these two tools lies within 
what each tool aims to detect.  The AUDIT and CAGE screening questionnaires are 
designed to detect alcohol dependency or problem drinking within a general 
population.  Whereas alcohol biomarkers are designed to detect if drinking has 
taken place within a recent time frame (CDT detects heavy drinking within a 2 week 
period), either by way of blood alcohol or breath alcohol and furthermore is used to 
monitor alcohol abstinence in alcohol dependent populations.  The alcohol 
biomarkers in common usage, including CDT are not actively used to diagnose 
dependence, which could explain the poor correlation between the two tools and 
further emphasises the different uses of each tool (Jeppsson et al. 2007).    
 
The most recent alcohol consumption survey to take place in Scotland was the 
Scottish Health Survey 2003 (Bromley et al. 2003).  This nationwide survey asked 
specific questions relating to alcohol consumption, frequency and type of beverage.  
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The survey also included selected questions from the CAGE questionnaire and over 
13 questions specifically relating to the frequency, type and location of alcohol 
consumption.  A survey conducted by University of Aberdeen and NHS Grampian 
known as “The Grampian Lifestyle Survey” specifically looked at alcohol 
consumption in 16-24 year olds (University of Aberdeen 2009).  The Office of 
National Statistics (ONS) also incorporates alcohol consumption into their Good 
Household Survey (Goddard 2001). 
 
In many general consumption questionnaires; including ones issued by the ONS 
(Goddard 2001), respondents are asked to equate their alcohol consumption to a 
given volume of alcohol.  An example of this is where the alcoholic drink is 
measured as follows, one unit is equal to: one glass of wine, half a pint of beer or a 
measure of spirit.  This information given to respondents is actually inaccurate and 
as a result is underestimating a respondent’s true alcohol consumption.  To equate 
one unit to a glass of wine, is underestimating the true unit measurement.  A glass 
of 12% wine measuring 250 ml actually contains three UK units (24 g) of alcohol.  
The underestimation of alcohol intake from questionnaires results in dangerous 
alcohol drinking patterns, such as sessional drinking being underestimated (Catto 
2008; Gill and Donaghy 2004; MacAskill et al. 2008).   
 
 
1.4.2 Diary 
 
Diaries have been in use in a number of studies to recall alcohol and/or food 
consumption (Dawson 2003).  Diet and/or alcohol diaries are a common tool within 
the nutrition and dietetics field to ascertain the diet history of individuals over a 
prescribed period of time (Gregory et al. 1995).   The two different types of diaries 
employed to determine self-reported alcohol consumption are listed in table 1.5. 
 
One of the main negative issues associated with the use of a diary is the honesty 
and accuracy of the respondent.  A retrospective diary requires the participant to 
work back in time and remember how much, and which type of alcohol beverage 
they consumed up to a week ago, which can be problematic for some individuals.  
However the use of a prospective diary reduces the need to remember when alcohol 
was consumed and what volume, as this type of diary is completed on a daily basis.   
34 
The use of technology has now enabled alcohol diary software to be functional on 
mobile phones and personal digital assistants (PDAs), which allows the alcohol 
consumption data to be entered into the program as soon as a beverage has been 
consumed.  A recently published study in the United States of America (USA) has 
employed this technology whereby a PDA handheld computer was given to student 
participants to enter their daily alcohol consumption.   This allowed the data to be 
downloaded onto a central computer (Bernhardt et al. 2007).  This system has the 
potential benefit of reducing the likelihood of data being lost as might be the case, if 
recorded in a paper diary.  Additionally data can be analysed on a daily basis, e.g. 
after an episode of sessional drinking, to quickly ascertain the volume and type of 
alcohol consumed. 
 
Recording alcohol consumption within a prospective or retrospective diary requires 
accuracy of recall (Dawson 2003).  For example if an individual undertook an 
episode of sessional drinking on a weekend, and left it until Monday to complete the 
diary then due to the effects of alcohol on the body, the accuracy of recall of that 
individual would be less than someone who had just one small glass of wine.  The 
report “How much is Scotland drinking” investigated the self-reporting of alcohol 
consumption and concluded that people tend to underestimate their true alcohol 
consumption (Catto 2008).  A study published by Perrine et al. 1997 undertook an 
observational study to investigate alcohol consumption recording, when the 
participants were observed in a public bar settling and the subsequent self reports.  
The study found that the self-reported alcohol consumption was significantly lowered 
than that of the observed data.   
 
A search of the literature found only one journal paper, which assessed the use of 
AUDIT, quantity/frequency questionnaire and one week alcohol diary and their 
reliability and sensitivity (Shakeshaft et al. 1998).  The study published in Australia 
in 1998, found that of the three tools listed above, AUDIT was the most sensitive in 
detecting, what the study referred to as “binge drinkers”, however the definition of 
binge was not given.  The study found similar results when comparing the quantity 
frequency questionnaire and alcohol diaries and also between the quantity 
frequency question and AUDIT.  No correlation was found between the AUDIT and 
one week drinking diaries (Shakeshaft et al. 1998).   The study by Shakeshaft et al. 
(1998) did conclude that the most appropriate tool to use was dependent on the 
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study design and what data was required, as a 1 week drinking dairy can produce 
more information on drinking pattern, type and frequency in comparison to the other 
tools used.   
 
Following on from the Perrine et al. (1997) study, it is also important to note diary 
entries, which state alcohol was consumed in a bar or club, as opposed to alcohol 
consumed and poured in the home, which are known to differ in volume (MacAskill 
et al. 2008).  Due to the standardised measures available within licensed premises, 
the accuracy of a poured drink within a licensed premise is going to be more 
accurate than that of a drink poured at home.  A study by Gill and O’May (2007) 
investigated if drinks poured at home were of a greater volume compared with 
measures usually served in licensed premises.  Study participants were asked to 
pour a glass of wine or measure of spirit which they would usually have at home.  
The results of the study showed that drinks which were self-poured were of a 
greater volume than what would be served within a licensed premise (Gill and 
O'May 2007).  This is an important point to consider when analysing alcohol diaries 
for consumption.   Furthermore the analysis of alcohol consumption within the diary 
itself requires thought.   Determination of the alcohol consumption can be calculated 
manually from drinks stated provided there is standard definition of measures (e.g. 
25 ml spirit shot or 250 ml for a large glass of wine) and an example of a unit 
calculator can be obtained from the Drink Aware website (Drinkaware.co.uk 2008).  
The unit calculator provided on the Drink Aware website does not include the full 
spectrum of all alcoholic drinks available in the UK, and the development of an 
alcohol drink database or spreadsheet would therefore improve the accuracy of 
alcohol diary analysis.  The use of dietary software, which is commercially available, 
could also be used to analyse alcohol diaries, however a literature search has not 
identified any studies using this method.  The WinDiets software, developed in 
Scotland (WinDiets Research Version, Univation Ltd), has the potential to be used 
for alcohol analysis, however brand names are not included in the database and 
alcohol measurements, including the %ABV of each drink is not given.  Alcohol 
consumption analysis generated from the use of the WinDiets program, requires 
caution and the data generated compared to a more detailed tool, such as the unit 
calculator on Drink Aware Website.  A search of the literature has proved no 
evidence on the reliability or validity of WinDiets for the assessment of alcohol 
consumption.  An alternative method, not involving individual recall and analysis of 
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questionnaires and/or diaries, is the use of biological markers to assess if alcohol 
has been consumed.   
 
1.4.3 Biological Alcohol Detection 
 
Biological markers can be measured within a number of body fluids including; blood, 
breath, hair, sweat or urine.  There are a number of biological markers for alcohol 
consumption that are currently in use.  These so called ‘biomarkers’, are used for 
clinical diagnosis of alcoholism and also used within the forensic field to ascertain 
alcohol involvement in criminal activity (Morini et al. 2009).  An accurate, sensitive 
and specific biomarker is of great importance, as this will enable a quantifiable 
estimation for alcohol consumption in individuals who are consuming alcohol in 
patterns which can be acute or chronic and over a varying length of time.  
 
1.4.3.1 Biomarkers of Alcohol Consumption  
 
A biomarker of recent drinking patterns would be a major research advance.  
Currently blood alcohol concentration (BAC) is the standard biomarker for recent 
alcohol consumption, however it can only reflect alcohol intoxication within a 
relatively short preceding period.  Ethanol can be identified accurately in body fluids 
or vapours by chemical and enzymatic methods.  Ethanol is short lived in the body 
with complex metabolism and distribution which can vary between individuals 
causing the relationship between ethanol concentration consumed and that 
measured in body fluids to be inaccurate (Das et al. 2004; Das et al. 2008, Swift 
2003).  Blood, urine, breath, hair and sweat are used to identify ethanol in vivo but 
there is controversy over the accuracy (Das et al. 2008; Morini et al. 2009).   
 
Common laboratory tests used for individuals abusing (drinking in a harmful pattern 
and above responsible drinking guidelines, see table 1.1) alcohol include: patients 
with liver conditions which present with hyperbilirubinaemia (increase in serum 
bilirubin levels, both unconjugated and conjugated) and is more prevalent in alcohol 
dependent patients (Ahlgren et al. 1988; Das et al. 2008; Das et al. 2003; Wadstein 
and Skude 1979), plasma urate levels can also be used as they correlate with 
recent alcohol intake (Das et al. 2008).  Heavy drinkers are found to have slightly 
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raised serum alkaline phosphatase (Chalmers et al. 1981) and urea concentration 
can also be measured as the levels reduce as alcohol inhibits the enzymes in the 
urea cycle (Paton 1994).   A review of the literature by Das et al. (2008) stated the 
following as common alcohol consumption biomarkers: Gamma-glutamyltransferase 
(GGT); Mean corpuscular volume (MCV); Platelet Monoamine Oxidase Type B 
(MAO-B), Transaminases; AST to platelet ratio index (APRI); Albumin and globulin; 
Acetaldehyde; Haemoglobin associated acetaldehyde (HAA); Dehydrogenases; 
Lipid profile; Total serum sialic acid; Plasma sialic acid index of apolioprotein J 
(ApoJ); Carbohydrate Deficient Transferrin (CDT); Serum beta hexosaminidase; 
Hyaluronic acid; Ethyl glucuronide; Blood alcohol concentration (BAC); Type IV 
collagen; Cytokines and the Oxidant-antioxidant system.  The sensitive and 
specificity of the aforementioned biomarkers are shown in table 1.8. 
 
Table 1.8: Sensitivity and specificity of alcohol consumption biomarkers as reviewed 
by Hannuksela et al. 2007 
Biomarker Sensitivity (%) Specificity (%) 
Ethanol  0-100 100 
Urinary 5-HTOL/5-HIAA 0-100 >90 
Serum GGT 34-85 11-95 
Urinary GGT 71 81 
MCV 34-89 26-96 
AST 15-69 Low 
ALT 18-58 Low 
Serum CDT 39-94 82-100 
Serum TSA 48-82 18-96 
Plasma SIJ 90-92 100 
Serum β-HEX 69-94 69-98 
Urinary β-HEX 81-85 84-96 
EtG Not detectable Not detectable 
PEth 97-99 100 
EtS Not detectable Not detectable 
Hair FAEE 89-100 90 
Urinary dolichol 9-68 96 
Platelet MAO-B Not detectable Not detectable 
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However a more detailed investigation into the literature has shown the following 
biomarkers are the most accurate markers of assessing alcohol consumption: 
carbohydrate-deficient transferrin (CDT); gamma-glutamyltransferase (GGT); ethyl 
glucuronide (EtG) (in hair and plasma); Phosphatidyl ethanol (PEth); Fatty Acid Ethy 
Esters (FAEEs); aspirate aminotransferase (AST); alanine aminotransferase (ALT) 
and mean corpuscular volume (MCV).  The sensitivity and specificity of the alcohol 
biomarkers shown in table 1.8, have changed since the review by Hannuksela et al. 
(2007) and specifically relates to Ethyl Glucuronide (EtG).  A recently published 
paper by Morini et al. (2009), which examined the use of EtG in hair for the detection 
of chronic alcohol consumption, showed that it had a sensitivity up to 89% and 
specificity of 100%.  The paper also suggested that EtG measured in hair, was a 
good biomarker of heavy alcohol use as CDT.  However, EtG has not been 
investigated as thoroughly as CDT (Fleming et al. 2009; Morini et al. 2009).  Similar 
evidence has been suggested for the use of Ethyl Sulphate (EtS), however it has not 
been investigated as in depth as EtG (Hoiseth et al. 2008).  Both EtS and EtG are 
described as direct ethanol metabolites, and they are produced as a by-product of 
ethanol metabolism and do not readily exist normally within the body (Hoiseth et al. 
2008).  CDT is different from EtG and EtS, as the transferrin protein is present in 
vivo and is altered in the presence of alcohol 
 
These aforementioned biomarkers with the exception of CDT are affected by 
physiological and pathological conditions and also have low sensitivity and 
specificity (Morini et al. 2009), as shown in table 1.8.   CDT has been selected as 
the primary biomarker for alcohol consumption by the WHO and International 
Federation of Clinical Chemistry (IFCC), due to the large volume of published peer-
reviewed research, which determines CDT as the primary focus biomarker for 
monitoring alcohol consumption during alcohol abstinence (Jeppsson et al. 2007; 
Oberrauch et al. 2008).   
 
1.4.3.2 Carbohydrate-Deficient Transferrin (CDT) 
 
CDT is a biomarker used for identifying recent and regular alcohol consumption and 
can also be used for monitoring abstinence in patients undergoing detoxification and 
rehabilitation (Helander et al. 2003).  Elevated levels of CDT in serum appear after 2 
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weeks of consuming >50-80 g/day of alcohol, which can equate to 6-10 units or 1 
bottle of 12% wine per day (Jeppsson et al. 2007).  CDT levels can remain elevated 
for more than one week after consumption has stopped (Helander et al. 1996; 
Jeppsson et al. 2007).  The use of CDT as a predictor of consumption within 
samples of healthy individuals who consume alcohol in a sessional pattern has yet 
to be determined.   
 
1.4.3.2.1 Biochemistry of CDT 
 
Transferrin is a globular protein which transports iron in the plasma (Aisen and 
Listowsky 1980; Das et al. 2008; Putnam 1975).  Transferrin consists of a single 
polypeptide chain consisting of 679 amino acids arranged in two independent metal 
ion binding globular domains, known as the N-terminal and the C-terminal.  The N-
terminal combines the amino acids sequence 1-336 and the C-terminal combines 
amino acid sequence 337-679.  Transferrin also has two N-linked complex glycan 
chains positioned at 413 and 611 (MacGillivray et al. 1983).  The N-glycan 
complexes are the carbohydrate portion of transferrin.  The two transferrin N-glycan 
chains differ in their branching structure by showing bi, tri or tetra antennary 
structures.  Each antenna ends with a sialic acid molecule which is negatively 
charged.  This results in asialotransferrin and the various sialylated forms monosialo 
right through to octasialotransferrin, are identifiable in serum (van Noort, de Jong, 
and van Eijik 1994).  The carbohydrate part of the transferrin molecule only 
represents 6% of the total transferrin molecule (Kamboh and Ferrell 1987).  
Transferrin reversibly binds polycations which include: iron, copper, zinc, cobalt and 
calcium, however it is the binding of iron and copper which is of physiological 
significance.  A transferrin molecule can bind with two atoms of ferric ions and an 
anion, which is usually a bicarbonate ion and this process requires a constant pH 
(Ehrenberg and Laurell 1955; Schade et al. 1949).  The two N-glycan structures 
bind a maximum of six sialic acid residues.  In vivo the mean half-life for CDT is 14-
17 days (Morini et al. 2009).  See figure 1.3, which illustrates the differences 
between each of the gylcoforms which form CDT.   
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Figure 1.3: Glycoforms of CDT 
 
Alcohol promotes the absorption of ferric iron from the GI tract, potentially by 
inducing the gastric secretion of hydrochloric acid (HCI) (Charlton et al. 1964).  
Transferrin is important as it is required for iron homeostasis.  It attaches to the 
receptor on the surface of the cells before iron is released into the cell.  Post alcohol 
consumption causes an increase in iron levels to occur but a decrease in the 
transferrin synthesis, this results in an in-balance in iron homeostasis, which will 
increase iron levels, without corresponding increases in transferrin. 
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41 
1.4.3.2.2 CDT as a Biomarker of Alcohol Consumption  
 
CDT has been approved by the FDA as a clinical diagnostic test for the detection of 
heavy alcohol consumption (Anton et al. 2001).  CDT is the term used to refer to the 
glycoforms of transferrin which are deficient in sialic acid residues; known as 
asiolotransferrin, monosialotransferrin and disialotransferrin (Stibler 1991).  Recent 
published literature has confimed that disialotransferrin is the key glycoform altered 
by excessive alcohol consumption (Jeppsson et al. 2007) 
 
It was in 1970 that Stibler showed abnormal transferrin glycoform patterns in serum 
and cerebrospinal fluid in relation to alcohol misuse.  Stibler used the technique of 
isoelectric focusing, where the specific glycoforms associated with alcohol showed 
isoelectric points at or above pH 5.7 (Jeppsson et al. 2007).  When the sample was 
iron saturated, the alcohol affected glycoforms were shown to possess lower sialic 
acid content in comparison with the major glycoform tetrasialotransferrin, this 
resulted in the name CDT (Jeppsson et al. 2007; Stibler 1991).   
 
Alcohol consumption can affect a number of enzymes, which includes enzymes 
responsible for CDT synthesis.  Possible enzymes which can be affected are sialy 
transferase and plasma sialidase which can be responsible for increasing the 
intracellular level of CDT.  A change in the protein transport during the post-
translational modification could be a primary mechanism in the impairment of protein 
metabolism associated with chronic alcohol dependency (Das and Vasudevan 
2004). 
     
Patients with liver disease can have normal CDT levels (Behrens et al. 1988; Stibler 
1991).  However advanced chronic liver disease, primary biliary cirrhosis, chronic 
active hepatitis and drug induced hepatic insufficiency causes false positive CDT 
results (Stibler 1991).  This can be problematic as a high proportion of alcohol 
dependent patients have advanced cirrhosis, which means detailed investigation 
into patient’s medical histories is required before a final diagnosis of alcohol use via 
CDT results is made.   A suggestion has been made in the literature that in these 
cases the result determined by CDT be confirmed with the use of another alcohol 
biomarker, such as GGT before a diagnosis of alcohol dependence is confirmed 
(Bianchi et al. 2008).    
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CDT has high sensitivity (39-94%) and specificity (82-100%) for chronic heavy 
drinkers and can distinguish them from abstainers or light social drinker (Allen et al. 
1994; Behrens et al. 1988; Sillanaukee 1996).  The accuracy of CDT is decreased: 
in individuals who consume lower levels of alcohol and can be classified as 
responsible drinkers (UK guidelines) (Grönbaek et al. 1995); young alcoholics 
(Huseby et al. 1997) and women (La Grange et al. 1994; Stibler et al. 1988).  
However there have been few studies which have examined the potential of CDT as 
a marker of alcohol consumption in sessional drinkers.   
 
A gender difference, affects which transferrin glycoforms are increased by alcohol, 
but further work is required to investigate this gender differentiation (Das et al. 
2008).  No categorical pattern of alcohol consumption, apart from chronic alcohol 
dependency, has been shown to cause an absolute elevation of CDT in serum 
(Sillanaukee 1996). 
 
Transferrin is a steroid responsive protein which suggests that sex hormones could 
contribute to variations in CDT levels.  Varying changes in plasma hormones levels 
induced by conditions such as pregnancy, contraceptives, menstrual cycle and 
menopause can alter iron homeostasis in women, resulting in a change in CDT 
levels (Das et al. 2008).  The levels of CDT can also be affected by the condition, 
carbohydrate-deficient glycoprotein (CDG) syndrome.  CDG is a group of autosomal 
recessive diseases, where there is a carbohydrate defect in the serum transferrin.  
There are two variants, transferrin-B and transferrin-D, where both can interfere in 
CDT analysis.  False negative results can occur due to the genetic D-variants of 
transferrin and also by primary biliary cirrhosis, hepatocellular carcinoma, viral liver 
cirrhosis, pancreas and kidney transplantation and also by the drugs which are used 
to treat these conditions (Sillanaukee et al. 2001).  The interpretation of CDT levels 
in relation to alcohol consumption can therefore require a thorough background 
investigation of an individual’s medical history.   
 
The interpretation of CDT by clinicians needs careful consideration.  When CDT 
values are reported it is important for the testing laboratory to report not only the 
CDT level but also the cut off level, the reference range and the method employed.  
This is important as there are several methods used to detect CDT in serum, which 
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include High Pressure Liquid Chromatography (HPLC), Capillary Electrophoresis 
(CE) and immunoassays.  All of these methods have different reference ranges and 
cut-off values for a positive result.  It is therefore important, when reporting CDT 
results to state the method used.   
 
1.4.3.2.3 Standardization of CDT 
 
Due to these varying analytical methodologies, a need for standardization of a CDT 
method is required.  The International Federation of Clinical Chemistry and 
Laboratory Medicine (IFCC) established a working group for the standardization of 
CDT (WG-CDT) (Jeppsson et al. 2007).  The tasks of the WG-CDT were to define 
and validate a specific target analyte of CDT, select a suitable reference method, 
produce reference materials and establish the clinical usage of CDT.   
 
CDT was originally defined as the sum of asialo, monosialo and disialotransferrin.  
However later studies have shown disialotransferrin and asialotransferrin are 
missing terminal sialic-acid residues as well as one complete N-glycan in the case of 
disialotransferrin.  Both N-glyans are missing within asialotransferrin (Jeppsson et 
al. 2007).  Monosialotransferrin is not a suitable target glycoform for CDT 
determination as it is associated with high trisialotransferrin, within the sample and 
not specifically related to the levels of alcohol consumed (Jeppsson et al. 2007).  
However asialotransferrin and disialotransferrin are clearly related to alcohol 
consumption but do have different sensitivity and specificity (Jeppsson et al. 2007).    
  
Asialotransferrin is not detectable in abstinent or social drinkers using current 
methods, but does become detectable in chronic heavy drinkers (Jeppsson et al. 
2007).  In chronic heavy drinkers disialotransferrin is detectable and asialotransferrin 
accompanies this (Jeppsson et al. 2007).   The diagnostic sensitivity of 
asialotransferrin is lower compared with disialotransferrin and too low when 
detecting chronic to moderate alcohol use.  This has resulted in disialotransferrin 
becoming the current glycoform for CDT detection and will be known as the primary 
target molecule (Jeppsson et al. 2007).   
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1.4.3.2.4 CDT Laboratory Methodology  
 
The CDT methodologies in use at present rely on differences in charge (isoelectric 
point) between disialotransferrin and the other glycoforms (Jeppsson et al. 2007).  
The measurement of CDT should be obtained after complete iron saturation of the 
sample, as this influences the isoelectric point and chemical structure, all of which 
are specific to the method being used.  The WG-CDT have suggested that the gold 
standard method for CDT analysis would be Liquid Chromatography-Mass 
Spectrometry (LC-MS), however this method is still in development (Oberrauch et al. 
2008).  At present the reference method for CDT analysis is HPLC (Helander et al. 
2003).  HPLC can provide specific iron transferrin detection at 460-470 nm with low 
interference risk; separation of transferrin glycoforms; quantification of 
disialotransferrin by measuring peak height or area under the curve, which is 
illustrated on a HPLC chromatograph (Jeppsson et al. 2007).  The current reference 
method was published by Helander et al. (2003) and following that publication, 
commercial HPLC kits have become available for HPLC CDT analysis by Bio-Rad. 
 
The two other methodologies available for CDT detection are Capillary 
Electrophoresis (CE) and immunoassays (e.g. N-Latex) (Delanghe and De Buyzere 
2009; Delanghe et al. 2007).  The CE method is an unspecific, measurement of the 
peptide bond at 200 nm.  This wavelength is not specific for transferrin, which can 
cause interference with C-reactive protein.  This method also has a lower sensitivity 
than HPLC.   However, new methods are being developed.  Currently Kings College 
in London use Capillary Electrophoresis for detection of CDT using the SEBIA 
capillary system (Kings College Hospital 2007). 
 
The third method for CDT detection is the immunoassay technique.  There have 
been various immunoassay techniques, however, the latest technique and the most 
common in use now, is the Dade Behring N-Latex CDT immunoassay (Delanghe et 
al. 2007).  The N-Latex assay is the first direct immunoassay where there is no need 
for separation of the transferrin glycoforms on a mini-column prior to the 
immunoassay (Delanghe et al. 2007).  The function of the N-Latex immunoassay is 
by way of the antibody mAb, which recognizes the transferrin glycoforms which lack 
one or both entire N-glycans.  This means that the N-Latex assay only recognises 
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the following alcohol affected glycoforms; mono, asialo and disalo-transferrin 
(Delanghe et al. 2007).     
 
At present CDT results can be expressed as mg/l, U/l or as a percentage of total 
CDT within the sample.  The reference range for %CDT is 0.8-6%, which 
encompasses all laboratory methods which are currently in use.  CDT is expressed 
as a percentage as this includes the percentage of bound CDT glycoforms within the 
serum sample.  However, each method does have a specific reference range or cut-
off value.  The variation of expression of CDT results is causing confusion for 
researchers and clinicians when diagnosing alcohol dependence.  This is a major 
reason for the need of a standard method for CDT analysis which can be used 
globally.   
 
 
1.5 CARDIOVASCULAR DISEASE AND ALCOHOL CONSUMPTION  
 
The detrimental effects of heavy alcohol consumption have been well documented 
(British Medical Association Board of Science 2008; Catto 2008), however clinical 
and epidemiological evidence have suggested light to moderate drinking is 
associated with a reduced risk of CHD; total and ischemic stroke and total mortality 
in men aged greater than forty years of age and post-menopausal women (Agarwal 
and Srivastava 2001; DiCasteinuovo et al. 2009; Kloner and Rezkalla 2007; 
Lakshman et al. 2009). The effect of alcohol consumption on CVD is independent of 
many other known and suspected risk factors which include smoking, diet, obesity 
and socioecominc status (Meister et al. 2000; Panagiotakos et al. 2005).   
 
The key mechanisms underlying this protective effect are: an increase in HDL 
cholesterol levels, decrease in platelet aggregation via inhibition of prostaglandins 
synthesis and changes in fibrinogen, tissue-plasminogen activator (t-PA) and 
plasminogen-activator inhibitor (PAI)-1 levels, improvement of endothelial function, 
reduction of inflammation and promotion of antioxidant effects (DiCasteinuovo et al. 
2009; Kloner and Rezkalla 2007; Lakshman et al. 2009; Song 2009).  The key 
mechanisms described above are all involved in the reduction of major CVD events 
(myocardial infarction, stroke and atherosclerosis) however the exact mechanism of 
action has yet to be determined  (DiCasteinuovo et al. 2009).  Studies have shown 
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an inverse relationship between HDL to CAD risk, where HDL binds with cholesterol 
in the tissues and may aid in preventing tissue oxidation by LDL cholesterol (Klatsky 
2010).  The effect of this action by HDL reduces plaque build up in the major 
arteries, including the coronary arteries (Klatsky 2010).  Alcohol has been shown to 
inhibit the development of atherosclerotic lesions, via dose-dependent mechanisms, 
in clinical and animal studies (De Gaetano et al. 2002; Haskell et al. 1984; Linn et al. 
1993; Renaud and De Lorgeril 1992; Rimm et al. 1999).  Recently published 
literature suggests that the relationship between alcohol consumption and the 
beneficial effects on CHD are genetic and specifically related to the metabolism of 
alcohol via the alcohol degrading enzymes (Tolstrup et al. 2009), however this 
requires further investigation.   
 
A meta-analysis of 30 cohort studies have shown that the consumption of half a 
measure of a standard drink (24-28 g/day for men and 12-14 g/day for women) per 
day was enough to show a positive effect on reducing CHD risk (Agarwal 2002; 
Agarwal and Srivastava 2001; Meister et al. 2000).  The meta-analysis also 
highlighted that there was no increased beneficial effect of consuming more than 
one standard drink on CHD risk (Meister et al. 2000).  Recent literature has stated 
that the dose of alcohol required to be cardioprotective is one or two drinks per day 
for men and only one drink per day for women (Lakshman et al. 2009).  This 
recommendation was made on a drink being defined as approximately 14 g of 
ethanol, which is equivalent to 12 oz of beer (375 ml), 5 oz or wine (150 ml) or 1.5 
oz (45 ml) of 80-proof spirit (Lakshman et al. 2009).  It is important to note that this 
drink definition is almost double the ethanol content of one alcohol drink in the UK 
(Lakshman et al. 2009).  A standard unit in the UK contains 8 g of ethanol, which is 
equated to 83 ml of 12% wine, 25 ml of spirit or half a pint of 3.6% beer.   
 
The relationship between alcohol and CVD can be described by a J or U shaped 
curve, which can be explained in the following terms: risk is higher when alcohol 
consumption is high, lower when alcohol consumption is low or moderate; however 
the risk increases within individuals who abstain from alcohol consumption (Agarwal 
and Srivastava 2001; DiCasteinuovo et al. 2009; Sander et al. 2005).  Figure 1.4 
represents a graphical interpretation of a J and U-shaped curve in terms of alcohol 
providing a cardioprotective effect 
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Figure 1.4: Graphical interpretation of a J shaped curve.  Adapted from Sander et al. 
2005 
 
A review by Rimm et al. 1996 investigated 12 ecological (Artaud-Wild et al. 1993; 
Criqui and Ringel 1994; Hegsted and Ausman 1988; LaPorte and Cauley 1981; 
LaPorte et al. 1980; Leger et al. 1979; Nanji 1985; Nanji and French 1986; Renaud 
and De Lorgeril 1992; Schmidt and Popham 1981; Werth 1980), 3 case-control 
(Hennekens et al. 1979; Kaufman et al. 1985; Rosenberg et al. 1981) and 10 cohort 
studies (Farchi et al. 1992; Friedman and Kimball 1986; Gronbaek et al. 1995; 
Kagen et al. 1981; Kittner et al. 1983; Klatsky and Armstrong 1992; Klatsky and 
Armstrong 1993; Klatsky et al. 1986; Klatsky et al. 1990; Kozararevic et al. 1980; 
Rimm et al. 1991; Salonen et al. 1983; Stampfer et al. 1988; Yano et al. 1977) 
where strong evidence was reported showing moderate alcohol consumption was 
linked to lower risk of coronary heart disease.  It is important to note that in the 
literature the use of the phrase “moderate” or “light” drinking does not accurately 
refer to the exact measure of alcohol required to induce these beneficial effects 
(Andreasson 1998).  In terms of a public health messages, it is important to move 
away from using terms such as “moderate” to describe beneficial alcohol drinking 
and more towards actual standard measures in either UK units or grams of alcohol.  
 
Alcohol 
Consumption 
CVD
Risk  
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Recent studies have tried to ascertain the risk of CVD with other lifestyle factors 
such as diet and exercise, while also taking into consideration the consumption of 
alcohol (Lakshman et al. 2009; Panagiotakos et al. 2005).  The consumption of 
saturated fat has been well documented to cause an increase in CVD risk and major 
CHD events, however this was not found in France, and has been termed the 
‘French Paradox’ (Lakshman et al. 2009).  In France there is a high consumption 
rate of red wine, which is known to have a high content of antioxidants and 
flavonoids which are known to reduce oxidative stress, and thereby reduce 
endothelial dysfunction (Lakshman et al. 2009).  In several Mediterranean countries, 
it is normal to consume alcohol with a meal, as opposed to in the UK where most 
alcohol consumption takes place socially and not around meal times (Measham and 
Østergaard 2009).  Red wine consumption in several countries has shown inverse 
correlations to CHD mortality (Lakshman et al. 2009) and a clinical trial investigating 
the effects of grape extract showed a beneficial effect on the susceptibility of LDL 
oxidation in heavy smokers, who were at risk of CVD (Vigna et al. 2003).     This 
evidence suggests that the type of alcohol and the pattern of consumption may have 
an influence on the ability of alcohol to act as a protective factor against CVD. 
Studies have shown that drinking wine with meals provided the greatest health 
effects by preventing the development of atheromatous lesions, but also highlighted 
that sessional drinking was associated with a higher risk of CHD (DeJong et al. 
2003; DiCasteinuovo et al. 2009; Kauhanen et al. 1997; McElduff and Dobson 1997; 
Ursini et al. 1998).  The evidence in the published literature does suggest that 
alcohol can have a beneficial effect on the cardiovascular system however, it is 
important to note that the exact volume of alcohol known to be cardioprotective has 
yet to be established.   
 
Alcohol consumption has been linked to increased blood levels of the amino acid 
homocysteine, which is an independent risk factor for CVD (Antoniades et al. 2009; 
Refsum et al. 1998).  Alcohol raises homocysteine levels in two ways, firstly by 
inhibiting the conversion of homocysteine to another amino acid, methionine and 
secondly as a consequence of alcohol-induced vitamin deficiencies, altering its 
metabolism (Bleich et al. 2000a).  It is this accumulation of homocysteine, which 
causes atherosclerosis by a direct effect on arterial tissue resulting in increased risk 
of CHD, stroke and MI (McCully 2001).  As excessive alcohol consumption and 
sessional drinking are associated with adverse cardiovascular risk, the 
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measurement of homocysteine can give an insight into the potential risk of 
developing cardiovascular disease (Song 2009).   
 
1.6 HOMOCYSTEINE  
 
1.6.1 Introduction 
 
Homocysteine is a non-protein forming, sulfhydryl containing amino acid and is an 
intermediate in the remethylation of the amino acid, methionine (Vinukonda 2008).  
The chemical structure is shown in figure 1.5.   
 
 
 
 
 
 
 
 
 
Figure 1.5: Chemical Structure of Homocysteine (Jakubowski 2006) 
 
The metabolism of homocysteine can occur in two ways; either using the 
transsulphuration pathway or the remethylation cycle.  Homocysteine can be 
transsulphurated to cystathionine or remethylated to methionine, and these 
reactions are controlled by enzyme action. Methionine is regenerated by the 
remethylation pathway under the action of methionine synthase (MS).   These 
reactions are dependent on the presence of methylenetetrahydrofolate (MTHF) 
which is controlled by the enzyme methylenetetrahydrofolate reductase (MTHFR) 
and the co-factors tetrahydrofolate (folate) and methylcobalamine (vitamin B12). The 
remethylation and transsulphuration of homocysteine from methionine, in terms of 
chemical structure is shown in figure 1.6.   
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Figure 1.6: Remethylation and transsulphuration of homocysteine in terms of 
chemical structure.  Adapted from McCully (2001).   
 
In 1962 the first homocysteine metabolism abnormality was reported in mentally 
retarded children due to frequent thromboembolic events.  Seven years later it was 
McCully (McCully and Wilson 1975) who descibed the vascular pathology of 
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homocysteinuria, followed by Wilcken and Wilcken 1976 who showed the frequent 
association between abnormal plasma homocysteine and coronary disease.  The 
importance of the pathophysiological actions of homocysteine is illustrated in the 
following lists of conditions: neural tube defects, pregnancy complications, mental 
disorders, cognitive functions, cancer and cardiovascular disease.   
1.6.2 Biochemistry of Homocysteine  
 
The remethylation of homocysteine to methionine is dependent on methionine being 
available in the diet.  Methionine is an essential amino acid, found in meat, milk and 
eggs (Trabetti 2008).  During the remethylation cycle, homocysteine gains a methyl 
group from 5-methylenetetrahydrofolate (5-MTHF) to form methionine, as catalysed 
by methionine synthase.  This reaction requires vitamin B12 and folate, in their 
biologically active forms; tetrahydrofolate and methylcobalamine and are referred to 
as cofactors of the reaction.  This reaction occurs in all tissues.  When this reaction 
occurs in the liver, as methionine is highly active within this organ, another enzyme 
becomes involved; betaine-homocysteine-methyltransferase (BHMT).  It acts as a 
methyl donor (Trabetti 2008).    Methionine is metabolised into s-
adenosylmethionine (SAM) by the enzyme methionine adenosyltransferase (MAT).  
The function of SAM is to act as a methyl donor, where the loss of two methyl 
groups from SAM results in the production of S-adenosylhomocysteine (SAH).  
From SAH, homocysteine is hydrolysed in a reversible reaction by the enzyme S-
adenosylhomocysteine (SAHH).  There is competition between SAM and SAH at 
different binding sites which can inhibit the methylation (Trabetti 2008).  
 
The second metabolic pathway that is relevant to the biochemistry of homocysteine 
is transsulphuration.  In this pathway homocysteine condenses with serine to 
produce cystathionine, by the enzyme cystathionine ß-synthase (CBS). 
Cysthathionine is then hydrolysed to cysteine by the enzyme γ-cystathionase (CYS) 
(Trabetti 2008). Both these reactions require vitamin B6 in the biological form; 
pyrioxidal 5’-phosphate (Trabetti 2008).  This reaction only occurs if there is an 
excess of dietary methionine, as the enzyme methionine synthase becomes 
inhibited, thus activating the transsulphuration pathway (Trabetti 2008).  Figure 1.7 
demonstrates the biochemistry of homocysteine.  
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Figure 1.7: Biochemistry of Homocysteine (adapted from Kharbanda and Barak 
2005 and Vinukonda 2008) 
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Under normal physiological conditions homocysteine formation and degradation are 
balanced; where 50% is remethylated to methionine and the excess homocysteine 
is moved into the circulation (Hankey and Eikelboom 1999).  In the circulation <1% 
of homocysteine is present in its reduced form (Trabetti 2008).  Approximately 10-
20% of total homocysteine is present as homocysteine-cysteine mixed disulphide 
and homocystine (a dimer of homocysteine) (McCully 2001).  The remaining 80-90% 
of homocysteine is protein bound (Trabetti 2008).   
 
1.6.3 History of Homocysteine Discovery 
 
Homocysteine was discovered in 1932, by the American biochemist Vincent 
DuVigneaud (DuVigneaud 1952).  The discovery was made by removing the methyl 
group of methionine, which indicated that homocysteine was an intermediate of 
methionine metabolism.  Homocysteine has the same functional group as the amino 
acid cysteine; specifically sulphydryl, amino and carboxyl groups, but has one 
additional carbon atom, thus naming it homocysteine (DuVigneaud 1952).  The four 
carbon backbone of homocysteine enables formation of an internal anhydride called 
homocysteine thiolactone.  Homocysteine thiolactone is a five member ring which 
forms stable salts with strong acids, but when neutralised with weak bases, the ring 
of bonds opens resulting in the formation of two peptide bonds between two 
molecules of the thiolactone and produces the compound homocysteine 
diketopiperazine.  Homocysteine can be produced from homocysteine thiolactone by 
hydrolysis with strong bases.   
 
It was not until 1962 that the significance of homocysteine was realised.  Children 
with mental retardation, accelerated growth and propensity to thrombosis of the 
arteries and veins were found to excrete homocysteine in urine, a condition known 
as homocystinuria (McCully 2001).  The significance of homocysteine in this 
condition was first realised by the American biochemist Kilmer S. McCully, who 
spent his career developing the theory of homocysteine. 
 
McCully studied a number of cases of homocystinuria in children who died suddenly.  
The first case he studied was an archived case from 1933, where an 8 year old boy 
who was found to have widespread arteriosclerotic plaques and thrombosis of the 
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carotid artery and death was caused by stroke.  McCully hypothesised that 
homocystinuria was due to a deficiency of the enzyme cystathionine synthase, a 
pyridoxal phosphate dependant enzyme (McCully 2001).  McCully investigated a 
second case study of homocystinuria, in 1968, eight years after the initial 
significance of homocysteine was realised, which showed that homocystinuria was 
caused by deficiency in the enzyme methionine synthase which is a folate and 
vitamin B12 dependent enzyme.  This case identified the important potential of 
excess homocysteine to cause atherogenic plaques.  The 1968 case was of a 2-
month old baby boy who had advanced atherogenic plaques in arteries that supplied 
blood to the major organs throughout his body.  From the two case studies that 
McCully analysed, he concluded that due to differences in the enzymes involved, 
homocysteine caused atherosclerosis by a direct effect on the cells and tissues of 
the arteries (McCully 2001).  The conclusion by McCully was furthered due to the 
discovery in later years that homocystinuria was also caused by a deficiency in the 
enzyme methylenetetrahydrofolate reductase (MTHFR), which is shown in figure 
1.7. 
 
Further investigations into the condition, homocystinuria did not occur until 1962 
when investigators in Northern Ireland, began screening the urine of children with 
mental retardation for the presence of amino acids using newly developed 
techniques of paper and column chromatography (McCully 2001).  Several children 
were found to have homocysteine present in their urine, and were diagnosed with 
homocystinuria.   Children with homocystinuria were found not only to be mentally 
retarded but also have accelerated growth, dislocated ocular lenses, osteoporosis 
and a tendency to develop thrombosis in arteries and veins (McCully 2001).  Mudd 
and co-workers at the National Institutes of Health discovered cystathionine 
synthase, the vitamin B6 dependent enzyme, which is a co-factor for homocysteine 
to cystathionine metabolism and was deficient in many cases (McCully 2001).  
Following on from the research conducted by Mudd,   Spaeth and co-workers in 
Philadelphia discovered that vitamin B6 supplementation was an effective treatment 
for homocystinuria (McCully 2001) as this was involved in the transsulphuration 
pathway, shown in figure 1.7. 
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1.6.4 Procedures to Consider when Measuring Homocysteine in Body Fluids 
 
At physiological pH, homocysteine in its reduced form exists in only trace amounts 
in vivo, whereas most homocysteine occurs in various disulfide forms (Ducros et al. 
2002).  Around 70% of homocysteine is bound to albumin, as either protein-bound 
homocysteine or homocysteine-albumin mixed disulfide (Ducros et al. 2002).  The 
remaining 30% exists as mixed disulfides with other thiols.  The most abundant is 
cysteine-homocysteine disulfide (Ducros et al. 2002).  The storage of whole plasma 
and serum causes redistribution of plasma thiols so the protein-bound fraction 
increases at the expense of the free acid soluble fraction (Ducros et al. 2002).  
Determination of free homocysteine requires immediate blocking of free thiols at the 
sampling time, which is not convenient for regular daily laboratory practice.  
Homocysteine is measured as total homocysteine (free and bound) and not free 
homocysteine (Ueland 1995).  The anthropometric and laboratory conditions which 
can affect homocysteine levels are detailed in table 1.9 and 1.10. 
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Table 1.9: Conditions which effect homocysteine analysis (Ducros et al. 2002). 
Fasting 
Conditions  
Blood sampling should be carried out after a fast of 12 hours, with a light meal the evening before (Rasmussen 
and Moller 2000).  A high protein or low protein diet can effect homocysteine measurements (Refsum et al. 
1998; Ueland et al. 1993). 
Influence of Age Plasma homocysteine concentrations are related to age and gender.  An age-related increase of plasma 
homocysteine levels is linked to a decline in glomerular function; as this is known to decrease in functionality 
with age (Norlund et al. 1998).  Also the uptake of B-vitamins declines with age, which influences levels of 
homocysteine, due to the B-vitamins acting as co-factors within the conversion of methionine to homocysteine.   
Influence of Sex Women have a lower homocysteine concentration than men, up until the menopause.  However the influence 
of sex hormones on homocysteine has not been established (Rasmussen and Moller 2000; Wouters et al. 
1995).  The possible differences in plasma homocysteine levels between genders could be explained by the 
higher muscle mass in men and higher creatinine synthesis in men compared to womens due to plasma 
creatinine and homocysteine concentration being significantly correlated in healthy subjects (Ducros et al. 
2002). 
Influence of 
Ethnicity  
The differences in homocysteine concentrations in ethnic groups are not consistent (Rasmussen and Moller 
2000).  However the differences could be explained by the C677T mutation in the methylenetetrahydrofolate 
reductase (MTHFR) enzyme.  There is a variability of this enzyme in ethnic populations, where there is a 10% 
occurrence within the Caucasian population, in comparison to the African and American populations, where 
this mutation is almost absent.  The MTHFR(C677T) polymorphism causes elevated plasma homocysteine 
concentrations, regardless of folate and vitamin B12 status.  
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Table 1.10: Laboratory Conditions which effect homocysteine (Ducros et al. 2002) 
Posture During venepuncture, the participant should be sitting in the supine position.  Two studies suggest that the position can affect 
homocysteine concentration (Rasmussen et al. 1999; Thirup and Ekelund 1999). 
Anti-
coagulant  
The determination of homocysteine is carried out on plasma as opposed to serum.  Homocysteine is constantly produced in the 
erythrocytes which is released to the extracellular compartment.  This is why a faster centrifugation is required and sampling on 
dry ice is avoided (Ueland et al. 1993), as the temperature of dry ice will cause the haemolysis of red blood cells, resulting in the 
inability to produce plasma.  It is therefore recommended that whole blood be stored on wet ice.  The most commonly used 
anticoagulant is EDTA (Ducros et al. 2002). 
Blood 
Storage 
The intra-erythrocyte concentration of homocysteine has been evaluated at 0.8 µM; a level 10 times less than in plasma (Ubbink 
et al. 1992).  The speed of release of homocysteine from blood cells is nearly constant and is independent of plasma 
homocysteine concentrations.  The storage of whole blood at room temperature, before centrifugation can cause the following 
increases in plasma homocysteine levels: for up to 1 hour=10%; 4 hours=20-35% and after 24 hours=60-75% (Fiskerstrand et 
al. 1993; Ueland et al. 1993).   However a study by Houze et al. 1999 showed a lower increase in homocysteine concentration at 
room temperature, where there was a significant increase of 25% between the fourth hour to the tenth hour of storage.  When 
blood samples are drawn into EDTA tubes and stored on ice, total homocysteine is stable for 4 hours (Ducros et al. 2002; 
Fiskerstrand et al. 1993) 
Plasma 
Storage 
After centrifugation, homocysteine is stable for 4 days at room temperature, several weeks at 0-2ºC and years at -20ºC 
(Israelsson et al. 1993; Ubbink et al. 1992). 
Haemolysis  Does not influence plasma homocysteine concentrations and does not increase concentration (Fiskerstrand et al. 1993; Ueland 
et al. 1993). 
Variation  Intra-individual variation range of 7-15% of normal homocysteine plasma concentration (Clarke 1998; Garg et al. 1997). 
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1.6.5. Homocysteine Analytical Laboratory Methodology 
 
Homocysteine can be detected in a variety of different laboratory techniques, which 
include: chromatography, electrophoresis, immunoassay and enzymatic assay 
(detailed in table 1.11).  
 
In regard to the analytical homocysteine chromatography methods the most 
commonly used methods are: Mass spectrometry (MS) with liquid chromatography 
(LC) or gas chromatography (GC), high pressure liquid chromatography (HPLC); 
and ion-exchange liquid chromatography.   
 
1.6.5.1. High Pressure Liquid Chromatography  
 
This is the most commonly used technique.  A major advantage of this method is the 
ability to jointly determine the different plasma thiols compounds along with 
homocysteine.  The HPLC method utalises three different detection techniques, 
which include; photometric, fluorescence and electrochemical.  Overviews of each of 
the HPLC detection methods are described in table 1.12.  The plasma homocysteine 
HPLC-ED method by Houze et al. (2001) and Cummins (2005) was adapted and 
employed for the sample analysis within this thesis.   
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Table 1.11: Analytical methods for homocysteine determination, adapted from Ducros et al. (2002).  
Method Sample Pre-treatment Plasma 
Volume (µl) 
Upper Limit of 
Linearity (µmol/l) 
CV Inter-assay for 
mean total 
homocysteine level 
(%) 
Throughput (per day 
or hour) 
GC-ID-MS High workload and derivatization 100 30-300 2.6, 5.3, 5.7 96/day; 160/day 
LC-MS-MS High workload 100 60 5.9 40/hour 
HPLC-FD High workload and derizatization 
Wavelength range 380-510 
depending on fluorogenic reagent 
60-150 
50 (Bio-Rad) 
50-300 
100 (Bio-Rad) 
3.2 
4.8 (Bio-Rad) 
90/day 
150/day (Bio-Rad) 
HPLC-ED High workload 
Oxidation potential +0.80 volts 
60 100 5.6 60/day 
IEC Medium workload 500 100-1000 7.8 25-50/day 
FPIA None 50 45-50 3.1 20/hour (IMX) 
60/hour AxSYM 
ICL None 15 50 3.9 150/hour 
EIA Low workload 25 50 6.2 96 tests/2.5 hours 
Enzymatic 
method 
Low workload 
None 
100 
5 
80 
100 
2.8 
3.7 
45/hour 
CE-LIF High workload and derivatization 100 200 7.8 100/day 
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Table 1.12: HPLC detection methods used for the analysis of homocysteine (Ducros et al. 2002). 
Detection 
Method 
Overview Advantages Disadvantages 
Photometric The sample is reduced by dithiothretiol, separation of thiols by HPLC and post-column 
derivatization with the 4,4’-dithiodipyridine thiol specific labelling agent and 
subsequent detection of products by ultraviolet detection at 324 nm.  This method 
gives high precision with an intra-assay of 1.5%, inter-assay of 2.5% and sensitivity of 
less than 50 nm.  This technique is commonly used in laboratories where a 
fluorescence detector is not available. 
High sensitivity. Laborious method, 
Modest throughput. 
Flurometric This detection method is the mostly commonly used along with HPLC (Ducros et al. 
2002).  It involves precolumn derivatization with flurogenic reagents for thiols, which is 
then followed by HPLC. For this method the mean within-assay CV is 1% and mean 
between-assay CV is 3.2%.  The reagents used with this method must be 
nonfluorescent, contain no fluorescence impurities and react rapidly and specifically 
with homocysteine and other thiols to form stable products. Examples are: 
monobromobimane (mBrB; excitation 380 nm, emission 470 nm), 
halogenosulfonylbenzofurazans (sBD-F and ABD-F; excitation 380 nm, emission 510 
nm) and o-phthaldialdehyde (OPA; excitation 340 nm, emission 450 nm). 
 
 
 
High sensitivity, 
High precision 
(1.0%; 3.2%). 
High throughput. 
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Detection 
Method 
Overview Advantages Disadvantages 
Electrochemical For this detection no derivatization of thiols is required prior to detection. This method 
does have a higher mean intra and inter assay CV of 3.9% and 5.6% (D'Eramo et al. 
1998).  The reference method was reported by Malinow et al. 1989 and modified by 
Smolin and Schneider 1988.  The assay for detection of total homocysteine using 
HPLC-ED involves the reduction of the biological sample with sodium borohydride, 
separation of thiols by HPLC and detection of non-derivatized thiols with duel mercury 
and gold amalgam electrodes, which has greater specificity towards sulfhydryl 
components (Rabenstein and Yamashita 1989).  The flaw with the Rabenstein and 
Yamashita (1989) method is the possible contamination of flow cells and fouling on 
electrode, causing deterioration, whereby inducing a decrease in the sensitivity of the 
assay.  To combat this problem a gold electrode is now used (Wu et al. 1994).  The 
gold electrode requires less preparation and maintenance, exhibits good sensitivity for 
thiols and does not use toxic mercury.  A commonly and extensively used HPLC-ED 
method for detecting homocysteine in plasma was published by Houze et al. (2001).  
 
High sensitivity; 
high specificity; no 
derivatisation.  
Full automation.  
Precision is less and 
detector 
maintenance 
required. 
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1.6.6 Homocysteinaemia  
 
Homocysteinaemia is defined as the total amount of all homocysteine forms in the 
plasma (tHcy) (Hankey and Eikelboom 1999).  The plasma total homocysteine 
concentration may vary greatly, while intracellular levels have a narrow range (Moat 
et al 2004).  Plasma concentrations are dependent on the diet within a given 
population and can even vary within groups of the same population (Trabetti 2008).  
The range of concentrations of homocysteine found in human plasma are shown in 
table 1.13. 
 
Under physiological conditions, 5-20 mmol of homocysteine is synthesized each day 
(Refsum et al. 1998).  A high percentage of homocysteine is converted to cysteine 
by the enzyme cystathionine β-synthase (CBS) or to methionine.  The CBS enzyme 
regulates plasma homocysteine levels so normal basal concentrations range from 5 
to 15 µM with a mean of 10 µM (Ducros et al. 2002).  The level of homocysteine in 
plasma can be indicative of hyperhomocysteinemia, which is outlined in table 1.13.  
Hyperhomocsyteinemia is defined as the elevation of circulating homocysteine 
above the normal reference range of 5-15 µmol/l in plasma (Hankey and Eikelboom 
1999).   
 
Table 1.13: Plasma concentrations in human plasma (Kang 1995) 
Plasma Homocysteine Range Concentration in Plasma (µmol/l) 
Normal 5-15 
Moderate hyperhomocysteinaemia 15-30 
Intermediate hyperhomocysteinaemia 30-100 
Severe hyperhomocysteinaemia >100 
 
The accumulation of homocysteine can be due to three causes: transsulphuration 
defects based on cysthathionine ß-synthase deficiency; remethylation defects based 
on methionine synthase deficiency and MTHFR deficiency (Trabetti 2008).  Another 
confounding factor in the metabolism of homocysteine is the shortage of cofactors: 
vitamin B6, B12 and folate which can cause elevated levels (Mason and Choi 2005).  
The transsulphuration and remethylation pathways are shown in figure 1.7.     
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Elevated plasma homocysteine can be caused by the following: 
1. Mutations in enzymes of metabolism mainly methylenetetrahydrofolate 
(MTHFR) and methionine synthase (MS) (Maron and Loscalzo 2009). 
2. Nutritional deficiencies of vitamin co-factors such as B6, B12 and folate 
(Maron and Loscalzo 2009). 
3. Diseases such as chronic renal failure, malignancies, acute 
lymphoblastic leukaemia, anaemia, hypothyroidism and diabetes 
(Trabetti 2008). 
4. Physiological factors such as age and gender (Jacobsen 2009). 
5. Pharmaceutical medications which include: methotrexate, phenytoin, 
carbamazepine, nitrous oxide, theophylline, metaformin, colestipol, 
niacin, penicillamina, thiazide and diuretics (Ducros et al. 2002). 
6. Lifestyle factors including smoking, coffee, alcohol consumption, 
alcoholism and physical activity (Ducros et al. 2002). 
 
1.6.7 Pathology Associated with Hyperhomocysteinaemia 
 
As previously noted, hyperhomocysteinaemia has been implicated in the following 
conditions: vascular damage, cognitive impairment, pregnancy complications, 
neurologic and psychiatric complication and neoplastic diseases (Trabetti 2008). 
 
There are common pathogenetic mechanisms which can cause vascular injury, and 
can lead to the manifestation of clinical signs which have been linked with increased 
homocysteine levels.  A review of the literature by Trabetti (2008) has identified the 
key mechanisms, which are described in table 1.14. 
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Table 1.14: Key mechanisms of vascular pathogenesis induced by elevated 
homocysteine (Trabetti 2008). 
Mechanism References 
Oxidative damage of the 
endothelium by the 
suppression of 
vasodilator nitric oxide 
(NO) 
(Chambers et al. 2000; Durand et al. 2001; Harker, 
Harlan, and Ross 1983; Kanani et al. 1999; McCully 
and Ragsdale 1970; McCully and Wilson 1975; Stamler 
and Loscalzo 1992; Starkebaum and Harlan 1986; 
Upchurch et al. 1997; Visioli et al. 2002) 
Promotion of platelet 
activation and 
aggregation 
(Di Minno et al. 1993; Durand et al. 1996; Durand et al. 
1997; Harker et al. 1976; Harpel et al. 1996; Stamler et 
al. 1993; Upchurch et al. 1997) 
Alteration of normal 
procoagulant-
anticoagulant balance 
promoting thrombosis 
(Coppola et al. 1997; Fryer et al. 1993; Hajjar et al. 
1998; Harpel et al. 1996; Lentz and Sadler 1991; Lentz 
et al. 1996; Nishinaga et al. 1993; Ratnoff 1968; 
Rodgers and Conn 1990) 
Impaired methylation of 
homocysteine 
(Bilsborough et al. 2003; Jonasson et al. 2003; Leoncini 
et al. 2003; Stuhhlinger et al. 2003; Upchurch et al. 
1996; Wanby et al. 2003) 
Vascular smooth muscle 
cell proliferation 
(Majors et al. 1997; Tsai et al. 1994; Wang et al. 1997) 
 
Hyperhomocysteinaemia encourages endothelial oxidative damage and dysfunction 
by inhibiting nitric oxide (NO) synthase which decreases the bioavailability of NO 
(Trabetti 2008).  Under normal physiological conditions NO detoxifies homocysteine 
by forming S-nitroso-homocysteine which is a vasodilator.  Excess homocysteine is 
not fully neutralised by NO but is auto-oxidised to homocystine which in turn 
produces free radicals which are toxic to endothelial cells (Trabetti 2008).    Also 
under normal physiological conditions glutathione neutralises free radicals but 
elevated homocysteine decreases glutathione peroxidase activity (Trabetti 2008).  
Another mechanism of endothelial injury is by the reduced catabolism of asymmetric 
dimethylargnine which acts as a strong inhibitor of NO synthase (Stamler and 
Loscalzo 1992; Stuhhlinger et al. 2003; Wanby et al. 2003).   
 
Excess homocysteine can be converted to homocysteine thiolactone, which is a 
thioester of homocysteine.  There is an association between homocysteine-
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thiolactone and low density lipoprotein (LDL) as it produces atherogenic oxidative 
damage to the endothelium (Trabetti 2008).  A report by Chwatko et al. 2007 has 
shown homocysteine thiolactone is elevated in patients who are deficient in the 
enzymes cystathionine ß-synthase and MTHFR.   
 
In patients with hyperhomocysteinaemia, platelets have a normal lifespan of 10 days 
and morphology.  Trabetti et al (2008) has suggested that homocysteine might 
activate platelets which can increase their aggregation and adhesion.  The 
biosynthesis of platelet thromboxane A2 is highly increased in individuals with 
homocysteinuria and the increased production of thromboxane A2 could be the 
cause of an increased risk for thrombosis (Trabetti 2008).   Homocysteine in plasma 
is auto-oxidised to produce free oxygen radicals which initiates lipid peroxidation in 
the endothelial plasma membrane or in lipoproteins (Trabetti 2008).  Platelets are 
activated by oxidised LDL, which is atherogenic.  Studies have shown that 
thrombosis is promoted by homocysteine as it alters the procoagulant-anticoagulant 
balance due to increasing or decreasing the levels of coagulation factors (Trabetti 
2008). 
 
The elevated levels of homocysteine which cause hyperhomocysteinaemia can 
have a negative impact on DNA methylation (Trabetti 2008).  This results in altered 
gene expression which can affect the endothelial and smooth muscle cells of the 
vascular wall.  Several publications have suggested that elevated levels of 
homocysteine can induce proliferation of the vascular smooth muscle cells, which 
can lead to luminal narrowing, whereby reducing blood flow and increasing 
endothelial dysfunction (Trabetti 2008).   
 
Ross et al. (1999) has suggested that excess homocysteine can induce 
inflammation and atherosclerosis.  Homocysteine activates Nuclear Factor-KappaB 
(NF-KB) which induces the expression of monocytes chemoattractant protein 1 
(MCP-1) and interleukin 8 (Poddar et al. 2001; Wang and O 2001; Wang et al. 
2001).  The ability of homocysteine to activate monocytes and cause their 
proliferation will induce the expression of cytokines and the inhibition of the 
expression of macrophage migration inhibitory factors (Su et al. 2005) and thereby 
induce an inflammatory response within the endothelium. 
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A number of lifestyle factors have been shown to elevate plasma homocysteine and 
cause hyperhomocsyteinemia (Panagiotakos et al. 2005).  Alcohol consumption is 
one such lifestyle factor and published literature has shown that alcohol-
dependence can elevate plasma homocysteine levels (Bleich et al. 2000d; Cravo 
and Camilo 2000), however this has not been shown in healthy individuals who 
consume alcohol in a range of patterns.  Figure 1.8 demonstrates the pathway of 
hyperhomocysteinemia from cause to effect. 
 
 
Figure 1.8: Effects of elevated homocysteine adapted from McCully (2001) 
1.6.8 Homocysteine and Alcohol Consumption 
 
Alcohol can have detrimental effects on homocysteine metabolism through the 
following actions: inhibition of methionine synthase by acetaldehyde causing 
elevation of homocysteine (Lutz et al. 2006).  Alcohol consumption also reduces the 
bioavailability  of folate and vitamin B12, which are important co-factors in 
homocysteine metabolism (Lutz et al. 2006).  Chronic alcoholism can induce 
hyperhomocysteinaemia (>100µmol/l in plasma) (Bleich et al. 2004), however the 
influence of sessional drinking is less well described (Chiuve et al. 2005).  Within the 
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18-24 yrs age group, which includes students and young professionals, sessional 
drinking is often the preferred method of consumption (Gill 2002).  The possibility 
that this particular pattern of drinking may, through changes in plasma homocysteine 
levels affect CVD disease risk profile in the early decades of life, requires 
investigation. 
 
There have been two studies published in 2008/2009 which investigated the effect 
of alcohol consumption on homocysteine levels (see appendix 1B).  A study by 
Devika et al. 2008 investigated the effect of alcohol withdrawal in a sample of 
alcohol dependent individuals.  The study by Gibson et al. 2008 conducted an 
intervention using two different types of alcohol (red wine and vodka) for a two week 
period and subsequently analysed homocysteine levels at the end of the 
intervention. 
 
Devika et al. (2008) conducted an alcohol withdrawal study with a sample size of 50. 
Males and females were recruited into either group one, which was an eight week 
detoxification or group two (participants did not undergo a detoxification regime).  
Homocysteine was analysed by ELISA.   Results showed that after detoxification, 
homocysteine levels significantly decreased (p<0.002) within group one participants; 
on admission homocysteine concentration were 26±13.36 µmol/l and after 
detoxification it had been reduced to 14.31±5.7 µmol/l which is within the reference 
range.  It is important to note that the study participants recruited to this study 
received folic acid, vitamin B6 and B12 supplementation, during the detoxification 
regime, which is known to have a reducing effect on homocysteine levels. 
 
The study design adapted by Devika et al. (2008) was similar to a study conducted 
by Bleich et al. 2000a, in Germany, which employed a shorter detoxification over a 
period of 3 days.  The main difference between these studies was that Bleich did not 
supplement his participants with folic acid and vitamin B12 over the detoxification 
period, and still produced data which showed homocysteine reducing over time of 
detoxification (on day one of admission 33.6±25.2 µmol/l; on day three 13.9±8.8 
µmol/l) (p<0.001).  This suggests that without supplementation, plasma 
homocysteine levels can be reduced to within normal reference levels, once heavy 
alcohol consumption has ceased.  A study by Cravo et al. 1996 investigated 
homocysteine in an alcohol dependent sample, however unlike Bleich or Devika, the 
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study which Cravo conducted investigated homocysteine levels with no 
detoxification or intervention.  Cravo found that homocysteine was two times higher 
in a sample of alcoholic dependent individuals compared to controls and that those 
who were abusing beer did have significantly lower levels of homocysteine, 
compared to individuals who were drinking other alcohol beverages heavily (Cravo 
et al. 1996).  This could be due to the higher levels of folate in beer compared to 
other alcoholic beverages (Bleich et al. 2000c).   
  
Gibson et al. (2008) conducted an alcohol “dosing” study, where males were 
recruited into two different groups; group one (N=40) consumed only red wine and 
group two (N=45) consumed only vodka.  Participants were asked to consume 24 g 
(3 UK units) of alcohol daily and were classified as responsible drinkers, according 
to the UK recommended daily consumption guidelines before undertaking the study 
(UK Department of Health 1995).  Homocysteine was analysed by HPLC-FD.  
Gibson found that homocysteine levels increased after the two week red wine 
intervention by 5% (p=0.03), but not in the group receiving the vodka intervention.  
This finding is interesting and not expected as there has been published literature 
showing the positive effects of moderate red wine consumption on increasing 
antioxidant status and reducing plasma homocysteine levels (Tsang et al. 2005).   
The results found by Gibson et al. (2008) were also consistent with published 
literature, whereby when homocysteine levels increase, folate and vitamin B12 
decrease (Antoniades et al. 2009; Refsum et al. 1998).  The study conducted by 
Gibson, is reflective of a study conducted by Bleich, which was published in 2001 
(Bleich et al. 2001).  The study conducted by Bleich was a 6 week alcohol 
intervention, where participants consumed 30 g of beer, wine or spirits daily. At the 
end of the 6 week intervention the results showed that homocysteine significantly 
increased (p<0.02) regardless of which alcohol was consumed.   
 
1.6.9 Homocysteine and B-Vitamins 
 
The B-vitamin family are a group of water-soluble vitamins, found in yeast, germ 
seeds, eggs, liver and vegetables.  B-vitamins have varied metabolic functions 
including growth factors and co-enzymes and are also known as the B-complex.   
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Vitamin B12 and folate are inter-linked through the B12-dependent methionine 
synthase reaction where homocysteine is converted to methionine by donation of a 
methyl group from the circulating methytetrahydrofolate to produce tetrahydrolate 
which is required for thymidine and DNA synthesis.  If there is deficiency of vitamin 
B12 or folate then there is a decrease in DNA.  A deficiency of DNA can lead to the 
presence of immature megaloblasts in tissues such as bone marrow and small 
intestine which have a rapid cellular turnover (Halsted and Keen 1990). 
 
Deficiency of vitamin B12 is not common as the recommended daily allowance 
(RDA) is as low as 1 µg while it is stored in the body to a maximum of 2-3 mg.  If 
dietary intake of vitamin B12 is low then stored vitamin B12 is sufficient to allow 
normal function for several years.  However the levels of vitamin B12 in the serum 
can often be elevated due to displacement of vitamin B12 from the liver and also 
possibly by increased binding to plasma transcobalamin (Halsted and Keen 1990). 
 
Nutritional deficiencies of the B vitamin family, specifically folate and vitamin B12 are 
often associated with high total homocysteine levels which results in 
hyperhomocysteinemia. Vitamin B12 deficiency may result in considerable 
hyperhomocysteinemia which is rapidly normalised after replenishment with the 
specific deficient vitamin (Brattstrom 1996).   
 
Table 1.15: Dietary vitamins and synthetic supplement (Brattstrom 1996) 
Dietary Vitamin Synthetic Supplement  
B12 Cyanocobalamin 
Folate Folic acid 
 
The synthetic oral supplement, listed in table 1.15 can be taken by individuals to 
increase folate and/or vitamin B12.  Several studies have shown oral treatment of 
folic acid (5-10 mg/day) reduces hyperhomocysteinemia by 30-60% (Brattstrom 
1996).  1 mg of folic acid and 0.4 mg cyanocobalamin are sufficient therapeutic 
doses to effectively reduce homocysteine levels (Brattstrom 1996). 
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1.6.9.1 Folate 
 
Folate in the form of tetrahydrofolate (THF) is a substrate and coenzyme in the 
acquisition, transport and enzymatic processing, of one-carbon molecules for amino 
and nucleic acid metabolism and metabolic regulation.  Folate donates one-carbon 
molecules during the methylation of homocysteine to methionine, which is used by 
S-adenosylmethionine in cellular methylation reactions and protein synthesis.  The 
presence of folate is also key in supporting nucleic acid synthesis as it acts as a 
carbon donor during the synthesis of purines and thymidylate and during 
deoxycytoine methylation.  The involvement of folate is also important for the 
interconversion of glycine and serine and during the breakdown reaction of histidine 
to form glutamate.  The normal metabolism of folate is showed in figure 1.9. 
 
Folate and homocysteine levels are affected by gender, where males have 
approximately 25% higher levels of circulating homocysteine compared to females 
(Fabris et al. 2009).  The MTHFR(C677T) genotype in conjunction with low folate 
status, strongly affects homocysteine levels in males and to a certain extent in 
females (Fabris et al. 2009).  Published literature has shown that there is strong 
evidence which suggests that there is a relationship between inadequate folate 
status and an elevated homocysteine concentration, which leads to the subsequent 
risk of the following conditions: coronary heart disease, venous thrombosis, carotid 
artery stenosis, and other cardiovascular diseases (Quinlivan et al. 2006; Stowell et 
al. 1997).     
 
 
 
 
 
 
 
 
 
 
Figure 1.9: Normal metabolism of folate adapted from Mason and Choi (2005).  
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The ingestion of alcohol lowers serum folate levels and impairs haematological 
recovery, which is possibly through a catabolic effect of alcohol metabolism on the 
folate molecule (Halsted and Keen 1990).  Low serum folate levels has been shown 
in more than two thirds of sessional drinkers (Halsted and Keen 1990).  A study by 
Shai et al. 2004 has shown that total homocysteine is inversely associated with 
dietary folate and B vitamins and positively associated with alcohol consumption.  
The acute or chronic consumption of alcohol evokes the inhibition of the enzyme 
MS, as shown in figure 1.10 (Lutz et al. 2006).  Folate and vitamin B12 are substrates 
and co-enzymes of this reaction.  The inhibition of MS by ethanol reduces the 
intracellular concentration of methionine and SAM, but increases the circulating 
concentration of the reaction precursor, homocysteine (Mason and Choi 2005).  It is 
also important to note that alcohol consumption can deplete the levels of circulating 
folate specifically, highlighting that a sufficient volume of THF will not be present to 
act as a co-factor within the reaction (Mason and Choi 2005). 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.10: Effect of alcohol on the metabolism of folate adapted from Mason and 
Choi (2005).  
 
1.6.9.2 Vitamin B12 
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methylmalonyl-CoA mutase for the conversion of methionine to homocysteine 
(Morel et al. 2005).  The metabolism of vitamin B12 is shown in figure 1.11.  Chronic 
consumption of alcohol impairs the uptake and rention of vitamin B12 by the liver and 
other peripheral tissues (Cravo and Camilo 2000). 
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Figure 1.11: Metabolism of Cobalamin (Vitamin B12) adapted from Morel et al. (2005) 
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Thiol derivatives of cobalamin have been identified, and are known as 
thiolatocobalamins.  An important cobalamin thiol derivative is glutathionylcobalamin 
(GSCbl) which was identified in 1960 (Birch et al. 2009).  GSCbl is more active in 
promoting the synthesis of methionine via the enzyme methionine synthase.  This 
suggests that thiolactocobalamins could be more effective in treating conditions 
associated with hyperhomocysteinemia and oxidative stress in comparison to other 
cobalamins (Birch et al. 2009), therefore reducing homocysteine levels by 
supplementation. 
 
The recommended daily intake (RDI) of vitamin B12 is very low, at 2-3 µg.  Vitamin 
B12 is stored within the body for a long period of time, and does not deplete rapidly, 
which results in the low RDI value (Solomon 2007).  Deficiency of vitamin B12 can 
cause megaloblastic anaemia, decline in neurocognitive function, and also adverse 
effects have been reported on bone formation and immune system response 
(Kräutler 2005; Solomon 2007).    
 
1.6.9.3 The Relationship between Homocysteine, Folate and Vitamin B12  
 
Several studies were published in 2008 and 2009 which investigated the impact of 
folate and vitamin B12 supplementation on homocysteine status (Appendix 1C). 
 
Pfeiffer et al. (2008), Stea et al. (2008) and Wotherspoon et al. (2008) conducted 
intervention studies where the diet was supplemented with folate and/or vitamin B12.  
In the study conducted by Stea et al. (2008), plasma homocysteine decreased by 
10% after intervention (p=0.002).  The change in homocysteine concentration was 
inversely related to the change in folate levels.  A similar study conducted by 
Wotherspoon et al. (2008), was a randomised control trial (RCT) where participants 
were randomised to receive; either a 5 mg folate supplement daily or a placebo.  
Data showed that plasma homocysteine levels were reduced by 25% in the group 
which received the folate supplement (p=0.03), however biomarkers of endothelial 
function (NO and prostaglandins) showed no difference after supplementation.   It 
should be noted that the participants who were recruited into the Wotherspoon et al. 
(2008) study were individuals who were diagnosed with type 2 diabetes and 
microalbuminuria.  The results produced from this study, are indicative of this study 
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sample, which might not be reflected in a healthy sample, such as the sample within 
the study by Pfeiffer et al. (2008).  The article published by Pfeiffer et al (2008) 
examined the data from The 3rd National Health and Nutrition Examination Survey 
(NHANES III) survey conducted within the USA before and after folate fortification.  
The data showed that there was a 10% reduction of homocysteine levels within the 
USA sample population after folate fortification was introduced in the country.   
 
The above studies suggest that folate supplementation can successfully reduce 
circulating homocysteine levels and there is an inverse relationship between 
homocysteine and folate.   
 
Another investigation into the relationship between homocysteine, folate, vitamin B12 
and CVD was conducted by Dangour et al. (2008).  The study was conducted within 
an older adult population (age was greater than 75 years) and both genders were 
recruited.  The study found that participants, who had homocysteine levels within the 
highest percentile, had a two times greater risk of all cause mortality in comparison 
to participants who had homocysteine levels in the lower percentile.  The authors 
found no association between folate and vitamin B12 and mortality, but cautioned 
that this could be due to low statistical power (Dangour et al. 2008). 
 
An assessment of folate and vitamin B12 status in adolescents was conducted by Al-
Tahan et al. (2008).  The study found that homocysteine was higher in males, but 
vitamin B12 was higher in females.  Supporting existing literature, Al-Tahan found 
that the presence of the MTHFR polymorphism increases plasma homocysteine as 
serum folate decreases (Frosst et al. 1995).  The study by Al-Tahan et al. (2008) 
also links with the publication by Tanaka et al. (2009) who investigated the genetic 
factors which affect plasma homocysteine, folate and vitamin B12.  Tanaka et al. 
(2009) confirmed by meta-analysis that MTHFR is consistently association with 
homocysteine status. 
 
In the forgoing work the analysis of folate and vitamin B12 were carried out almost 
exclusively by immunoassay (enzymatic and radioimmunoassay) (Al-Tahan et al. 
2008; Dangour et al. 2008; Stea et al. 2008). However alternative methods exist, 
which include colourmetric assay and chromatography.  A study by Mitchell et al. 
(2009) evaluates a method of liquid chromatography-multiple reaction monitoring-
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mass spectrometry (LC-MRM/MS) for identifying folate and homocysteine.  The 
author found that this method produced results with a reduced error and greater 
statistical power, in comparison with the method mentioned previously (Mitchell et 
al. 2009).  This finding should be considered when choosing a methodology for 
folate laboratory analysis.  
 
1.6.10 Methylenetetrahydrofolate Reductase (MTHFR) 
 
The enzyme 5,10-methylenetetrahydrofolate reductase (MTHFR) has a key function 
in the folate cycle and contributes to homocysteine metabolism (see figure 1.7) 
(Fabris et al. 2009).  The MTHFR enzyme catalyzes irreversibly the reduction of 
5,10-methylenetetrahydrofolate (5,10-MTHF) to 5-methyltetrahydrofolate (5-MTHF) 
(Fabris et al. 2009).  5-MTHR is the main circulatory form of folate under 
physiological conditions and acts as a carbon donor during the conversion reaction 
of homocysteine to methionine (Fabris et al. 2009).  Within the MTHFR gene a 
single nucleotide polymorphism (SNP), located on the 1p36.3 chromosome, has 
been identified.  This SNP has introduced a Cysteine to Thymine transition at the 
nucleotide 677 (C677T) in exon (a nucleotide sequence in DNA that carries the code 
for the final mRNA molecule and thus defines a protein's amino acid sequence) four 
which has resulted in an alanine to valine amino acid exchange which affects the 
reaction potential of the enzyme (Fabris et al. 2009; Frosst et al. 1995).  The amino 
acid exchange results in a thermo-labile variant of MTHFR, known as t-MTHFR 
being produced which has a reduced enzyme capacity (Fabris et al. 2009; Frosst et 
al. 1995). Studies have shown that individuals who posses the TT (mutant 
homozygote) or CT (heterozygote) genotype have approximately 30% and 65% 
reduced MTHFR enzyme activity compared to individuals who have the wild-type 
heterozygote CC genotype (Fabris et al. 2009; Frosst et al. 1995; Kluijtmans et al. 
1996).  This reduced enzyme activity in the individuals who posses either mutant 
genotype results in circulating homocysteine level (Fabris et al. 2009), whereby 
highlighting the importance of the MTHFR enzyme activity and its effect on 
circulating homocysteine levels.  Studies within alcoholic dependent patients have 
shown a higher prevalence of the MTHFR polymorphism within this group (Lutz et 
al. 2006).  However this has not been investigated in healthy individuals who 
consume alcohol in a range of non-dependent patterns. 
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1.6.10.1 The Relationship between Homocysteine and the MTHFR Enzyme 
 
A search of the literature found several studies published since 2008 which directly 
associate the effect of the methylenetetrahydrofolate (MTHFR) polymorphism on 
homocysteine status (Appendix 1D). 
 
All studies reported an association between the presence of the MTHFR 
polymorphism and levels of homocysteine.  Alessio et al. (2008) investigated the 
prevalence of MTHFR and CBS in Brazilian children (N=220) and found that the 
677TT, 1298AA and 68WW mutations in the MTHFR gene were associated with an 
increase in homocysteine concentrations.  Folate and vitamin B12 were also 
measured in the sample and were found to not be significantly different in each 
mutation group.  The study concluded that there was a genetic influence which was 
affecting homocysteine concentrations, independently of vitamin B12 and folate 
levels (Alessio et al. 2008). 
 
Yang et al. (2008) conducted a large scale study (N=6793) of participants who were 
genotyped from The 3rd National Health and Nutrition Examination Survey (NHANES 
III) study.  Yang found that in participants who carried the MTHFR polymorphism, 
regardless of ethnicity or race, there was significantly higher plasma homocysteine 
levels coupled with lower serum folate levels.  The study conducted by Yang et al. 
(2008) also investigated alcohol consumption and found alcohol consumption was 
significantly associated with serum homocysteine concentrations, in a sample of 
individuals who consumed alcohol in a range of patterns.  The mean serum 
homocysteine concentration increased from 8.5 µmol/l in abstainers to 9.3 µmol/l 
within participants who consumed ≥7 drinks per week (p=0.0028). The study 
participants who were found to carry the MTHFR(C677T) polymorphism had 22% lower 
serum folate levels and 25.7% higher homocysteine levels compared with an 
individual who carried the CC genotype.  The study also concluded that 
supplementation with folic acid reduced homocysteine levels in individuals carrying 
the MTHFR polymorphism (p<0.001) (Yang et al. 2008).   
 
The importance of MTHFR in relation to CVD was investigated by Grassi et al. 
(2008) and Naess et al. (2008).  Both studies found that the MTHFR(C677T) 
polymorphism, when present, caused an increasing effect on homocysteine 
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concentrations (Grassi et al. 2008; Naess et al. 2008).  Naess et al (2008) found that 
homocysteine levels in men were higher when, MTHFR was present and this could 
predict onset of venous thromobosis.  This association however was not found in 
women.  An important study by Nagele et al. (2008) highlighted the potential effects 
of anaesthesia on homocysteine levels.  Nagele et al (2008) conducted a study with 
140 participants who were undergoing a surgical procedure using nitrous oxide 
(N2O) as anaesthetic.  Participant’s blood samples were analysed for homocysteine, 
folate, vitamin B12 and the MTHFR polymorphism. The study found that participants 
who carried the MTHFR polymorphism C677T or A1298A were at a higher risk of 
developing increased homocysteine levels after undergoing N2O anaesthesia 
(p=0.03) (Nagele et al. 2008). This may have important implications from individuals 
undergoing surgery, especially cardiovascular surgery, where homocysteine may 
already be elevated.    
 
Husemoen et al. (2009) investigated the relationship between lifestyle factors, 
homocysteine and the MTHFR(C677T) polymorphism in a 5 year follow up study.  All 
lifestyle factors were investigated including alcohol consumption and the prevalence 
of the MTHFR polymorphism.  Husemoen et al (2009) found that blood levels of 
homocysteine were not affected by any lifestyle factors including the consumption of 
alcohol, however in individuals who carried the TT polymorphism there was an 
inverse relationship between homocysteine and beer consumption.  This was not 
present within CC/CT individuals.  The presence of the TT polymorphism is found to 
make individuals more susceptible to B-vitamins supplementation, which could 
explain the inverse relationship of homocysteine levels and beer consumption as 
certain types of beer contain a high level of folate (Cravo and Camilo 2000; Cravo et 
al. 1996; Husemoen et al. 2009). 
 
 
1.7. HOMOCYSTEINE AND CARDIOVASCULAR DISEASE RISK 
 
It is widely accepted within the published literature that homocysteine is associated 
with cardiovascular disease (CVD) risk and is independent of other atherosclerotic 
risk factors (Lutz et al. 2006; Refsum et al. 2006).  Homocysteinaemia causes 
increased CVD risk due to several mechanisms: increased thrombogenicity; 
increased oxidative stress; over activation of redox sensitive inflammatory pathways; 
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impaired endothelial function and atherogensis (Antoniades et al. 2009).  Moderate 
hyperhomocysteinaemia occurs in 20-30% of patients with atherosclerosis (Refsum 
et al. 1998).  Homocysteine measured on admission can predict later on-set of CVD 
events, including MI, cardiac death and acute coronary syndromes (Antoniades et 
al. 2009).  This suggests that homocysteine is a good CVD risk predictor in a 
healthy population and also within a population which already has established CVD.     
 
1.7.1 Homocysteine and Potential for Development of Atherosclerosis 
 
Autopsy studies of children dying with homocystinuria in 1964, linked death due to 
thrombosis of arteries and veins in the major organs.  Changes found in arteries 
were attributed to the atherogenic effect of homocysteine on connective tissues 
because of molecular similarity with penicillamine  (McCully 2001).  Penicillamine is 
similar in its chemical structure to homocysteine and can form mixed disulfides with 
sulfhydryl agents that have the potential to induce cell injury within the endothelium.  
The effect of penicillamine has been investigated within the literature and has been 
shown to not effect the endothelium in terms of cell injury (Wall et al. 1980) In 
certain cases of homocystinuria, arterial lesions were described as atheromas, but 
in most reports there was no mention of the relation to atherosclerosis.  The 
tendency of patients with homocysteinuria to develop arterial and venous 
thrombosis was attributed to increased adhesiveness of platelets (McCully 2001).   
 
Atherosclerotic plaques have been induced in monkey and rat animal models 
(McCully 2001).  In the monkey animal model, the animal was deficient in vitamin 
B6, which causes hyperhomocysteinemia due to inhibition of cystathionine synthase, 
which is the enzyme responsible for the conversion of homocysteine to 
cystathionine and is the most common deficiency in cases of homocystinuria 
(McCully 2001).  The rat animal model was deficient in choline, folic acid and vitamin 
B12 (McCully 2001).   Dietary choline deficiency produces hyperhomocysteinemia 
because of an inhibition of transmethylation of homocysteine to methionine, causing 
homocystinuria by methionine synthase deficiency (McCully 2001).  In 1972 a third 
cause of homocystinuria was discovered, a deficiency in the 
methyenetetrahydrofolate reductase enzyme (McCully 1983).  This publication 
supported McCully’s hypothesis that homocysteine can cause plaques by a direct 
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effect on the cells and tissues of the arteries regardless of the enzyme deficiency 
causing hyperhomocysteinemia (McCully 2001). 
 
1.7.2 Homocysteine Theory of Atherosclerosis 
 
During the 1960s no research showed altered protein metabolism had an effect on 
atherosclerosis (McCully 2001).  Work by Moses Suzman, a South African 
cardiologist found pyridoxine (vitamin B6) benefited patients with coronary heart 
disease.  Through collaboration with McCully, Suzman, suggested more research on 
homocysteine and linking an elevation within this amino acid to the aetiology of 
atherosclerosis. 
 
Ignoatowsky conducted experiments in 1908, whereby he induced atherosclerosis 
by feeding rabbits milk, eggs and meats.  Following on from Ignoatowsky’s 
experiments, Harry Newburgh conducted experiments in the early 1920s whereby 
removing all lipids and cholesterol from the meats fed to laboratory animals, so 
meats containing only protein were given, thus showing atherogenesis without lipid 
feeding.  Following this experiment with rabbits, Newburgh infused amino acids 
intravenously in dogs, however they did not show atherosclerotic plaques in the 
arteries.  Methionine and homocysteine were discovered in the early 1920s so the 
relevance of Ignoatowsky’s experiments has only just become relevant.  The 
experiments conducted by Newburgh and Ignatowsky suggested an important role 
in protein feeding and vitamin B6 deficiency, with a suggested role in atherogenesis.   
 
Experiments conducted by Klavins, showed that, homocysteine in a synthetic, man-
made diet fed to rats did not produce arterial plaques (McCully 2001).  The early 
experiments conducted by McCully involved injecting homocysteine into rabbits 
(McCully 1971).  After three weeks of initial injections early fibrous arteriosclerotic 
plaques were demonstrated in coronary arteries.  Rabbits in these experiments were 
also fed cholesterol in their diets which resulted in lipid deposition within these 
plaques, also the diets were deficient in vitamin B6 which increased the severity of 
the plaques.  Increased doses of homocysteine or methionine given to the rabbits 
over a 2 month period resulted in advanced plaques and the death of several rabbits 
from pulmonary embolism, a complication often found in children with 
homocystinuria.  In some of the rabbits, thrombosis and embolism were prevented 
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by injecting vitamin B6.  Feeding rabbits a synthetic diet which contained 
homocysteine and methionine also produced arteriosclerotic plaques and the 
addition of lipids in the form of butter to the diet converted fibrous plaques to 
fibrolipid plaques.  McCully’s in vivo experiments were confirmed by Harker et al. 
(1976) where homocysteine was injected into a primate animal model.  The baboons 
were shown to have endothelial damage, thrombosis of peripheral arteries and 
fibrous arteriosclerotic plaques post injection (Harker et al. 1976).    The results of 
animal experiments in vivo are consistent with the hypothesis which demonstrated 
the atherogenic potential of homocysteine. 
 
Early reports suggest atherosclerosis in the human population is linked to a 
deficiency of vitamin B6.  Food processing has been suggested to cause a 
significant reduction of vitamin B6, folic acid, mineral and fibre (Schroeder 1971).  
McCully found that the processing of foods, milling of grains, canning, chemical 
additives, extraction of sugar and oils from plants were responsible for a widespread 
deficiency of vitamin B6 and folic acid in populations susceptible to vascular disease 
(McCully and McCully 1999). 
 
McCully’s homocysteine theory of atherosclerosis in 1972 proposes that the 
underlying cause of vascular disease is a deficiency disease of B-vitamins as 
opposed to the supposed effects of dietary cholesterol and fats which is the 
traditional diet/heart hypothesis for atherosclerosis.   
 
1.7.3 The Cellular Changes Associated with Arteriosclerotic Plaques Induced 
by Altered Homocysteine Metabolism 
 
Cultured skin cells from patients with homocystinuria, were prepared to aid the 
understanding of the arteriosclerotic plaques induced in homocystinuria and 
experimentally induced atherogenesis (McCully 2001).  Cells were found to be 
deficient in cystathionine synthase.   
 
Naruszewicz (1994) observed that homocysteine thiolactone (thio-ester of 
homocysteine) converts LDL to a small dense form.  These particles are associated 
with increased risk of vascular disease (Naruszewicz et al. 1994).   Homocysteine 
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links to the apolipoprotein B (apoB) protein by a peptide bound homocysteinyl 
groups which causes aggregation and precipitation of the LDL particles.  ApoB is an 
essential primary apolipoprotein of large plasma lipoproteins, very low density 
lipoproteins (VLDL), intermediate density lipoproteins (IDL) and low density proteins 
(LDL) and is produced in the liver (Mahley et al. 1984). The function of 
apolipoproteins is to transport and redistribute lipid among various tissues in the 
body (Kastelein et al. 2006; Mahley et al. 1984).  The presence of apoB has been 
shown in the literature to be a high predictor of cardiovascular disease risk 
(Kastelein et al. 2006).  The resulting homocysteine LDL aggregates are taken up by 
macrophages which form foam cells.  The foam cells deposit in the artery wall, 
which leads to the deposit of cholesterol and fats within the atherosclerotic plaques, 
induced by the effects of homocysteine on arterial cells.  These observations by 
McCully suggest that LDL is a carrier of homocysteine in the pathogenesis of 
atherosclerotic plaques.  Figure 1.12 illustrates this process.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.12: Process of formation of foam cells through the binding of homocysteine 
thiolactone, apoB and LDL particles.  Adapted from Ferguson et al. 1999  
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The first clinical and epidemiological studies within human populations did not 
become available until 1976, when Wilcken and Wilcken (1976) published the first 
human study of homocysteine metabolism in coronary heart disease.  A number of 
major studies have highlighted the potential significance of homocysteine in the 
pathogenesis of atherosclerosis; e.g. Physicians Health Study (1982); Framingham 
Health Study (1948); Nurses Health Study (1976); European Concerted Action 
Project on Homocysteine (1997), Hordaland Homocysteine Study in Norway (1992) 
and British United Provident Association Study (BUPA) (1975-1982) (McCully 2001).  
In 1983 McCully made the following comment: “The decline of cardiovascular 
disease in the United States in the past 35 years can be attributable to the addition 
of vitamin B6 and folic acid to the food supply in the form of voluntary fortification of 
cereals and vitamin supplements”. The changes in diet, particularity through the 
increase in alcohol consumption, which is evident in many countries, particularly the 
U.K. in the past decades, may through a counter productive action on homocysteine 
metabolism challenge the truth of McCully’s above statement at the present time.  
This requires a clearer investigation into the exact effect homocysteine has on the 
cardiovascular system. 
 
1.7.4 Previous Homocysteine and Cardiovascular Disease Studies  
 
The first meta-analysis of the effect of homocysteine on CVD was conducted in 
1995 by Boushey (Boushey et al. 1995).  A study by Verhoef et al. (1998) also 
showed similar results whereby an increase of 1 µmol/l in fasting plasma 
homocysteine has been associated with an increased risk of coronary heart disease 
(CHD) by 10-20%.   There was a strong association between vascular disease and 
elevated homocysteine, whereby 5 µmol/l increase was equivalent to a 20 mg/dl 
increase in plasma cholesterol in terms of Coronary Artery Disease (CAD) risk 
(Verhoef et al. 1998).  Following on from this The Homocysteine Studies 
Collaboration meta-analysis on CAD in stroke patients concluded that a 3 µmol/l 
decrease in homocysteine concentration reduced the risk of CAD by 11% and stoke 
by 19% (The Homocysteine Studies Collaboration 2002).  Clarke and Armitage 2000 
state that a realistic reduction in CVD should be reached by a 10-15% reduction in 
the levels of homocysteine, which is of the greatest clinical and economic interest.  
This finding was also found by Hornberger 1998.   
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A number of studies have illustrated through clinical trials and experiments that diet 
supplementation with folate, vitamin B6 and vitamin B12 have the potential to 
normalise plasma homocysteine levels (Appel et al. 2000; Brunner et al. 1997; 
Jacobsen 1998; Malinow et al. 1998; Vermeulen et al. 2000).  Folate intake of at 
least 0.4-0.5 mg/day with or without vitamin B6 (16.5 mg/daily) and vitamin B12 (0.5 
mg/daily) gives optimal homocysteine concentrations (Homocysteine Trialists 
Collaboration 1998; Malinow et al. 1999).  A definitive answer on the benefit of 
vitamin supplementation on reducing homocysteine levels, can only be achieved 
through the development and design of large scale randomised controlled trials, as 
demonstrated by; Clarke 1998; Clarke and Armitage 2000; Eikelboom et al. 1999; 
Sunder-Plassmann et al. 2000.  This leads onto other studies which concluded that 
reducing homocysteine by 3 µmol/l through folic acid supplementation, could reduce 
the risk of ischemic heart disease by 16%; Deep Vein Thrombosis (DVT) by 25% 
and stroke by 24% (Wald et al. 2002).   
 
Two large scale clinical trials investigating homocysteine lowering and 
cardiovascular disease risk were published in 2006; HOPE-2 (Lonn et al. 2006) and 
NORVIT (Bonaa et al. 2006).  Both of these trials concluded that treatment with folic 
acid and vitamin B12 did reduce homocysteine levels in patients who had been 
previously diagnosed with CVD.  However the reduction of homocysteine levels did 
not reduce the risk of ongoing CVD risk factors.  These studies suggest that even 
though homocysteine levels have actively reduced the risk of CVD, developing 
ongoing related conditions were not reduced.  This indicates that further research is 
required to investigate the exact type of B-vitamin dose and combination needed to 
actively reduce homocysteine concentration and the CVD risk potential.  It is 
important to note that each study reviewed did use different doses of folic acid, 
vitamin B12 and vitamin B6 for their interventions. 
 
1.7.5. Current Homocysteine and Cardiovascular Disease Risk Research  
 
In the last two years there have been more than 30 studies published in peer 
reviewed journals which investigate the relationship between homocysteine and 
cardiovascular disease (see appendix 1E).  Of these studies, five were large scale 
trials with greater than 1000 participants and are summarised in table 1.16 (Albert et 
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al. 2008; Collings et al. 2008; Cui et al. 2008; Ebbing et al. 2008; Min et al. 2009).  
However a large proportion of these studies investigated the relationship between 
homocysteine levels and established cardiovascular diseases such as stroke and 
myocardial infarction in samples already diagnosed with these conditions.   
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Table 1.16: Key studies published in 2008-2009 investigating the relationship between homocysteine and cardiovascular disease. 
Reference 
& Country 
Aim Main Findings  
(Cui et al. 
2008) 
Japan 
Investigate the association of serum 
homocysteine and cardiovascular disease in 
an Asian population. 
At 10 year follow-up there were 444 cardiovascular related deaths.  
Participants within the highest total homocysteine quartile (>15.3 µmol/l) had 
higher mortality, in comparison with the lower quartile (<10.5 µmol/l).  High 
serum total homocysteine level were associated with increased mortality from 
ischemic stroke, coronary heart disease and total cardiovascular disease 
among a Japanese population. 
(Albert et al. 
2008) 
USA 
Investigate intervention of vitamins B6, B12 
and folic acid supplementation in high risk 
women with and without CVD.  
The intervention group’s plasma homocysteine was decreased by 18.5% 
(p<0.001), by a difference of 2.27 µmol/l in comparison with placebo group.  
After the 7.3 year intervention, the combination pill did not decrease the risk 
of CVD events in high risk female, despite a significant decrease in plasma 
homocysteine. 
(Ebbing et 
al. 2008) 
Norway 
Investigate the dosing of folic acid, vitamins 
B12 and B6 on patients with coronary artery 
disease and aortic valve stenosis. 
Mean plasma total homocysteine concentrations were reduced by 30% after 1 
year of treatment in the groups receiving folic acid and vitamin B12.  The trial 
was terminated early because of concern among participants due to 
preliminary results from a contemporaneous Norwegian trial, suggesting 
adverse reactions from the intervention.  The trial did not find any effective 
results for the treatment of folic acid/vitamin B12 or vitamin B6 on total mortality 
or cardiovascular events.   
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Reference 
& Country 
Aim Main Findings  
(Collings et 
al. 2008) 
Finland 
Investigate whether common risk variables 
interact with the connexin (Cx37) C1019T 
polymorphism causing possible interactions 
with early markers of atherosclerosis  
Homocysteine in subjects with the TT genotype were found to be associated 
with higher flow mediated dilatation (FMD) values (p for interaction 0.038).  
Study concluded the effect of smoking and homocysteine levels on arterial 
endothelial functions and elasticity were modified by the allelic variation of the 
Cx37 gene.   
(Min et al. 
2009) 
Korea 
Evaluate the usefulness of baseline 
homocysteine levels for predicting the risk of 
short or long-term cardiovascular events 
after successful coronary stenting. 
After multi-variate logistic analysis, homocysteine levels, female sex, 
hypertension, multivessel diseases, American Heart Association lesion type 
B2/C and stent length were independently associated with peroiprocediral MI.  
Study concluded that preprocedural levels of homocysteine were an 
independent predictor for preprocedural MI and death or MI after successful 
coronary stenting. 
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The Japan Collaborative Cohort (JACC) Study for Evaluation of Cancer Risk, was a 
large 10 year follow-up trial (Cui et al. 2008).  At the 10 year follow up stage of this 
study, there were 444 CVD related deaths.  The subsequent data analysis showed 
that individuals with the highest plasma homocysteine levels (>15.3µmol/l) had 
greater mortality.  Cui et al. (2008) concluded that high homocysteine levels were 
associated with increased mortality from ischemic stroke, CAD and CVD in a 
Japanese population.  Similar results were shown in a study conducted by Bonaa et 
al. (2006). 
 
A randomised double blinded placebo controlled trial conducted by Albert et al. 
(2008) was designed whereby folic acid, vitamin B12 and vitamin B6 were given as 
supplements to women (N=5442) aged greater than 42 years.  The 7.3 year 
intervention found that the folate, vitamin B12 and B6 intervention did not reduce CVD 
risk, even though there was a 18.5% reduction in the plasma homocysteine levels 
(p<0.001).  There was a 2.27 µmol/l difference in homocysteine concentrations 
between the intervention and placebo group.  A similar trial was conducted by 
Ebbing et al. (2008) with a sample population who had an established diagnosis of 
CAD and/or aortic value stenosis.  This trial was terminated before conclusion, 
because preliminary data showed that plasma homocysteine was reduced by 30% 
in the intervention group, but the intervention of supplementation with folic acid, 
vitamins B12 and B6 did not decrease CVD risk, even in the presence of reduced 
homocysteine levels.   
 
Studies have also been conducted in samples of young adults, to determine 
homocysteine levels.  Collings et al. (2008) investigated lifestyle factors on early 
makers of atherosclerosis in a population of young adults (N=1440).  Data was 
examined from the Cardiovascular Risk in Young Finns study.  The study data 
analysis showed that participants with the MTHFR TT genotype had a higher 
association with flow mediated dilatation (FMD) (p for interaction 0.038). 
 
The literature search resulted in a low number of studies which investigated 
cardiovascular disease risk and homocysteine levels in healthy individuals who have 
varying degrees of alcohol consumption and other lifestyle factors (appendix 1E).  
The literature search also highlighted the number of studies which investigated 
homocysteine levels in samples of individuals with established CVD (Freitas et al. 
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2008; Keles et al. 2009; Shammas et al. 2009; Vaya et al. 2008).   These studies 
investigated the levels of homocysteine in samples of individuals where CVD is 
established, with the aim of investigating if homocysteine can act as a biomarker for 
possible CVD events.   Min et al. (2009) found that homocysteine was not an 
independent predictor for determining risk of CVD events after coronary artery 
stenting.  This data was presented as a poster abstract and very limited 
methodology was available.   The published studies which are listed in appendix 1E 
investigated homocysteine levels in samples of patients with established CVD, did 
consistently show that homocysteine, either within serum or plasma, was at a higher 
concentration within individuals who were exhibiting signs of cardiovascular disease.   
 
The studies which investigated actively reducing homocysteine levels in either 
samples, where CVD was established (Albert et al. 2008; Arnesen et al. 1995; 
Ghosh et al. 2009; Saposnik et al. 2009) or in healthy individual samples (Cui et al. 
2008; Ebbing et al. 2008), concluded that homocysteine in either serum or plasma 
was significantly reduced by folic acid, vitamin B6 and/or vitamin B12 intervention, 
however a reduction in overall risk of developing CVD was not found.   
 
The use of folic acid at a dose of 400 µg/day, has a positive effect on the vascular 
wall, by improving endothelial function, lowering intracellular redox states and 
improving the elastic properties of large vessels in vivo (Antoniades et al. 2009).  
This was found to be effective in patients with CAD (Antoniades et al. 2009).  
However, increasing the dose of folic acid to 5 mg/day, did not increase the positive 
effects on the vascular wall and endothelium, therefore rendering this higher dose to 
be ineffective (Antoniades et al. 2009).  This can be explained as both a high (5 
mg/day) and low (400 µg/day) dose induce a similar level of 5-MTHF in the vascular 
endothelium, even though a higher level of 5-MTHF is induced in the plasma using 
the 5 mg/day higher dose, therefore a lower dose of 400 µg/day is just as effective.   
 
Recently published literature on the effect of high dose folic acid on the myocardium 
within a model of ischaemia and reperfusion has shown positive effects (Antoniades 
et al. 2009; Moens et al. 2008).  The cardioprotective effects of folic acid are 
potentially due to the preservation of high energy phosphates and endothelial nitric 
oxide synthase (eNOS) coupling, improvement of myocardial redox and prevention 
of mycocardial cell death (Moens et al. 2008).  However this work is preliminary and 
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more research is needed to demonstrate the full effect of folic acid on the 
myocardium.  
 
Another possible reason why folic acid supplementation does reduce homocysteine 
levels, but not over all CVD risk, could be the enhancement of the methylation 
pathway, when excess folic acid is administered (Antoniades et al. 2009).  Increased 
methylation of arginine residues increases asymmetrical dimethylarginine (ADMA) 
levels, which can adversely affect clinical outcomes, by inhibiting or uncoupling 
eNOS (Antoniades et al. 2009).  In addition to the inhibiting or uncoupling of eNOS, 
the altered methylation of cells can impact on gene expression; whereby 
hypermethylation of the promoter region of several pro-atherogenic genes, can 
result in the up regulation of pro-atherogenic molecules (Antoniades et al. 2009).  
Another important reason why CVD risk is not reduced by folic acid supplementation 
is through the involvement of folic acid in the synthesis of thymidine, which can lead 
to cell proliferation and so to worsening atherosclerosis (Antoniades et al. 2009).   
 
The reduction of homocysteine in plasma by 25-30% can be achieved by a daily 
dose of 400 µg of folic acid (Antoniades et al. 2009).  Homocysteine plasma levels 
can be further reduced by another 7% by the additional dose of 0.02-1 mg daily of 
vitamin B12 (Antoniades et al. 2009).  Recent clinical trials by Bonaa et al. (2006) 
and Lonn et al. (2006) did not show an achievable reduction in CVD risk using the 
above supplementation doses, however a large scale clinical trial has yet to be 
conducted within a healthy patient sample, where there is no CVD present and key 
lifestyle factors such as alcohol consumption have been measured.  The evidence in 
the literature that alcohol consumption, in a range of patterns has an increasing 
effect on plasma homocysteine levels and therefore detrimental effects on the 
cardiovascular system, suggests that a large scale Randomised Controlled Trial 
(RCT) investigating the effect of different patterns of alcohol consumption on plasma 
homocysteine and the subsequent risk of cardiovascular disease risk is required.   
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1.8 AIMS 
 
The aim of this thesis was to investigate the effect of non-dependent and 
dependent patterns of alcohol consumption on cardiovascular disease (CVD) 
risk, though the measurement of the CVD risk biomarker, homocysteine. 
 
The consumption of alcohol can be categorised into pre-defined patterns using the 
guidelines set out by the UK Department of Health (UK Department of Health 1995).  
These guidelines and alcohol drinking patterns led to the following objectives: 
1. To recruit a sample of individuals representing a range of consumption 
patterns; abstainers (consume no alcohol or less than 1-2 alcoholic drinks 
per year), responsible drinkers (consume no more than 16-24 g (female) or 
24-32 g (male) daily), sessional drinkers (consume >48 g (female) or >64 g 
(male) daily) and alcohol-dependent individuals (diagnosed as being 
dependent on alcohol by a medical professional and undergoing a medically 
supervised detoxification).  
2. Categorise participants drinking patterns using alcohol consumption 
questionnaires and detailed analysis of drink diaries where appropriate.  
Carbohydrate-deficient transferrin (CDT) has been shown to be effective as a 
biomarker of alcohol consumption when monitoring alcohol abstinence in samples of 
alcohol dependent individuals who are undergoing detoxification and alcohol 
withdrawal (Jeppsson et al. 2007).  However, the use of CDT as a biomarker of 
alcohol consumption in a sample of individuals who consume alcohol in non-
dependent patterns is less well investigated.  This has led to two objectives which 
will:  
3. Investigate the levels of serum CDT in individuals previously assigned to the 
alcohol dinking patterns identified above.   
4. To develop a HPLC method for the detection of CDT in serum at Queen 
Margaret University using a published method (Helander et al. 2003). 
Published literature has established homocysteine as a biomarker of cardiovascular 
disease (CVD) risk (Antoniades et al. 2009).   Evidence has also highlighted that 
plasma homocysteine increases during the consumption of alcohol, as shown in 
alcohol-dependent patients (Bleich et al. 2000b), but this is less well investigated in 
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individuals who consume alcohol in a range of non-dependent patterns (Gibson et 
al. 2008), therefore an aim is to:   
5. Investigate the effect a range of alcohol drinking patterns have on plasma 
homocysteine levels.   
The detection of homocysteine in body fluids has been shown to be most commonly 
undertaken in serum or plasma.  However, there have been publications which 
suggest that homocysteine can be detected in urine, which is a less invasive sample 
to collect (Thomson and Tucker 1986; Thomson and Tucker 1985).   Therefore an 
objective is to: 
6. Develop and then validate a method for the detection of homocysteine in 
urine using high pressure liquid chromatography (HPLC). 
Circulating levels of homocysteine in plasma have been shown to increase in the 
presence of the MTHFR(C677T) polymorphism (Bennouar et al. 2007). However the 
prevalence of the MTHFR(C677T) polymorphism has not been investigated in a sample 
of Scottish drinkers, or been investigated in association with plasma homocysteine 
levels.  Therefore an objective was to: 
7. Determine if the presence of the MTHFR(C677T) polymorphism affected 
plasma homocysteine levels and to estimate its prevalence within a sample 
of Scottish drinkers, who were both dependent and non-dependent on 
alcohol.   
The metabolism of homocysteine is dependent on two vitamin co-factors; folate and 
vitamin B12 (Mason and Choi 2005).  It has been established that the consumption of 
alcohol lowers and depletes the circulating levels of folate and vitamin B12 in vivo.  
However, this finding has not been investigated in a sample of healthy individuals 
who consume alcohol in a non-dependent pattern (Mason and Choi 2005)  
Therefore, the final objective was to:   
8. Investigate the levels of folate and vitamin B12 in the sample of individuals 
who consume alcohol in a range of patterns and also within the sample of 
alcohol dependent individuals and to investigate potential associations 
between the two vitamin co-factors and plasma homocysteine.  
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This materials and methods chapter relates to the following three studies: Healthy 
Individuals Study (HI), Alcohol Dependant Individuals (ADI) Study and the Stability 
Study. 
 
2.1 Healthy Individual (HI) Study 
2.1.1 Ethical Approval 
 
Queen Margaret University (QMU) and Napier University Ethics Committee gave 
favourable ethical opinion for the study entitled “Varying alcohol drinking patterns in 
healthy individuals (HI)” (Appendix 2A, 2B and 2C) on the 29th March 2007 and 29th 
May 2007 respectively. 
 
2.1.2 Research and Development (R&D) Approval  
 
Research and development approval was not applicable for the HI study, as the 
recruitment for this study was not undertaken within the National Health Service 
(NHS) and did not involve NHS Lothian staff, patients or facilities. 
 
2.1.3 Study Protocol 
2.1.3.1 Inclusion and Exclusion Criteria  
 
The inclusion criteria for participants in the healthy individuals (HI) studies were as 
follows: 
 
Inclusion Criteria 
• male or female aged 18 to 50 years  
• in general good health 
 
The inclusion criteria were justified due to the literature evidence on alcohol 
consumption within the age range of 18 to 50 years (Catto 2008).  The 18 year 
minimum age for inclusion into the study was due to ethical reasons, as it would be 
unethical to recruit participants for this type of research who are below 18 years of 
age.  The literature evidence suggest that sessional drinking occurs prominently in 
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the 18-25 year group, which includes students, graduates and young professional, 
identifying this as a key group to investigate in terms of drinking patterns and the 
subsequent comparison to the study biomarkers (Catto 2008; Gill 2002).  The 
Alcohol Statistics 2009 report highlights that 60% of males and females aged 
between 16-24 years consume more than twice the recommended daily limit of 
alcohol (NHS Scotland 2009).  Furthermore by recruiting an older age group (26-50 
years), this allows for a comparison to be undertaken in terms of alcohol drinking 
patterns and the study biomarkers levels between the two groups.   The maximum 
age limit for the HI study was 50 years and this is justified by evidence within the 
Alcohol Statistics 2009 report, which shows that alcohol consumption declines after 
50 years of age within the Scottish population (NHS Scotland 2009).   By recruiting 
only participants who have self-reported they are in good health, this minimises any 
other medical conditions affecting the potential correlation between alcohol 
consumption and the study biomarkers.   
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Table 2.1: HI Study Exclusion Criteria 
Exclusion Criteria Reason for Exclusion 
Pregnant, trying to become pregnant or 
breast-feeding 
Unethical to conduct this type of research 
on women of child bearing age due to 
possible risk to mother and baby 
(European Medicines Agency 2009; 
World Medical Association 2008). 
Self-reported history of cardiovascular 
disease 
 
Potential confounding effect of pathology 
on homocysteine biomarker (Antoniades 
et al. 2009). 
Self-reported history of cancer 
 
Potential effect of pathology on normal 
metabolism (Ducros et al. 2002). 
Self-reported diabetes mellitus 
 
Participants would be unable to fast for 
blood sampling (Ducros et al. 2002). 
Self-reported gastric or duodenal ulcers 
 
Potential confounding effect on nutritional 
absorption and could be damaging 
fasting for blood sampling (Ducros et al. 
2002). 
Self-reported liver or gall bladder 
disease  
 
Potential effect of liver dysfunction on 
homocysteine and CDT biomarker levels 
(Antoniades et al. 2009; Das et al. 2008).  
Self-reported known history of blood 
borne viruses  
To minimise the risk to the researcher 
through needlestick injury (Health 
Protection Scotland 2010; NHS Lothian 
2008). 
 
However in the case that a blood borne viral infection was not disclosed and if a 
needle stick injury occurred, occupational prophylactics were available for the PhD 
researcher.  The practices employed by the researcher while collecting data and 
blood samples were influenced by the safety code published by the Social Research 
Association, along with QMU safety guidelines (The Social Research Association 
2001).  This included always carrying a mobile telephone, informing the PhD 
researcher’s supervisory team of her location, when consenting and asking 
participants to complete study questionnaires and further more when in a room with 
a participant, the PhD researcher was always positioned nearest to the door.   
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Participants for the HI Study were also screened for the 5,10-methylene-
tetrahydrofolate reductase (MTHFR(C677T)) polymorphism, which is a common 
genetic polymorphism found in more than 1% of the general population. The 
mutation in the gene which produces the enzyme MTHFR, prevents homocysteine 
being metabolised into methionine, resulting in an abnormally high circulating 
homocysteine concentration. If a participant was found to be positive for the 
MTHFR(C677T) polymorphism, they were informed by letter and advised to contact 
their general practioner (GP).  They were at this point also asked to give their 
permission for their data to be analysed in a separate group, by signing and 
returning a second consent form.  This was a protocol deviation from the original 
information shown in appendix 2G, but was approved by the QMU research ethics 
committee and a modified information sheet was generated as shown in appendix 
2H. 
 
The inclusion and exclusion criteria were detailed on the information sheet 
(Appendix 2G and 2H), which every participant was given to read before consenting 
to undertake this study.  Once a participant had decided to take part in this study, a 
consent form was dated and signed by the participant and researcher (Appendix 2I).   
 
2.1.3.2 Recruitment of Participants 
 
Participants for the HI study were recruited from QMU and Napier University in 
Edinburgh.  QMU has a 77% female student population, compared to Napier 
University, where 54% of students are female.  It is therefore anticipated that 
recruitment from QMU would be biased towards females and formed part of the 
exploratory nature of the HI study.     Recruitment was undertaken using the 
university controlled institutional e-mail system (which were vetted by information 
technology staff within the university then sent out to all students and/or staff on the 
university email system), posters and advertisements on student-centred official 
university intranet pages.   Recruitment was directed to both staff and students from 
each institution and was carried out from May 2007 until March 2008.  Emails were 
sent out to all staff and students via the QMU Moderator Email System for the 
duration of the 10 month recruitment period of the HI study.  A permanent poster 
advertisement was placed on the Student and Staff Intranet pages of Napier 
University for the HI study recruitment period.  Appendix 2F details the email and 
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poster advertisements employed.  Potential participants were not offered any 
payment for taking part in the HI study, which is in line with similar studies, 
published in the literature that did not offer payment for taking part in research 
(McMahon et al. 2007).  Furthermore budget restraints prevented payment for 
participation being offered.  There is however evidence in the literature that does 
suggest that paying potential participants, does increase recruitment rates and 
retention (Gul and Ali 2010).  Participants who consented to taking part in the study 
and had to travel to either QMU or Napier University for study appointments were 
offered reimbursement for their travel expenses.       
 
2.1.3.3 Sample Size 
 
Alcohol dependence has been shown in the literature to increase plasma 
homocysteine levels (Bleich et al. 2000d), however the effect of non-dependent 
alcohol drinking on plasma homocysteine levels has not been established within the 
literature.  The HI study was deemed to be an exploratory study, to determine if non-
dependent drinking would induce a change in plasma homocysteine levels within 
healthy individuals, therefore a sample size calculation was not applicable.     
 
2.1.3.4 Recruitment Procedures  
 
At the beginning of the study, participants who met the inclusion and exclusion 
criteria, were asked to attend a pre-study interview, where a consent form (Appendix 
2I) and study questionnaire (Appendix 2L) were completed and signed.    At this 
initial meeting, blood sampling appointments were also arranged.  The study 
questionnaire was used to categorise each participant according to their age and 
alcohol drinking pattern.  Table 2.2 details the potential categories which participants 
were assigned to. 
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Table 2.2: Participant’s alcohol consumption categories 
Group 
Number 
Gender Age Group (Years) Alcohol Drinking Pattern 
1 Male 18-25  Abstainer 
2 Male 18-25 Responsible Drinker 
3 Male 18-25 Sessional Drinker 
4 Male 26-50 Abstainer 
5 Male  26-50 Responsible Drinker 
6 Male 26-50 Sessional Drinker 
7 Female 18-25 Abstainer 
8 Female 18-25 Responsible Drinker 
9 Female 18-25 Sessional Drinker 
10 Female 26-50 Abstainer 
11 Female 26-50 Responsible Drinker 
12 Female 26-50 Sessional Drinker 
 
Participants were categorised as abstainers if they consumed one or less alcoholic 
drinks per year.  Participants were categorised as a responsible drinker if they drank 
within the UK recommended drinking guidelines, e.g. 3-4 units/day (24-32 g/day) for 
a man and 2-3 units/day (16-24 g/day) for a women (UK Department of Health 
1995).  Participants were categorised as sessional drinkers if they consumed more 
than 6 units (48 g) (female) and 8 units (64 g) (male) on a single occasion (NHS 
Scotland 2009).  In the UK one alcohol unit is defined as 8 g of pure ethanol (UK 
Department of Health 1995). 
 
Each participant recruited to the HI study was given a timetable for the length of the 
study (table 2.3).  This detailed when they would be required to keep a diet and 
alcohol diary and also when blood sampling appointments were due.  Diet and 
alcohol diaries are required to be completed, to collect data on food and alcohol 
consumption, during the 7-day monitoring period.  Participants were provided with a 
7-day diet diary, which would be completed 7 days prior to blood sampling on day 8 
(Appendix 2M).  Diet diaries for the 3 month and 6 month time-points would be 
mailed to participants near to their scheduled blood sampling appointment for the 
later study time-points.   
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Table 2.3: HI Study Timetable given to Participants 
Timetable What is required of participant 
Questionnaire and 
Introduction. Meeting at a 
place and time most 
convenient to the participant. 
You will be asked to complete a questionnaire and will be given a urine sample container and a 7-day 
alcohol and diet diary.  Female participants will be asked to return the questionnaire in a pre-paid 
envelope.  The diet and alcohol diary should be completed for the seven days prior to the blood 
sampling appointment on day eight,   
Day 1 (Baseline) at QMU You will be asked to bring to the meeting a waking urine sample, and the completed alcohol and diet 
diary.  Fasting* blood sample will be taken, by the PhD researcher.  You will be given another 7-day 
diet and alcohol diary, to complete for the seven days prior to blood sampling on day eight. 
An appointment for 3 months time will be made to return to QMU for blood and urine sampling. 
Day 2 (Three months from 
date of baseline sampling) at 
QMU 
You will be asked to bring to the meeting a waking urine sample, and the completed alcohol and diet 
diary.  Fasting* blood sample will be taken, by the PhD researcher.  You will be given another 7-day 
diet and alcohol diary to complete for the seven days prior to blood sampling on day eight. 
An appointment for 3 months time will be made to return to QMU for blood and urine sampling. 
Day 3 (Six Months from date 
of baseline sampling) at QMU 
You will be asked to bring to the meeting a waking urine sample, and the completed alcohol and diet 
diary.  A final fasting* blood sample will be taken, by the PhD researcher. 
*You should not eat 12 hours before the time of your blood sampling appointment. For example if your appointment is at 8 am you should eat nothing 
after 8 pm the previous night.  Once the blood sample has been taken you will be offered a soft drink and biscuits before you leave. 
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2.1.3.5 Study Questionnaire 
 
The HI study questionnaire is shown in Appendix 2L.  The study questionnaire was 
piloted among a selected group of staff and students from QMU (N=10).  The group 
was asked for feedback on the questionnaire, regarding ease of completion and 
understanding of each question.  After feedback was complete from the pilot group, 
no changes were required.  For this study the questionnaire was designed to gain 
information relating to participant’s self-reported drinking frequency, pattern and 
volume consumed.   
 
The study questionnaire is a three page document with nine questions, designed to 
be completed in 10 minutes.  The first section of the questionnaire collected 
demographic information, including age, gender and occupation (i.e. student or 
employee). The questions in section two were designed to collect information on the 
amount of alcohol consumed, either in units or grams, which could then be 
compared quantitatively to the study biomarkers.  The questions on alcohol 
consumption were designed in reflection to other alcohol consumption 
questionnaires used by the UK Government (Office of National Statistics) and other 
health screening bodies and have been published in the literature (Catto 2008; 
Goddard 2001). Validated questionnaires which are used as screening tools, 
including AUDIT and CAGE were not used, as these questionnaires screen for 
alcohol dependency and problem drinking and do not give information on units or 
grams of alcohol consumed.   Retrospective questionnaire data could then be 
compared to data from diet diaries which were completed prospectively.   
 
Female participants only were asked to complete the last page of the questionnaire, 
which related to the participant’s menstrual cycle and contraceptive use.  To respect 
female’s privacy, the option to complete this section, of the questionnaire in private, 
was given. This information was included in the questionnaire as the literature 
suggests a link between menopausal status and homocysteine levels (Russo et al. 
2008). 
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2.1.3.6 Biological Sample Collection 
2.1.3.6.1 Venepuncture and Blood Sample Processing  
 
A fasting blood sample was taken from each participant at three pre-arranged time 
points.  Participants were asked to fast for 12 hours prior to their blood sampling 
appointment. 
 
Each participant was asked to sit in an upright position with their chosen arm 
outstretched and supported by a pillow.  A 21G (Greiner Bio-One, Brunel Way, 
Stroudwater Business Park, Stonehouse, GL10 3SX) hypodermic needle was 
inserted into a suitable vein in the anti-cubital fossa.  Blood (9 ml) was withdrawn 
into an EDTA vacuette (Greiner Bio-One) and 16 ml of blood withdrawn into two 
serum clot activator vacuettes (Greiner Bio-One). 
 
Serum clot activator vacuettes were placed in a refrigerator (to allow whole blood to 
clot), for 30 minutes.  Following this, the serum clot activator vacuettes were 
centrifuged (Jouan BR3.11, Jouan Ltd, 10 rue Duguay Trouin, 44807 Saint-Herblain) 
at 3000 rpm (1000 g) for 10 minutes at room temperature, to produce serum.  
Serum was aliquoted into 1.5 ml eppendorf tubes (Fisher Scientific, Bishop Meadow 
Road, Loughborough, Leicestershire, LE11 5RG) and stored at -80 ºC, awaiting 
CDT analysis by the HPLC method outlined by Helander et al. (2003) and combined 
Folate/Vitamin B12 assay at the Royal Infirmary, Edinburgh. 
 
Anticoagulated blood (5 µl) was removed from the EDTA vacuette prior to 
centrifugation for DNA extraction (Rudbeck and Dissing 1998).  EDTA vacuettes 
(Greiner Bio-One) containing anti-coagulated blood were centrifuged (Jouan) at 
3000 rpm (1000 g) for 5 minutes at 4 ºC to produce plasma.  Plasma was aliquoted 
into 1.5 ml eppendorf tubes (Fisher Scientific) and stored at -80 ºC, awaiting 
homocysteine analysis by HPLC (Cummins 2005; Houze et al. 2001). 
 
Serum and plasma samples from HI study participants were stored at -80 ºC.  Urine 
samples from HI study participants were stored at -20 ºC.  All biological samples 
collected from HI study participants were stored at QMU.   
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2.1.3.6.2 Urine Collection  
 
Participants were asked to produce a waking urine sample on the morning of their 
blood sampling appointment.  Urine was collected in 30 ml universal containers 
(Fisher Scientific) and stored at -20 ºC, awaiting homocysteine analysis by HPLC 
 
2.1.3.6.3 Diet Diary Analysis 
 
Each participant in the HI study was asked to record their diet and alcohol 
consumption for 7 days leading up to blood sampling on day 8.  Participants were 
supplied with a diet and alcohol diary which were adapted from Gregory et al. 1995 
(appendix 2M).  In total, participants each recorded three diet and alcohol diaries 
over the course of the 6 month HI study, at the baseline, 3-month and 6-month time-
points. 
 
Participants completed 7 day prospective diet diaries which were analysed using 
WinDiets 2005 (WinDiets Research Version, Univation Ltd; c/o The Robert Gordon 
University; CREDO; Schoolhill; Aberdeen; AB10 1FR).  Diet diaries were used to 
analyse folate and vitamin B12 intake (section 2.4.6) as well as alcohol consumption 
(section 2.3).  For the diet diary analysis a selection of random participants (N=7) 
were chosen to have their complete diet diaries analysed using WinDiets and the 
results of this analysis compared with the biological folate and vitamin B12 levels.  
This enabled a comparison of the data and permit investigation of the level of 
agreement between folate and vitamin B12 intake compared with the levels found in 
vivo. 
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2.2 Alcohol Dependent Individual (ADI) Study  
2.2.1 Ethical Approval 
 
NHS Research Ethics Committee (LREC 02) gave favourable ethical opinion for the 
study entitled “CVD and alcohol biomarker measurements in alcohol-dependant 
individuals (ADI)” (Appendix 2D) on the 20th July 2007.   
 
2.2.2 Research and Development (R&D) Approval 
 
The Lothian NHS Trust granted research and development approval for this study 
on 27th September 2007 (Appendix 2E). 
 
2.2.3 Study Protocol 
2.2.3.1 Inclusion and Exclusion Criteria 
 
The Inclusion criteria for the ADI study were as follows: 
• Male or female aged 18-55 years  
• Patients undergoing alcohol detoxification as an out or in-patient of the 
Alcohol Problems Service (APS) in Edinburgh. 
• Prescribed Chlordiazepoxide, which is a benzodiazepine, to control and aid 
withdrawal symptoms. 
 
The protocol for the ADI study was based on a previously published study by Bleich 
et al. (2000) and the inclusion criteria reflected the Bleich protocol.  The maximum 
age limit for the ADI study was increased after advice from the collaborating clinician 
at the APS, due to a higher prevalence of individuals who are admitted to the in-
patient clinic, being over the age of 50 years.   
 
The exclusion criteria for the ADI study are shown in table 2.4.   Patients were 
screened by the admissions doctor, for the exclusion criteria before being offered 
the study information sheet.  Patients in the ADI study did not self-report to the 
researcher any medical conditions outlined in table 2.4.  The prescribing of the two 
B-vitamin supplements, Pabrinex and Thiamine were also recorded (dose per day).  
Thiamine (vitamin B1) is routinely prescribed as an oral supplement to alcohol-
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dependent individuals, whereas Pabrinex (vitamins B1, B2, B6, B3, (nicotinamide) and 
vitamin C) is given as an intra muscular injection when patients exhibit severe 
malnutrition symptoms; including diarrhoea, vomiting or have unsteady gait, 
peripheral neuropathy, or any signs of brain damage. The prescribing of Thiamine 
and Pabrinex is by the clinical judgement of the admission doctors and not 
prescribed as the result of blood test results.  Thiamine and Pabrinex preparations 
do not not contain vitamin B12 or folic acid.   
 
The safety of the researcher during the data collection of the ADI study is explained 
in section 2.1.3.1.   
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Table 2.4: ADI Study Participant Inclusion and Exclusion criteria  
Exclusion Criteria Reason for Exclusion 
Trying to become pregnant, pregnant or 
breast-feeding 
 Unethical to conduct this type of research 
on women of child bearing age due to 
possible risk to mother and baby 
(European Medicines Agency 2009; 
World Medical Association 2008). 
History of alcohol withdrawal seizures; 
being prescribed anticonvulsants and/or 
history of alcohol-induced cerebral 
disease or lesions 
Literature suggests withdrawal seizures 
can affect homocysteine concentrations 
(Bleich et al. 2000a).   
Prescribed methotrexate Inhibits the action of folic acid.  Risk factor 
for hyperhomocysteinaemia (Bleich et al. 
2001). 
Prescribed folate supplements Folate supplementation would affect 
folate assay results (Bleich et al. 2000d) 
History of cardiovascular disease Potential confounding effect on 
homocysteine metabolism (Ducros et al. 
2002). 
History of cancer Potential effect on normal metabolism 
(Ducros et al. 2002) 
Diabetes mellitus Unethical to ask patient to provide a 
fasting blood sample (World Medical 
Association 2008). 
Gastric or duodenal ulcers Potential effect on nutritional absorption 
and could be damaging fasting for blood 
sampling (Ducros et al. 2002). 
History of established liver cirrhosis 
from medical history 
Change in liver metabolism due to 
disease process (Bleich et al. 2000d). 
Known history of blood-borne viruses To minimise the risk to the researcher 
through needle stick injury (Health 
Protection Scotland 2010; NHS Lothian 
2008). 
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The safety of the researcher while undertaking the ADI study followed the same 
guidelines as stated in section 2.1.3.1.  Patients within the ADI Study were also 
screened for the MTHFR(C677T) polymorphism.  As this screening was the same for 
HI study participants, the same conditions applied, as detailed in section 2.1.3.1.   
 
The inclusion and exclusion criteria were detailed on the information sheet 
(Appendix 2J), which every participant was given to read before consenting to 
undertaking this study.  Once a participant had decided to take part in this study, a 
consent form was dated and signed by the participant and PhD researcher 
(Appendix 2K).  
 
2.2.3.2 Recruitment of Participants  
 
Participants for the ADI study were recruited as either out-patients undergoing 
detoxification from the Alcohol Problems Service (APS) or from in-patient 
admissions to the Ritson Clinic, which is an alcohol detoxification ward, within the 
Royal Edinburgh Hospital.   Recruitment was undertaken by admission doctors from 
the alcohol problems service (APS), who used their clinical judgements to approach 
patients who they deemed clinically suitable for the study and met the inclusion and 
exclusion criteria.   The ADI study was overseen and supported by Dr Jonathan 
Chick, consultant psychiatrist at the APS.  Recruitment was carried out from October 
2007 until December 2008. 
 
2.2.3.3 Sample Size  
 
The ADI study design was reviewed by QMU statistician, Mr Robert Rush.  The 
required sample size for the ADI study was calculated to be 31 which reflects the 
large effect size of 0.55 between days 1 and 3 in homocysteine levels, and the 
proposed paired T-test analysis with an attrition of approximately 10%.  A previous 
study by Bleich et al. (2000) has shown an effect size of this magnitude is 
achievable with an effect size of approximately 1.0 from day 0 to day 3.   
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2.2.3.4 Recruitment Procedures  
 
At the beginning of the study, participants who met the inclusion and exclusion 
criteria as determined by the APS admissions doctor, were asked if they wished to 
undertake the study.   If verbal consent was given by the patient, the researcher was 
then contacted and an appointment for the next morning was organised.  In the 
event that verbal consent was given, the patient was advised by the admissions 
doctor to fast for the blood sample, which would be taken the following day.   On 
Day 1 of the study the PhD researcher met with the patient, where the consent form 
(Appendix 2K) and study questionnaire (Appendix 2N) were completed, day 1 
fasting blood samples were taken and a waking urine sample was given.  The study 
questionnaire is a three page document, designed to be completed in 10 minutes.  
The participant was then informed of the study timetable, which is shown below in 
table 2.5. 
 
Table 2.5: ADI Study Timetable for Participants: 
Timetable What is required of participant 
Questionnaire at the Ritson Clinic or 
Alcohol Problems Clinic (Out-patients).  
Day 1 (Baseline) at Ritson Clinic or 
Alcohol Problems Clinic (Out-patients). 
You will be asked to complete a 
questionnaire. 
Female participants will be asked to 
complete a section of the questionnaire 
in private. 
Fasting* blood sample will be taken, by 
PhD researcher. 
Waking urine sample. 
Day 3 at Ritson Clinic or Alcohol 
Problems Clinic (Out-patients). 
Fasting* blood sample will be taken, by 
PhD researcher. 
Waking urine sample. 
* You should not eat 12 hours prior to your blood sampling appointment.   
 
Female participants were asked to complete the last page of the questionnaire in 
private as this related to the participants menstrual cycle and contraceptive use.  To 
respect female’s privacy and confidentiality, the option to complete this section, of 
the questionnaire in private, was given.   
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2.2.3.5 ADI Study Questionnaire 
 
The ADI study questionnaire is shown in appendix 2N.  The study questionnaire was 
piloted among the clinical staff of the Ritson Clinic, which included the nursing staff, 
admissions doctors and Dr Chick (consultant).  The medical staff were asked to give 
their clinical opinion of the functionality and ease of completeness and 
understanding of each question and the questionnaire as a whole.  After feedback 
from piloting the questionnaire to clinic medical staff, no changes were made to the 
questionnaire.   
 
The study questionnaire is a three page document with twelve questions, designed 
to be completed in 10 minutes.  The first section of the questionnaire collected 
demographic information, including age, gender and smoking status. The following 
section asks questions’ relating to the length of time the participant has been 
dependent on alcohol, followed by the type, frequency and grams of alcohol 
consumed on a typical drinking day.   The questions in the study questionnaire were 
used to gauge the amount of alcohol patients consumed, prior to entering alcohol 
detoxification treatment and were based on similar questions asked within the study 
by Bleich et al. (2000).  Validated questionnaires including AUDIT and CAGE were 
not used as the patient sample were already clinically diagnosed as being alcohol-
dependent.  The retrospective questionnaire was used at baseline for detailing 
alcohol consumption of the ADI patients who agreed to participate in the study.  
Patients were asked to detail their alcohol consumption pre-admission to the 
detoxification ward (volume of alcohol consumed of a typical day), frequency of 
consumption, type of alcohol consumed and the date of their last alcohol drink.  
 
Female participants were also asked to give details relating to their menstrual cycle, 
contraceptive use and menopausal status as described in section 2.1.3.5. 
 
2.2.3.6 Biological Sample Collection 
2.2.3.6.1 Venepuncture and Blood Sample Processing  
 
A fasting blood sample was taken from each participant on day 1 and day 3 (see 
table 2.5).  Participants were asked to fast for 12 hours prior to their blood sampling 
appointment. 
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Venepuncture and blood sample processing was conducted as described in section 
2.1.3.6.1.  Due to NHS standardised venepuncture practises, the blood collection 
system known as Monovette was used (Sarstedt Ltd, 68 Boston road, Beaumont 
Leys, Leicester, LE4 1AW).   
 
The medication which study participants were prescribed was recorded from 
admission (day 0) to completion of study (day 3).  The only medications recorded 
were chlordiazepoxide, thiamine and Pabrinex. 
 
Serum, plasma and urine for the ADI study was stored at the Alcohol Problems 
Service clinic at 35 Morningside park, Edinburgh.   Serum, plasma and urine were 
stored at -20 ºC.  According to the review by Ducros et al. (2002) serum, plasma 
and urine can be stored at -20 ºC or -80 ºC, without affecting the stability of 
homocysteine.  
 
2.2.3.6.2 Urine Collection  
 
Participants were asked to produce a waking urine sample on the morning of their 
blood sampling appointment.  Urine samples were stored as described in section 
2.1.3.6.2. 
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2.3 Alcohol Consumption Analysis 
 
This section describes the methods for analysing the alcohol diaries which 
participants were asked to complete for the HI study.  The questionnaires for both 
the HI and ADI studies, used the Alcohol Manufacturers (AM) method to analyse the 
grams alcohol consumed, stated in questions six and nine respectively.   
 
Each participant kept an alcohol diary for seven days prior to their blood sampling 
appointment, on day eight.  In the diet diary, each participant recorded all alcoholic 
beverages they consumed, including where possible if the beverage was self-
poured, the volume, the percentage Alcohol by Volume (%ABV) and the alcohol 
brand name.   
 
Participant’s alcohol consumption was calculated using three different methods:  
1. According to the method adapted by the Office of National Statistics (ONS) 
questionnaire (Goddard 2001).  ONS questionnaires quantify alcohol 
consumption in terms of unit content per drink, for example: one alcohol unit 
is defined as half a pint of beer/lager/cider, small glass of wine or one 
measure of spirit (Goddard 2001). 
 
2. WinDiets 2005 dietary software (WinDiets Research Version, Univation Ltd).  
Analysis using WinDiets software provides a data output showing the grams 
of alcohol consumed per day by each participant.  The software provides a 
list of alcohol beverages, which the researcher selects, from information 
provided by the participants.  This is shown in figure 2.1.  WinDiets software 
then calculates the grams of alcohol consumed daily and over the duration of 
the diet diary period.  WinDiets however does not provide alcohol information 
in relation to %ABV of alcohol consumed, but more simply as a type of 
alcohol e.g. cider, beer, lager.  Also it does not take into account of the wide 
variety of drinks with a range of %ABV regularly consumed in the UK, e.g. 
11% ABV white wine.   
 
3. Using the information recorded by each participant within their diet diary this 
was then analysed using Alcohol Manufacturers (AM) information. The third 
method, was created by the researcher, where all common branded drinks 
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commercially available in the UK were listed and the grams of alcohol were 
calculated per volume of alcoholic beverage that is available or served in 
licensed premises; for example, pint, half pint, large measure or small 
measure.  This method was recorded in the form of a spreadsheet (Appendix 
2O).  The most common brands of alcoholic beverage were selected from 
www.drinkaware.co.uk and major supermarkets.  Any alcoholic beverage 
that a participant consumed that was not already recorded in the 
spreadsheet was added.  The following formula was used to calculate the 
grams of alcohol in each volume that was consumed: 
 
No of UK Units in Alcoholic Drink = %ABV x Volume of drink (ml)/1000 
 
Grams of Ethanol in Alcoholic Beverage = No of U.K. Units X 8  
 
 
Figure 2.1: Alcoholic beverages provided by WinDiets 2005 
 
Participant’s alcohol diaries and questionnaires were analysed according to the 
standard measures listed in tables 2.6 and 2.7.  When a participant recorded a 
brand name of alcohol, that specific brand was used for the analysis.  In the cases 
where a participant did not record the brand name of the alcoholic beverage they 
consumed, a standard % ABV measurement was used from table 2.7. 
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Table 2.6: Standard Measures  
Standard Alcoholic Beverage Measure Volume (ml) 
Small Measure 25 
Large Measure 50 
Small Wine Glass 175 
Large Wine Glass 250 
Pint 568 
Half Pint 284 
Can 440 
Bottle (beer/lager) 330 
Bottle (wine) 750 
 
Table 2.7: Standard %ABV 
Alcoholic Beverage %ABV 
Wine 12 
Champagne and Sparkling Wine 12 
Beer 4 
Cider/Perry 5 
Lager 5 
Light Spirit 37.5 
Dark Spirit 40 
Fortified Wine 18 
Designer Drink or Ready to Drink (RTD)  
e.g. Smirnoff Ice or WKD 
5 
 
 
Each participant’s number of drinking days were recorded from their diet diary and 
alcohol consumption during drinking days was calculated using each of the three 
analytical methods.  In addition the number of drinking days and alcohol free days 
within the period of the alcohol diary were recorded. 
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2.4 Laboratory Analysis 
 
This section describes the laboratory analytical techniques which were undertaken 
for the HI and ADI studies.   
 
2.4.1 Method Development for the Detection of Carbohydrate-Deficient 
Transferrin (CDT) in Serum 
 
Method development was carried out at QMU and also at the Edinburgh Protein 
Production Facility (EPPF) within the University of Edinburgh.  The Edinburgh 
Protein Production Facility is supported by The Wellcome Trust and the Scottish 
University Life Sciences Alliance. 
 
2.4.1.1 HPLC Apparatus 
 
At QMU the chromatography system consisted of a Waters 1525 Binary HPLC (High 
Pressure Liquid Chromatography) Pump (Waters) and a Waters 717 plus 
Autosampler (Waters).  The CDT metabolites were detected by a Waters 2465 
Ultraviolet (UV) Detector (Waters) at a wavelength of 470 nm.  The UV detector was 
connected to a Dell computer which controlled the HPLC data acquisition and 
integration using Breeze data management software (Waters).  Separation and 
quantification of CDT was performed on a Clarity Wax column 150 x 4.6 mm 
(Phenomenex). 
 
At the EPPF, the chromatography system consisted of an ÅKTA Purifier 10 HPLC 
(High Pressure Liquid Chromatography) pump with a buffer preparation and an eight 
position buffer value (GE Healthcare, Pollards Wood, Nightingales Lane, Chalfont 
St, Giles, Bucks, HP8 4SP). The CDT metabolites were detected by a UV900 
Ultraviolet (UV) Detector (GE Healthcare) at a wavelength of 470 nm.  The UV 
detector was connected to a Dell computer which controlled the HPLC data 
acquisition and integration using Unicorn data management software (GE 
Healthcare).  Separation and quantification of CDT was performed on a Clarity Wax 
column 150 x 4.6 mm (Phenomenex). 
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2.4.1.2 Preparation of Samples 
 
For method development pooled serum samples were used, which were collected 
for the quality control stability study.  The pooled serum samples used for the CDT 
method development were excess samples collected and utilised for the method 
development.   
 
Samples were thawed overnight at 4 ºC and centrifuged (Microfuge 22 R Centrifuge, 
Beckman Coulter) at 6000 rpm (3500 g) for 5 minutes at 4 ºC before analysis.  
Serum (100 µl) was mixed with 20 µl of Ferric Nitrilotriacetic acid (FeNTA) (Sigma) 
solution.  The FeNTA solution was prepared using 275 mg Nitrilotriacetic (NTA) 
(Sigma) and 270 mg Ferric Chloride (FeCl3) (Sigma) which were dissolved in 90 ml 
of distilled water and pH adjusted to 7.0 with 1 mol/l Sodium Hydroxide (NaOH) 
(Sigma).  Distilled water was added to give a final volume of 100 ml.  The FeNTA 
solution was stored at 4 ºC.  Dextran Sulphate-Calcium Chloride (CaCl2) (both 
Sigma) solution was prepared using equal volumes of 20 g/l dextran sulphate and 
1.0 mol/l CaCl2, and was stored at 4 ºC.  To the sample 20 µl of Dextran Sulphate-
CaCl2 was added and after gentle mixing, samples were left in the cold (4 ºC) for 30-
60 minutes.  The use of Dextran Sulphate-CaCl2 as a lipoprotein precipitating agent 
has been reported in the literature and has an efficiency of between 90-95% at 
removing lipoproteins from serum (Walton and Scott 1964).   Samples were then 
centrifuged at 6000 rpm (3500 g) at 5 ºC for 5 minutes.  The prepared serum sample 
was centrifuged at 5 ºC to keep the temperature constant after addition of Dextran 
Sulphate-CaCl2 solution.  Supernatant (100 µl) was diluted with 400 µl of distilled 
water and transferred to a glass HPLC vial for HPLC at QMU.  The diluted serum 
sample was injected manually onto the HPLC instrument at the EPPF, using a 1 ml 
syringe.  The serum sample was diluted with distilled water, so as to keep the 
sample within the reference range of transferrin, which has been established as 0.5-
5.0 g/l in serum (Helander et al. 2003).     
 
During the method development of this assay, the sample preparation was altered to 
increase the iron saturation and lipid precipitation within the serum sample.  This 
section of the method development was a result of the first HPLC sample runs, 
which showed that the transferrin glycoforms which were eluting from the column 
were not fully iron saturated.  The sample preparation was altered to increase the 
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volume of FeNTA solution from 20 µl to 40 µl and the volume of the lipid 
precipitation solution was also doubled to 40 µl.  The rest of the sample preparation 
remained the same.    
 
It is important to state that standards were not used as they were not commercially 
available.  Therefore the retention time was based on the times published in the 
paper by Helander et al. (2003).  The lack of standards for CDT HPLC analysis has 
been reported in the literature and clearly stated in the method paper by Helander et 
al. (2003), which was the basis for this method development.  Recent publications 
have stated that a standard of disialotransferrin, will soon become commercially 
available (Oberrauch et al. 2008). 
 
2.4.1.2.1 QMU Mobile Phase Gradient  
 
The mobile phase was developed according to the method of Helander et al. (2003).  
The Water HPLC system which was used for this method at QMU consisted of two 
pumps and two buffer lines, which resulted in the mobile phase gradient being 
altered from the original method.  The aqueous mobile phase consisted of two buffer 
solutions: 10 mmol/l Bis-Tris adjusted to pH 6.2 with 2 mol/l HCI (buffer A) and 2.0 
mol/l NaCl (buffer D) adjusted to pH 6.2 with 2mol/l HCI.  The mobile phase was 
degassed in a bath type sonicator (Decon).  The mobile phase ran as a gradient 
according to table 2.8, as developed from Helander et al. (2003). 
 
Table 2.8:  Mobile Phase Gradient Profile for CDT HPLC Method adapted from 
Helander et al (2003).  
Time (Min.Sec) Buffer A % Buffer D % 
0.00 100 0 
1.00 100 0 
30.00 95 5 
30.01 0 100 
35.00 0 100 
35.50 100 0 
37.00 100 0 
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2.4.1.2.2 EPPF Mobile Phase Gradient  
 
The HPLC (GE Healthcare) instrument at the EPPF consisted of two pumps and 
multiple buffer inlet lines, which allowed for the gradient to be set up as per the 
method by Helander et al. (2003).  The aqueous mobile phase consisted of four 
buffer solutions: 10 mmol/l Bis-Tris adjusted to pH 7.0 with 2 mol/l HCI (buffer A); 10 
mmol/l Bis-Tris and 0.5 mol/l NaCl, pH adjusted to 6.2 (buffer B); 10 mmol/l Bis-Tris 
with pH 6.2 (buffer C) and 2.0 mol/l NaCl (buffer D).   Each mobile phase buffer 
were filtered through 0.2 µm filters (Scientific Laboratory Supplied Ltd, Wilford 
Industrial Estate, Nottingham, NG11 7EP) and degassed under vacuum.  A mobile 
phase gradient according to the published method was programmed into the HPLC 
instrument at the EPPF, shown in table 2.9.  As part of the method development of 
this assay a second mobile gradient profile was developed and adapted from the 
published method and this shown in table 2.10. 
 
Table 2.9: Mobile phase gradient profile for CDT HPLC method at EPPF (Helander 
et al. 2003). 
Time 
(Min.Sec) 
Buffer A % Buffer B % Buffer C % Buffer D % 
0.00 100 0 0 0 
1.00 100 0 0 0 
1.01 0 0 100 0 
30.00 0 20 80 0 
30.01 0 0 0 100 
35.00 0 0 0 100 
35.50 100 0 0 0 
37.00 100 0 0 0 
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Table 2.10: Developed and adapted mobile phase gradient profile for CDT HPLC 
method at EPPF (Helander et al. 2003). 
Time 
(Min.Sec 
Buffer A % Buffer B % Buffer C % Buffer D % 
0.00 100 0 0 0 
1.00 100 0 0 0 
1.01 0 0 100 0 
30.00 0 100 0 0 
30.01 0 0 0 100 
35.00 0 0 0 100 
35.50 100 0 0 0 
37.00 100 0 0 0 
 
2.4.1.3 Running Conditions 
 
At both QMU and the Edinburgh Protein Production Facility (EPPF), HPLC was 
performed at room temperature (21 ºC).  Flow rate was 1.0 ml per minute.  Under 
these conditions and according to the published method by Helander et al. (2003), 
the peaks representing the CDT glycoforms eluted approximately at the following 
times: disialotransferrin eluted at 16 minutes; trisialotransferrin eluted at 18 minutes; 
tetrasialotransferrin eluted at 21.5 minutes and hexasialotransferrin eluted at 26.5 
minutes, with a total run time of 40 minutes. 
 
2.4.1.4 Fractionation  
 
A benefit of the GE Healthcare HPLC within the EPPF, was the ability to collect 
fractions over the period of the HPLC run.  During the method development of this 
assay, the mobile phase gradient which is shown in table 2.10, produced the most 
evident peak of the transferrin protein, however this was a single peak, as opposed 
to the anticipated, four peaks, of each of the transferrin glycoforms.  The HPLC 
method programme was altered to include the collection of fractions during the run. 
The volume of fraction which was collected was 250 µl.   To identify the exact 
content of the peak which eluted at 15 minutes, fractions were collected across this 
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peak, as shown in figure 2.2.  Fractions which were collected were 1E8, 1E9, 1E10, 
1E11, 1E12, 1F1, 1F2, 1F3.  The fractions collected were then subsequently 
analysed using protein gel electrophoresis and mass spectrometry. 
 
 
Figure 2.2: Fractions collected using HPLC with UV detection (X-axis: Retention 
time (minutes); Y-Axis: Wavelength (nm) 
 
2.4.1.5 Protein Gel Electrophoresis 
 
The approximate molecular weight of each of the fractions obtained in 2.4.1.4 were 
analysed using pre-prepared 4-20% Polyacrylamide LongLife gels (NuSep Ltd, 22 
Rosborough Road, Frenchs Forest, NSW, 2086, Australia) which identified the 
approximate molecular weight of each fraction collected by HPLC with UV detection.  
The LongLife gels were placed within a Mini-Protean Tetra Cell electrophoresis tank 
(Bio-Rad) and filled with 1X Tris-Hepes SDS running buffer (NuSep).  Each well was 
flushed with running buffer before samples were loaded to ensure the sample 
completely filled each well.  TruSep sample loading buffer (NuSep) (10 µl) was 
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added to each 10 µl fraction sample and mixed well to ensure homogeneity.  Within 
each well 20 µl of sample was aliquoted.  For each gel a 250 kDa Precision Plus 
Protein Standard (Bio-Rad) marker was used to identify band size.  Gel 
electrophoresis was carried out at 150 volts for 40 minutes.  Once electrophoresis 
was complete the gels were removed from the plastic casing and washed every 5 
minutes over a 15 minute period, in distilled water.  During the washing process the 
gels were placed in plastic sealed containers containing distilled water and placed 
on a Gyro-Rocker SSL3 bench top shaker (Stuart Scientific), to facilitate the 
washing process. 
 
Polyacrylamide gels were stained with Instant Blue, which is a Coomassie based 
staining solution for protein gels (Generon Ltd, Rawcliffe House, Howarth road, 
Maidenhead, Berkshire SL6 1AP).  Gels were subjected to staining for 10 minutes 
then rinsed with distilled water and returned to the Gyro-Rocker SSL3 bench top 
shaker (Stuart Scientific) for 1 hour before photography; this was to ensure all stain 
was removed and banding allowed to develop. 
 
Polyacrylamide gels were photographed under white light using a Gel Doc XR Gel 
Scanner Molecular Imager (Bio-Rad).  Quantity One V4.6.5 software (Bio-Rad) was 
used to identify protein bands.   
 
2.4.1.6 Desalting and Concentration of Fractions 
 
Mass spectrometry is a sensitive technique used to detect the presence of a specific 
protein within biological samples.  The content of salt within a serum sample can 
cause interference within the mass spectrometry analysis; the de-salting of serum 
samples reduces the interference thus providing a more detailed mass spectrometry 
identification.  Also, by concentrating the fractions, by removing excess water and 
salt the sample therefore becomes more potent in terms of protein concentration, 
aiding the mass spectrometry analysis.   
 
Desalting of the fractions involved subjecting each sample to a run through a 
desalting column, to remove all salt content from the fraction sample.  As this 
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method involved a high sodium chloride buffer, this was an important step to 
achieve a more detailed and clearer mass spectrometry result. 
 
The column used was a HiTrap Desalting column (GE Healthcare).  The mobile 
phase used was 20 mM ammonium acetate (Fisher Scientific) at pH 6.8.   
Ammonium acetate was used as the mobile phase buffer during the desalting 
process, as the literature suggests that the transferrin protein is stable within this 
buffer (Estela de Castillo Busto et al. 2005). The fraction sample (250 µl) was 
manually injected directly into the HPLC system using a 1 ml syringe (BD Plastipak).  
Flow rate was 5 ml per minute.  The HiTrap column, removed all salt ions from the 
sample, and the protein elutes from the column separately due to its larger 
molecular weight.  The protein fraction, which is now free of salt, was collected as 
fractions into a 96-well Masterblock plate (Grenier Bio-One) in volumes of 250 µl. 
 
To increase the concentration of the fractions which were free of salt ions, the 
fractions were subjected to a concentrating procedure, where all excess ammonium 
acetate buffer was removed, thus making the sample a purer protein sample.   
Before use, the VivaSpin 500 30 KDa Molecular Weight Concentrating eppendorfs 
(Scientific Laboratory Supplies Ltd) were washed with ammonium acetate buffer, by 
aliquoting 200 µl of ammonium acetate buffer into each tube and centrifuging at 
6000 rpm (2000 g) for 5 minutes at 4 °C.  The ammonium acetate buff er was then 
removed from the collection section of the eppendorf and discarded.   The 250 µl 
fraction sample was aliquoted into a VivaSpin 500 30 KDa Molecular Weight 
Concentrating eppendorfs and centrifuged at 2000 rpm (500 g) for initially 3 minutes 
at 4 °C.  Samples were centrifuged until they reach ed the 25 µl level marker on the 
tube.  This required close monitoring of the samples during the centrifugation period, 
which is why a definitive centrifugation time is not given.   
 
2.4.1.7 Mass Spectrometry 
 
To identify the protein(s) contained within the peak that eluted from the HPLC 
column at 15 minutes, the fractions collected over that peak, were subjected to 
mass spectroscopy (Matrix-Assisted Laser Desorption/Ionization-Time of Flight 
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(MALDI-TOF)).  The MALDI-TOF mass spectroscopy was conducted at the 
University of Edinburgh. 
 
Published literature indicate that the molecular weight of the CDT glycoforms are: 
Disialotransferrin 77365 Da; Trisialotransferrin 79281 Da; Tetrasialotransferrin 
79573; Pentasialotransferrin 80232/80379 Da (Oberrauch et al. 2008).   
 
Fractions were prepared for MALDI-TOF mass spectroscopy as follows: 0.5 µl of 
fraction was spotted onto the MALDI metal 96 well plate, followed by another spot of 
0.5 µl sinapinic acid (Sigma).  The function of sinapinic acid was to immobilise the 
sample before being subjected MALDI-TOF mass spectroscopy (Estela de Castillo 
Busto et al. 2005). The volume in each well was 1 µl.  The sample wells were 
allowed to dry for 30 minutes.  The samples were analysed using a PerSeptive 
Biosystems Vovager-DE STR BioSpectrometry workstation.  The mass 
spectroscopy conditions are shown in table 2.11. 
 
Table 2.11: MALDI-TOF Mass Spectroscopy Conditions 
Acquisition control Manual 
Instrument mode Linear 
Extraction mode Delayed 
Polarity Positive 
Matrix Sinapinic acid 
Laser intensity 2086 
Spectrum acquisition: shots/spectrum 300 
Spectrum acquisition: mass range 50,000 – 100,000 
Accelerating Voltage  25000 V 
Voltages: grid 93% 
Voltages: delay time 800 nano seconds 
Guide wire 0 0.15% 
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2.4.1.8 Conclusion  
 
The method development described in section 2.4.1 for the detection of CDT in 
serum using a HPLC-UV method from a published paper (Helander et al. 2003) 
proved unsuccessful.  The method did not provide four identifiable peaks of each of 
the transferrin glycoforms under investigation.  The method development resulted in 
another analytical method for the development of CDT being employed.    The 
method used to analyse serum samples collected for the HI and ADI study, was the 
N-Latex method and is described in the following section. 
 
 
2.4.2 Serum Carbohydrate-Deficient Transferrin (CDT) Analysis for HI and ADI 
Study Samples   
 
This method was used as the HPLC method development was not successful in 
separating each of the CDT glycoforms.  This sections describes the analysis of 
serum samples for CDT by the N Latex CDT immunoassay (Dade Behring, Marburg 
GmbH, Emil-von-Behring-Str. 76 35041 Marburg, Germany).   
 
The CDT analysis was conducted within the immunology department, Northern 
General Hospital in Sheffield, with the kind support and collaboration of Dr. Graham 
Wild. 
 
2.4.2.1 Sample Shipment  
 
Serum samples were thawed from -80 °C and 600 µl of  serum was aliquoted into 
labelled eppendorf tubes.  Samples were blinded for analysis within the immunology 
department.   Serum samples were shipped within 24 hours on dry ice by courier 
from QMU to the Northern General Hospital in Sheffield. 
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2.4.2.2 Principles of Method  
 
Daily alcohol consumption of 50-60 g over a two week period can lead to increase in 
CDT levels (Helander et al. 2003).  After a period of two week abstinence, CDT 
levels can return to normal; however this is dependent upon the initial increase of 
CDT levels, thus the higher the level the longer it will take to normalise.  
 
The N Latex CDT kit is a competitive immunoassay where CDT present in the 
serum sample competes with CDT coated polystyrene particles, bind with specific 
monoclonal antibodies of human CDT, which are likewise bound to polystyrene 
particles.  The binding of the CDT particles to the antibodies generates a light signal 
which can be measured and quantified. In the presence of CDT within the serum 
sample there is either no or little aggregation of the polystyrene particles.  In the 
absence of CDT in the sample, the polystyrene particles aggregate.  The higher the 
CDT content in the assay, the lower the scattered light signal.  The elevation of the 
results is performed by comparison with a standard of known concentrations, which 
is provided within the kit.   
 
The reference curves are generated by multi-point calibration with the reagents 
provided within the N Latex CDT kit and the resulting calibration curve is 
automatically generated by the software within the BN ProSpec System© (Dade 
Behring).  The reference curves are valid for two weeks, but must be repeated if 
new reagents from different kit batches are used.  The calculation of %CDT is 
automatically performed using the software integrated within the BN ProSpec 
System©.   
 
2.4.3 Homocysteine in Plasma 
 
Plasma homocysteine was analysed using High Pressure Liquid Chromatography 
(HPLC) with Electrochemical Detection (ED), in all samples from the HI and ADI 
studies.   
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2.4.3.1 HPLC Apparatus 
 
The chromatography system consisted of a Waters 1525 Binary HPLC (High 
Pressure Liquid Chromatography) Pump (Waters Limited, 730-740 Centennial 
Court, Centennial Park, Elstree, Hertfordshire, WD6 3ZS, UK) and a Waters 717 
plus Autosampler (Waters).  Detection of the homocysteine thiol function was 
carried out on a Waters 2465 Electrochemical Detector (Waters) consisting of a 
3mm Gold (Au) reference electrode (Waters).  The electrochemical detector was 
connected to a Dell computer which controlled the HPLC data acquisition and 
integration.  Separation and quantification of homocysteine was performed on a 
Gemini-NX 5u C18 column (150 x 4.6 mm) (Phenomenex UK Ltd, Melville House, 
Queens Avenue, Hurdsfield Industrial Estate, Macclesfield, Cheshire SK10 2BN, 
UK).  A precolumn was not used prior to homocysteine separation on the Gemini-NX 
C18 column, however guard columns were used to protect and increase the lifespan 
of the Gemini-NX C18 column.   
 
2.4.3.2 Preparation of Calibration Curve 
 
For each batch of samples analysed, a calibration curve was produced.  The 
calibration curve was prepared using dilutions from a stock solution of HPLC grade 
homocysteine (Sigma).  Homocysteine was diluted within mobile phase.  The mobile 
phase for this HPLC analysis consisted of 1% phosphoric acid, 10% methanol, 2 
mM potassium chloride and 1 mM sodium octylsulphate (SOS).  Six concentrations 
were adopted for the study in light of the evidence provided by Mansoor et al. 1992, 
which detailed the average homocysteine concentration found in human plasma.  
The calibration curve represented a concentration range of 0%, 50%, 100%, 150% 
and 200% of the expected normal levels of homocysteine found in plasma.  
 
2.4.3.3 Preparations of Samples 
 
This method for the detection of homocysteine in plasma was developed from a pre-
existing HPLC method, which had been previously validated at Queen Margaret 
University (Cummins 2005). 
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Plasma samples were thawed from -80 ºC and processed in duplicate.  200 µl of 
plasma was added to 200 µl of 1 mM EDTA (Sigma) and 20 µl of Octanol-1 (Sigma), 
which acted as an anti-foaming agent.  100 µl of sodium borohydride (Sigma), a 
potent reductant was added and the solution was then vortexed and incubated at 50 
ºC for 30 minutes in a water bath (Waterbath Shaker SBS30, Stuart Scientific, 
Beacon Road, Stone, Staffordshire, ST15 0SA, UK).   NaBH4 (Sigma) was prepared 
immediately before use by adding 74 mg NaBH4 (Sigma) to 10 ml EDTA (Sigma) 
containing 140 µl of 10M NaOH (Sigma).  100 µl of 1M perchloric acid (BDH 
Laboratory Supplies, Poole, England BH15 1TD) was added to precipitate proteins 
(Hobbs et al. 2005).  The use of perchloric acid to precipitate protein, prior to 
homocysteine analysis by HPLC-ED, has been established in the literature.  The 
average amount of protein remaining in the plasma supernatant after perchloric acid 
precipitation is approximately 1.2 mg/ml  (Jacobsen et al. 1989).  Within normal 
human plasma, homocysteine at a mean concentration of 16 nmol/ml represents 
approximately 4% of the total soluble thiol reactivity after reduction by sodium 
borohydride and perchloric acid precipitation (Jacobsen et al. 1989).  This evidence 
from the literature suggests that perchloric acid is approximately 96% efficient at 
protein precipitation (Jacobsen et al. 1989).  Samples were vortexed (WhirliMixer, 
Oldmixon Crescent, Weston-Super-Mare, North Somerset BS24 9BL) and 
centrifuged (MSE Micro Centaur Microcentrifuge, Sanyo Biomedical, Sanyo 
Commercial Solutions, 1300 Michael Drive, Suite A, Wood Dale, IL 60191 USA) at 
13,000 rpm (15,000 g) for 30 minutes to separate the precipitated proteins and the 
supernatant.  The supernatant was transferred to a 1 ml clear glass vial suitable for 
the auto-sampler injector.  A volume of 20 µl was injected into the HPLC system.  
Separation of homocysteine was achieved isocratically using an aqueous mobile 
phase. 
 
2.4.3.4 Mobile Phase 
 
The mobile phase was developed from the work by Cummins (2005) and the Waters 
2465 Electrochemical Detector Guide.  The aqueous mobile phase consisted of: 2 
mM potassium chloride (Sigma), 1% phosphoric acid, (BDH) 10% methanol (Fisher 
Scientific) and 1 mM sodium octylsulphate (SOS) (Sigma).  The pH of the mobile 
phase was adjusted to 1.75 using 10M NaOH (Sigma).  The mobile phase was 
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degassed under vacuum in a bath type sonicator (Deacon DS100b, Decon 
Laboratories Ltd, Hove, East Sussex, U.K.). 
 
2.4.3.5 Running Conditions 
 
HPLC was performed at room temperature.  Flow rate was 0.8 ml per minute at 
+0.86 volts (V) with a range of 500 nanoAmps (nA).  The oxidation potential of +0.86 
volts was used, as this was the oxidation used in the original method by Houze et al. 
(2001) and from the method which was established by Cummins (2005) at QMU. 
Under these conditions the homocysteine peak eluted at approximately 9.40 
minutes, with a total run time of 15 minutes.   
 
2.4.3.6 Validation of Homocysteine HPLC Method 
2.4.3.6.1 Linearity 
 
A calibration curve was generated for homocysteine, using a stock solution prepared 
from commercially available homocysteine (Sigma) and diluted with mobile phase as 
described in section 2.4.3.4.  From a review of the literature, six concentrations in a 
range were adopted for the calibration.  The concentrations were 0%, 25%, 50%, 
100%, 150% and 200% of the normal level of homocysteine found in human plasma 
(Mansoor et al. 1992).   
 
2.4.3.6.2 Precision  
 
For the homocysteine assay the precision was determined by analysing two 
standard concentrations of homocysteine in one run.  The samples were the 
standards (25% and 200%) which represent the low and high range of the 
calibration curve.  The 25% and 200% standards were analysed in a single run, with 
three replicate injections per sample.  A percentage coefficient of variation (%CV) 
was calculated to determine the intraassay precision. 
 
The precision of the interassay was also established. The low (25%) and high 
(200%) standards were analysed in two different runs, which were undertaken on 
128 
different days.  A percentage coefficient of variation (%CV) was calculated to 
determine the interassay precision.   
 
2.4.3.6.3 Statistical Analysis 
 
All data was analysed using Microsoft Office Excel (version 2003).  Calibration 
curves were plotted by linear regression and an equation was calculated for the 
regression curve. 
 
2.4.4 Homocysteine in Urine 
Homocysteine in urine was analysed using High Pressure Liquid Chromatography 
(HPLC) with Electrochemical Detection (ED), in all samples from the HI and ADI 
studies.   
 
2.4.4.1 HPLC Apparatus 
 
The chromatography system consisted of a Waters 1525 Binary HPLC (High 
Pressure Liquid Chromatography) Pump (Waters) and a Waters 717 plus 
Autosampler (Waters).  Detection of the homocysteine thiol function was carried out 
on a Waters 2465 Electrochemical Detector (Waters) consisting of a 3 mm Gold 
(Au) reference electrode (Waters).  The electrochemical detector was connected to 
a Dell computer which controls the HPLC data acquisition and integration.  
Separation and quantification of homocysteine was performed on a Gemini-NX 5u 
C18 column (150 x 4.6 mm) (Phenomenex). 
 
2.4.4.2 Preparation of Samples 
 
The identification of homocysteine in urine was developed from the method 
published by Thomson and Tucker (1986). 
 
Urine samples were collected into a 30 ml universal containers (Fisher Scientific) 
and stored at -20 ºC until analysis.  Literature evidence suggest that urine, which will 
be subsequently analysed for homocysteine using HPLC-ED, can be stored without 
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the addition of acid to stabilise the thiols (Kusmierek et al. 2006; Thomson and 
Tucker 1986).  Urine samples were thawed from -20 ºC.  Urine (5 ml) was aliquoted 
into a centrifuge tube (Fisher Scientific) and 1 ml of 2M perchloric acid (BHD) was 
added to the centrifuge tube and mixed well, to prevent thiol oxidation.  Samples 
were centrifuged (Jouan) at 2000 rpm (500 g) for 5 minutes.  Supernatant (1 ml) was 
transferred, into a 1 ml clear glass vial suitable for the autosampler injector.  A 
volume of 20 µl was injected into the HPLC system.  Separation of homocysteine 
was achieved isocratically using an aqueous mobile phase.   
 
2.4.4.3 Mobile Phase 
 
The mobile phase was developed from the work of Cummins (2005) and the Waters 
2465 Electrochemical Detector Guide.  The aqueous mobile phase consisted of: 2 
mM potassium chloride (Sigma), 1% phosphoric acid (BDH), 10% methanol (Fisher 
Scientific) and 1 mM sodium octylsulphate (SOS) (Sigma).  The pH of the mobile 
phase was adjusted to 1.75 using 10 M NaOH (Sigma).  The mobile phase was 
degassed under vacuum in a bath type sonicator (Decon). 
 
2.4.4.4 Running Conditions 
 
HPLC was performed at room temperature.  Flow rate was 0.8 ml per minute at 
+0.86V with a range of 500 nanoAmps (nA).  Under these conditions the 
homocysteine peak eluted at approximately 9.40 minutes, with a total run time of 15 
minutes.   
 
2.4.4.5 Creatinine in Urine  
 
The measurement of homocysteine in urine is expressed as a ratio with creatinine, 
(Thomson and Tucker 1986).  Creatinine is used as comparative value when 
expressing homocysteine as the concentrations of creatinine excreted by each 
individual is relatively constant and allows the concentration of homocysteine to be 
normalised against a constant (Thomson and Tucker 1986). 
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The creatinine assay was calibrated using known standards prior to analysis of the 
study urine samples.  A calibration curve was generated for creatinine using three 
standards, which were provided within the Infinity™ reagent kit.  The three 
concentrations, within the commercial kit, which were adopted for the calibration 
curve, were: 0.01 mg/ml, 0.03 mg/ml and 0.1 mg/l.    For each batch analysed the 
calibration curve was linear, with a coefficient of determination of greater than 0.99.  
The concentration of creatinine was determined from the calibration curve.     
 
Creatinine was determined using the Infinity™ Creatinine Liquid Stable Reagent 
(Thermo Electron Corporation, Thermo Fisher Scientific Inc. 
81 Wyman Street, Waltham, MA 02454).  Urine (30 µl) was aliquoted into each well 
on a 96 well-plate (Greiner Bio-One).  300 µL of Infinity™ Creatinine Liquid Stable 
Reagent was added to each well and the plate was analysed on a plate reader at 
550 nm.  Samples were analysed in duplicate.   
 
2.4.5 MTHFR(C677T) Polymorphism 
2.4.5.1 DNA Extraction 
 
DNA Extraction was undertaken according to published methods (Rudbeck and 
Dissing 1998; von Ahsen et al. 1999).  Anticoagulated blood (5 µl) was aliquoted 
into sterile 1.5 ml eppendorf tubes (Fisher Scientific) and 1 ml of PCR grade sterile 
water (Fisher Scientific) was added.  Samples were centrifuged at 9600 rpm (12,000 
g) for 1 minute with a microcentrifuge (MSE Micro Centaur Microcentrifuge, Sanyo 
Biomedical, Sanyo Commercial Solutions, 1300 Michael drive, Suite A, Wood Dale 
IL 60191 USA) and the supernatant was removed.  The remaining pellet was lysed 
by the addition of 20 µl of 0.2 mol/l NaOH (Fisher Scientific), vortex mixed 
thoroughly and incubated at room temperature for 5 minutes.  180 µl of 0.04 mol/l 
Tris-HCl buffer (Sigma) were added to restore a pH of 7.5.  Extracted DNA solution 
was stored at -80 ºC awaiting, spectrophotometric analysis followed by the Real-
Time Polymerase Chain Reaction (PCR). 
 
 
 
131 
2.4.5.2 Spectrophotometric Analysis 
 
Extracted DNA solution was analysed using a NanoVue Spectrophotometer (GE 
Healthcare, Pollards Wood, Nightingales Lane, Chalfont St, Giles, Bucks, HP8 4SP), 
at Napier University, Edinburgh. Neat DNA solution (2 µl) was placed on the reader 
plate and the sample was analysed.  The spectrophotometer provided the 
absorbance of the sample at 260 nm, which allowed protein contamination to be 
identified.  The analysis of the DNA sample using the NanoVue spectrophotometer 
(GE Healthcare), calculated the volume of DNA required for PCR analysis, which 
was important to achieve an identifiable PCR analysis for the MTHFR(C677T) 
polymorphism. 
2.4.5.3 DNA Quality 
 
The fragile nature of DNA can in certain cases cause extraction from a biological 
fluid to be unsuccessful.  Many external sources of contamination e.g. high 
temperatures can cause DNA to degrade, resulting in the samples being unsuitable 
for PCR amplification.   To ascertain the DNA samples (which were extracted in 
section 2.4.5.1) were not degraded and were of a suitable quality, an accuracy 
experiment on the extracted DNA was first performed.  This accuracy experiment 
confirmed that the extracted DNA was suitable for Real-Time PCR.     Using 
conventional PCR, the presence of the housekeeping gene Glyceraldehyde 3-
Phosphate Dehydrogenase (GAPDH) was identified in the DNA of two randomly 
selected participants.  GAPDH was chosen as an accuracy marker as this gene is 
present in every cell and its presence indicates that DNA is feasible and present.   
 
GAPDH sense and antisense primers (Sigma), were stored at -20 ºC and 
centrifuged (Mikro 200, Hettich, Seestrasse 204a, CH-8806,  Bäch, Germany) at 
2000 rpm (1000 g) for 2 minutes prior to use.   GAPDH primers were diluted 1 in 10 
with diethylpyrocarbonate (DEPC) water.  The following master mix was prepared as 
shown in table 2.12. 
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Table 2.12: GAPDH PCR Master Mix (N= No of samples + 1) 
Reagent Volume (µl) N (µl) 
GAPDH Sense Primer 1 4 
GAPDH Anti-Sense 
Primer 
1 4 
Sterile PCR-grade H2O 18 90 
Total  20 98 
 
To a 0.5 ml PCR reaction tube containing a PureTaq Ready-To-Go PCR bead (GE 
Healthcare), 20 µl of master mix was added and mixed well.  A 5 µl aliquot of the 
appropriate DNA was added to each labelled PCR tube.  For the negative control 5 
µl of sterile water (Baxter) replaced the DNA sample.   
 
Each sample was amplified in the PCR thermal cycler to produce GAPDH cDNA, 
using the program shown in table 2.13. 
 
Table 2.13: GAPDH PCR Program 
Parameter Denaturation Cycling Elongation  Cooling 
Cycles 1 25 1 1 
Segment 1 1 2 3 1 1 2 
Target (ºC) 94 95 60 68 68 20 4 
Hold 
(hh:mm:ss) 
00:2:00 00:00:30 00:10:00 00:02:00 00:07:00 00:01:00 08:00:00 
 
2.4.5.4 Gel Electrophoresis 
 
After PCR amplification, the resulting GAPDH cDNA was examined using gel 
electrophoresis.  The presence of GAPDH cDNA at 500 base pairs is indicative of a 
positive result, where GAPDH has been successfully amplified and the original DNA 
was of suitable quality to permit PCR amplification.   
 
The gel electrophoresis method by Lewis 2009 was used.  Agarose (0.5 g) 
(Invitrogen) was weighed out into a 250 ml conical flask, and 50 ml of 0.5X Tris 
Borate EDTA (TBE) (Sigma) buffer was added.  The flask was swirled to mix and 
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was placed in a microwave at full power (800 watts) for 1 minute to allow the 
agarose to dissolve.   The solution was allowed to cool for 5 minutes, within a fume 
cupboard, 1 µl of Ethidium bromide (Sigma) was added.  Ethidium bromide is added 
to the solution, as it binds to DNA to allow the PCR bands to be viewed under ultra-
violet light.   The agarose solution was poured into an electrophoresis tank (Bio-
Rad) and allowed to set for 30 minutes.  Once the gel had set, 250 ml of 0.5X TBE 
buffer was poured into the tank to submerge the gel.  The TBE buffer acted as a 
running buffer.   
 
PCR products were prepared in 0.5 ml PCR reaction tubes (GE Healthcare), prior to 
gel electrophoresis.  A 10 µl PCR product was aliquoted into each PCR reaction 
tube and 2 µl of loading buffer was added.  A 100 base pair DNA ladder (Sigma) 
was also prepared, where 10 µl of the DNA ladder was aliquoted into a PCR 
reaction tube and 2 µl of loading buffer was added.  All samples were mixed well 
and 12 µl of each sample and 12 µl of DNA ladder were dispensed into each well 
within the gel.  Gel electrophoresis was carried out at 100 volts for 30 minutes.  To 
view cDNA bands, the gel was photographed under UV light, using a Syngene 
Imager (Syngene, Beacon House, Nuffield Road, Cambridge, United Kingdom, CB4 
1TF).     
 
2.4.5.5 Preparation of Samples 
 
MTHFR(C677T) primers were purchased from Tib MolBiol (GmbH. Berlin Germany).  
Primers were stored at room temperature and protected from light.  The PCR 
reaction is highly sensitive, results can be obtained from 1 ng of genomic DNA and 
generated within 1 hour (Rudbeck and Dissing 1998).   
 
Reagent vials containing all primers and probes were removed from the Tib MiolBiol 
kit and 66 µl of PCR grade water was added to each volume.  The solutions were 
vortexed and centrifuged (Hettich).  A 4 µl volume of primer and probe reagent were 
sufficient for a 20 µl PCR reaction, for each sample being analysed. 
 
Due to the small volumes used in a PCR reaction, a master mix was used to reduce 
pipetting errors.  To create a master mix, the kit, LightCycler FastStart DNA Master 
134 
HybProbe was purchased from Roche (Roche Applied Science, 68298 Mannheim, 
Germany).  A reaction tube was cooled to 4 ºC and the master mix was prepared by 
multiplying each volume for a single reaction by the number of reactions to be 
cycled plus one additional reaction.  The reagents used in the master mix are 
detailed in table 2.14. 
 
N (volume required) = number of participant samples + 1 x reagent volumes 
 
Table 2.14: MTHFR(C677T) PCR Reaction Master Mix 
Master Mix Reagent Volume (µl) 
PCR grade Water 7.4 
Mg2+ Solution 25 mM 1.6 
Reagent Mix 4.0 
FastStart Mix 2.0 
Total Volume 15 
 
Reaction master mix was mixed gently, centrifuged (Jounan) and 15 µl was 
transferred to a LightCyler capillary (Roche).  Participant DNA samples or DNA 
control (5 µl) were added to each LightCycler capillary (Roche) to give a final 
reaction volume of 20 µl. 
 
2.4.5.6 Control DNA 
 
For each PCR analysis a positive and negative control was included with the 
participant’s samples.  For the positive DNA control a template DNA sample was 
provided with the MTHFR kit (Tib MolBiol).  PCR grade water (40 µl) was added to 
the control DNA vial.  The sample was mixed well by pipetting the solution up and 
down 10 times.  A 5 µl volume of the control DNA sample was required for a 20 µl 
PCR reaction. 
 
A negative DNA control was prepared in the same way as the positive control, 
where the template DNA was replaced with PCR grade water.   
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2.4.5.7 Real-Time PCR Program 
 
The MTHFR(C677T) Real-Time PCR program consisted of 4 steps: 
1. Denaturation of sample and activation of enzyme. 
2. PCR amplification of the target DNA. 
3. Melting curve for identification of the genotype. 
4. Cooling of the instrument. 
 
The following program shown in table 2.15 was programmed into the LightCycler 
software (Roche) to detect the MTHFR(C677T) polymorphism: 
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Table 2.15: MTHFR(C677T) Real-Time PCR Program 
Parameter Denaturation Cycling Melting Cooling 
Analysis Mode None Quantification Melting Curve None 
No of Cycles 1 45 1 1 
Segment 1 1 2 3 1 2 3 1 
Target (ºC) 95 95 55 72 95 40 85 40 
Hold  10 mins .05 sec 10 sec 15 sec 20 sec 20 sec  0 sec 30 sec 
Ramp Rate (ºC/s) 20 20 20 20 20 20 0.2 20 
Acquisition Mode None None Single None None None Continuous None 
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2.4.5.8 Data Analysis 
 
The polynominal calculation method was employed for analysing the melting peaks.  
The Roche LightCycler software program for Real-Time PCR amplification carried 
out the polynominal calculation.  The melting temperature was determined with the 
manual Tm setting.  The MTHFR(C677T) data was viewed in channel 640 using the 
melting curves analysis mode.  The negative control showed no signal, due to no 
presence of DNA within the sample. 
 
2.4.6 Serum Combined Folate and Vitamin B12 Assay 
 
Within participant’s serum samples, folate and vitamin B12 analyses were conducted 
within the biochemistry laboratories at the Royal Infirmary of Edinburgh (RIE).  The 
assay was conducted by the laboratory biomedical staff.  Folate and vitamin B12 are 
analysed as a joint assay in duplicate. 
 
Serum samples were thawed from -80 ºC to room temperature (20 ºC) and 800 µl of 
serum was aliquoted into chilled 5 ml centrifuge tubes (Sarstedt).  Centrifuge tubes 
were labelled with barcodes, provided by the biochemistry laboratories at RIE.  
Samples were transferred to RIE on wet ice.   
 
2.4.6.1 Folate Analysis 
 
Folate was analysed within serum using the ADVIA Centaur Folate assay, which is a 
competitive immunoassay, using direct chemiluminescent technology (Bayer 
HealthCare LLC 2006).  The principle of this method involves the sample being 
pretreated to release the folate from endogenous binding proteins in the sample.  
The results from this assay are based on the inverse relationship between the 
amount of folate present in the participant sample and the amount of relative light 
units (RLU), detected by the system.  The sensitivity range of this assay is 0.35 - 25 
ng/ml (0.79–54.36 nmol/l) (Bayer HealthCare LLC 2006) and the clinical reference 
range for folate in human serum is 5-24 µg/l. 
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2.4.6.2 Vitamin B12 Analysis 
 
Vitamin B12 was analysed within serum using the ADVIA Centaur VB12 assay, 
which is a competitive immunoassay using direct chemiluminescent technology 
(Bayer HealthCare LLC 2004).  The principle of the assay uses sodium hydroxide as 
a releasing agent and DTT to release the vitamin B12 from the endogenous binding 
proteins in the sample and cobinamide to prevent rebinding after the solid phase is 
added to the sample.  The results from this assay are interpretated in a similar way 
to that of the folate assay where there is an inverse relationship between the amount 
of vitamin B12 in the sample and the relative light units (RLU) detected by the 
system.    The sensitivity range of this assay is 45–2000 pg/ml (33–1476 pmol/L) 
(Bayer HealthCare LLC 2004) and the clinical reference range for vitamin B12 is 
human serum is 200-900 ng/l. 
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2.5 Summary  
 
Participant’s biological samples, questionnaire’s and alcohol diaries were analysed as detailed in table 2.16 as per each method 
described within this chapter. 
 
Table 2.16: Summary HI and ADI Study Analysis 
Study Plasma 
Homocysteine 
Serum Folate Serum 
Vitamin B12 
Serum CDT MTHFR(C677T) 
Polymorphism 
Diet & Alcohol 
Diary  
(grams of 
alcohol per 
drinking day) 
Questionnaire 
(grams of 
alcohol per 
drinking day) 
HI •  •  •  •  •  •  •  
ADI •  •  •  •  •   •  
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2.6 Quality Control: Investigation of the Stability of Study Biomarkers during 
Storage (Stability Study) 
 
The stability of the metabolite being analysed is a highly important consideration, 
impacting on the choice of methods used to collect, handle and store biological 
samples.  Several studies have investigated the differing conditions in which 
samples can be stored before analysis was carried out.  This study was developed 
to identify the effects of repeated thawing and re-freezing on the stability of 
homocysteine, carbohydrate-deficient transferrin (CDT), folate and vitamin B12. 
 
Plasma and serum prepared from the blood samples provided by both the HI and 
ADI study participants were stored, frozen until batch analysis could be performed.  
To confirm the stability of the various biomarkers under investigation during this time 
it was necessary to perform supporting stability studies.   
 
2.6.1 Stability Study Protocol 
 
This study required a large volume of human plasma (40 ml) and serum (80 ml).  It 
was obtained from participants who were recruited from QMU, through e-mail 
advertisement.  Recruitment was conducted over a week long period in May 2008. 
 
2.6.1.1 Sample Storage 
 
Four groups were designed for this study, each group of samples were exposed to 
different sets of thawing and re-freezing time-points, during a 3-month period, which 
are detailed in table 2.17.  
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Table 2.17: Storage conditions for stability study sample groups 
Group 
Number 
Conditions Contents 
1 ‘Spiked’ Samples at 
Constant -80 ºC 
• 10 x 1 ml Homocysteine spiked plasma  
• 10 x 1 ml CDT spiked serum  
• 10 x 1 ml Folate/Vitamin B12 spiked serum  
2 ‘Spiked’ Samples 
Freeze/Thaw from  
-80 ºC on 3 
occasions 
• 10 x 1 ml Homocysteine spiked plasma  
• 10 x 1 ml CDT spiked serum  
• 10 x 1 ml Folate/Vitamin B12 spiked serum 
3 Samples at Constant 
-80 ºC 
• 10 x 1 ml Homocysteine plasma 
• 10 x 1 ml CDT serum 
• 10 x 1 ml Folate/Vitamin B12 serum 
4 Samples 
Freeze/Thaw from  
-80 ºC on 3 
occasions 
• 10 x 1 ml Homocysteine plasma 
• 10 x 1 ml CDT serum 
• 10 x 1 ml Folate/Vitamin B12 serum 
 
For each metabolite there were ten 1 ml samples (eppendorfs) stored in each group.  
Within groups 1 and 2 plasma and serum samples were ‘spiked’ with artificial 
standards (described in section 2.6.1.4), which were commercially available.  Folate 
in the form of folic acid and Vitamin B12 were purchased from Sigma.  CDT Test Mix 
were purchased from Bio-Rad. 
 
2.6.1.2 Thawing and Re-Freezing Procedures 
 
Group 1 and 3 samples were kept at a constant -80 ºC temperature during the 3 
month duration of the study.   On a monthly basis the samples within groups 2 and 4 
were thawed at specific time points, as detailed in table 2.18.  Each thawing time-
point was one month apart.  After each thawing time-point the samples were 
returned to the -80 ºC freezer.  For the final thawing time-point, the samples were 
completely thawed, before being returned to -80 °C storage.   
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Table 2.18: Monthly Freezing and Thawing Time-points 
Thawing Time-point Temperature Change (ºC) Time Period (hours) 
Month 1 -80 ºC to -20 ºC 24 hours  
Month 2 -80 ºC to -20 ºC 24 hours 
Month 3 -80 ºC to 0 ºC 6 hours 
 
2.6.1.3 Stability Study Venepuncture and Sample Processing  
 
All stability study participants were asked to attend a clinic at QMU, so all 
venepuncture, could be undertaken at the same time.  They were asked to fast for 
12 hours prior to their blood sampling appointment.  A fasting blood sample was 
taken from each participant.   
 
Venepuncture and blood sample processing was conducted as described in section 
2.1.3.6.1.  All serum samples were pooled in a glass beaker (Fisher Scientific), 
mixed well and a 1 ml sample was aliquoted into ten 1.5 ml eppendorf tubes (Fisher 
Scientific) and stored at -80 ºC, awaiting CDT analysis by immunoassay and 
combined Folate/Vitamin B12 competitive immunoassay at the Royal Infirmary of 
Edinburgh.  All plasma samples were pooled together in a glass beaker mixed well 
and ten 1 ml samples were aliquoted into 1.5 ml eppendorf tubes (Fisher Scientific) 
and stored at -80 ºC, awaiting homocysteine analysis by HPLC (Cummins 2005; 
Houze et al. 2001).  Serum and plasma samples for the Stability Study were stored 
at QMU 
 
2.6.1.4 Stability Study Standards 
 
This section describes the preparation of the standards used to spike the pooled 
serum samples; which were subjected to the varying temperature manipulations as 
per described in table 2.18. 
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2.6.1.4.1 Homocysteine Standards 
 
Homocysteine was purchased from Sigma (Sigma-Aldrich Company Ltd, The Old 
Brickyard, New Road, Gillingham, Dorset, SP8 4XT).  For standards a 1 litre stock 
solution was prepared to a concentration of 12.7 µmol/l.  0.1 g of homocysteine was 
dissolved in 1 litre of distilled water.  The solution was mixed well and homogeneity 
was ensured.  10 µl of stock solution was aliquoted into each 1 ml pooled plasma 
sample.  Each 10 µl aliquot has a concentration of 7.4 nmol/10 µl.  Samples were 
stored according to group allocation, see table 2.17. 
 
2.6.1.4.2 CDT Standards 
 
A CDT Test Mix was purchased from Bio-Rad Laboratories.   The CDT Test Mix was 
left to stand for 30 minutes at room temperature (21 ºC) before reconstitution, due to 
the product being supplied in lyophilized form.  Distilled water (1 ml) was added to 
the test mix.  The stopper was replaced and the reconstituted test mix was allowed 
to stand for 10 minutes.  After 10 minutes the test mix was agitated and 
homogeneity was ensured.  The test mix (50 µl) was added to each 1 ml serum 
sample and stored according to group allocation.      
 
The test mix is commercially available from Bio-Rad and is used for calibration with 
the Bio-RAD %CDT HPLC kit.  The test mix contains disialotransferrin, 
trialaotransferrin, tetrasialotransferrin and pentasialotransferrin.  The text mix was 
used for the stability study, as it was the only way of spiking the serum samples with 
additional CDT glycoforms.   
  
2.6.1.4.3 Folate Standards 
 
Folic acid was purchased from Sigma.  Folic acid was stored at 2-8 ºC and 
protected from sunlight.  For standards a 1 litre stock solution was prepared, to a 
concentration of 0.75 mg/l (0.75 mg of folic acid was dissolved in 1 litre of distilled 
water).  The solution was mixed well and homogeneity was ensured.  The rationale 
for using 0.75 mg/l of folic acid, to spike the serum sample, was to keep the final 
concentration below the maximum clinical reference value of 20 µg/l and prevent the 
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concentration from reaching a level above the maximum cut-off value.  Stock 
solution (10 µl) was aliquoted into each 1 ml serum sample, resulting in an added 
concentration of 7.5 ng/10 µl.  Samples were stored according to group allocation. 
 
2.6.1.4.4 Vitamin B12 Standards 
 
Vitamin B12 was purchased from Sigma.  Vitamin B12 was stored at 2-8 ºC.  For 
standards a 1 litre stock solution was prepared, to a concentration of 35 mg/l (35 mg 
of Vitamin B12 was dissolved in 1 litre of distilled water).  The solution was mixed 
well and homogeneity was ensured.  The rationale for using 35 mg/l of vitamin B12, 
to spike the serum sample, was to keep the final concentration below the maximum 
clinical reference value of 900 ng/l and prevent the concentration from reaching a 
level above the maximum cut-off value.  Stock solution (10 µl) was aliquoted into 
each 1 ml serum sample, producing a final concentration of 350 ng/10 µl.  Samples 
were stored according to group allocation  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 145
2.7 Statistical Analysis 
 
Non-parametric statistical analysis was employed due to the small sample number, 
also as biological markers were not normally distributed.  
 
2.7.1 Statistical Software 
 
The statistical software used to conduct all statistical tests, data analysis, tables and 
graphs was SPSS (Version 17) and Microsoft Excel (Version 2003). 
 
2.7.2 Test for Normality 
 
A Shapiro-Wilk test was carried out on all data from each study conducted to test for 
normality. 
 
2.7.3 Statistical Tests 
 
All statistical tests which were conducted using SPSS, were two-tailed and with a 
significant p value of less than or equal to 0.05.  The following non-parametric 
statistical tests were employed:   Mann-Whitney test (for between group analysis), 
Friedman’s test (multiple measures of three time-points), Spearman’s test (for 
correlation analysis) and Wilcoxon test (for within pair-wise group analysis). 
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3.1 Demographic Study Information 
 
Participants in the Healthy Individual (HI) study (N=35) were recruited from Queen 
Margaret University (QMU) and Napier University in Edinburgh.  Study participants 
for the Alcohol Dependent Individual (ADI) study (N=18) were recruited from the 
Ritson Clinic and Alcohol Problems Service which are an in-patient alcohol 
detoxification ward and an out-patient clinic within the Royal Edinburgh Hospital.  
The demographic information relating to each group of participants is shown in table 
3.1. 
 
Table 3.1: Comparison of demographic information from the HI and ADI studies  
(* denotes significance) 
 
HI Participants 
(N=35) 
ADI Participants 
(N=18) 
p-value 
Age in years:  
median, mean 
(SD; range) 
29, 30 (8; 20-49) 39, 41 (8.9; 26-55) 0.023* 
Age Groups 
Percentage (N) 
18-25 years 31.4% 
(11) 
26-50 years 68.6% 
(24) 
18-25 years 0%  
26-50 years 100% 
(18) 
<0.001* 
Gender 
Percentage (N) 
Male 34.3% (12) 
Female 65.7% (23) 
Male 83.3% (15) 
Female 16.7% (3) 
0.891 
Female 
Hormonal 
Contraceptive 
Users 
Percentage  (N) 
39.1% (9) 0%  NA 
Smokers 
Percentage (N) 
11.4% (4) 
Female (3) 
Male (1) 
55.56% (10) 
Female (2) 
Male (8) 
0.001* 
Occupation 
Percentage (N) 
Students 74.3% (26) 
Employed 25.7% (9) 
Not recorded by 
questionnaire 
NA 
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The median age of study participants was significantly lower (p<0.05) in the HI study 
compared with the patients recruited into the ADI study.  There were no participants 
recruited into the 18-25 year group within the ADI study, due to lack of patients of 
this age group being in the alcohol treatment ward during the recruitment period.  
There was a higher percentage of female participants, in the HI study, compared to 
the ADI study.  None of the ADI female participants used hormonal contraception, 
compared with 39.1% of the females in the HI study.  More ADI participants were 
smokers in comparison to the HI study participants (p<0.05).  Figures 3.1 and 3.2 
illustrate the CONSORT diagrams for both the HI and ADI studies. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.1: HI study CONSORT diagram 
Excluded (N=62) 
• Not meeting inclusion 
criteria (N=7) 
• Declined to participate 
(N=49) 
• Other reasons (e.g. lack 
of payment) (N=6) 
Entered into Study (N=35) 
Baseline Time-Point (N=35) 
• Withdrawn (N=0) 
3-Month Time-Point (N=33) 
• Withdrawn (N=1) 
• Failed to return diet diary (N=1) 
6-Month Time-Point (N=33) 
• Withdrawn (N=2) 
Assessed for eligibility (N=97) 
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Figure 3.2: ADI study CONSORT diagram 
 
Additionally all ADI patients (N=18) were prescribed the benzodiazepine drug, 
Chlordiazepoxide to reduce alcohol withdrawal symptoms.  Chlordiazepoxide was 
prescribed using a reducing regime from admission.  Both out-patients and in-
patients were prescribed Chlordiazepoxide.  ADI study participants were also 
prescribed Thiamine (N=10) or Pabrinex (N=11), with five ADI participants being 
prescribed both.  Pabrinex and Thiamine are B-vitamin supplements, which are 
routinely prescribed for malnutrition.  Thiamine is prescribed most commonly when 
malnutrition is present, however in more severe cases of malnutrition, Pabrinex is 
prescribed.    In the ADI study, 61.6% of the sample were prescribed Pabrinex which 
indicates that severe malnutrition was present.   Pabrinex and Thiamine 
supplements do not contain folic acid or vitamin B12, meaning the prescribing of 
Excluded (N=10) 
• Not meeting inclusion 
criteria (N=7) 
• Declined to participate 
(N=2) 
• Other reasons (e.g. lack 
of payment)  (N=1) 
Entered into Study (N=18) 
Day 1 Time-point (N=18) 
• Withdrawn (N=0) 
Day 3 Time-Point (N=18) 
• Withdrawn (N=0) 
Assessed for eligibility (N=28) 
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these supplements did not artificially increase folate or vitamin B12 levels and 
therefore impact on subsequent test results. 
 
3.2 Alcohol Consumption Analysis Methods used to Assess Alcohol Intake 
from Diary Recall (HI Study) 
 
Baseline alcohol consumption data for 26 drinkers (18 female and 8 male), who 
undertook the HI study (74% of total HI sample) were analysed using three separate 
methods as detailed in chapter 2.   Additionally two people withdrew and 7 were 
abstainers. The three methods employed were as follows: dietary analysis using 
alcohol manufacturer data (AM); WinDiets dietary analysis software (WD) and 
alcohol consumption quantification methods employed in the Office of National 
Statistics (ONS) questionnaires (Goddard 2001). 
 
Participant’s alcohol consumption during drinking days and the variability between 
the three methods are shown in Appendix 3A and 3B.  The results of participants 
mean alcohol consumption during drinking days using the three methods stated 
above are shown in table 3.2.   
 
Table 3.2: Mean (SD) Alcohol Consumption of all drinkers (N=26) during drinking 
days at baseline analysed using the ONS, WD and AM methods (*denotes 
significance) 
 
Mean (SD) Alcohol Consumption During  
Drinking Days (g) 
ONS WD AM p-value 
All Participants  (N=26) 33.9 (22.8) 48.6 (29.6) 53.3 (37.5) <0.001* 
Female Participants 
(N=18) 27.7 (21.0) 41.4 (28.1) 44.8 (34.0) <0.001* 
Male Participants (N=8) 47.7 (21.7) 65.0 (27.7) 72.4 (40.3) 0.010* 
 
Baseline mean alcohol consumption during drinking days was calculated in 
grams/day. Due to the greater number of females, compared to males (18 versus 8), 
it was possible to further group female participant’s data (N=18) according to the 
following drinking categories: “responsible” (<24g/day); “exceeding daily limits” (24-
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47g) and “sessional” (>48g) at one session using the AM method.   Their alcohol 
consumption at baseline was then calculated using the ONS, WD and AM methods 
and compared (figure 3.3).    The number of female participants categorised to each 
drinking pattern using each of the ONS, WD or AM methods is shown in figure 3.4.   
 
If it is assumed that consideration of specific alcohol contents and drink sizes will 
produce the most accurate estimate of alcohol intake (i.e. the AM method), then the 
WD method underestimates average consumption by 8.8% and the ONS method by 
36.4%.  A significant decrease (p<0.001) was evident for the mean alcohol 
consumption during drinking days analysed by the ONS method compared to AM 
but there was no significant difference (p=0.258) for the WD alcohol analysis when 
compared to AM.  
 
WD and ONS miscategorised 11% and 55% of participants, respectively and is 
shown in Figure 3.4.  A significant difference (p=0.0001) between the number of 
participants categorised to each drinking pattern using the AM and WD method was 
evident  It is clear that female participants who were undertaking sessional drinking, 
calculated using the AM method, would in fact not be found to be sessionally 
drinking, if their diaries were analysed using the ONS method (figure 3.3) 
  
3.2.1 Summary 
 
Self-reported alcohol consumption data can be collected and then analysed using a 
number of different methods.  From the results reported in this section it is clear, that 
the AM method is the most accurate as it takes into consideration relevant 
information needed to calculate alcohol consumption, including brand of alcoholic 
beverage, %ABV and volume.  All diaries and questionnaire data relating to alcohol 
consumption were subsequently analysed using the AM method.  
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Figure 3.3: Baseline alcohol consumption analysed using AM and compared to ONS and WD of female participants categorised according 
to U.K. alcohol drinking guidelines (mean and standard deviation) 
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Figure 3.4: Categorisation of female participants’ self-reported drinking patterns at baseline using three different calculation methods 
(ONS, WD and AM data)
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3.3 Alcohol Drinking Patterns and Consumption 
3.3.1 HI Study 
 
A comparison of HI study participants’ median alcohol consumption across time-
points, suggested that alcohol consumption decreased during the 6-month study 
period, see figure 3.5, however this was not statistically significant (p=0.910).  It is 
possible that the monitoring effect of the study could have influenced alcohol 
drinking, producing a change in normal consumption; however the lack of statistical 
significance is not consistent with this possibility.  However all baseline biomarker 
data were compared to alcohol consumption levels and drinking patterns at baseline 
for the HI study analysis.   
 
Figure 3.5: Mean alcohol consumption during drinking days of HI study participants 
at the pre-defined study time-points (N=35).  (Box plots represents the following: solid 
bar in box (median 50th percentile), top of box (75th percentile (upper quartile), bottom of box 
25th percentile (lower quartile), top whisker (largest value which is not an outlier or extreme 
score), bottom whisker (smallest value which is not an outlier or extreme score).  ● = Outlier 
(More than 1.5 box lengths above or below the box).  * = Extreme case (more than 3 box 
lengths above or below the box. 
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The consumption of alcohol can be categorised into alcohol drinking patterns using 
the recognised criteria as described in table 3.3. 
 
Table 3.3: Alcohol drinking pattern criteria 
Alcohol Drinking Pattern Criteria 
Abstainer Consume no alcohol or less than 1-2 alcoholic drinks 
per year. 
Responsible drinker Consume alcohol according to UK Department of 
Health guidelines, not exceeding 16-24 g (female) 
and 24-32 g (male) per day (UK Department of 
Health 1995). 
Exceeding Responsible 
Guidelines but NOT 
Sessional Drinkers 
Consume greater than 24 g (female) and 32 g (male) 
of alcohol but less than sessional drinker on any 
drinking day. 
Sessional drinker Consume greater than 48 g (female) and 64 g (male) 
of alcohol on any drinking day in a typical week (UK 
Department of Health 2009). 
 
HI study participants were asked if they would consume more than 6 (48 g; female) 
or 8 (64 g; male) units of alcohol in a session, which is the definition for sessional 
drinking, 53.6% (N=14) of the HI study sample answered “yes” to this question.  As 
shown in table 3.4, from analysis of the baseline diet diaries, 18 (51.4%) HI study 
participants were found to undertake sessional drinking, which indicates that four HI 
study participants did not self-report their sessional drinking.  The demographic 
characteristics of the HI study participants, who were categorised according to their 
baseline diaries, are shown in table 3.4.  Figure 3.6 representing the grams of mean 
alcohol consumed per drinking day within each alcohol drinking pattern at the three 
pre-defined study time-points, determined from baseline diaries.  The abstaining 
individuals (N=7) were identified from the study questionnaire and confirmed by 
diary analysis.   The median value for the mean alcohol consumption per drinking 
days in the sessional drinkers group did not significant decrease (p=0.642) at each 
pre-defined study time-point.   
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Table 3.4: Demographic study information of all HI study participants (N=35) categorised according to alcohol drinking pattern using 
baseline diet diaries.  *denotes significant difference between groups. 
 
Abstainer (N=7) Responsible 
Drinkers (N=2) 
Exceeding  
Responsible 
Guidelines  
but NOT Sessional 
Drinker (N=8) 
Sessional  
Drinkers (N=18) 
p-value  
Age (years): (Median; Mean (SD; Range)) 32; 33 (10; 20-45) 23; 23 (1; 22-23) 30; 33 (8; 26-49) 28; 30 (8; 21-46) 0.120 
Age Groups Distribution, Percentage (N) 18-25 yrs 28.6% (2) 
26-50 yrs 71.4% (5) 
18-25 yrs 100% (2) 
26-50 yrs 0%  
18-25 yrs 0%  
26-50 yrs 100% (8) 
18-25 yrs 38.9% (7) 
26-50 yrs 61.1% 
(11) 
0.002* 
Gender Distribution Percentage (N) Male 57.1% (4) 
Female 42.9% (3) 
Male 0%  
Female 100% (2) 
Male 10% (1)  
Female 90% (7) 
Males 38.9% (7) 
Females 61.1%  
(11) 
0.002* 
Regular Period in Females Percentage (N) 33.3% (1)  50% (1) 85.7% (6) 81.8% (9) 0.012* 
Female (N=23) Hormonal Contraceptive Users 
Percentage (N) 
33.3% (1) 50% (1) 16.6% (1) 54.5% (6) 0.040* 
Distribution of Smokers Percentage (N) 0%  0%  12.5% (1) 16.6% (3) 0.317 
Distribution of Occupation Percentage (N) 71.4% Students (5) 
28.6% Employed (2) 
100% Students (2) 
0% Employed 
50% Students (4) 
50% Employed (4) 
83.3% Students (15) 
16.6% Employed (3) 
0.002* 
Percentage of Individuals who stated they would 
consume >6 (female) or >8 (male) units in a 
session (Self-reported from questionnaire) 
0%  50% (1) 12.5% (1) 77.8% (14) <0.001* 
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Figure 3.6: Box plots of mean alcohol consumption (g) during drinking days in HI study sample (N=35) during the course of the study.  For 
each of the alcohol drinking patterns, data are presented for the three time-points; baseline, 3-months and 6-months.  (Box plots represents 
the following: solid bar in box (median 50th percentile), top of box (75th percentile (upper quartile), bottom of box 25th percentile (lower quartile), top 
whisker (largest value which is not an outlier or extreme score), bottom whisker (smallest value which is not an outlier or extreme score).  ● = Outlier 
(More than 1.5 box lengths above or below the box).  * = Extreme case (more than 3 box lengths above or below the box). 
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The number of drinking days at each pre-defined study time-point was recorded for 
each HI study participant and categorised using the prospective diary, reported in 
table 3.5. 
 
Table 3.5: HI study participant’s number of drinking days at each pre-defined study 
time-points, categorised according to alcohol drinking pattern (N=35) 
No of Drinking 
Days per Week 
at each study 
time-point 
 
Abstainer 
(N=7) 
Responsible 
Drinker 
(N=2) 
Exceeding 
Responsible 
Guidelines 
but NOT 
Sessional 
Drinker 
(N=8) 
Sessional 
Drinker (N=18) 
Baseline 
(Median; Mean 
(SD; Range)) 
__ 0; 0  
(1; 0-1) 
3; 4 (2; 2-6) 5; 4  
(2; 0-7) 
3-Month 
(Median; Mean 
(SD; Range)) 
__ 1; 1  
(0; 1-1) 
2; 2.3  
(1.6; 0-5) 
3; 2.8  
(1.9; 0-7) 
6-Month 
(Median; Mean 
(SD; Range)) 
__ __ 4; 4.3  
(2.3; 0-7) 
2.0; 2.7  
(2.1; 0-7) 
 
Figure 3.7 presents the number of HI study participants and their specific alcohol 
drinking pattern at each time-point.   At the 3-month time-point, 13 participants had 
changed their alcohol drinking patterns.  At the 6-month time-point, 12 participants 
had changed their alcohol drinking patterns. The number of sessional drinkers 
decreased over the study period.  Additionally five individuals changed their alcohol 
consumption pattern to consuming no alcohol in the week prior to blood sampling at 
the three and six month time-points.  Figure 3.7 demonstrates the potential influence 
of the study on the drinking patterns of study participants.  
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Figure 3.7: HI Study participants’ (N=35) alcohol drinking patterns during study 
period. 
 
3.3.2 HI Study Participants who Consume Alcohol in a Sessional Pattern   
 
The HI study participants were sub-grouped to investigate only sessional drinkers 
(N=17).  The consumption of alcohol by sessional drinkers was investigated and the 
number of days for which sessional alcohol consumption was undertaken at 
baseline and compared to the number of non-sessional drinking days (consumption 
of less than 48 g (females) and 64 g (male)) and the number of alcohol-free days, as 
shown in figure 3.8.   
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Figure 3.8: Alcohol consumption compared in a sample of sessional drinkers (N=17)  
 
From figure 3.8, it is clear that sessional alcohol consumption was most commonly 
undertaken on one day within a week, within this sample, and is further illustrated in 
figure 3.9, where the grams of alcohol consumption on day 2 has the highest 
median value and range.  Day 2 had the largest range of grams of alcohol 
consumed and the highest median value, which for 82.3% (N=14) of the sample was 
a week day.  Day two was a weekend day for three participants (N=3).  This finding 
links with figure 3.9, where the highest sessional consumption of alcohol was 
undertaken on just one day. 
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Figure 3.9: Box plots of baseline alcohol consumption (g) per day of diet diary recall 
within sessional drinkers.  (Box plots represents the following: solid bar in box (median 
50th percentile), top of box (75th percentile (upper quartile), bottom of box 25th percentile 
(lower quartile), top whisker (largest value which is not an outlier or extreme score), bottom 
whisker (smallest value which is not an outlier or extreme score).  ● = Outlier (More than 1.5 
box lengths above or below the box).  * = Extreme case (more than 3 box lengths above or 
below the box. 
 
Male sessional drinkers consumed alcohol on more drinking days in comparison to 
females during the baseline week of monitoring.  There was a significant difference 
(p=0.038), in the number of sessional drinking days in a week between male and 
female sessional drinkers.  Males undertook sessional drinking more frequently in 
the baseline monitoring week in comparison to female sessional drinkers.   
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3.3.3 ADI Study  
 
The alcohol consumption of the ADI study participants was self-reported by each 
participant using the study questionnaire.  Table 3.6 describes the alcohol 
consumption within the sample of alcohol-dependent individuals.   
 
Table 3.6: Alcohol consumption by ADI study participants (N=18) 
First contact with Alcohol Problems 
Service (APS) (N) 
38.9% (7) <1 year of contact 
38.9% (7) 2-10 years of contact 
22.2% (4) >10 years of contact 
Type of Alcohol Consumed (N) 55.5% (10) consumed one type of 
alcoholic beverage 
44.4% consumed two or more types of 
alcoholic beverage 
Frequency of Consumption in Last Year 
(N) 
83.3% (15) Daily 
16.7% (3) Weekly 
Days Since Last Alcoholic Drink before 
Blood Sampling (Median; Mean (SD; 
Range)) 
2; 2, (1; 1-7) 
Hours Since Last Alcoholic Drink before 
Blood Sampling (Median; Mean (SD; 
Range)) 
48; 50 (37; 24-168) 
Reported number of days in month when 
alcohol was consumed (Median; Mean 
(SD; Range)) 
30; 29 (4;15-31) 
Alcohol Consumed/Daily (g) (Median; 
Mean (SD; Range)) 
222.0; 245.8 (125.4; 80-678.6) 
 
More than half of the sample, 55% (N=10) reported consumption of just one type of 
alcoholic drink (spirits (N=6), cider (N=2), beer (N=2)).  A high percentage of the 
sample consumed alcohol on a daily basis (median value of 2 alcohol free days 
before entering detoxification treatment).  The grams of alcohol consumed daily 
before entering treatment encompassed a wide range with the lowest value being 80 
g and the highest daily alcohol consumption level being 678.6 g.   
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3.3.4 Comparison of Alcohol Consumption between Healthy Individuals and 
Alcohol Dependent Individuals 
 
Alcohol consumption data was gathered from all study participants.  At baseline data 
from the ADI study was compared with data obtained from the HI study and is 
shown in figure 3.10.  
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Figure 3.10: Mean alcohol consumption per drinking day of HI study participants 
(N=35) and ADI study participants (N=18) at baseline.  Error bars represent 
standard deviation (SD). 
 
The direct comparison of the heaviest drinkers in the HI study (sessional drinkers) 
with alcohol dependent individuals is shown in figure 3.11.  The median alcohol 
consumed by sessional drinkers is lower that that of alcohol dependent patients.  
There was one outliner in each sample group, who consumed alcohol in an amount 
out with the range of the total sample.  There was a significant difference (p<0.05) in 
the grams of alcohol consumed per day by sessional drinkers when compared to 
alcohol dependent individuals.  However figure 3.11 clearly shows that sessional 
drinkers can consume the same grams of alcohol per day as an alcohol dependent 
individual.  
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Figure 3.11: Box plot of alcohol consumption (g) per daily of sessional drinkers and 
alcohol dependent individuals (▲p<0.05, Mann-Whitney test). (Box plots represents 
the following: solid bar in box (median 50th percentile), top of box (75th percentile (upper 
quartile), bottom of box 25th percentile (lower quartile), top whisker (largest value which is not 
an outlier or extreme score), bottom whisker (smallest value which is not an outlier or 
extreme score).  ● = Outlier (More than 1.5 box lengths above or below the box).  * = 
Extreme case (more than 3 box lengths above or below the box. 
 
 
 
 
 
 
 
 
 
▲ 
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3.4 Carbohydrate Deficient Transferrin (CDT): HPLC Method Development  
 
This method outlined by Helander et al. 2003 was implemented at QMU and 
University of Edinburgh laboratories as described in chapter 2.  This section will 
describe the results from the HPLC method development and the resulting use of 
the N-Latex CDT immunoassay for CDT sample analysis.   
3.4.1 Sample Preparation and Mobile Phase Development 
 
The preparation of serum samples for CDT analysis by HPLC involves the complete 
saturation of iron within the sample and lipid precipitation.  This is done by the 
addition of 20 µl FeNTA solution and 20 µl dextran sulphate-CaCl2.  The serum 
sample prepared as above and using the mobile phase gradient detailed in the 
method was injected into the HPLC system and the resulting chromatogram is 
shown in figure 3.12. 
 
The chromatogram in figure 3.12, does show a small peak at the retention time 
where transferrin should approximately elute from the column, according to the 
method by Helander et al. (2003).  However, the peak is only slightly visible.  To 
improve the separation of the transferrin glycoforms on the chromatogram, the 
volumes of FeNTA and dextran sulphate-CaCl2 were increased to 40 µl.  The 
gradient of the salt concentration within the mobile phase was also altered to 
increase the volume of salt being pumped into the column.  The gradient was 
increased to 100%, whereby the mobile phase buffers were not increased on a 
gradient incline, but were at the same flow rate, throughout the duration of the HPLC 
run.  The result of this alteration to the mobile phase and sample preparation is 
shown in chromatogram figure 3.13. 
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Figure 3.12: 20% Salt Gradient Mobile Phase and 20 µl FeNTA and Dextran Sulphate-CaCl2.  (X-axis = retention time (minutes); Y-axis = 
absorbance (mAU).  Detector: ultraviolet (UV); volume injected: 400 µl; wavelength: 470 nm; total run time: 20 minutes.  
Identifiable Peak  
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Figure 3.13: 100% salt gradient mobile phase and 40 µl FeNTA and Dextran Sulphate-CaCl2.  (X-axis=retention time (minutes), 
Y-axis=absorbance (mAU).  Detector: ultraviolet (UV); volume injected: 400 µl; wavelength: 470 nm; total run time: 20 minutes. 
Identifiable Peak  
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As illustrated in the chromatogram (figure 3.13), the increased salt mobile phase 
gradient, produced an increased iron saturation and lipid precipitation which 
provided a clearer and identifiable peak at 15 minutes.  As described by Helander et 
al. (2003) the first transferrin glycoform elutes from the column at approximately 15 
minutes.  To identify the peak which eluted at 15 minutes, fractions were collected 
and subjected to protein gel electrophoresis and mass spectroscopy, as described 
in chapter 2.   
 
3.4.2 Protein Gel Electrophoresis 
 
Ten fractions were collected from the HPLC run which identified a protein peak at 15 
minutes.  The fractions collected were subjected to protein gel electrophoresis to 
identify if a CDT glycoform had eluted from the column.    Figure 3.14 shows the gel 
electrophoresis result and highlights the presence of a protein which has a similar 
weight to the glycoforms which form CDT.  This suggested that further work was 
required to identify which CDT glycoforms were eluted from the HPLC column at 15 
minutes. 
 
 
Figure 3.14: Protein gel electrophoresis of fractions collected from the HPLC 
analysis shown in figure 3.13. 
Lane Number  
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Mass spectroscopy analysis was carried out on the fractions to further identify if one 
or all CDT glycoforms were present.  From the literature the molecular weights of 
the transferrin glycoforms which form CDT were identified and are shown in table 
3.7.  
 
Table 3.7: Molecular Weight of CDT Glycoforms (Oberrauch, Bergman and 
Helander 2008; Peter et al. 1998) 
CDT Glycoform Molecular Weight (Da) 
Asialotransferrin 75157 
Monosialotransferrin 77180 
Disialotransferrin 77365 
Triaialotransferrin 79281 
Tetrasialotransferrin 79573 
Pentasialotransferrin 80232/80379 
 
Transferrin glycoforms, which form CDT, were detected in each of the fractions 
collected, which was confirmed by mass spectrometry analysis.  The primary 
analyte for CDT analysis, Disialotransferrin (Jeppsson et al. 2007), was confirmed 
as being present in the fractions collected from the HPLC analysis, as illustrated in 
figure 3.15. 
 
From the data generated from the mass spectroscopy (figure 3.15), it can be 
suggested that within the peak which eluted at 15 minutes during the HPLC run 
there was evidence of the presence of CDT glycoforms, as the presence of the 
corresponding molecular weights were present in the mass spectroscopy 
spectrums.  However more work is required to fully investigate the exact contents of 
the peak which eluted at 15 minutes.  
 
3.4.3 Summary 
 
After subsequent method development using various techniques, the CDT HPLC 
method for the detection of CDT in human serum could not be validated at either 
QMU or University of Edinburgh laboratories.  At both laboratories the separation of 
the CDT glycoforms using HPLC was not successful, meaning the concentration of 
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the CDT glycoform which is affected by alcohol consumption, namely 
Disialotransferrin could not be determined.  This was due to the inability to separate 
the individual glycoforms which form CDT.  Further work is needed to validate this 
HPLC method.  It was for these reasons that, the N-Latex immunoassay method for 
CDT analysis implemented at the Northern General Hospital in Sheffield was used 
to analyse selected serum samples for CDT from the HI, ADI and stability studies.   
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Figure 3.15: Mass spectroscopy of fraction E9, showing presence of CDT glycoform, Disialotransferrin.  (Sample Volume: 0.5 µl; Matrix: 
Sinapinic acid; Matrix Volume: 0.5 µl; Total Well Volume: 1 µl; Polarity: Positive; Laser intensity: 2086; Accelerating Voltage: 25,000 volts).
Disialotransferrin 
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3.5 Carbohydrate Deficient Transferrin (CDT) and Alcohol Consumption 
 
The consumption of alcohol was determined using questionnaires and diaries.  
Alcohol consumption was also determined using biological biomarkers of alcohol 
consumption, which reduces the errors associated with memory recall and accuracy 
in recording alcohol consumption.    
 
3.5.1 CDT Levels within Healthy Individuals (HI) who Consume Alcohol in a 
Range of Patterns 
 
CDT was measured in serum using the N-Latex immunoassay at the Northern 
General Hospital in Sheffield, as described in chapter 2.  A positive test result using 
the CDT N-Latex immunoassay is indicated by a result of >2.6% of bound CDT in 
the serum sample.  A participant is deemed to have a positive test result for CDT 
levels, if the result is greater than 2.6% of bound CDT in the serum sample 
analysed.  If the result is greater than 2.6%, this result is indicative of the participant 
drinking in a harmful pattern and above the responsible UK drinking guidelines.  The 
percentage of CDT identified in each of the alcohol drinking pattern groups is 
presented in figure 3.16.  There was no significant difference in the levels of serum 
%CDT found in each alcohol drinking group at each of the pre-defined study time-
points, illustrated in figure 3.16. 
 
CDT is calculated by according to the instructions and calibrators provided within the 
Dade Behring N-Latex kit.  A reference curve is generated by multi-point calibration, 
which is performed by the Dade Behring BN ProSpec© System.  The results of each 
sample batch are performed automatically and the calculation of %CDT is integrated 
within the software used by the Dade Behring BN ProSpec© System.    The 
principle of the N-Latex method and calculation of %CDT is explained fully in 
chapter 2, section 2.4.2.2.   
 
Due to the high running costs of sample analysis by the N-Latex immunoassay, only 
12 study participants’ samples were analysed.  Study participants were selected 
from baseline alcohol consumption data, whereby serum samples analysed were 
from participants who either abstained from alcohol (control) or consumed alcohol 
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according to the definition of sessional drinking.  Serum samples from the selected 
study participants were analysed for every study time-point.   
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Figure 3.16: Box plots of %CDT in serum of HI study (N=12) sample categorised according to alcohol drinking pattern as determined by 
the AM method from diaries at baseline.  Horizontal line represents the cut-off value for a positive CDT result of >2.6%.  (Box plots 
represents the following: solid bar in box (median 50th percentile), top of box (75th percentile (upper quartile), bottom of box 25th percentile (lower 
quartile), top whisker (largest value which is not an outlier or extreme score), bottom whisker (smallest value which is not an outlier or extreme score).  
● = Outlier (More than 1.5 box lengths above or below the box).  * = Extreme case (more than 3 box lengths above or below the box). 
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%CDT at baseline and mean alcohol consumption during drinking days at baseline 
was not significant (p=0.656, R=-0.144), for all HI study participants who were 
selected for CDT analysis.  This association between the two variables was also not 
significant at the 3-month time-point.  However at the 6-month time-point, a 
significant positive correlation was identified between %CDT and mean alcohol 
consumption during drinking days (p=0.027, R=0.635).  The association, at the 6-
month time-point in shown in figure 3.17. 
 
 
Figure 3.17: Scatter plot of % CDT at baseline in serum for HI study sample (N=12) 
in relation to 6-month mean alcohol consumption per drinking day in grams, from 
diary (AM method) (p=0.027, R=0.635 Spearman’s test). 
 
 
 
 
176 
Of the HI study sample tested for CDT levels (N=12), 41.7% (N=5) had a positive 
test result of greater than 2.6% using the N-Latex immunoassay.   All were 
categorised from diaries as sessional drinkers.   
 
 
3.5.2 CDT Levels within Alcohol Dependent Individuals (ADI) 
 
The percentage of CDT (%CDT) identified in the ADI study sample at predetermined 
study time-points is shown in figure 3.18.   
 
 
Figure 3.18: Box plots of %CDT in serum in ADI study sample (N=18) at two 
predetermined study time-points (▲p=0.017, Mann-Whitney Test).  (Box plots 
represents the following: solid bar in box (median 50th percentile), top of box (75th percentile 
(upper quartile), bottom of box 25th percentile (lower quartile), top whisker (largest value 
which is not an outlier or extreme score), bottom whisker (smallest value which is not an 
outlier or extreme score).  ● = Outlier (More than 1.5 box lengths above or below the box).  * 
= Extreme case (more than 3 box lengths above or below the box. 
 
▲ 
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The box plots shown in figure 3.18 highlight the significant reduction (p=0.017) in 
CDT levels from day 1 to day 3, which has been influenced by alcohol detoxification 
treatment.  A dot plot, as shown in figure 3.19, shows that 69.2% (N=13) of the 
study sample had a positive %CDT result on day 1.    
 
 
Figure 3.19: Dot plot %CDT in serum of ADI participants (N=13) on day 1, in relation 
to positive result.  The vertical reference line represents the reference cut off value 
of >2.6% as a positive result within the %CDT N LATEX assay. 
 
 
3.5.3 CDT Levels within Drinkers Combined Sample (HI and ADI)  
 
In the sample of all drinkers (N=23), regardless of drinking pattern, the range of 
%CDT on day 1 was 1.55%-8.09%.  The sample number for CDT analysis 
decreased from N=44 to N=23, due to the limited provision for CDT analysis.   
 
The relationship between alcohol consumption and %CDT is shown in figure 3.20.  
An association between alcohol consumption and %CDT on day one/baseline was 
not significant (p=0.123, R=0.331).  The R value was recalculated after removal of 
the outlier (alcohol consumption of >600 g), which produced a significant correlation 
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(p=0.027, R=0.469).  The participant, who recorded in their study questionnaire that 
they consumed greater than 600 g of alcohol prior to alcohol detoxification 
treatment, was found to have a negative %CDT result, which would not be 
consistent with the volume of self-reported alcohol consumption.  Literature 
evidence (Jeppsson et al. 2007) suggests that the half-life of CDT is 2 weeks, which 
could indicate that this individual, could have consumed approximately 600 g of 
alcohol, however this was not within the 2 week period prior to blood sampling, 
further warranting the removal from correlation analysis.   This finding suggests that 
the participant was not accurate in his questionnaire completion.  This suggests that 
CDT can be used as a biomarker in a sample of individuals who consume alcohol in 
range of patterns, including non-dependent patterns.  
 
Figure 3.20: Serum %CDT plotted as a function of alcohol consumption per day.  
(p=0.027, R=0.469, Spearman’s test).  
 
3.5.4 CDT Levels in a Sample of Sessional Drinkers 
 
Literature suggests that serum CDT can be elevated following the consumption of 
more than 50 g of alcohol daily over a consistent period of 2 weeks (Jeppsson et al. 
2007).  The %CDT cut off value for a positive result is shown in figure 3.22, where 
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five sessional drinkers, within the study sample have a positive CDT result of greater 
than 2.6%.  This is indicative of 55.6% of the total sample of HI sessional drinkers 
(N=9), tested for CDT levels, having a positive result, indicating harmful drinking.   
 
 
Figure 3.21: Dot plot of %CDT in serum within sessional drinker’s sample (N=9), in 
relation to positive test result.  The vertical reference line represents the reference 
cut off of >2.6% as a positive result within the %CDT N LATEX assay. 
 
The value of %CDT at baseline did not significantly correlate with the number of 
drinking days within a week, using a Spearman’s test (p=0.124, R=0.551), which 
was also found at the three and six month time-points, in a sample of sessional 
drinkers.  A significant linear relationship (p=0.01, R=0.98) between the number of 
drinking days and the mean %CDT at baseline within a sample of sessional drinkers 
was identified (figure 3.22). 
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Figure 3.22: Linear relationship between %CDT at baseline in sessional drinkers 
(N=9) and number of drinking days in a week (p=0.01, R=0.98 Spearman’s test) 
 
3.5.5 CDT Levels Compared in Samples of Sessional Drinkers and Alcohol 
Dependent Individuals  
 
The median levels of serum %CDT were higher in alcohol dependent patients in 
comparison to sessional drinkers; as illustrated in figure 3.23.   There was one 
outlier within the sessional drinkers group, which was above the box plot range.  A 
significant difference between %CDT levels in sessional drinkers and alcohol 
dependent patients (p=0.030) was evident.  This result suggests that CDT levels are 
significantly different between the two studies; however the median %CDT levels for 
both studies were above the 2.6% cut-off value for a positive result, suggesting that 
sessional patterns of alcohol consumption and alcohol-dependent consumption can 
affect CDT levels.   
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Figure 3.23: Box plots of serum %CDT in a sample of sessional drinkers compared 
to alcohol dependent patients (▲p=0.030, Mann-Whitney test) (Box plots represents 
the following: solid bar in box (median 50th percentile), top of box (75th percentile (upper 
quartile), bottom of box 25th percentile (lower quartile), top whisker (largest value which is not 
an outlier or extreme score), bottom whisker (smallest value which is not an outlier or 
extreme score).  ● = Outlier (More than 1.5 box lengths above or below the box).  * = 
Extreme case (more than 3 box lengths above or below the box. 
 
3.6. Validation of Plasma Homocysteine Assay 
 
3.6.1 Linearity 
 
The calibration graph for the determination of homocysteine in plasma is shown in 
figure 3.24.  The calibration graph of an aqueous solution of homocysteine was 
linear in the concentration range of 0-20 µmol/l.  The equation of the regression 
graph was y=33258X+76144.  The coefficient of determination for the calibration 
curve, R2=0.998, which is greater than 0.99 which is the value required for an 
▲ 
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accurate HPLC analysis.    A sample chromatogram of a homocysteine standard is 
shown in figure 3.25.  Furthermore figure 3.26 shows a chromatogram of 
homocysteine detected in a plasma sample. 
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Figure 3.24: Area under the peak plotted as a function of homocysteine standard 
concentration (µmol/l).  (R=0.9994) 
 
 
 
Figure 3.25: Chromatogram showing a homocysteine standard separation by HPLC.  
MilliVolts (mV) plotted as a function of time (minutes).  (Detector: electrochemical 
(ED); Volume Injected: 20 µl; Sensitivity Setting: +0.86 volts; Flow Rate: 0.8 
ml/minute; Total Run Time: 20 minutes). 
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Figure 3.26: Chromatogram showing homocysteine in plasma separated using 
HPLC.  MilliVolts (mV) plotted as a function of time (minutes).  (Detector: 
electrochemical; volume Injected: 20 µl; sensitivity setting: +0.86 volts; flow rate: 0.8 
ml/minute; total run time: 20 minutes). 
 
3.6.2 Precision (Intra and Inter-assay) 
 
Duplicate injections of the homocysteine standards 25% and 200% (which 
represents the upper and lower concentrations of the range) were performed.  The 
%CV was compared for HPLC runs conducted on the same day (intra-assay) and 
compared with results obtained on different days (inter-assay) as shown in table 3.8 
and 3.9 respectively.   
 
 
 
 
 
 
 
 
Homocysteine  
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Table 3.8: Intra-Assay measurements for both 25% and 200% concentrations of 
homocysteine.   
Standard   
Concentration 
(%) 
Injection 1 
% (µmol/l) 
Injection 2 
% (µmol/l) 
Injection 3 
% (µmol/l) 
Mean ±SD % 
(µmol/l) 
CV 
(%) 
200%  
(20 µmol/l) 
195.2 
(20.6) 
195.2 
(20.6) 
195.2 
(20.6) 
195.2±0.0 
(20.6±0.0) 
0.0 
(0.0) 
25%  
(2.5 µmol/l) 
19.1  
(2.0) 
18.7 
(1.9) 
18.9 
(2.0) 
18.9±0.2 
(2.0±0.00) 
1.0 
(0.0) 
 
Table 3.9: Inter-Assay measurements for both 25% and 200% concentrations of 
homocysteine.   
Standard 
Concentration 
(%) 
Injection 1 
%  
(µmol/l) 
Injection  2 
%  
(µmol/l) 
Injection  3 
% 
 (µmol/l) 
Mean ±SD % 
(µmol/l) 
CV 
(%) 
200%  
(20 µmol/l) 
195.5 
(20.8) 
194.7 
(20.6) 
194.6 
(20.6) 
195.3±0.9 
(20.6±0.1) 
0.4 
(0.6) 
25%  
(2.5 µmol/l) 
24.9 
(2.6) 
24.2 
(2.6) 
24.3 
(2.6) 
24.5±0.4 
(2.6±0.0) 
1.6  
(1.6) 
 
3.6.3 Summary 
 
The %CV for both intra and inter assays was less than 5%, concluding that this 
HPLC method is a valid and reliable assay for the detection of homocysteine in 
plasma.
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3.7 Plasma Homocysteine and Alcohol Consumption  
 
Homocysteine was measured in plasma using high pressure liquid chromatograph 
(HPLC) with electrochemical detection (ED) as described in chapter 2.   
3.7.1 Plasma Homocysteine Levels within Healthy Individuals (HI) who 
Consumed Alcohol in a Range of Patterns 
 
The homocysteine concentration identified in each of the alcohol drinking patterns is 
represented in figure 3.27. 
 
 
Figure 3.27: Box plots of plasma homocysteine levels (µmol/l) at each study time-
point in healthy individuals (HI; N=35) grouped according to alcohol drinking pattern 
(Box plots represents the following: solid bar in box (median 50th percentile), top of box (75th 
percentile (upper quartile), bottom of box 25th percentile (lower quartile), top whisker (largest 
value which is not an outlier or extreme score), bottom whisker (smallest value which is not 
an outlier or extreme score).  ● = Outlier (More than 1.5 box lengths above or below the 
box).  * = Extreme case (more than 3 box lengths above or below the box. 
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The median plasma homocysteine remained relatively constant and did not change 
significantly for the total HI study sample over the study period.  There was a non-
significant increase (p=0.135) in plasma homocysteine levels at each pre-defined 
study time-point for the responsible drinkers (N=2).  There was also no significant 
difference between plasma homocysteine at each study time-point for the other 
drinking pattern groups.  There was no significant association between baseline 
plasma homocysteine measurement and number of drinking days at baseline.  No 
significant difference between plasma homocysteine at baseline and frequency of 
alcohol consumption as stated by participants in the study questionnaire was 
evident.  Plasma homocysteine baseline values and mean alcohol consumption 
during drinking days at baseline showed no correlation for each of the alcohol 
drinking patterns (figure 3.28).  The association between these two variables was 
also not significant at the 3-month and 6-month time-points.   
 
Figure 3.28: Scatter plot of plasma homocysteine concentration (µmol/l) in relation 
to HI study participant’s mean alcohol consumption during drinking days  
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Plasma homocysteine can be affected by age and gender (Antoniades et al. 2009).  
However no association between plasma homocysteine baseline measurement and 
age of participants was evident.  There was no significant difference between 
plasma homocysteine levels in female and male participants at baseline (p=0.099), 
suggesting there was no difference in the levels of plasma homocysteine between 
the two genders.  There was also no significant difference in plasma homocysteine 
between the two genders at the three and six month time-points.  Figure 3.29, 
illustrated the plasma homocysteine levels in female and male participants recruited 
to the HI study, at baseline. 
Figure 3.29: Boxplot of plasma homocysteine (µmol/l) at baseline in relation to HI 
study participant’s gender (Box plots represents the following: solid bar in box (median 
50th percentile), top of box (75th percentile (upper quartile), bottom of box 25th percentile 
(lower quartile), top whisker (largest value which is not an outlier or extreme score), bottom 
whisker (smallest value which is not an outlier or extreme score).  ● = Outlier (More than 1.5 
box lengths above or below the box).  * = Extreme case (more than 3 box lengths above or 
below the box. 
 
Literature evidence suggests certain lifestyle factors including smoking, hormonal 
contraception and the menopause can influence plasma homocysteine levels 
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(Russo et al. 2008).  Participants were asked to self-report on their study 
questionnaire if they were cigarette smokers.  There was no significant difference in 
plasma homocysteine levels at all time-points between smokers (N=4) and non-
smokers (N=31), indicating that in the study sample smoking did not have an effect 
on plasma homocysteine levels.  Female participants were asked to state if they 
used hormonal contraception and if they were menopausal.  No female participants 
were recruited into the HI study that were menopausal.  The participants who used 
hormonal contraception (N=9), were asked to state the brand of hormonal 
contraception used, either combined (N=5) or progesterone only contraceptives 
(N=4).  There was no significant difference in the plasma homocysteine levels at all 
time-points for the female participants who used either progesterone only 
contraceptives and combined contraceptives.  This finding suggests that hormonal 
contraception did not impact on plasma homocysteine levels in the sample.   
 
The utility of both plasma homocysteine and serum CDT to act as biomarkers of 
cardiovascular disease and alcohol consumption respectively, have not been  
investigated in terms of a identifying a potential correlation between these 
biomarkers.  An association was investigated between the levels of CDT (%) and 
plasma homocysteine (µmol/l) in the HI study sample.  All Spearman’s tests were 
not significant for an association between elevated CDT and plasma homocysteine 
in the HI study sample.   
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3.7.2 Plasma Homocysteine Levels within Alcohol Dependent Individuals (ADI) 
 
Plasma homocysteine concentrations at the pre-defined study time-points are 
represented in figure 3.30. 
 
 
Figure 3.30: Box plots of homocysteine in plasma (µmol/l) for ADI study sample 
(N=18) (Box plots represents the following: solid bar in box (median 50th percentile), top of 
box (75th percentile (upper quartile), bottom of box 25th percentile (lower quartile), top 
whisker (largest value which is not an outlier or extreme score), bottom whisker (smallest 
value which is not an outlier or extreme score).  ● = Outlier (More than 1.5 box lengths 
above or below the box).  * = Extreme case (more than 3 box lengths above or below the 
box. 
 
No significant difference between homocysteine measured on day 1 and day 3 
(p=0.117) was seen. Homocysteine measurement on day 1 or day 3 did not 
significantly correlate with daily alcohol consumption in grams.  No association 
between homocysteine measured on day 1 and patient age was evident.  There was 
no association between plasma homocysteine and serum CDT, which reflect the 
result found in the HI study sample. 
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The effect of smoking on plasma homocysteine levels was also investigated in the 
ADI study sample.   There was a higher number of smokers in the ADI study (N=10), 
compared to the HI study, however there was no significant difference in the plasma 
homocysteine levels at each study time-point between smokers and non-smokers, 
further indicating that smoking did not affect plasma homocysteine.  The effect of 
hormonal contraception could not be investigated in the female participants (N=3) of 
the ADI study, as no female participants self-reported that they used hormonal 
contraception.  
 
A possible relationship between homocysteine concentrations and type of alcohol 
consumed on both days 1 and 3 was investigated and is shown in figure 3.31.  
Twelve participants consumed one type of alcoholic beverage only.  A higher 
number of participants consumed spirits only (N=6), compared with participants who 
consumed only cider (N=2) and beer (N=2).   From the bar chart shown in figure 
3.31, only consumption of beer suggested there was a reduction in plasma 
homocysteine levels from day 1 to day 3; however this did not take into 
consideration the amount of alcohol consumed.   
 
 
Figure 3.31: Bar chart of plasma homocysteine (µmol/l) in relation to type of alcohol 
consumed. 
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3.7.3. Plasma Homocysteine Levels in a Sample of Sessional Drinkers 
 
The range of plasma homocysteine measured at baseline in a sample of sessional 
drinkers, showed the presence of one outlier and three extreme outliers within the 
sample.   
 
Figure 3.32 presents the plasma homocysteine levels detected within the group of 
sessional drinkers in relation to the clinical reference range.   The four sessional 
drinker who were outside of the clinical reference range of 5-15 µmol/l (Antoniades 
et al. 2009), were evenly split relating to gender, male (N=2), female (N=2), as 
highlighted in figure 3.32.  The four participants who exhibited plasma homocysteine 
levels above the maximum reference range limit of 15 µmol/l, the plasma 
homocysteine levels did not significantly change (p=0.652) during the study period.  
For these four outliers their mean alcohol consumption during drinking days did not 
statistically (p=0.642) change for the study period.  Furthermore the vitamin co-
factors, folate and vitamin B12 were also exhibiting low levels, below 5 µg/l for folate 
and 200-300 ng/l for vitamin B12.  For serum folate there was a significant increase 
(p<0.05) during the study duration, however there was no significant increase 
(p=0.184) in vitamin B12 levels.   This would be consistent with the literature 
evidence which clearly identifies the link between elevated plasma homocysteine 
and low levels of vitamin B12 and folate (Antoniades et al. 2009).  There was a lack 
of an inverse significant correlation between plasma homocysteine and the serum 
vitamin co-factors in these outlying participants, however this could be due to the 
low sample number (N=4)   Further analysis of these individuals who were 
undertaking sessional drinking, highlighted that none of these participates were 
shown to carry the mutant MTHFR(C677T) polymorphism, further highlighting a 
potential link between sessional alcohol consumption and elevated plasma 
homocysteine levels.  There was no clinical data, e.g. liver function, blood pressure, 
cholesterol or lipid levels available, on the aforementioned outliers.  It is important to 
state that as part of the HI study protocol, clinical data on liver function, blood 
pressure, cholesterol or lipid levels for any participant was not collected or part of 
the study design.   
 
Although plasma homocysteine is not routinely used as a diagnostic biomarker 
within UK hospital laboratories, the use of homocysteine as a predictor of 
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cardiovascular disease risk has been well established in the literature, through 
numerous laboratory studies and clinical trials (Antoniades et al. 2009; Bonaa et al. 
2006; Lonn 2008; Refsum et al. 1998).  Many peer reviewed studies have been 
published showing a clear link between elevated plasma homocysteine and clinical 
signs of the on-set of cardiovascular disease.  Furthermore there is no evidence in 
the literature that diuresis has an effect on circulating homocysteine levels (Verhoef 
et al. 2002).  This is an important point to consider, as alcohol consumption does 
have an impact on diuresis.   
 
 
Figure 3.32: Dot plot of sessional drinkers (N=17) plasma homocysteine (µmol/l) 
levels, in relation to clinical reference range.  The vertical reference lines represent 
the minimum (5 µmol/l) and maximum (15 µmol/l) clinical reference range for plasma 
homocysteine. 
  
There was no association between plasma homocysteine and mean alcohol 
consumption during drinking days at baseline in a sample of sessional drinkers, 
(p=0.743, R=-0.086). The non-significant correlation was also found at the at 3-
month and 6-month time-points.  
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3.7.4 Plasma Homocysteine Levels within Drinkers Combined Sample (HI and 
ADI)  
 
The plasma homocysteine, median and range recorded for all drinkers (the HI and 
ADI study combined samples, not including the abstainers), (N=44) was 
investigated.  There were six outliers within the sample.  Figure 3.33 represents 
each drinker’s plasma homocysteine concentration and where it falls within the 
clinical reference range; 23.53% (N=11) of the sample had plasma homocysteine 
above 15 µmol/l.  Of this percentage 9.1% were ADI study participants and 15.9% 
were HI study participants.   
 
 
Figure 3.33: Dot plot of homocysteine in plasma (µmol/l) for all drinkers (N=44) in 
the sample and relationship to clinical reference range.  The vertical reference lines 
represent the minimum (5 µmol/l) and maximum (15 µmol/l) clinical reference range 
for plasma homocysteine. 
 
There was no significant correlation between daily alcohol consumption in grams 
and plasma homocysteine levels in a sample of individuals who consume alcohol, 
regardless of pattern (p=0.795, R=-0.043).  
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3.7.5 Comparison of Plasma Homocysteine Levels between Sessional 
Drinkers and Alcohol Dependent Individuals  
 
The median plasma homocysteine levels in sessional drinkers and alcohol 
dependent patient group were similar, 7.20 µmol/l and 7.89 µmol/l respectively and 
is illustrated in figure 3.34.  Within the box plots shown in figure 3.34, the sessional 
drinkers group did shown 3 extreme outliers and 1 outlier within the sample, 
compared with just one outlier within the alcohol dependent patient sample.  There 
was no significant difference between the levels of homocysteine in each patient 
group (p=0.818).   
 
Figure 3.34: Box plots of homocysteine in plasma in a sample of sessional drinkers 
compared to alcohol dependent patients (Box plots represents the following: solid bar in 
box (median 50th percentile), top of box (75th percentile (upper quartile), bottom of box 25th 
percentile (lower quartile), top whisker (largest value which is not an outlier or extreme 
score), bottom whisker (smallest value which is not an outlier or extreme score).  ● = Outlier 
(More than 1.5 box lengths above or below the box).  * = Extreme case (more than 3 box 
lengths above or below the box. 
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3.8 Homocysteine in Urine: Method Development  
 
As described in chapter 2, method development for the detection of homocysteine in 
human urine was undertaken.  In published literature homocysteine is analysed 
within serum and plasma routinely, however, methods have also been published for 
the detection of homocysteine in urine (Thomson and Tucker 1986; Thomson and 
Tucker 1985).  Urine is a less invasive biological fluid to collect, reducing the need to 
carry out venepuncture.  A detection method for homocysteine in urine would be 
useful clinically and for research.   
 
In the published method (Thomson and Tucker 1986) for the detection of 
homocysteine in urine, the result was expressed as homocysteine per milligrams of 
creatinine.  Therefore every urine sample analysed for homocysteine was also 
analysed for creatinine concentration using the Jaffe method as described in chapter 
2.  Creatinine is commonly used to normalise urinary markers however there are 
problems associated with the sensitivity and efficiency of the assay (Waikar et al. 
2010).  The problems associated with creatinine levels, can be induced through 
injury to the kidney which disrupts urine production, therefore causing an inbalance 
in creatinine kinetics and urine excretion, therefore resulting in the underestimation 
of both creatinine and the subsequent biomarker (Waikar et al. 2010).  It is important 
to note that no participants in either study (HI and ADI) self-reported kidney injury or 
problems with urination.  There are other substances used to determine normal 
urinary excretion, which includes p-aminobenzoic acid (PABA).  The use of PABA 
can determine if urine 24 hour collection has been completed by determining the 
recovery of the compound.  However this involves measuring PABA which was 
ingested and both the HI and ADI studies did not ask participants to ingest PABA to 
determine its recovery and as only a single waking urine sample was required, the 
use of PABA was not justified.     The use of creatinine to normalise urinary 
homocysteine and other alcohol biomarkers has been well established in the 
literature (Bergström et al. 2003; Kusmierek et al. 2006; Thomson and Tucker 
1986).   
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3.8.1 Calibration 
 
A calibration standard curve of homocysteine was carried out using the same 
procedure as described for the analysis of homocysteine in plasma.  The calibration 
graph of an aqueous solution of homocysteine was linear in the concentration range 
of 0-20 µmol/l.  The equation of the linear graph was y=25241X+114619 and the 
coefficient of determination for the calibration was R2=0.99.  The calibration graph is 
shown in figure 3.35. 
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Figure 3.35: Calibration of homocysteine measured in urine 
3.8.2 Results 
 
All samples were analysed for homocysteine in urine, both from the HI and ADI 
studies.  HPLC runs were conducted in batches and in duplicate as described in the 
method chapter.  Homocysteine expressed in urine, eluted form the HPLC column at 
approximately 8 minutes, which is consistent with the retention time stated in the 
peer-reviewed method paper (Thomson and Tucker 1986).  The retention time for 
urine was different from plasma homocysteine analysis, by a difference of two 
minutes, meaning the homocysteine peak detected in urine elutes from the column 
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earlier.  The potential reasons for this could be based in the different types of 
biological fluid and their interaction with the column binding sites, causing a faster 
elution profile.    Figures 3.36 and 3.37 are examples of chromatograms with a 
positive homocysteine detection and negative homocysteine detection in urine 
respectively.   
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Figure 3.36: Positive Homocysteine in Urine Chromatogram  Figure 3.37: Negative Homocysteine in Urine Chromatogram 
Detector: electrochemical; volume injected: 20 µl; flow 
rate: 0.8 ml/min; sensitivity setting: +0.86 volts; total run 
time: 15 minutes.   
Detector: electrochemical; volume injected: 20 µl; flow 
rate: 0.8 ml/min; sensitivity setting: +0.86 volts; total run 
time 15 minutes. 
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There were a total of 35 HI participant urine samples analysed in duplicate and from 
these samples, 22.9% (N=8) generated a peak for homocysteine at the anticipated 
retention time.  Over 75% of the urine samples did not contain detectable levels of 
homocysteine.  Table 3.10 details the HI study samples and homocysteine levels in 
urine with additional urinary creatinine concentrations.   
 
Table 3.10: HI study levels of homocysteine in urine  
Participant 
Number 
Time 
point 
Urinary 
Homocysteine 
(µmol/l) 
Urinary 
Creatinine 
(mmol/l) 
Homocysteine/Creatinine 
Ratio 
11 Baseline 1.82 1.86 0.98 
25 3-month 0.82 17.15 0.05 
30 3-month 1.51 12.29 0.12 
31 3-month 0.54 9.19 0.06 
31 6-month 1.33 4.33 0.31 
32 Baseline 0.92 18.48 0.05 
33 3-month 0.89 7.87 0.11 
35 3-month 1.76 8.04 0.22 
35 6-month 1.48 6.81 0.22 
36 3-month 0.52 7.16 0.07 
36 6-month 0.65 6.45 0.10 
 
Within the ADI study, six participant samples contained detectable levels of 
homocysteine in urine.  This represents 38.9% of the total sample analysed (N=18).  
Table 3.11 shows the detectable levels of homocysteine in urine with urinary 
creatinine concentrations.   
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Table 3.11: ADI Study levels of homocysteine in urine 
Participant 
Number 
Time 
point 
Urinary 
Homocysteine 
(µmol/l) 
Urinary 
Creatinine 
(mmol/l) 
Homocysteine/Creatinine 
Ratio 
102 Day 1 0.24 21.22 0.10 
111 Day 1 1.25 19.80 0.56 
111 Day 3 1.26 7.78 1.43 
112 Day 3 0.35 25.55 0.12 
114 Day 1 0.73 15.03 0.43 
114  Day 3 0.50 21.48 0.21 
115 Day 3 1.19 7.96 1.32 
117 Day 3 0.39 16.80 0.21 
 
 
Further work was undertaken to investigate if the ratio of urinary homocysteine to 
creatinine was associated with daily alcohol consumption, expressed in grams and 
the alcohol biomarker CDT, measured in serum.  CDT results were not available for 
all study participants.  There was no association between %CDT in serum and 
urinary homocysteine/creatinine ratio, for the study sample, however the sample 
size was very small (N=5), which is not a large enough sample size for correlation 
analysis. 
 
There was a significant inverse correlation between the daily alcohol consumption in 
grams and urinary homocysteine/creatinine ratio in the sample of ADI and HI study 
participants found to express homocysteine in urine (N=19) (figure 3.38). 
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Figure 3.38: Scatter plot of association between daily alcohol consumption and 
urinary homocysteine/creatinine ratio in the sample of HI (N=11) and ADI (N=8) 
study participants with homocysteine expressed in their urine (p=0.038, R=-0.480 
Spearman’s test) 
 
Further investigation was carried out to determine if there was an association 
between plasma homocysteine and the ratio of homocysteine/creatinine levels in 
urine, shown in figure 3.39.   No significant correlation (p=0.107, R=-0.381) between 
the levels of plasma homocysteine and the levels of homocysteine expressed as a 
ratio with creatinine in urine were evident.   
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Figure 3.39: Scatter plot of homocysteine/creatinine ratio plotted as a function of 
plasma homocysteine (p=0.107, R=-0.381 Spearman’s test) 
 
3.8.3 Summary 
 
The results from this method development indicates that the HPLC method outlined 
does show potential (detection in nineteen samples) however more work within this 
area is required to determine if this method can produce an accurate and more 
sensitive determination of homocysteine in urine.  An association was investigated 
to determine if there was a link between the levels of plasma homocysteine and 
urinary homocysteine expressed as a ratio with creatinine.  No association was 
evident; however this could improve with a more sensitive urinary homocysteine 
assay.   Further investigation is required to develop a sensitive HPLC assay for the 
detection of homocysteine in urine, which can be utilised as a biomarker of alcohol 
consumption. 
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3.9 Plasma Homocysteine and the MTHFR(C677T) Polymorphism  
 
Since the presence of the mutant form on the MTHFR(C677T) polymorphism can 
promote an increase in circulating plasma homocysteine, it is essential to determine 
its existence when investigating the cause of observed changes in plasma 
homocysteine levels.   
 
3.9.1 Prevalence of the MTHFR(C677T) Polymorphism within Healthy Individuals 
(HI) who Consume Alcohol in a Range of Drinking Patterns 
 
The prevalence of the MTHFR(C677T) polymorphism in relation to participant’s alcohol 
drinking pattern is shown in table 3.12;  17.1% (N=6) of the study population tested 
positive for the mutant MTHFR(C677T) polymorphism.   
 
Table 3.12: Prevalence of the MTHFR(C677T) polymorphism within the HI study 
participants (N=35), categorised according to baseline alcohol drinking pattern 
Genotype Abstainer 
(N=7) 
Responsible 
Drinker 
(N=2) 
Exceeding 
Responsible 
Guidelines but 
NOT Sessional 
Drinker (N=8) 
Sessional 
Drinker 
(N=18) 
Heterozygote 
(N=11) 
3 0 0 8 
Wild-Type 
Homozygote 
(N=18) 
2 1 6 9 
Mutant 
Homozygote 
(N=6) 
2 1 2 1 
Total (N=35) 7 2 8 18 
 
Six HI study participants were found to have the mutant MTHFR(C677T) 
polymorphism, however only five participants consented for their biological samples 
to be analysed to investigate specifically the impact of the mutant polymorphism on 
levels of plasma homocysteine.  This explains the reduction in sample number from 
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six to five participants.   The concentration of plasma homocysteine found in the 
study sample in relation to the presence of the MTHFR(C677T) polymorphism and 
alcohol drinking pattern is shown in figure 3.40.   Plasma homocysteine levels did 
not significantly increase (p=0.165) at each pre-defined study time-point in the 
individuals who were found to have the mutant MTHFR(C677T) polymorphism.   
Figure 3.40: Box plots of plasma homocysteine (µmol/l) at different time points for 
individual genotyped according to MTHFR(C677T) polymorphism (Box plots represents 
the following: solid bar in box (median 50th percentile), top of box (75th percentile (upper 
quartile), bottom of box 25th percentile (lower quartile), top whisker (largest value which is not 
an outlier or extreme score), bottom whisker (smallest value which is not an outlier or 
extreme score).  ● = Outlier (More than 1.5 box lengths above or below the box).  * = 
Extreme case (more than 3 box lengths above or below the box. 
 
In relation to serum folate levels, which like plasma homocysteine levels, are linked 
to the presence of the mutant MTHFR(C677T) polymorphism, only one participant with 
the mutant MTHFR(C677T) polymorphism was found to have serum folate levels below 
the minimum clinical reference range of 5 µg/l at the baseline and 3-month time-
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point.  However serum folate increased to greater than 5 µg/l by the 6-month time-
point.  All other participants (N=4), had serum folate levels within the clinical 
reference range at all time-points.  In relation to vitamin B12 levels, all participants 
who were found to carry the mutant MTHFR(C677T) polymorphism had vitamin B12 
levels within the clinical reference range of 200-900 ng/l. 
 
The association between plasma homocysteine concentrations in relation to the 
grams of alcohol consumed per drinking day at baseline, by each of the study 
participants and the subsequent genotyping for the MTHFR(C677T) polymorphism was 
investigated (table 3.13).  The ratio of plasma homocysteine to mean alcohol 
consumption during drinking days was significantly higher (p<0.05) in the 
participants who were genotyped for the mutant MTHFR(C677T) polymorphism.   
 
Table 3.13: Drinking characteristics of different MTHFR(C677T) polymorphism 
genotypes found in the HI study (*denotes significance) 
Baseline Time-Point Heterozygote 
(N=11) 
Wild-Type 
Heterozygote 
(N=18) 
Mutant 
Homozygote 
(N=5) 
Plasma Homocysteine  
(µmol/l) Median, Mean 
(SD; Range) 
8.8, 18.5  
(18.0; 4.7-50.7) 
6.7, 17.6 
(20.4; 3.2-63.4) 
7.7, 8.4  
(3.3; 5.1-13.8) 
Mean alcohol consumption 
per drinking day (g)  
Median, Mean 
(SD; Range) 
48.0, 55.9 
(52.4; 0.0-
153.0) 
30.2, 33.5 
(26.6; 0.0-92.5) 
20.0, 33.4  
(48.5; 0.0-117.0) 
Ratio of median plasma 
homocysteine to median 
alcohol consumption (g) 
per drinking day 
0.18 0.22 0.35* 
 
No significant association was found between plasma homocysteine at baseline and 
study participants baseline mean alcohol consumption during drinking days in 
participant’s who were genotyped as heterozygote (p=0.552) and wild-type 
homozygote (p=0.538) for the MTHFR(C677T) polymorphism.  However a significant 
correlation was revealed between plasma homocysteine at baseline and mean 
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alcohol consumption during drinking days for participant’s genotyped as mutant 
homozygote for the MTHFR(C677T) polymorphism.  From figure 3.41 a significant 
linear relationship is identified in participants who carry the mutant MTHFR(C677T) 
polymorphism (p<0.05, R=0.975).  In this group increasing alcohol consumption was 
associated with increasing plasma homocysteine levels.   
 
 
Figure 3.41: Homocysteine in plasma (µmol/l) in relation to baseline alcohol 
consumption (g) in a sample of HI study participants (N=5) with the mutant 
MTHFR(C677T) polymorphism (p<0.05, R=0.975 Spearman’s test) 
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3.9.2 Prevalence of the MTHFR(C677T) Polymorphism within Alcohol Dependent 
Individuals (ADI) 
 
The patients who participated in this study were genotyped for the MTHFR(C677T) 
polymorphism, the results of which are shown in table 3.14.  Two participants did not 
provide sufficient blood samples for DNA extraction. 
 
Table 3.14: Frequency of MTHFR(C677T) Polymorphism within study sample  
 
Heterozygote Wild-Type 
Homozygote 
Mutant 
Homozygote 
Number of 
Participants 
6 10 0 
 
No patients within the ADI study were found to carry the mutant MTHFR(C677T) 
polymorphism.  The homocysteine concentrations on day 1 and day 3, in relation to 
the MTHFR(C677T) polymorphism are shown in figure 3.42.   
 
There was no significant difference in plasma homocysteine levels between days 1 
and 3 in ADI participants genotyped as having either the heterozygote or wild type 
homozygote MTHFR(C677T) polymorphism.   There was also no significant difference 
in plasma homocysteine levels on days 1 and 3 between the two different 
MTHFR(C677T) genotypes.  The result suggests that the wild-type homozygote and 
heterozygote variants of the MTHFR gene did not affect the plasma homocysteine 
levels in a sample of dependent individuals.   
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Figure 3.42: Box plots of homocysteine in plasma (µmol/l) for ADI study (N=16) sample in relation to prevalence of MTHFR(C677T) 
polymorphism at each study time-point (Box plots represents the following: solid bar in box (median 50th percentile), top of box (75th percentile 
(upper quartile), bottom of box 25th percentile (lower quartile), top whisker (largest value which is not an outlier or extreme score), bottom whisker 
(smallest value which is not an outlier or extreme score).  ● = Outlier (More than 1.5 box lengths above or below the box).  * = Extreme case (more than 
3 box lengths above or below the box. 
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3.9.3 Prevalence of the MTHFR(C677T) Polymorphism: Comparison of Sessional 
Drinkers and Alcohol Dependent Individuals  
 
The prevalence of the MTHFR(C677T) polymorphism was identified in both the sample 
of sessional drinkers and alcohol dependent patients and is illustrated in table 3.15.   
 
Table 3.15: Frequency of MTHFR polymorphism in sub-analysis sample 
 
Sessional Drinkers 
(N=17) 
Alcohol Dependent 
Patients (N=16)* 
Heterozygote 8 6 
Wild-type 8 10 
Mutant 1 0 
*Two ADI study participants did not provide sufficient blood sample for DNA 
extraction.   
 
The plasma homocysteine levels in relation to the MTHFR(C677T) genotyping are 
illustrated in figure 3.43.   The plasma homocysteine levels for the participant who 
carried the mutant MTHFR(C677T) polymorphism was 13.85 µmol/l, which was higher 
in comparison to the other MTHFR(C677T) genotypes, in both the alcohol dependent 
individuals and sessional drinkers.  It was not possible to compare the mutant 
MTHFR(C677T) polymorphism within the alcohol dependent patient group, due to no 
participant carrying the mutant gene.  There was no significant difference (p=0.380) 
between the plasma homocysteine levels found in the participants who carried either 
the heterozygote and wild-type genotypes. 
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Figure 3.43: Box plots of plasma homocysteine levels (µmol/l) in relation to type of drinker and MTHFR(C677T) genotyping (Box plots 
represents the following: solid bar in box (median 50th percentile), top of box (75th percentile (upper quartile), bottom of box 25th percentile (lower 
quartile), top whisker (largest value which is not an outlier or extreme score), bottom whisker (smallest value which is not an outlier or extreme score).  
● = Outlier (More than 1.5 box lengths above or below the box).  * = Extreme case (more than 3 box lengths above or below the box.. 
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3.10 Homocysteine Vitamin Co-Factors and Alcohol Consumption  
 
The remethylation of homocysteine to methionine is mediated by methionine 
synthase using two vitamins, folate and vitamin B12.  A lack of folate and vitamin B12 
in this reaction, causes elevated circulating levels of homocysteine in the plasma or 
serum.   
3.10.1 Serum Folate Levels within Healthy Individuals (HI) who Consume 
Alcohol in a Range of Patterns  
 
Folate, was measured in serum using the AVIDA method at the biochemistry 
laboratories within the Royal Infirmary of Edinburgh (RIE), as described in chapter 2.  
The concentrations of serum folate detected in each alcohol drinking pattern is 
represented in figure 3.44.   
 
Serum folate was shown to increase over the study duration, which could be linked 
to the decrease in alcohol consumption, which was also found.  Serum folate levels 
significantly increased over the study duration for abstainers and sessional drinkers 
(p=0.016 and p=0.005 respectively).  This significant increase was not found in the 
other two drinking pattern groups.  Since the remethylation of homocysteine to 
methionine is dependent on folate as a cofactor, a correlation analysis was 
performed between baseline serum folate and baseline plasma homocysteine levels 
but was not found to be significant (p=0.61, R=-0.324).  The participants with 
elevated plasma homocysteine but low serum folate levels shown in figure 3.45, all 
had various drinking patterns, four were females and four were males, and none of 
the participants were found to carry the mutant MTHFR(C677T) polymorphism.  
However five of the participants did consume alcohol out with the responsible 
drinking guidelines.  There was no significant correlation between plasma 
homocysteine and serum folate for any of the alcohol drinking patterns at baseline.  
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Figure 3.44: Box plots of serum folate (µg/l) for HI study (N=35) sample, categorised according to alcohol drinking pattern over study 
duration (Box plots represents the following: solid bar in box (median 50th percentile), top of box (75th percentile (upper quartile), bottom of box 25th 
percentile (lower quartile), top whisker (largest value which is not an outlier or extreme score), bottom whisker (smallest value which is not an outlier or 
extreme score).  ● = Outlier (More than 1.5 box lengths above or below the box).  * = Extreme case (more than 3 box lengths above or below the box. 
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Figure 3.45: Scatter plot of serum folate and plasma homocysteine in a sample of 
healthy individuals (N=35) with a range of alcohol drinking patterns  
 
The dot plot, shown in figure 3.46 represents the folate concentration in relation to 
the clinical reference range.  Within the sample 40.6% of individuals had serum 
folate levels below the 5.0 µg/l minimum reference range.  Of this group more were 
female (N=9) compared to male (N=5).  Of the study participants (N=14), who had 
folate levels below 5.0 µg/l, 66.7% were sessional drinkers.  Of the remaining 
participants, 13.3% exceeded responsible guidelines but were not sessional drinkers 
and 6.6% were abstaining individuals.  
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Figure 3.46: Dot plot of serum folate (µg/l) levels within HI Study (N=35) sample, in 
relation to clinical reference range.   The vertical reference lines represent the 
minimum (5 µg/l) and maximum (20 µg/l) clinical reference range for serum folate. 
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3.10.2 Serum Folate Levels within Alcohol Dependent Individuals (ADI) 
 
The concentrations of folate identified in samples are shown in figure 3.47.   
 
Figure 3.47: Box plots of folate in serum (µmol/l) in ADI study sample at the 
predetermined study time-points (▲p=0.007, Friedman’s test) (Box plots represents 
the following: solid bar in box (median 50th percentile), top of box (75th percentile (upper 
quartile), bottom of box 25th percentile (lower quartile), top whisker (largest value which is not 
an outlier or extreme score), bottom whisker (smallest value which is not an outlier or 
extreme score).  ● = Outlier (More than 1.5 box lengths above or below the box).  * = 
Extreme case (more than 3 box lengths above or below the box.   
 
A significant reduction in the levels of folate measured on days 0, 1 and 3 (p=0.007) 
was seen, highlighting a change in folate during the first 72 hours of alcohol 
detoxification, as shown in figure 3.47.  For most participants, serum folate was 
shown to decrease as detoxification treatment progressed.  However this was not 
true in the group of participants who consumed wine and beer prior to detoxification 
(figure 3.48), however the increase was not significant (p=1.000).  This non 
significant increase in serum folate levels was not found in the two ADI participants 
who consumed only beer.  Participants were not asked which type of wine they 
consumed, i.e. red, white or rose).    
▲ 
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Figure 3.48: Serum folate (µg/l) of ADI study sample during detoxification in relation to type of alcohol consumed. 
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Serum folate has an inverse relationship with plasma homocysteine concentrations, 
as folate acts as a methyl donor during the remethylation of homocysteine to 
methionine (Antoniades et al. 2009).  If folate is not present during the remethylation 
reaction, homocysteine cannot be converted to methionine, causing an increase in 
circulating homocysteine.  There was no correlation found between plasma 
homocysteine and serum folate measured on day 1 (p=0.140, R=-0.452). The 
correlation was repeated for serum folate and plasma homocysteine measurements 
on day 3; which was also not significant, (p=0.154, R=-0.460). 
 
A dot plot (figure 3.49) of each ADI participant’s serum folate concentration was 
created to identify the percentage of the study sample which was within the 
acceptable folate clinical reference range (5-20 µg/l); 35.29% of the study sample 
were below the minimum reference folate level of 5 µg/l.   The percentage of study 
participants who had folate levels below the minimum clinical reference range of 5 
µg/l increased to 61.5% at day 1 and 81.8% at day 3, which confirms that folate 
levels were reducing during alcohol detoxification.  There was no significant 
correlation between the serum folate levels and amount of alcohol consumed prior 
to detoxification on day 3 (p=0.498, R=-0.229). 
 
 
Figure 3.49: Dot plot of serum folate (µg/l) in ADI study (N=18) sample, in relation to 
clinical reference range.  The vertical reference lines represent the minimum (5 µg/l) 
and maximum (20 µg/l) clinical reference range for serum folate. 
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3.10.3 Serum Folate Levels within a Comparison of Sessional Drinkers and 
Alcohol Dependent Individuals  
 
The median serum folate level in sessional drinkers was 4.70 µg/l compared with 
alcohol dependent individuals group, which was 3.30 µg/l (Figure 3.50).  Both 
median values are below the lower limit of the clinical reference range of 5 µg/l.  
There was no significant difference between the levels of folate in a sample of 
sessional drinkers compared to alcohol dependent individuals (p=0.116).     
 
Figure 3.50: Box plots of serum folate in a sample of sessional drinkers (measured 
at baseline) compared to alcohol dependent patients (measured on day 1) (Box plots 
represents the following: solid bar in box (median 50th percentile), top of box (75th percentile 
(upper quartile), bottom of box 25th percentile (lower quartile), top whisker (largest value 
which is not an outlier or extreme score), bottom whisker (smallest value which is not an 
outlier or extreme score).  ● = Outlier (More than 1.5 box lengths above or below the box).  * 
= Extreme case (more than 3 box lengths above or below the box. 
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3.10.4 Serum Vitamin B12 Levels within Healthy Individuals (HI) who Consume 
Alcohol in a Range of Patterns 
 
The vitamin B12 concentration identified in each of the alcohol drinking pattern 
groups is presented in figure 3.51.  There was no significant (p=0.139) change in 
serum vitamin B12 levels at each pre-defined study time-point.  In the abstainers 
group the vitamin B12 levels significantly increased (p=0.01) throughout the duration 
of the study.  However there was no significant change in vitamin B12 for the other 
alcohol drinking groups.   
 
Since the remethylation of homocysteine to methionine is dependent on vitamin B12 
as a cofactor, a correlation was used to determine if there was an association 
between serum vitamin B12 and plasma homocysteine at baseline measurement and 
no correlation was evident.  There was also no correlation between plasma 
homocysteine and serum vitamin B12 at the subsequent three and six month point 
time-points.   
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Figure 3.51: Box plots of serum Vitamin B12 (ng/l) for HI study (N=35) categorised according to alcohol drinking pattern over duration of 
study (Box plots represents the following: solid bar in box (median 50th percentile), top of box (75th percentile (upper quartile), bottom of box 25th 
percentile (lower quartile), top whisker (largest value which is not an outlier or extreme score), bottom whisker (smallest value which is not an outlier or 
extreme score).  ● = Outlier (More than 1.5 box lengths above or below the box).  * = Extreme case (more than 3 box lengths above or below the box. 
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At baseline, 91.4% (N=32) of the sample had serum levels within the clinical 
reference range (200-900 ng/l) for vitamin B12 levels.  The remaining 8.6% of the 
sample (N=3) had vitamin B12 levels below the minimum clinical reference level of 
200 ng/l in serum.  These participants were female (see figure 3.52).  All, had 
different drinking patterns, none were abstainers.  One participant also had a serum 
folate level at baseline below the clinical reference range of 5 µg/l.   
 
 
Figure 3.52: Dot plot of Vitamin B12 levels in HI Study sample (N=35), in relation to 
clinical reference range.  The vertical reference line represents the minimum (200 
ng/l) clinical reference range for vitamin B12. 
 
3.10.5 Serum Vitamin B12 Levels within Alcohol Dependent Individuals (ADI) 
 
The concentrations of vitamin B12 identified in the ADI study sample at the 
predetermined study time-points are shown in figure 3.53.  Vitamin B12 serum levels 
did not change significantly over the first 72 hours of alcohol detoxification 
(p=0.119).   
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Figure 3.53: Box plots of vitamin B12 in serum (ng/l) for ADI study sample at three 
predetermined time-points (Box plots represents the following: solid bar in box (median 
50th percentile), top of box (75th percentile (upper quartile), bottom of box 25th percentile 
(lower quartile), top whisker (largest value which is not an outlier or extreme score), bottom 
whisker (smallest value which is not an outlier or extreme score).  ● = Outlier (More than 1.5 
box lengths above or below the box).  * = Extreme case (more than 3 box lengths above or 
below the box. 
 
As illustrated within figure 3.53 all participants’ serum vitamin B12 levels were within 
the clinical reference range of 200-900 ng/l at each time-point.  There was no 
significant correlation between volume of daily alcohol consumption and vitamin B12 
levels at each time-point in the ADI study sample.  There was a significant inverse 
correlation between serum vitamin B12 measured on day 1 and homocysteine 
measured on day 1 (p=0.042, R=-0.594) (see figure 3.54).  The statistical test was 
repeated for measurements on day 3, where the result was more significant and the 
correlation coefficient increased (p=0.001, R=-0.864), which is highlighted in figure 
3.55.   
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Figure 3.54: Scatter plot of serum vitamin B12 and plasma homocysteine on day 1 in 
a sample of ADI participants (p=0.042, R=-0.594 Spearman’s test). 
 
Figure 3.55: Scatter plot of serum vitamin B12 and plasma homocysteine on day 3 in 
a sample of ADI participants (p=0.001, R=-0.864 Spearman’s test). 
224 
3.10.6 Serum Vitamin B12 Levels within Drinkers Combined Sample (HI and 
ADI) 
 
The range of vitamin B12 levels in serum within a sample of drinkers (N=44) 
highlighted that 5.13% of the study sample was below the minimum clinical 
reference range.  A Spearman’s two tailed correlation test showed there was no 
significant association between plasma homocysteine and serum vitamin B12 within 
this study sample (p=0.165, R=-0.230).  There was a significant correlation 
(p=0.004) between alcohol consumption per day and vitamin B12 status in the 
combined sample (N=44) who consumed alcohol in a range of patterns (figure 3.56). 
 
Figure 3.56: Scatter plot of serum vitamin B12 in serum (ng/l) in drinkers study 
sample in relation to alcohol consumed per day (g).  (p=0.004, R=0.449 Spearman’s 
test) 
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3.10.7 A
 
Comparison Serum Vitamin B12 Levels within Sessional Drinkers and 
Alcohol Dependent Individuals  
 
The median serum vitamin B12 level was higher in the alcohol dependent patient 
group compare with the sessional drinkers; 357 ng/l and 280 ng/l respectively (figure 
3.57).  Both these medians are within the clinical reference range for vitamin B12 of 
200-900 ng/l.  Within the sessional drinkers group there was one outlier, which was 
outwith the range of the box plot, and represented a value below the minimum 
clinical reference range of 132 ng/l.  There was a significant (p=0.004) difference 
between the levels of vitamin B12 in the serum of sessional drinkers compared to 
that of alcohol dependent patients.  This result suggests that vitamin B12 is 
significantly lower in sessional drinkers compared to alcohol dependent patients. 
 
Figure 3.57: Box plots of serum vitamin B12 in a sample of sessional drinkers 
compared to alcohol dependent patients (▲p=0.004, Mann-Whitney test) (Box plots 
represents the following: solid bar in box (median 50th percentile), top of box (75th percentile 
(upper quartile), bottom of box 25th percentile (lower quartile), top whisker (largest value 
which is not an outlier or extreme score), bottom whisker (smallest value which is not an 
outlier or extreme score).  ● = Outlier (More than 1.5 box lengths above or below the box).  * 
= Extreme case (more than 3 box lengths above or below the box.  
▲ 
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3.10.8: A Comparison of Biological Laboratory Analysis and Diet Diary 
Analysis for Folate and Vitamin B12 
 
Dietary nutrients including vitamin B12 and folate can be determined using either 
biological samples or through analysis of diet diaries.   
3.10.8.1 Folate 
 
For eight participants, folate was estimated both by biological laboratory analysis 
and through recorded dietary intake.  No significant (p=0.693, R=0.167) association 
was detected between laboratory biological sample analysis and diet diary folate 
analysis.  
 
3.10.8.2 Vitamin B12 
 
For eight participants, serum vitamin B12 was estimated in biological laboratory 
analysis and also from participant’s dietary diary recall.  No significant (p=0.289, R=-
0.429) association was detected between laboratory biological sample analysis and 
diet diary vitamin B12 analysis.   
 
3.11 Stability Study  
 
Since the study design of both the HI study and ADI study required the storage of 
biological samples for periods of up to two years prior to analysis, it was essential to 
investigate the stability of the biomarkers under these conditions.  Pooled serum and 
plasma samples were used to conduct the stability study and were subjected to the 
following conditions as described shown in table 3.16. 
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Table 3.16: Sample group freezing and thawing conditions for biological samples.   
Group 
No. 
Storage Condition 
1 Spiked* samples at constant -80 °C (N=10).  
2 Spiked* samples stored at a constant temperature (-80 °C) but 
subjected to 3 occasions of thawing and refreezing (N=10) 
3 Samples at constant -80 °C (N=10)  
4 Samples stored at a constant temperature (-80 °C) b ut subjected to 3 
occasions of thawing and refreezing (N=10) 
 *Known concentration of homocysteine, folate, vitamin B12 and CDT standard. 
 
3.11.1 Plasma Homocysteine  
 
Table 3.17 describes the levels of plasma homocysteine found in each group and 
the percentage coefficient of variation for each group of test samples exposed to 
different storage temperatures, and thawing conditions.   
 
Table 3.17: Plasma Homocysteine (µmol/l) within stability study groups subjected to 
different conditions (N=10) 
 
Group 1 Group 2 Group 3 Group 4 
Median, Mean 
(SD; Range)  
8.1, 8.4 
(2.8, 5.2-13.4) 
11.9, 12.1 
(2.1, 9.0, 16.6) 
1.3, 1.3  
(0.3, 0.8-1.6) 
5.2, 5.6  
(1.3, 4.7-9.2) 
%CV 33.2 17.3 24.4 23.8 
 
There was a significant difference (p=0.005) between the plasma homocysteine 
levels detected within the group one and two samples.  A significant difference 
(p=0.005) was also found between the samples stored according to the conditions of 
groups three and four.  The samples in group one and group two were spiked with 
synthetic homocysteine, as described in the methods chapter.  The concentration of 
the spike was 7.4 nmol/10 µl.  The recovery of the spike in the samples stored in 
groups one and two is reported in table 3.18.  The concentration of the mean spiked 
samples, mean non-spiked samples and percentage recovery of homocysteine are 
reported.   
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Table 3.18: Mean plasma homocysteine (µmol/l) levels in group one and two in 
relation to spike recovery 
 
Plasma Samples Plasma Samples  
With Spike (µmol/l) 8.4 (group 1) 12.1 (group 2) 
Without Spike (µmol/l) 1.3 (group 3) 5.6 (group 4) 
Recovery (%) 92.0 86.0 
 
Plasma homocysteine concentrations must be directly compared to the storage 
conditions of each group.  Whereby group one is compared to group three and 
group two compared to group four, as these samples were kept under the same 
storage conditions.  The mean plasma homocysteine levels for groups one and 
three was 8.4 µmol/l and 1.3 µmol/l respectively, with a recovery of 92.0% of the 
synthetic homocysteine spike within the group 1 samples.   The mean plasma 
homocysteine levels for groups two and four was 12.1 µmol/l and 5.6 µmol/l 
respectively, with a recovery of 86.0% in the plasma samples stored within group 
two and spiked with synthetic homocysteine.   
 
The HPLC batch analysis of the samples was undertaken as two separate runs, with 
samples in groups one and three analysed together and samples in group two and 
four together.  After investigating each of the batch calibrations it was identified that 
there was a 20% inter-assay variation, which explains the difference in the values 
for each group, meaning a direct comparison of groups one and three and groups 
two and four is not feasible.  However the recovery of the spike does suggest that 
the samples were not affected by the repeated freezing and thawing.  The 
explanation for the difference in the inter-assay variation could be due to HPLC 
column degradation and this requires more investigation.   
   
3.11.2 Serum Folate  
 
Table 3.19 describes the levels of serum folate found in each group and the 
percentage coefficient of variation found in each stability group which were exposed 
to different temperature and thawing conditions.  The results for groups one and two 
were above the maximum assay detection limit of 20 µg/l, due to the spiking of the 
sample with folic acid, meaning no results could be reported.   
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Table 3.19: Serum Folate (µg/l) within groups subjected to different conditions 
(N=10) 
 
Group 3 Group 4 
Median, Mean 
(SD; Range)  
12.6, 12.5  
(0.2, 12.1-12.9) 
12.6, 12.5  
(0.5, 11.2-13.0) 
%CV 1.9 4.1 
 
There was no significant difference (p=0.858) between the samples stored 
according to the conditions of groups three and four.  The coefficient of variation 
between each group was below 10%, indicating that there was no variation between 
samples.  Repeated thawing and refreezing of serum samples had no effect on 
serum folate estimation.   
 
3.11.3 Vitamin B12 
 
Table 3.20 describes the levels of serum vitamin B12 found in each group and the 
percentage coefficient of variation found in each stability group which were exposed 
to different storage temperature and thawing conditions.  The spiked samples in 
groups one and two, elevated the levels of vitamin B12 above the maximum assay 
detection limit of 900 ng/l, explaining the non-reporting of groups one and two 
results.   
 
Table 3.20: Serum Vitamin B12 (ng/l) within groups subjected to different conditions 
(N=10) 
 
Group 3 Group 4 
Median, Mean 
(SD; Range) 
348.0, 368.1  
(66.2, 320.0-545.0) 
337.5, 341.40 
(23.5, 315.0-388.0) 
%CV 2.6 6.9 
 
There was no significant difference (p=0.333) between the samples stored 
according to the storage conditions of group three and four.  Therefore suggesting 
that repeated thawing and refreezing of the serum samples had no effect on vitamin 
B12 levels.   
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3.11.4 Carbohydrate Deficient Transferrin (CDT) 
 
Table 3.21 describes the percentage coefficient of variation and %CDT 
concentrations found in each stability group, exposed to different temperature and 
thawing conditions.  Only five samples from each group were analysed for CDT 
levels.  
 
Table 3.21: %CDT in serum, within groups subjected to different conditions (N=5) 
 
Group 1 Group 2 Group 3 Group 4 
Median, Mean 
(SD;  Range)  
1.5, 1.5  
(0.1, 1.5-1.6) 
1.73, 1.71 
(0.1, 1.6-1.8) 
1.92, 1.88  
(0.2, 1.5-2.0) 
1.9, 1.9  
(0.2, 1.7-2.1) 
%CV 4.6 4.1 10.6 8.3 
 
There was a significant difference (p=0.042) between groups one and two. However 
there was no significant difference (p=0.893) between the samples stored under the 
conditions applicable to groups three and four. The percentage coefficient of 
variation between all groups was less than 10%, indicating a low variation between 
each sample within the groups.  The statistical tests therefore indicted that repeated 
freezing and thawing did not effect serum samples and subsequent CDT analysis.  
The presence of the synthetic CDT spike in groups one and two, could have 
interfered with the N-Latex immunoassay resulting in the significant difference in the 
two groups, however this does require more investigation.  
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CHAPTER 4: DISCUSSION 
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4.1 Measurement of Alcohol consumption 
4.1.1 Alcohol Consumption Analysis from Questionnaires and Diary Recall 
 
The determination of alcohol consumption through the use of questionnaires and 
prospective diaries allowed for the categorisation of study participants into drinking 
patterns and also determined the accuracy of self-reported alcohol consumption.   
 
The HI study questionnaire did highlight the finding that 77.7% (N=14) of HI study 
participants classified themselves as sessional drinkers.  From diary recall, analysed 
using the AM method, 18 participants in the HI study were found to be sessionally 
drinking.  However from the HI study questionnaire, four participants did not classify 
themselves as sessional drinkers, but were found to be sessional drinkers from their 
diary recall.  This could suggest they were unaware of their true alcohol drinking 
pattern or they did not want to disclose this information.  This finding suggests that 
diaries are providing more detailed alcohol consumption information in comparison 
to questionnaires.   The HI study participants completed prospective diaries for a 
period of seven days which allowed for a detailed analysis of alcohol consumption, 
within a typical week.  As the diaries were seven days long, it included a weekend, 
which has been shown in the literature to be more commonly associated with 
sessional drinking (Deas and Clark 2009).  The use of the prospective diary reduced 
the need for memory recall, which can be affected especially if alcohol consumption 
is heavy, however the completion of the diary after heavy consumption can still 
induce error in recall.    
 
The information provided by the ADI sample in the study questionnaire gave a key 
insight into the type of alcohol and volume of alcohol which was consumed in a 
dependent pattern, and as stated above, the range was very large, up to 600 g per 
day.  It would have been valuable to ask ADI study participants to distinguish which 
type of wine they consume (e.g. red, white or rose) and also which type of cider they 
regularly consumed (e.g. white or fruit cider), as it has been described in the 
literature that homocysteine can be influenced by type of alcohol (Bleich et al. 
2000c; Tsang et al. 2005).  This additional information would have allowed a 
comparison of biomarker levels in relation to type of alcohol consumption and this 
type of question should be considered in future research.   
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The recording of alcohol consumption in questionnaires and diaries has been shown 
to be useful in both the HI and ADI studies and the published literature (MacAskill et 
al. 2008).  ADI study participants were not asked to keep diaries as they were 
undergoing detoxification treatment and it was advised by the collaborating clinician 
that diaries would not be maintained successfully during this time. To truly quantify 
the consumption of alcohol it is important to use the most definitive method to 
analyse the consumption levels recorded, as the method of analysis can determine 
drinking pattern and therefore theorise about associated risk.  However the use of a 
less detailed consumption method analysis can wrongly categorise an individual into 
the incorrect alcohol drinking pattern.  This was demonstrated when alcohol diaries 
were analysed using the AM, WD and ONS methods. 
 
Alcohol consumption was underestimated by both the WinDiets software method 
and the ONS guidelines scale, however there was a significant difference (p=0.001) 
in the alcohol analysis results, when comparing the ONS method to the AM method.  
The ONS guidelines method significantly underestimated alcohol consumption 
within a sample of HI study participants.  The results also showed that the WD 
method and ONS method of analysis miscategorised individuals drinking patterns by 
11% and 55% respectively and was significantly (p=0.0001) different to the 
participants categorised using the AM method.  Further analysis of two participants 
who would have been miscategorised using the WD and ONS methods as non-
sessional drinkers, exhibited plasma homocysteine levels above the maximum 
clinical reference range of greater than 15 µmol/l, suggesting potential CVD risk, 
due to elevated plasma homocysteine.  It could be argued that WinDiets dietary 
analysis software is not primarily used to analyse alcohol consumption.  However 
this suggests that specific alcohol analysis software should be made available and 
updated regularly with new alcohol brands being made available and sold to the 
general public.  The AM method is a simple method, however it can be time 
consuming but in comparison to other alcohol consumption analysis methods it did 
prove more accurate, as it takes into consideration beverage brand, volume and 
%ABV.  It is also important to note that although the AM method takes into 
consideration important alcohol consumption information, it is still dependent on the 
honesty and recall of the participant.   
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The present findings indicate that in studies dependent on participant recall of 
alcohol intake, a failure to account for individual drink sizes and specific drink 
alcohol content, may seriously underestimate intake and the proportion of drinkers 
exceeding responsible guidelines. This is clearly true of the ONS method, whereby 
over 35% of participants were miscategorised.  Investigations which explore the 
relationship between alcohol intake and CVD disease risk will benefit from measures 
which improve the accuracy of the quantification of alcohol intake. In turn the 
evidence base of health guidelines will likely be improved (see appendix 4) 
(Murdoch et al. 2009).   
 
From the investigation into the grams of alcohol consumed per day within the HI 
study a fourth group was identified, which was named as “exceeding responsible 
guidelines but not sessional drinkers”.  This group of HI study participants consumed 
alcohol out with the UK Department of Health’s guidelines of 16-24 g (female) and 
24-47 g (male) per day, but did not exceed the sessional drinking definition of 
greater than 48 g (female) and 64 g (male).  Within the HI study sample there were 
eight participants who were included within this alcohol drinking pattern category.  
This finding of a fourth alcohol drinking pattern, which is not defined in the literature, 
shows that alcohol drinking patterns can not be easily defined without quantitatively 
investigating an individual’s alcohol consumption.  
 
Over the 6-month period of the HI study the alcohol drinking patterns of the study 
participants did change in relation to their consumption, whereby 37.1% (N=13) of 
the sample changed their alcohol drinking pattern at the 3-month time point, and 
34.3% (N=12) of the sample changed their alcohol drinking pattern at the 6 month 
time point.  The finding highlights the fact that drinking patterns do fluctuate over 
time and are subject to change.  The total HI study sample median alcohol 
consumption during drinking days did decrease over the study duration, however 
this was not statistically significant (p=0.910).  The effect of monitoring an 
individual’s drinking patterns is also evident whereby over the six month period of 
the study the number of abstaining individuals increased, however this figure did 
include the original abstainers, but was increased by those participants who did not 
consume alcohol on the subsequent week at the time of monitoring.   
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The consumption data collected allowed for a comparison of the grams of alcohol 
consumed by both an alcohol dependent individual and a healthy individual who 
consumed alcohol in a range of patterns.  The result indicates that sessional 
drinkers are potentially exposing themselves to the same level of alcohol intoxication 
and health risks as an individual who is dependent, however the level of potential 
health risk would be determined by the number of times sessional drinking is being 
undertaken, e.g. every weekend.  It is also important to clarify that alcohol 
consumption determined from questionnaires and diaries and compared to a 
biological variable, does pose a potential serious error, as alcohol consumption 
determined from questionnaires and diaries is dependent on memory recall.  Under 
heavy alcohol consumption, accuracy of memory recall is reduced, therefore 
evoking a potentially serious error.   
 
4.2. Carbohydrate Deficient Transferrin (CDT) as a Biomarker of Alcohol 
Consumption 
 
In an attempt to investigate the utility of Carbohydrate Deficient Transferrin (CDT) as 
a biomarker, analysis of serum samples was undertaken for both the HI and ADI 
studies.  Within the ADI study, CDT levels were shown to significantly decrease 
(p=0.017) from day 1 to day 3, indicating that CDT was affected by alcohol 
consumption and subsequent alcohol detoxification. Within this group 69.2% 
(N=18), had a %CDT of greater than 2.6% which is a positive result using the N-
Latex immunoassay on day 1.   From self report, median daily alcohol consumption 
prior to entering detoxification treatment was 222 g and the range of consumption 
over the entire sample was 80-678.6 g.  This range of alcohol consumption would be 
more than sufficient to elevate CDT levels in each of the ADI participants.  Published 
literature (Jeppsson et al. 2007) has shown that CDT is a sensitive biomarker for 
alcohol intake exceeding 50 grams per day.  
 
All sessional drinkers were shown to have a positive CDT result of greater than 
2.6%.  In specifically investigating the results from the CDT analysis of sessional 
drinkers a linear relationship (p=0.01, R=0.98) was identified between the number of 
drinking days within a 7 day period and a %CDT positive result.  This suggests that 
the number of days within a week, whereby sessional drinking is undertaken, 
increases the level of serum CDT, resulting in a positive diagnostic result.  A search 
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of the literature has identified that the linear correlation coefficient stated above, 
where the association between the number of drinking days and the %CDT result 
using the N-Latex immunoassay has not been identified before, in a sample of self-
reporting healthy individuals who undertake sessional drinking.   Due to the 
expensive nature of the N-Latex immunoassay, only a specific number of samples 
from the HI study could be analysed and as the published literature lacked research 
into the use of CDT as a biomarker within non-alcohol dependent individuals, serum 
samples were selected from the study, which were from participants who consumed 
alcohol in a sessional pattern or above the responsible alcohol consumption 
guidelines.  To act as a control, serum samples from self-reported abstainers were 
also included for analysis, and showed no elevation, as would have been expected.   
 
As stated previously the results of the HI and ADI studies have shown that healthy 
individuals who consume alcohol in a sessional pattern can consume the same 
amount of alcohol (grams) as an alcohol dependent individual on a given day.  This 
has allowed for a direct comparison of sessional drinkers to alcohol dependent 
patients for CDT levels, which showed that both study groups had median CDT 
values which were positive (>2.6%), although significantly higher (p=0.030) in the 
ADI group.  This higher result could be explained by the time-point at which blood 
was taken for both study samples.  The serum samples taken for the ADI group 
were 24 hours after beginning detoxification treatment, compared with day eight of 
the sessional drinker’s blood sample.  Theoretically the sessional drinkers could 
have consumed alcohol earlier in the seven day monitoring period and had more 
alcohol free days before blood sampling, producing a lower CDT results.  The 
rationale for the previous statement can be justified directly from the literature 
(Helander 2007), as the half-life of CDT is seven days, whereby if a HI participant 
had consumed alcohol on day one of their monitoring week and had six alcohol free 
days, this alcohol free period, would be a sufficient time period to allow CDT levels 
to potentially return to normal levels (e.g. a negative results of less than 2.6% in 
serum).  However, the median and mean %CDT measurements in the sessional 
drinkers group was positive (>2.6%), suggesting that this biomarker can be used to 
monitor alcohol consumption, in a sample of sessional drinkers.   As widely stated in 
the literature, the consumption of greater than 50 g of alcohol for a two week period 
is sufficient to elevate CDT levels.  The results of the CDT analysis from sessional 
drinker’s serum samples, suggests that sessional drinkers were consuming 50 g or 
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greater of alcohol, daily, for a two week period before blood sampling.  However the 
HI study monitoring period was a 7 day period, and a suggestion of this work, could 
be to increase the monitoring period to 14 days, which would give a more definitive 
answer in terms of the amount of alcohol required to elevate CDT levels in sessional 
drinkers.  It would also allow the determination of exactly how many drinking days is 
required to elevate CDT levels, with a view to potentially finding that it is less than 
two weeks of daily alcohol consumption to induce an elevation, as stated in the 
literature. 
 
There was no significant (p=0.893) difference between the CDT levels found in the 
serum samples which were stored at either constant -80 ºC or subjected to multiple 
thawing and refreezing.  The co-efficient of variation between each group was less 
than 10%, indicating no great variability between the samples. From the work 
carried out within this quality control study for the stability of CDT, it can be 
suggested that repeated freezing and thawing of the serum sample does not affect 
the analysis of CDT using the N-Latex immunoassay.  The implications of this are, a 
recommendation can be suggested to laboratory researchers investigating CDT 
using the N-Latex immunoassay, that serum samples can be stored at -80 °C and 
repeatedly thawed and refrozen without effecting the subsequent analysis and 
results.   
 
The results from the stability study did show a significant (p=0.042) difference 
between samples which were spiked with a synthetic CDT reagent and stored either 
at -80 ºC or multiple occurrences of thawing and refreezing.  It is important to note 
that these samples were spiked with a synthetic CDT reagent which is used for 
calibrating an HPLC system for CDT analysis and this could have interfered with the 
N-Latex immunoassay which was used.  The synthetic CDT reagent was purchased 
from Bio-Rad and is specially prepared human serum, with additional synthetic CDT 
added and is normally used to calibrate an HPLC system prior to analytical runs.  
The effect of this reagent being analysed by the N-Latex immunoassay method is 
unknown and from the stability study results, it is suggested that the N-Latex method 
does not detect the synthetic CDT.  The multiple temperature changes, potential 
effects on this synthetic CDT reagent has not been established and could be the 
cause for the difference in the groups, however the non-spiked groups did show no 
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significant difference in CDT levels, thereby concluding that it was the artificial CDT 
which resulted in the difference between the groups.   
 
4.2.1 Method Development for the Detection of Carbohydrate-Deficient 
Transferrin (CDT) in Serum Using HPLC 
 
There are several methods which can be utilised to measures CDT in serum and 
include: HPLC, immunoassay and capillary electrophoresis.  The current reference 
method for CDT analysis is HPLC with ultraviolet detection (UV).  However there is 
work being undertaken to validate a LC-MS method for the detection of CDT, which 
will provide more sensitive analysis (Oberrauch et al. 2008).  The current reference 
method published by Helander et al. (2003), was developed as part of this thesis 
and will be described within the following section. 
 
CDT has been described in the published literature as a stable and reproducible 
biomarker for the detection of alcohol consumption.  It has mainly been used to 
monitor abstaining within individuals who are dependent upon alcohol and are 
undergoing detoxification treatment.  According to the International Federation of 
Clinical Chemistry Working Group on CDT (IFCC-WG-CDT) the current 
methodology used for the detection of CDT in human serum is by HPLC using UV 
detection and is outlined in the following published paper (Helander et al. 2003).   
 
This work was unsuccessful, in validating a functioning HPLC CDT assay, using an 
HPLC system at QMU and a separate HPLC system at the University of Edinburgh.  
During the method development at both institutions, careful preparation was carried 
out to make sure the pH and ionic strength of the mobile phases were exactly as 
stated in the paper by Helander et al. (2003), as this can have an effect on ion-
exchange HPLC.  The major difference between the work which was carried out 
during the method development for this assay and the method outlined within the 
published paper was the manufacturer of the HPLC column, which was used for the 
separation of the CDT glycoforms.    The column used in the method development 
for this technique was an ion-exchange column manufactured by Phenomenex, 
whereas within the method paper published by Helander et al. (2003), the column 
used by the authors was manufactured by GE Healthcare.   
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The HPLC columns manufactured by Phenomenex and GE Healthcare are ion-
exchange columns, which are suitable for separation of the CDT glycoforms.  
However as separation of the individual glycoforms was not successful, using the 
Phenomenex branded column, it would have been good practice to carry out the 
HPLC analysis using the GE Healthcare column, which was the chosen column 
within the published method paper.  Unfortunately this could not be carried out due 
to the cost of the GE Healthcare column.  The manufacturer of the HPLC column 
was the only major change in the method development for the detection of CDT, it 
can be suggested that this was the cause of the unsuccessful separation of the CDT 
glycoforms.   The functionality of both the Phenomenex column and the GE 
Healthcare column was to act as an ion-exchange separation device, whereby the 
glycoforms of CDT would be separated within the column and eluted at the 
appropriate retention time.  Each differently manufactured column can have different 
chemical resins, which can alter the binding of the CDT glycoforms to the column 
and thus alter the elution and retention times, however both the GE Healthcare and 
Phenomenex columns were the same type of ion-exchange column and variation of 
chemical resins should not have altered the separation of CDT, to a point where 
separation was not possible.  The resin used within the Phenomenex Clarity Wax 
column was high purity silica bound to a cross-linked polyamide polymer and the 
resin used within the GE Healthcare SOURCE 15Q PE 4.6/100 column was 
polystyrene/divinyl benzene.  The resin within the GE healthcare column, is a more 
commonly used resin for ion-exchange chromatography, however the Phenomenex 
column was chosen as it is a direct equivalent to the GE Healthcare column.  
Furthermore due to budget restraints the Phenomenex column was chosen, due to it 
lower purchase price.  As the Phenomenex column is a direct equivalent to the GE 
Healthcare column, it was not predicated to cause non-detection of the CDT 
glycoforms, however as the method development work did not produce a working 
HPLC assay, it must be considered that the different type of column impacted on the 
assay development and functionality.   
 
The method development results for CDT did show that using the Phenomenex 
column an identifiable transferrin peak at approximately 15 minutes eluted, however 
further mass spectrometry of separated fractions, showed that the peak at 15 
minutes included all transferrin glycoforms but did not identify the individual 
glycoforms, which give a CDT concentration.  This result does suggest that although 
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the Phenomenex column did separate and elute transferrin glycoforms from the 
serum sample, it wasn’t sensitive enough to separate out each glycoform into 
identifiable peaks.  This could be the reason why the method development did not 
produce a working method as outlined in Helander et al. (2003).  Another point to 
consider when investigating why the method did not work was the lack of detail 
within the Helander et al. (2003) published paper, from which the method 
development was based on.  The published paper could have lacked specific detail 
on the HPLC system, sample preparation or mobile phase gradients, which would 
have contributed to the lack of success in developing a method which would suitably 
separate each CDT glycoform.   
 
Further work would have to be conducted, with a view of comparing the method 
development conducted in this thesis and the use of the exact column described 
within the peer-reviewed article (Helander et al. 2003).  It is also important to note 
that the HPLC method for the detection of CDT in human serum is an intermediate 
method until a fully validated liquid chromatography-mass spectroscopy (LC-MS) 
method has been approved by the IFCC-WG-CDT (Jeppsson et al. 2007).  The LC-
MS method, which is more sensitive and accurate in comparison to HPLC, is 
currently under development, and work relating to the method has been published in 
the literature (Oberrauch et al. 2008).   
 
The N-Latex immunoassay showed sensitivity and specificity to samples from each 
study, whereby identifying that CDT can be used as a biomarker to detect alcohol 
consumption in the form of sessional drinking as well as alcohol dependent drinking.  
This has shown that the N-Latex immunoassay, although not as sensitive as HPLC 
or LC-MS techniques does have potential to identify participants who are consuming 
alcohol in sessional and dependent patterns.  The use of the N-Latex immunoassay 
to confirm hazardous alcohol consumption in a sample of sessional drinkers has not 
been published in the literature.   
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4.3 Plasma Levels of the CVD Risk Biomarker Homocysteine within Individuals 
with a Range of Alcohol Consumption Patterns  
 
Within the HI group of drinkers, some individuals (N=8) exhibited plasma 
homocysteine levels out-with the normal clinical reference range of 5-15 µmol/l;  two 
of those participants exceeded responsible drinking guidelines and four were 
sessional drinkers.  However within the entire HI group, there was no correlation 
between the mean alcohol consumption during drinking days for the 7 day period of 
monitoring and plasma homocysteine levels. This was also true when the analysis 
was repeated for each of the time-points within the HI study.   
 
Within sessional drinkers (N=17), the median plasma homocysteine levels were 
shown to be higher than that of abstaining individuals and  four participants had 
homocysteine levels which were out with the normal clinical reference range of 5-15 
µmol/l.  There was no significant association between the mean alcohol 
consumption per drinking days and plasma homocysteine levels in sessional 
drinkers.  A larger sample size could have clarified if an association was evident or 
not.       
 
Further investigation of the drinkers in the HI study showed that the median plasma 
homocysteine levels increased for the sessional drinkers and responsible drinkers at 
each subsequent time-point during the study period, but this was not statistically 
significant. No change in median plasma homocysteine levels during the study was 
found in abstaining individuals.  Unexpectedly the two responsible drinkers were 
shown to have plasma homocysteine levels which were higher than the sessional 
and exceeding responsible guideline drinkers.  However this could simply be 
explained by the impact of factors unrelated to alcohol consumption.  One of the 
responsible drinkers was positive for the mutant MTHFR(C677T) polymorphism which 
is associated with higher plasma homocysteine levels.  The other responsible 
drinker was genotyped as wild-type heterozygote for the MTHFR(C677T) 
polymorphism.     
 
In the ADI study, a number of participants (N=4) exhibited plasma homocysteine on 
day 1 which were above the clinical reference range.  By day 3, 72 hours after 
alcohol detoxification treatment was initiated, the median plasma homocysteine level 
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was above 15 µmol/l, however this was not a significant increase (p=0.117) from 
day 1.  There was a non-significant correlation between the self reported amount of 
daily alcohol consumed prior to detoxification and plasma homocysteine levels on 
day 1 (p=0.754, R=0.096) and day 3 (p=0.615, R=-0.142).  Literature evidence 
would suggest the opposite; plasma homocysteine is likely to fall during this time 
period (Bleich et al. 2000 and Devika et al. 2008).  The work by Bleich and co-
workers showed a reduction in homocysteine from 33.6±25.2 µmol/l to 13.9±8.8 
µmol/l in a 72 hour period from the beginning of detoxification treatment; however 
the paper by Bleich et al. 2000 did not state if this reduction was significant and no 
p-value was stated.  Devika et al. (2008) found homocysteine significantly (p<0.002) 
reduced from 26.00±13.36 µmol/l to 14.31±5.7 µmol/l within eight weeks under the 
influence of supplementation with folic acid and vitamin B12.  As the study by Devika 
et al. (2008), was over a longer time period and involved vitamin-reducing 
supplementation, the study cannot be directly compared to the ADI study.  However, 
one possible, but speculative explanation (given the low number of participants) for 
the discrepancy between the present findings and those of Bleich et al. (2000) is the 
potential impact of the type of alcohol has on homocysteine levels.  In the ADI study 
the largest rise in the amino acid was detected in the two participants who 
consumed cider.  The studies by Devika and Bleich were in Indian and German 
alcohol detoxification clinics, respectively. The particular type of drinks consumed by 
their participants is not reported. 
 
It is important to state that the participants recruited to the ADI study were 
undergoing a medically supervised alcohol detoxification, which included the 
prescription of Chlordiazepoxide (benzodiazepine) to reduce the withdrawal side 
effects from alcohol. This was part of the protocol for this study and was similar to 
other studies of this design published in the literature (Bleich et al. 2000a; Bleich et 
al. 2000d; Cravo and Camilo 2000; Cravo et al. 1996).  Known side-effects of the 
withdrawal from alcohol dependence include vomiting, tremors, seizures and 
headaches (Kumar et al. 2009).  The use of Chlordiazepoxide was prescribed as a 
reducing regime over the course of the detoxification.  All participants recruited to 
the ADI study were prescribed Chlordiazepoxide in a dose which ranged from 40 mg 
to 180 mg per day.  There is no evidence published in the literature that suggests 
Chlordiazepoxide interacts with, or affects, plasma homocysteine levels.  
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A literature search provided one recent study, published in the last two years, which 
investigated the relationship between plasma homocysteine and alcohol 
consumption, but only investigated healthy male subjects (Gibson et al. 2008).  (In 
the HI study only 34.3% (N=12) of the participants were male.)  This randomised, 
cross-over study, was an intervention whereby participants were asked to consume 
either 24 g of vodka or red wine daily, for a two week period and plasma 
homocysteine was measured before and after the intervention.  The amount of 
alcohol consumed (24 g; 3 UK units) was within the UK Department of Health 
guidelines for responsible daily consumption for males (UK Department of Health 
1995).  Results indicated that the consumption of 24 g of red wine for a 2 week 
period significantly (p=0.03) elevated plasma homocysteine levels compared to 
levels before the start of the intervention, however there was no significant increase 
in plasma homocysteine levels in the vodka drinking group.  When both 
interventions were compared there was no significant difference (p=0.57) found 
between the levels of plasma homocysteine after the 2 week consumption of either 
red wine or vodka.  
 
A similar study by Bleich et al. 2000c, who investigated alcohol consumption in a 
sample of male social drinkers (N=45) compared to abstainers (N=15)  confirmed 
that red wine elevated homocysteine levels in serum, but also found an elevation in 
the serum of spirit drinkers. Additional literature suggests that red wine consumption 
reduces homocysteine levels due to the potential antioxidant effects of red wine 
(Tsang et al. 2005) in human subjects.  The study by Tsang et al (2005), was a 
randomised control study, where study participants (N=12) were asked to consume 
375 ml of 12% red wine (36 g; 4.5 UK units), daily for a two week period.  The 
results from the Tsang et al. (2005) study shows that after the red wine intervention, 
plasma homocysteine levels reduced from 8.1 µmol/l to 7.8 µmol/l, but increased in 
the control group (N=8) from 9.8 µmol/l to 10.0 µmol/l.  The consumption levels of 
red wine in the Tsang et al. (2005) study is above the UK Department of Health’s 
recommended daily alcohol consumption guidelines of 3 units (female) and 4 units 
(male) per day, however the results show that there was a reduction in 
homocysteine levels after alcohol consumption, although this reduction was not 
statistically significant.  It is important to note that the gender of the participants was 
not stated.    The findings of the Tsang et al. (2005) study does contradict the 
findings of the Gibson study and ADI study, which further shows that there is 
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conflicting evidence to suggest that different types of alcohol vary in their influence 
on homocysteine levels and this warrants further investigation.  The findings of 
Gibson et al (2008) (intervention study) and preliminary findings from the present 
work (self-reported consumption) do agree that the type of alcohol consumption can 
impact on plasma homocysteine levels.  More work is required to investigate the 
exact type of alcohol and drinking patterns which promote a change in plasma 
homocysteine levels and thereby potentially increase the risk of cardiovascular 
disease.   
 
The most recent study investigating plasma homocysteine levels in alcohol-
dependent individuals was by Devika et al. 2008, who found a significant decrease 
(p<0.002) in serum homocysteine levels after an eight week alcohol detoxification.  
The eight week detoxification period, is longer in comparison to studies conducted 
by Bleich and co-workers and the present ADI study.  This longer period for alcohol 
withdrawal would give more time for plasma homocysteine to return to lower levels.  
Due to the different time-scales of the studies by Devika et al. (2008), it is not 
appropriate to compare findings from this study to the findings in the ADI study and 
by Bleich et al. (2000b).   Furthermore the study by Devika et al. (2008), also 
supplemented the participants with vitamin B12 and folic acid, which are known to 
decrease the circulating levels of homocysteine.  Other studies by Bleich, Cravo and 
co-workers found similar results, however these studies did not supplement their 
study participants with folic acid and vitamin B12 and concluded that the simple 
withdrawal from alcohol did, on its own, reduce homocysteine levels (Bleich et al. 
2000a; Bleich et al. 2000d; Cravo and Camilo 2000; Cravo et al. 1996).   
 
The design of the ADI and HI studies permitted comparison of healthy individuals 
who undertake sessional drinking with alcohol-dependent individuals. Findings 
suggest that healthy individuals who undertake patterns of sessional drinking can 
consume the same volume of alcohol as an alcohol dependent individual inducing 
the potential health related risk factors associated with excess alcohol consumption, 
including a rise in plasma homocysteine, which have been well documented in the 
literature (Bleich et al. 2001; Trabetti 2008). A comparison of plasma homocysteine 
levels between sessional drinkers (median 7.20 µmol/l) and ADI individuals (median 
7.89 µmol/l) showed no significant difference (p=0.818).  However, in both groups, 
the median plasma homocysteine levels are within the clinical reference range for 
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homocysteine, which is internationally recognised as being 5-15 µmol/l in plasma 
(Antoniades et al. 2009; Ducros et al. 2002).  The range of plasma homocysteine 
levels within each drinking pattern does extend above the clinical reference range, 
which suggests that hyperhomocysteinemia is present within sessional drinkers and 
alcohol dependent individuals.  Both drinking patterns may be associated with a 
potential CVD risk.   Therefore these individuals are at an increased risk of 
hyperhomocysteinemia, which includes oxidative stress and endothelium 
dysfunction, and can potentially lead to the development of cardiovascular disease 
(Trabetti 2008).  More research is required with a larger sample size, to ascertain 
the effect different alcohol drinking patterns have on plasma homocysteine levels 
within a sample of individuals who consume alcohol in a range of patterns.    
 
Since the present study design required the storage and subsequent batch analysis 
of homocysteine, it was essential that long term freezer storage did not jeopardise 
the stability of the amino acid and thereby invalidate laboratory analysis findings.  
Certainly literature evidence suggested that repeated freezing and thawing of 
plasma, has no effect on subsequent homocysteine analysis (Ducros et al. 2002).  A 
significant difference was found between sample groups which were either spiked 
with synthetic homocysteine or non-spiked (p=0.005, p=0.005 respectively) and 
subjected to either constant storage temperatures or repeated thawing and 
refreezing.  There was also a high percentage coefficient of variation within each 
group, above the threshold of 10% variation, which again highlights the evident 
effect of multiple freezing and thawing.  
 
However, when the recovery of the artificial homocysteine spike was taken into 
consideration the median levels of each comparable group were similar.  The batch 
analysis of the samples however did highlight that due to column degradation, there 
was a 20% variation in the inter-assay runs.  The column degradation, reflected in 
the inter-assay variation, may be explained by the number of sample runs which had 
been analysed by the column, prior to the analysis of the stability samples. The 
column instructions advised that the column was sustainable for up to 700 analyses 
and this upper limit was almost reached during the analysis of all plasma 
homocysteine from the HI, ADI and stability study duplicate batch analyses.    It 
would have been good laboratory practise to repeat the sample batch analyses on a 
new column, however financial restrictions prevented this.  This prevented the 
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comparison of groups, due to the inter-assay variation, meaning a definitive 
conclusion of the effect of freezer storage on plasma homocysteine could not be 
reached. The functionality of the HPLC assay did show specificity in recovering the 
artificial homocysteine spike.  Also the analysis of plasma samples was carried out 
using HPLC-ED, which produced consistent calibrations, with coefficients of 
determination of >0.99 and %CV of less that 5%, suggesting that the functionality of 
the assay method was reliable (Cummins 2005).    
 
4.3.1 Method Development for the Detection of Homocysteine in Urine 
 
Homocysteine was detected in urine but sensitivity was low and provided results for 
only 22.9% of HI study (N=35) urine samples and 38.9% of the total ADI study 
(N=18) urine samples.   The results found do suggest that homocysteine is 
expressed at very low concentrations and the use of creatinine as a constant to 
measure homocysteine against, is required.   
 
A reliable and accurate method for the detection of homocysteine in plasma or 
serum has been well established in the literature (Ducros et al. 2002; Houze et al. 
2001).  However the measurement of homocysteine in urine, would avoid the need 
for venepuncture, therefore reducing the risk of this procedure to both participants 
and phlebotomist.  Also urine is a more convenient and a less invasive biological 
sample to collect.  There was no significant correlation found between plasma 
homocysteine levels and homocysteine measured as a ratio with creatinine in urine.  
This finding suggests that plasma homocysteine is a superior method in analysing 
and determining homocysteine levels.  However the urinary homocysteine assay 
was not fully validated and did require more work.  It would be important to repeat 
this association with a fully validated urinary homocysteine assay and to test for any 
potential statistical association.     
 
The measurement of daily alcohol consumption derived from diaries was also used 
to determine if there was an association between urinary homocysteine and alcohol 
consumption.  This provided a large sample size (N=19).  Using daily alcohol 
consumption recorded in grams, a significant inverse correlation (p=0.038, R=-
0.480) was identified between self-reported alcohol consumption in grams (gained 
from questionnaires and diary recall) and urinary homocysteine expressed as a ratio 
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with creatinine.   However an inverse correlation was not expected, as it would be 
anticipated for alcohol consumption to increase urinary homocysteine levels not 
induce a decrease.  As the assay was not fully validated and lacked sensitivity, this 
could explain the findings.  This association requires more investigation with an 
increased sample size and fully validated urinary homocysteine assay.   
 
The urinary method by Thomson and Tucker 1986, was published several years ago 
using HPLC with electrochemical detection, which is the same technique used to 
measure plasma homocysteine.  More recently a method paper by Kuśmierek and 
co-workers established a method for the simultaneous detection of cysteine, 
cysteinylglycine and homocysteine in urine using HPLC with ultraviolet (UV) 
detection (Kusmierek et al. 2006).  However electrochemical detection is a more 
sensitive detection method to accompany HPLC, which produces more reliable 
results, in comparison to UV detection.  The reliability of HPLC-ED has been 
established for homocysteine analysis (both in plasma and urine), through method 
development by numerous authors (Cummins 2005; Houze et al. 1999; Houze et al. 
2001; Kusmierek et al. 2006).  It is important to note that electrochemical detection 
is prone to stability problems, in comparison to ultraviolet detection.  However the 
use of a gold-electrode has been established to improve sensitivity and counteract 
interference problems (Houze et al. 2001).  This was the reason, why the method by 
Thomas and Tucker (1986) was used to develop a urinary homocysteine assay, 
instead of the method adopted by Kusmierek et al. (2006).   
 
Details relating to another biomarker employed to estimate alcohol consumption is 
ethyl glucuronide, expressed relative to urinary creatinine levels has been previously 
published by Bergström et al. (2003).  This paper investigated creatinine content in 
urine in a sample of drivers whose blood alcohol level was above the legal driving 
limit. The authors compared urinary creatinine levels to urinary levels of ethyl 
glucuronide, which is a direct ethanol metabolite.  Urinary creatinine was measured 
using the Jaffe method, which is the same method employed within this thesis.  The 
paper by Bergström et al. (2003) stated that creatinine concentration of less than 0.2 
g/l in urine was a highly dilute specimen for detection of urinary biomarkers 
normalised using creatinine.   This dilute concentration of urine would be evident as 
a result of an alcohol induced diuresis.  This would occur during the early stages of 
alcohol consumption.  In the later stages the urine is more likely to become 
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concentrated.  Therefore Bergström et al. (2003) recommend that urine should be 
sampled at the second void, as opposed to the first void, to limit the effects of 
alcohol induced diuresis.   When comparing the levels of urinary creatinine found 
within both the HI and ADI study sample, it was found that all the samples which 
were found to contain detectable homocysteine, had creatinine levels of greater than 
0.2 g/l. This suggests that the remaining participant samples were simply too dilute 
(0.07-0.1 g/l creatinine), given the sensitivity of the urinary homocysteine assay.  
Alcohol dependent individuals may have provided a more concentrated urine 
sample at the beginning of alcohol detoxification, due to the dehydrating action of 
alcohol.  The consumption of alcohol on urine production has been well documented 
in the literature (Lieber 2004).  Consumption of alcohol, increases the metabolic rate 
of alcohol metabolism, by way of alcohol dehydrogenase, and the excretion of 
alcohol via the kidney.  Urine production is increased by the inhibition of antidiuretic 
hormone or vasopressin, released from the pituitary gland (Swift and Davidson 
1998).  When antidiuretic hormone is inhibited this prevents the kidney from 
reabsorbing and conserving water, thereby increasing urine production (Swift and 
Davidson 1998).  The urine produced during alcohol consumption is dilute and 
therefore biomarker measurement in urine must take into consideration the effect of 
alcohol on urine composition, which has been highlighted in the literature by 
Bergstom et al. (2003). 
 
The work by Bergström and co-workers did produce a significant correlation 
(p<0.001, R=0.62) between the alcohol biomarker ethyl glucronide and urinary 
creatinine within the sample of intoxicated drivers (Bergström et al. 2003).  However 
this correlation was more evident in the second urinary void sample, than the urine 
void directly after intoxication, as a more concentrated urine sample, produced a 
significant correlation of creatinine to ethyl glucuronide.  Bergström and co-workers 
suggested expressing the alcohol biomarker ethyl glucuronide as a ratio with 
creatinine.  The work by Bergström et al. (2003) has also highlighted that a dilute 
sample of less than 0.2 g/l of creatinine would produce less reliable results and 
dilute the levels of any potential biomarker which was being investigated, including 
ethyl glucuronide and the same theory can be applied to the investigation of 
homocysteine in urine.  A dilute urine sample, due to the diuresis effects of acute 
alcohol consumption, would produce a urine sample which was not sufficiently 
concentrated, to detect suitable levels of any potential biomarker.  Therefore when 
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using urine to determine an association between alcohol consumption and a 
biomarker (e.g. homocysteine), it is important to take into consideration the diluting 
effects of alcohol on urine, i.e. do not take a urine sample directly after intoxication. 
 
In summary the detection of homocysteine in urine has been shown to be 
moderately successful in samples of healthy individuals and alcohol dependent 
individuals.  However more work is required to develop the HPLC assay to detect 
the very low levels of homocysteine expressed in urine.  The suggestion by Chwatko 
and Jakubowski to measure homocysteine-thiolactone, which is a thioester of 
homocysteine in urine needs further consideration (Chwatko and Jakubowski 2005).  
However, evidence in the published literature, suggests homocysteine-thiolactone 
has not been fully accepted as a biomarker for CVD risk and the measurement of 
total homocysteine is still preferred (Antoniades et al. 2009).      The method 
published by Kusmierek and co-workers does show potential, and utilises HPLC 
with UV detection (which is more commonly available and less expensive to 
maintain).  However a suggestion for further work would be to use a more powerful 
and sensitive technique such as liquid chromatography with mass spectrometry (LC-
MS) (Ducros et al. 2002).   
 
4.3.2 Prevalence of the MTHFR(C677T) Polymorphism and Effect on Plasma 
Homocysteine 
 
A polymorphism is defined as a genetic mutation which is present in greater than 
1% of the population.  The mutant MTHFR(C677T) polymorphism was present in six 
participants within the HI study (N=35) but was not found in any participants in the 
ADI study (N=18).  The expression of the mutant MTHFR(C677T) polymorphism in six 
participants within a total study sample of fifty three (N=53, HI and ADI studies) 
would be expected, as this is greater than one percent of the sample (11.3%). The 
exact prevalence of the mutant MTHFR(C677T) polymorphism in the Scottish 
population is yet to be determined.    The presence of the mutant MTHFR(C677T) 
polymorphism is known to cause elevation of circulating plasma homocysteine 
levels, through the reduction in the activity of the MTHFR enzyme, whereby 5-
MTHFR cannot act as a carbon donor during the remethylation of homocysteine to 
methionine (Fabris et al. 2009).  Furthermore the presence of the mutant 
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MTHFR(C677T) polymorphism has also, therefore, been confirmed as a risk factor for 
cardiovascular disease due to consequent increase in homocysteine (Bennouar et 
al. 2007; Klerk et al. 2002). 
 
From the results shown in chapter 3, there was no significant difference between the 
concentrations of plasma homocysteine found in the mutant homozygote 
MTHFR(C677T) polymorphism group compared to the wild-type homozygote or the 
heterozygote variants.  The highest plasma values of homocysteine were in fact 
detected within participants who carried the wild-type homozygote genotype, which 
was not expected, however the median plasma homocysteine level within the 
mutant polymorphism group was higher and this finding is more consistent with what 
might be anticipated from literature results.   
 
There have been a number of studies published in 2008 and 2009 which 
investigated the link between elevated plasma homocysteine levels and the 
presence of the MTHFR(C677T) polymorphism.  The studies by; Alessio et al. (2008), 
Barbosa, et al. (2008), Grassi et al. (2008), Nagele et al. (2008) and Yang et al. 
(2008) all showed that the presence of the MTHFR(C677T) polymorphism affected 
homocysteine concentrations either in serum or plasma and was a major factor 
when investigating the cause of elevated homocysteine levels. When specifically 
investigating the participants who were found to carry the mutant MTHFR(C677T) 
polymorphism, the median plasma homocysteine range did increase over the 6-
month study period compared to other genotype groups. This change was not 
statistically significant but may suggest that lifestyle factors and the presence of the 
mutant MTHFR(C677T) polymorphism are causing an effect on plasma homocysteine.  
Given the small sample size (N=5), further investigation employing a larger sample 
size is merited. 
 
An analysis of the data for the HI study participants (N=5) who carried the 
MTHFR(C677T) mutation at baseline, found a significant linear correlation (p<0.05, 
R=0.975), between plasma homocysteine and mean alcohol consumption during 
drinking days.  This association was not found in participants who were wild-type 
homozygote and heterozygote for the MTHFR(C677T) polymorphism.  A comparison of 
the ratio of homocysteine to mean alcohol consumption during drinking days at 
baseline further highlighted the relationship between alcohol consumption and the 
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presence of the mutant MTHFR(C677T) polymorphism, where the ratio was higher in 
the group of participants who were genotyped for the mutant MTHFR(C677T) 
polymorphism.  This highlights the potential for the individuals who carry the mutant 
MTHFR(C677T) polymorphism to increase their plasma homocysteine levels to ‘at risk’ 
levels, of above the maximum clinical reference cut-off value of 15 µmol/l, when 
consuming alcohol in situations which could be termed ‘social drinking’.   This 
finding has not been reported or investigated in the current published literature. 
 
The relationship between the presence of the mutant MTHFR(C677T) polymorphism 
and the effect of alcohol consumption on plasma homocysteine levels requires more 
investigation within a larger sample of individuals who consume alcohol in a range of 
patterns, including dependency, to ascertain the effect of heavy alcohol 
consumption on plasma homocysteine levels in the presence of the MTHFR(C677T) 
polymorphism.  There were no ADI participants found to carry the mutant 
MTHFR(C677T) polymorphism and the presence of this polymorphism within a sample 
of alcohol dependent individuals does require investigation. 
 
4.4 Vitamin Co-factors of Homocysteine Metabolism  
4.4.1 Serum Folate 
 
Folate is an important co-factor involved in the normal remethylation of 
homocysteine to methionine. It is also well established in the literature that 
excessive alcohol consumption can reduce the bioavailability of folate in vivo, 
through a catabolic effect on the folate molecule.  
 
The levels of serum folate and serum vitamin B12 associated with particular patterns 
of alcohol consumption have yet to be determined (Cravo and Camilo 2000; Mason 
and Choi 2005).  The analysis of serum folate within the HI study sample highlighted 
that 40% (N=14) of participants had serum folate levels below that of the minimum 
clinical reference range (5 µg/l) and of these, nine were female.  Serum folate levels 
in the ADI study sample were also low and the median level was towards the lower 
level of the clinical reference range (5 µg/l).  There were more males in the ADI 
study compared to the HI study, however it was anticipated that there would be low 
folate levels in the alcohol-dependent patient sample as this has been established 
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within the published literature (Cravo and Camilo 2000; Cravo et al. 1996; Mason 
and Choi 2005).  In the studies published which investigated the relationship 
between folate and alcohol dependence, Bleich et al. (2000), reported a median 
serum folate of 9.2 µg/l in a sample of alcohol dependent patients at admission, 
which was higher than the median value found in the present ADI study.     
 
Folate is an important B-vitamin, which protects against anaemia and is crucial to 
the normal development of the foetus.  Participants recruited to the HI study were a 
convenience sample from a university population.  There was a gender bias in terms 
of recruitment as the student population of Queen Margaret University is 77% 
female.  A folate level of below the minimum healthy clinical reference range is 
concerning within a sample of females of reproductive age.  Interestingly, of the 
female participants who had folate levels below 5 µg/l, they were found to be 
undertaking sessional drinking.  The low folate level may be the consequence of at 
least two factors; firstly poor diet. The poor nutritional content of the diet of some 
university students has been reported in the literature  (Comrie et al. 2009). The 
second factor may be sessional drinking. The results presented here raise the 
possibility that young women of reproductive age may be exacerbating their poor 
dietary intake of folate through their alcohol drinking pattern and this question is  
worthy of further research.  
 
In the ADI study, serum folate levels were shown to significantly (p=0.007) decrease 
for the total sample, as detoxification treatment progressed.  Serum folate levels did 
increase in the participants who consumed both wine and beer, as alcohol 
detoxification treatment progressed.   This finding of a reduction in serum folate 
levels with time mirrors the finding of increased plasma homocysteine level, as 
alcohol detoxification treatment progresses.  The study by Gibson et al (2008), 
highlights that consumption of alcohol does significantly increase plasma 
homocysteine levels within responsible drinkers and agrees with published literature 
that as homocysteine levels increase, folate and vitamin B12 levels decrease 
(Antoniades et al. 2009; Bleich et al. 2000c).  The decrease in serum folate and 
increase in plasma homocysteine levels found in ADI participants was expected, as 
it has been widely reported in the literature that there is an inverse relationship 
between homocysteine and folate (Antoniades et al. 2009).  However this inverse 
relationship would be expected when the ADI participants were consuming alcohol 
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and not during alcohol detoxification treatment, whereby serum folate should 
increase in the presence of no alcohol consumption and plasma homocysteine 
should decrease.  The ADI study questionnaire asked the alcohol dependent 
participants which type of alcohol they regularly consumed or was their preferred 
drink.  There was a higher proportion of ADI participants who were dependent on 
only one type of alcoholic beverage (N=10).  While numbers were admittedly small, 
the potential effect of the type of alcohol on folate levels was investigated and it was 
found that those who drank only spirits had higher levels of serum folate prior to 
entering detoxification treatment.   
 
This finding does not agree with the published literature as, it has been shown that 
individuals who consume beer tend to have higher serum folate levels in 
comparisons to individuals who abuse alcohol using other types of alcoholic 
beverage (Bleich and Degner 2000; Bleich et al. 2000c).  Higher serum folate levels 
in beer drinkers are due to the high content of folate found in this alcoholic 
beverage.  As previously stated, ADI participants who consumed only beer did have 
reduced serum folate levels, as detoxification treatment progressed, however they 
were the only participants who were found to have a reduction in plasma 
homocysteine levels from day 1 to day 3.  Since only two participants consumed 
beer, it could be suggested that the consumption of beer, even when serum folate 
levels are low, does still have a reducing effect on plasma homocysteine and this 
finding requires more investigation.   
 
The reduction in serum folate levels, as alcohol detoxification continues suggest that 
participants should be supplemented with folic acid to increase the circulating levels 
of folate, as soon as detoxification treatment begins.  The supplementation of ADI 
participants by the prescribing of Pabrinex and Thiamine does increase B-vitamin 
levels and treat symptoms of malnutrition, but does not increase the levels of folate 
and vitamin B12. It is routine clinical practice for alcohol dependent patients to be 
prescribed B-vitamins, as it has been well reported in the literature that alcohol 
consumption depletes folate and vitamin B12.  The prescribing of Pabrinex and 
Thiamine was recorded to determine the nutritional status of the ADI study sample.  
The findings, reported in chapter 3, indicate that the nutritional health of the study 
participants was poor, as a high percentage of the sample were prescribed Pabrinex 
indicating that they were severely malnourished, consistent with the negative effect 
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of alcohol abuse.  The supplementation of folic acid would reduce the negative 
affects associated with decreased folate levels.  It would also be important to 
consider which type of alcohol was being consumed before treatment started, as 
this has shown to impact on serum folate levels.   This further influences the 
potential for the type of alcoholic drink to affect folate, therefore having an impact on 
homocysteine levels.     
 
It has been reported in the literature that serum folate levels are inversely correlated 
with plasma homocysteine levels in humans (Antoniades et al. 2009).  Bleich et al. 
(2000) also reported that serum folate was inversely correlated with plasma 
homocysteine in a sample of alcohol dependent individuals undergoing alcohol 
detoxification.  This relationship was suggested for the ADI study participants 
however, there was no significant correlation detected on day 1 (p=0.140, R=-0.452) 
and day 3 (p=0.154, R=-0.460).  For the HI study, again the correlation coefficient 
was not significant (p=0.61, R=-0.324).  It is important to note that the ADI 
participants were undergoing detoxification treatment and have been shown to be 
malnourished, which when compared to the HI study participants, who have not 
been undergoing an alcohol detoxification and have been continuing with their 
normal drinking and dietary intake.  Therefore the ADI study sample does not 
represent a continuum.  This area of work does require more investigation with a 
larger sample.   
 
Several facts give attest to the accuracy of the serum folate results presented for 
both the HI and ADI studies.  Levels of folate in control, pooled, serum samples 
stored under similar conditions to participant samples (-80 ºC storage) or subjected 
to multiple freezing and thawing, did not differ significantly (p=0.858).  In addition the 
coefficient of variation within a batch analysis of participant’s serum was confirmed 
to be less than 10% at each run.  
 
4.4.2 Serum Vitamin B12 
 
Like folate, vitamin B12 is also an important cofactor involved in the remethylation of 
homocysteine.  Within the HI study sample, serum levels of vitamin B12 were found 
not to change significantly during the 6 month period of the study (p=0.139).  When 
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investigating the status of vitamin B12 within HI study individuals, with different 
drinking patterns, the abstainers did have higher vitamin B12 levels, which 
significantly (p=0.01) increased as the study progressed.  The levels of vitamin B12 
in the other groups; responsible drinkers, exceeding responsible guideline drinkers 
and sessional drinkers all had similar vitamin B12 levels, which were lower than the 
abstaining individuals, which might be anticipated, due to the depleting effect of 
alcohol on vitamin B12 (Thuesen et al. 2010).  Alcohol consumption can impair the 
uptake or retention of vitamin B12 by the liver and other peripheral tissues (Cravo 
and Camilo 2000).     
 
In the present work there was no significant change in serum vitamin B12 within each 
alcohol drinking pattern at the study time-points.  Within the HI study sample there 
were three participants who had vitamin B12 levels below the minimum clinical cut-off 
value of 200 ng/l and two of these individuals consumed alcohol in a pattern which 
exceeded the responsible daily guidelines, suggesting a potential link to alcohol 
consumption. 
 
The status of vitamin B12 within the ADI study sample was also similar to that of the 
HI study sample, whereby the serum levels for all patients were within the clinical 
reference range.  This suggests that vitamin B12 is less affected by alcohol 
consumption in comparison to folate. The recommended daily intake (RDI) of 
vitamin B12 is very small, 2-3 µg, and can remain stored in the body for a long period 
of time, explaining the low RDI (Solomon 2007).   Consumption of alcohol does not 
deplete vitamin B12 as readily as folate, which could explain the normal range of 
serum levels for this vitamin detected in both the HI and ADI studies.  
 
It is well documented in the literature that alcohol consumption, in a heavy pattern 
does deplete B-vitamins (Birch et al. 2009; Brattstrom 1996).  For general population 
adult drinkers, a recent study highlighted the fact that alcohol consumption was 
significantly inversely associated with low vitamin B12 concentration (Thuesen et al. 
2010). However, surprisingly in the present study, a significant positive correlation 
(p=0.004, R=0.449) was detected between daily alcohol consumption in grams and 
vitamin B12 levels in drinkers (N=44) (HI and ADI study participants, excluding 
abstainers). A possible explanation of this apparent contradiction with previous 
studies is suggested by the finding that alcohol consumption in a dependent pattern 
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may cause falsely normal vitamin B12 levels in the serum, by vitamin B12 leaking out 
of hepatic cells or also by oxidative stress inactivating holotransocolabalmin 
(HoloTC), which is the active fraction of the vitamin B12 molecule (Fragasso et al. 
2010).  However this finding has not been established in a sample of healthy 
individuals, who consume alcohol in a range of non-dependent patterns.  It is also 
important to note that, like folate, vitamin B12 could be affected by dietary intake and 
not solely affected by alcohol consumption.  
 
Literature evidence suggests that there is an inverse relationship between plasma 
homocysteine and vitamin B12, where a high vitamin B12 concentration relates to a 
lower homocysteine level (Antoniades et al. 2009).  No significant correlation 
between vitamin B12 and plasma homocysteine was evident in the healthy 
individuals investigated at baseline (p=0.596; R=-0.093).  However within the ADI 
study sample a significant inverse correlation was found on day 1 (R=-0.594, 
p=0.042) and improved by day 3 (R=-0.864, p=0.001).  This finding suggests that 
vitamin B12 and homocysteine have a more defined relationship in alcohol 
dependent drinkers in comparison to ‘social’ drinkers.  A potential explanation for 
this reduced correlation in the HI study sample could be that the detrimental effects 
of alcohol consumption are not apparent. Vitamin B12 is stored in the body for a long 
period and is less readily depleted than folate. The difference between the two 
drinking groups in terms of vitamin B12 levels could be explained by the period of 
alcohol consumption, whereby the longer heavy alcohol consumption has been 
undertaken the more reducing effect this has on stored vitamin B12 levels.    
 
Investigation of an association between the diet diary vitamin B12 results with serum 
levels determined by biological assay revealed a non-significant inverse correlation 
(R=-0.429).    This finding was not expected and suggests that the WinDiet software 
does not produce a reliable result for vitamin B12 analysis. This finding could be 
suggested as the stability study results for the vitamin B12 assay showed that -80°C 
freezer storage and multiple thawing and refreezing did not affect the analysis of 
vitamin B12.  The vitamin B12 assay used, was within a hospital laboratory and the 
coefficient of variation was less than 10%, due to the strict variation guidelines within 
diagnostic laboratories.  The reason for a lack of association between diet diary 
vitamin B12 analysis and serum vitamin B12 assay has yet to be determined, and 
requires further investigation.  It is also important to note that the analysis of diet 
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diaries is dependent on the accuracy of participant recall.  Recently published work 
by Fragasso et al. (2010), has suggested that normal serum vitamin B12 levels are 
found in alcohol dependent individuals, due to mechanisms described previously, 
however, this has not been determined in healthy individuals who consume alcohol 
in various patterns and the functionality of the vitamin B12 assay does require 
clarification in light of this recent publication.   
 
4.4.3 The Effect of Folate and Vitamin B12 on Reducing Homocysteine Levels  
 
Dietary supplementation of folic acid and vitamin B12, has been shown to reduce the 
circulating levels of homocysteine in a number of studies and clinical trials (Al-Tahan 
et al. 2008; Antoniades et al. 2009; Bonaa et al. 2006; Dangour et al. 2008; Pfeiffer 
et al. 2008; Stea et al. 2008; The Heart Outcomes Prevention Evaluation (HOPE) 
2006; Wotherspoon et al. 2008).  This can have benefits in reducing homocysteine 
levels in patients with diagnosed cardiovascular disease (Antoniades et al. 2009).  
All of the studies, describing the influence of supplementation of folic acid and 
vitamin B12 on homocysteine levels, as listed in the table in appendix 4C, concluded 
that in humans, supplementation of combined doses of folic acid and vitamin B12 
reduced the plasma levels of homocysteine.  However, in samples where the 
participants had established CVD, the mortality risk was not reduced.  Several 
authors, dispute the most effective dose to actively reduce plasma homocysteine 
(Antoniades et al. 2009).  Current evidence suggests that a total dose of 400 µg of 
folic acid and 0.02-1 mg of vitamin B12 daily would actively reduce circulating 
homocysteine concentrations to within the clinical reference range of 5-15 µmol/l.   
Certain individuals within both the HI and ADI studies, exhibited homocysteine levels 
of above 15 µmol/l and it could be suggested that folic acid and vitamin B12 
supplementation could be beneficial for these individuals.    
 
The ability of folate and vitamin B12 to reduce plasma homocysteine levels is 
important to consider when investigating the detrimental effect of alcohol 
consumption on circulating levels of homocysteine.  The present results have clearly 
shown that for some individuals who consume alcohol in a range of patterns, 
including dependency, folate is below the minimum clinical reference range; (40% in 
HI sample; 61.5% in ADI sample), which increases the risks associated with 
258 
depleted folate levels, e.g. increase in circulating plasma homocysteine.  The dietary 
supplementation of folic acid and vitamin B12 (although this has been shown to be 
less affected by alcohol) needs to be investigated further to determine the potential 
of long term benefit of lowering homocysteine in a sample of known heavy drinkers 
(sessional drinkers and alcohol-dependent individuals).  In the literature there is a 
lack of studies which have actively investigated the potential value of dietary 
supplementation of folic acid and/or vitamin B12, in individuals with no history of 
CVD, who consume alcohol in a range of patterns, including sessional drinking.   
 
The findings from the HI study suggests that some alcohol consuming individuals 
who have self-reported themselves as being in good health are in fact at risk of 
hyperhomocysteinemia and the risks associated with this condition, the major one of 
which is cardiovascular disease.  As folic acid and vitamin B12 have been shown to 
actively reduce homocysteine concentrations, it would be appropriate to consider 
further studies and trials to investigate the potential for folic acid and or vitamin B12 
supplementation, as an intervention for reducing homocysteine levels and therefore 
risk of CVD, in a sample of individuals who consume alcohol in a range of patterns.  
If this further work, with a larger sample size was undertaken in a population where 
CVD was not established, a determination of homocysteine lowering on reducing 
mortality could be determined.       
 
4.5 Limitations of the HI and ADI Studies 
 
The recruitment of study participants into both studies was affected due to a number 
of reasons.  It is important to state that all study participants did not receive payment 
for taking part in the study, which could have reduced recruitment potential, however 
no payment did encourage participants to take part for non-financial reasons. The HI 
study design did make particular demands on the participants, e.g. six month study 
timescale, three clinical appointments where multiple blood and urine samples were 
taken, 12 hour fasting, and recording of alcohol diary for seven days on three 
occasions.  This likely did impact on recruitment and retention rates.  The literature 
has suggested that participant payment or incentives can potentially increase 
recruitment into clinical research studies and trials (Bentley and Thacker 2004). If 
both studies were repeated, it could be suggested that participant payment or 
incentives (e.g. shopping voucher), could be offered.  However it is important to note 
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that the inclusion of participant payment would be subject to ethical approval and the 
availability of funds within the study budget.   The recruitment into the HI study was 
subject to the gender bias of QMU, which has a 77% female population, therefore as 
previously stated there was a higher number of females in the HI study.  In terms of 
recruitment into the ADI study, this was limited due to the four monthly rotation of 
the FY1 (first year) junior doctors on the ward, which disrupted recruitment and 
screening of participants, as each new doctor had to be made aware of the study 
inclusion and exclusion criteria’s.  The low participant recruitment into both the HI 
and ADI studies, impacted on the statistical analysis and the type of analysis 
undertaken.  The ADI study, which was designed in relation to other previous 
studies in alcohol detoxification clinics, did have a specific sample size, however the 
required sample size was not met, therefore non-parametric statistical analysis had 
to be used within this data set.   For the HI study, there was no sample size 
calculation as this was a pilot study and had not been previously undertaken in the 
literature.  The total sample size was small, and this further impacted on the type of 
statistical tests used.  When the sample was further categorised into alcohol drinking 
pattern groups the sample size was further reduced and was not balanced.  It is 
important to note that significant findings were found, but as the sample size was 
small, these findings can only suggest possible associations between variables and 
requires further investigation in a larger sample.   
     
Problems associated with participant recruitment and retention to clinical trials and 
observational studies has been well documented in the published literature (Gul and 
Ali 2010).  Recent data has highlighted that only 31% of trials (N=122) in the UK, 
were successful in recruiting 100% of their target sample (Free et al. 2010).  This 
shows the difficultly in recruiting to not only major multi-centre trials but also to 
smaller observational studies, like the HI and ADI studies.   The effect of not 
recruiting the target sample reduces the study power and hence important 
differences in clinical markers will potentially not be identified. 
 
The HI study did not have an exact sample size, as the study was deemed pilot 
work, however the ADI study did have a required sample size of 31 participants.  
The ADI study did not recruit to target, and only recruited 58% of the required 
sample size.  The published literature does suggest certain reasons why under-
recruitment happens, however the general consensus, are the reasons for under-
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recruitment is poorly understood.  One possibility is that potential participants did not 
understand the benefit of taking part in the study/trial, not only to themselves but to 
the medical/scientific community as a whole (Free et al. 2010).  The paper by Free 
et al. (2010), suggested that the study/trial documentation should be piloted to 
potential participant groups before study initiation, with a view to gaining their 
opinion.  This was something that was carried out in the HI study, before recruitment 
began.  A focus group, would allow for potential participants to voice their 
opinions/concern.  The use of focus groups has been implemented as part of major 
multicentre RCTs.  Another point to consider are the clinical staff, who are recruiting 
participants, as their experience in working with certain groups of patients, will also 
be integral to finding out if a study can recruit to target; this was something that was 
implemented in the design of the ADI study.  
 
A number of journal papers have suggested that factors in participant’s personal 
lives can affect their participation (Woodward et al. 2010).  A conference abstract by 
Woodward et al. (2010) suggested that participants unwillingness to take part in 
research can be due to levels of trust in research staff, race (the study found 
significantly (p=0.01) more Caucasian than non-Caucasian’s takes part in research) 
and the presence of medical insurance was a major factor in participating in US 
trials/studies.   Furthermore the basic understanding of why the research is taking 
place can also hinder participant recruitment, especially if the target sample group 
does not understand why the research is taking place.  This issue can be tackled 
through the use of well worded patient information sheets and the ability for potential 
participants to discuss their participation with their GP or an independent clinician, 
not involved in the study.  The privacy of potential participants is another issue when 
taking part in research studies.  Papers have reported that participants feel by taking 
part in research and being monitored or followed-up for a long period of time (certain 
studies or trials can have a follow-up phase of up to 5 years), is invading privacy 
(Free et al. 2010).  This factor of privacy is something to especially consider when 
investigating alcohol consumption as both the ADI and HI study asked participants 
to report their drinking during a 6 month period (HI) and report their alcohol 
consumption prior to alcohol withdrawal treatment (ADI).  The questions asked, did 
require participants to be specific in reporting their consumption and if there were 
concerned or worried about their consumption levels; this could have affected their 
participation within each study, hence resulting in non-participation.   
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To tackle the issue of under-recruitment, a collaboration of Scottish Universities and 
the Scottish Government designed an advertising campaign, which was broadcast 
throughout Scotland, with an aim to better inform the Scottish Population about 
RCTs and taking part in research studies (Mackenzie et al. 2010).  Analysis of public 
opinion following the advertising campaign described by Mackenzie et al (2010), 
showed that there was statistically significant (p<0.01) better understanding of RCTs 
and the research study participation after the advertising campaign, however there 
was no statistical (p=0.92) difference in participants willingness to take part in 
research studies following the advertising campaign.  This research shows that by 
educating the general public about research studies, their awareness of research 
improves, however there is more work required to improve their willingness to take 
part and thus prevent under-recruitment to research studies.  
 
The individuals recruited into both studies formed a convenience sample, which was 
not stratified or randomly selected and were volunteers.  The HI study sample can 
be described as being a convenience sample, due to the nature of the recruitment 
site.   As previously described in earlier chapters, the HI study recruited from two 
Edinburgh universities, and the sample was entirely composed of participants who 
replied to the initial email and poster advertisement.  Participants were not directly 
targeted by age, gender, drinking patterns and the advertising of the study did not 
ask for individuals who consumed a certain quantity or type of alcohol.   Therefore 
the sample was composed of entirely willing and available participants within the 
given recruitment location.  This convenience sample is unlike a clinical trial sample, 
where patients are recruited through multiple sites and targeted due to a specific 
condition or disease which makes them eligible to take part within the trial.  The HI 
study therefore enabled data to be gathered on a sample of willing abstainers or 
alcohol consumers located within a major Scottish city.  The healthy individuals who 
consumed large volumes of alcohol were unlikely to have volunteered as they would 
not have wanted their consumption levels scrutinised, which means the findings of 
the HI study are not of a typical population and are isolated within the individuals 
who were recruited.  As previously stated there was a female bias in the HI study 
due to location of recruitment, meaning there was a lack of data on male alcohol 
consumption and subsequent comparison to biomarker results.  The finding of both 
studies can not be generalised and they point towards interesting findings within a 
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representative sample of Scottish adults, who volunteered for each research study 
(HI and ADI).  However these findings need to be investigated within a larger multi-
site sample.   
 
A major limitation of both the HI and ADI studies is memory and accuracy recall of 
the participants, when completing the questionnaires and diaries for both dietary and 
alcohol analysis.  It has been well documented in the literature that memory recall 
can impact on accuracy of alcohol data acquired from diaries and questionnaires 
(Catto 2008).  However the use of the analysis method to determine alcohol 
consumption had taken into consideration all the most relevant and required 
information when calculating consumption.  The use of the WinDiets software, 
although primarily not used for alcohol consumption analysis, did highlight 
underestimation of alcohol consumption when used and there was no reliability or 
validity data available on the WinDiets software within the literature.  The only true 
way to quantify and determinate true alcohol consumption is by watching and 
measuring alcohol as it is being consumed, which is highly impractical, therefore the 
use of an accurate and sensitive alcohol biomarker is of great importance.  Another 
issue which was a limiting factor to take into consideration was the effect the study 
had on participants self-reporting of both alcohol consumption and dietary intake, 
the so called “Hawthorne Effect”.  The Hawthorne effect can be defined as altering 
of behaviour or performance resulting from the participation in a research study  
(Campbell et al. 2005).  The results of the HI study clearly showed a change in 
alcohol drinking patterns over a 6-month period and a reduction in alcohol 
consumption; however this was not statistically significant.  The Hawthorne effect 
should be taken into consideration as a limiting factor, when investigating alcohol 
consumption, as this can influence the behaviour of the participants taking part in 
the research and effect subsequent findings.   
 
All laboratory analysis used established methods, which had coefficient of variations 
below 10%.  Each batch analysis for all biomarker analysis included standards and 
the production of a calibration curve, which ensured the functionally and accuracy of 
the assay.   The stability work on plasma homocysteine did highlight inter-assay 
variation in batch analysis.  This finding has a limiting factor in terms of how batch 
analysis should be organised, but it is important to note that this finding directly 
related to the maximum HPLC column usage, which suggests that the inter-assay 
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variation should be monitored closely in relation to the HPLC column life span.  The 
analysis of plasma homocysteine and CDT did not use the gold-standard methods, 
of LC-MS and HPLC respectively.  This potentially did reduce the sensitivity of the 
results, however neither method was available for use locally and the results 
produced from each method were from a suitable validated method.  The laboratory 
analysis used for the detection of the MTHFR(C677T) polymorphism, folate and vitamin 
B12 were derived from the most uptodate laboratory methods.   
 
The analysis of folate, vitamin B12 and CDT were conducted within hospital 
laboratories, which have strict guidelines on batch analysis procedures and 
coefficients of variation within batches, which gave added certainty to the accuracy 
of these biomarker results.  The recent publication by Fragasso et al (2010), suggest 
that vitamin B12 analysis within an alcohol dependent patient sample produces false 
normal vitamin B12 levels, however this has not been established in healthy 
individual who consume large volumes of alcohol.  This relatively new work, does 
requires more investigation and could potentially be a limiting factor in term of 
vitamin B12 analysis in a sample of heavy drinkers.  The assays for the 
determination of homocysteine in plasma and urine could also have been limited by 
participant’s failure to undertake the conditions required before blood sampling, 
whereby for plasma homocysteine analysis, participants were required to fast for 12 
hours and for urine analysis, the sample must be a waking sample.  All participants 
self-reported that they did adhere to these conditions, which again related to 
participant’s honesty, but must be a factor to take into consideration.   
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A comparison of the alcohol intake of participants within the HI study and the ADI 
study has highlighted that healthy individuals who consume alcohol in a sessional 
pattern can consume the same volume of alcohol as an individual who has been 
diagnosed as being alcohol dependent.   The analysis of alcohol consumption also 
provided preliminary evidence, entirely consistent with published literature, that 
when the consumption of alcohol is being monitored, this can have a modifying 
effect on the amount an individual consumes.   
 
The various methods used to analyse and calculate alcohol consumption from 
questionnaires and diaries has been investigated and compared in this thesis.  This 
work has highlighted the difference between each method, namely the alcohol 
manufacturer (AM) method using %ABV, the WinDiets (WD) dietary software 
method and finally the Office of National Statistics (ONS) guidelines.  The WinDiets 
and ONS method were both compared to the AM method, which was deemed to be 
more accurate as it takes into consideration the brand, the volume and %ABV 
alcohol content of each drink consumed.   The comparison of each method to the 
AM method provided results which concluded that the WD and ONS miscategorised 
healthy individuals in relation to their drinking pattern, meaning that drinkers were 
being categorised as responsible drinkers when actually they were consuming 
alcohol in a sessional pattern. The accuracy of alcohol consumption analysis is 
important when relating alcohol consumption to cardiovascular disease or other 
health risks.  
 
The estimation of alcohol consumption was also investigated using an alcohol 
biomarker, namely Carbohydrate Deficient Transferrin (CDT), in an attempt to 
reduce the errors associated with questionnaires and diaries, namely participant 
honesty and memory recall.   The study findings provided new evidence for its use 
as an alcohol biomarker within healthy individuals.  Published literature has already 
promoted the use of CDT as a biomarker for monitoring abstinence in alcohol 
abusing individuals.  The evidence provided within this thesis, suggests that CDT 
may also have a role in estimating sessional drinking within a sample of healthy i.e. 
social drinkers.  A linear relationship has been suggested between the number of 
drinking days in a 7-day period and a positive CDT test result.   
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The cardiovascular risk biomarker, homocysteine was investigated in plasma, in a 
sample of individuals who consumed alcohol in dependent and non-dependent 
patterns.  Plasma homocysteine levels in both studies exhibited a large range, 
however the median was found to be within the plasma homocysteine reference 
range of 5-15 µmol/l.  An interesting finding, which contradicts published literature, 
was found in the ADI study, where plasma homocysteine increased from day 1 to 
day 3 of detoxification.  The published literature has found that plasma 
homocysteine levels decrease with alcohol withdrawal.  However these studies have 
been conducted in other countries.  This suggest that it is possibly a new finding 
within a Scottish alcohol detoxification unit and the volume of alcohol and type of 
alcohol is having an opposing effect on plasma levels of homocysteine during 
alcohol withdrawal. This would indicate increasing risk. More work is required, with a 
large sample size to identify the effect of alcohol consumption on plasma 
homocysteine levels in both healthy individuals and alcohol dependent patients, who 
consume alcohol in different patterns.  
 
The presence of the MTHFR(C677T) polymorphism, affects homocysteine levels, 
increasing its concentration in circulating plasma.   Participants in both the HI and 
ADI studies were genotyped for the MTHFR(C677T) polymorphism using Real-Time 
PCR.  The results of the genotyping did not conclude that the presence of the 
mutant MTHFR(C677T) polymorphism promotes a higher circulating homocysteine 
level in plasma.  However, the low participant numbers are relevant and further work 
with a much greater number of participants in both HI and ADI groups is required.  
However, evidence from this work does suggest that there is a linear correlation 
between plasma homocysteine levels and volume of alcohol consumed, in 
individuals who carry the mutant MTHFR(C677T) polymorphism.  The implications of 
this if proven, are, that individuals who carry the MTHFR(C677T) polymorphism should 
be recommended to limit alcohol consumption to within responsible guidelines.  
Dietary advice for individuals found to carry the mutant MTHFR(C677T) polymorphism 
is to increase the folate content of their diet and also take a folic acid supplement, 
after consultation with a medical professional. 
 
The two vitamin co-factors, folate and vitamin B12 which are important in the 
metabolism of homocysteine were also investigated in a sample of healthy 
individuals and alcohol dependent patients.  Serum vitamin B12 concentrations were 
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found to be consistent throughout the duration of both studies and within the 200-
900 ng/l clinical reference range.  This suggests that alcohol consumption does not 
have a large impact on vitamin B12 status in both study samples.  However folate 
was found to be depleted in both the HI and ADI study sample.  A high percentage 
of both male and females in both studies had folate levels below the minimum 
clinical reference range of 5 µg/l in serum.  This result was anticipated within the 
ADI study, due to previously published findings in the literature, but not in the HI 
study.  This result suggests that alcohol consumption, out with the Governments 
drinking guidelines, and especially in the form of sessional drinking is having a 
negative effect on serum folate levels in healthy individuals. The implications may be 
more serious for young women of reproductive age. 
 
The work undertaken in this thesis, has provided evidence which suggests that 
alcohol consumption in varying patterns can influence levels of the CVD biomarker 
homocysteine.  More work is required to determine the true effect of alcohol drinking 
patterns and drink types on plasma homocysteine levels.  A large-scale study, 
investigating alcohol drinking patterns and the type of alcohol consumed, in the 
general population, could provide further evidence of the impact alcohol toxicology 
has on plasma homocysteine, and thus CVD risk.   
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A. Sessional Drinking and “Standard Drink” Definitions  
Reference for Paper Reference for 
Definition 
Country of 
Study 
Definition Definition of Drink 
(Alte et al. 2004) (Alte et al. 2004) Germany “Binge drinking: number of 
days with five or more 
drinks” 
“Pure ethanol weight proportions for 
beer, wine and spirits of 3.8, 8.7 and 
26.1% respectively were used” 
(Alvik et al. 2005) Alvik et al. (2005)  Norway “Binge drinking (five to seven 
SU po and ≥8 SU po)” 
“One SU is approximately 12 to 13 g 
of absolute alcohol and is defined as 
one bottle of wine cooler, one-third 
litre of beer, one wineglass of wine, 
one sherry of fortified wine, or one 
liquor glass of liquor” 
(Alvik et al. 2006) (Alvik et al. 2006) Norway “Binge drinking was defined 
as at least 5 SU p.o. on at 
least 1 occasion” 
“One SU was defined as 1 bottle of 
wine cooler, 1/3 L of beer, a 
wineglass of wine, a sherry glass of 
fortified wine, or a liquor glass of 
liquor (approximately 12-13 g of 
absolute alcohol)” 
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Reference of Paper Reference of 
Definition 
Country of  
Study 
Definition Definition of Drink 
(Barnett et al. 2004) (Wechsler et al. 
1994) 
U.S.A. “Binge drinking (typically 
defined as five or more 
consecutive drinks on one 
occasion for men and four or 
more consecutive drinks for 
women) 
None 
 
(Braithwaite et al. 
2005) 
(Samet et al. 2003) U.S.A. “binge drinkers as those 
individuals who reported 
consuming five or more 
standard drinks within a 
calendar day” 
“Standard” 
(Budde et al. 2007) (Windle 2003) Germany “binge drinking (i.e. more 
than 5 standard drinks in a 
row)” 
“six drinks are equivalent to 72 g 
ethanol”  
(Caetano et al. 2006) (National Institute 
on Alcohol Abuse 
and Alcoholism 
2004) 
U.S.A. “this is defined as drinking 4 
or more drinks on a single 
occasion” 
 
 
“1 ounce of ethanol (2 standard 
drinks)” 
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Reference for Paper Reference for 
Definition 
Country of 
Study 
Definition Definition of Drink 
(Callaci et al. 2004) (Witt 1994) U.S.A. “binge alcohol drinking is a 
pattern of alcohol 
consumption resulting in 
highly intoxicating blood 
alcohol concentrations 
(BAC’s)” 
None 
(Callaci et al. 2006) (Grossberg et al. 
2004) 
U.S.A. “6 or more drinks per 
occasion” 
None 
(Conigliaro et al. 2004) (Bush et al. 1998; 
Gordon et al. 2001) 
U.S.A. “We examined binge 
drinking, alone by using the 
third question in the AUDIT, 
which asks whether the 
patient has had six or more 
drinks on one occasion” 
None 
(Cranford et al. 2006) (Wechsler et al. 
1994) 
U.S.A. “Standard binge measure of 
consuming 5 or more drinks 
in a row for men (4 or more 
drinks for women)” 
 
“A drink was defined as a glass of 
wine, a bottle of beer or wine cooler, 
or a shot of liquor straight or in a 
mixed drink” 
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Reference of Paper Reference for 
Definition 
Country of 
Study 
Definition Definition of Drink 
(Cunradi 2007) (Cunradi 2007) U.S.A. “Binge drinker (drank 5 or 
more drinks on the same 
occasion)” 
 
 
None 
(Das et al. 2004) (Das et al. 2004) U.S.A. “Binge drinking was defined 
as consuming five or more 
drinks on one occasion” 
“A “standard drink” is 0.5 ounces of 
absolute ethanol” 
(Dawson et al. 2004) (Wechsler and 
Nelson 2001) 
U.S.A. “consumption of 4+ drinks is 
increasingly used as a 
measure of binge drinking 
for women” 
 
“2.4 ounces of ethanol = 4 drinks” 
(Day et al. 2002) (Day et al. 2002) U.S.A. “women drank four or more 
drinks per occasion.  This 
measure was dichotomized 
to represent binge versus 
nonbinge drinking” 
 
None 
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Reference of Paper Reference for 
Definition 
Country of 
Study 
Definition Definition of Drink 
(Doremus-Fitzwater 
and Spear 2007) 
(Johnston et al. 
2007) 
U.S.A. “drinking 5 or more drinks in 
a row within the last 2 
weeks, with this episodic 
drinking defined as “binge 
drinking” 
None 
(Faden and Fay 2004) (Johnston et al. 
2002) 
U.S.A. “heavy episodic drinking 
(frequently called binge 
drinking and defined as 
consuming five or more 
drinks on one occasion in 
the past two weeks” 
“a “drink” means “more than just a 
few sips” 
(Faden 2006) (Johnston et al. 
2003) 
U.S.A. “binge consumption (5+ on 
an occasion)” 
None 
(Flynn et al. 2003) (Flynn et al. 2003) U.S.A. “binge episodes (“How often 
have you had five or more 
drinks on one occasion?”)” 
“a drink was defined for the 
participants as one 12-ounce beer, 
one 4-ounce glass of wine, and one 
1-ounce shot liquor” 
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Reference of Paper Reference for 
Definition 
Country of 
Study 
Definition Definition of Drink 
(Gauthier et al. 2005) (Gauthier et al. 
2005) 
U.S.A. “consuming more than four 
drinks in a single day, the 
frequency of binge drinking” 
 
 
None 
(Gmel et al. 2006) (Gmel et al. 2006) Switzerland “Are they drinkers who 
usually drink heavily or 
heavy episodic drinkers 
(HED, also called binge 
drinkers)” 
“frequency of having had 5+ drinks 
(men) or 4+ drinks (women) in the 
past month” 
(Goldman 2006) (National Institute 
on Alcohol Abuse 
and Alcoholism 
2004) 
U.S.A. “consumed 5 drinks on an 
occasion could vary widely 
depending on the values of 
these variable.  This concern 
was reflected in the modified 
definition of binge drinking 
issued by the National 
Association on Alcohol 
Abuse and Alcoholism” 
None 
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Reference of Paper Reference for 
Definition 
Country of 
Study 
Definition Definition of Drink 
Haley et al. (2006)  (Haley et al. 2006) U.S.A. “binge drinking behaviour 
(i.e. 4 or more drinks per 
drinking day)” 
“drinks were converted into standard 
drink units 0.5 oz of ethanol” 
(Handmaker et al. 
2006) 
(Floyd and Sidhu 
2007) 
U.S.A. “bingeing (i.e. 5 or more 
drinks per occasion” 
“standard units of 0.5 ounces of 
ethanol” 
(Hartzler and Fromme 
2003) 
(Hartzler and 
Fromme 2003) 
U.S.A. “binge drinking (at least five 
consecutive drinks for men 
and at least four consecutive 
drinks for women)” 
“drinking quantity is the standard 
drinks consumed per drinking day” 
(Kable and Coles 
2004) 
(Kable and Coles 
2004) 
U.S.A. “maternal binge drinking or 
self-reported drinking five or 
more drinks per occasion 
during pregnancy”  
None 
(Kelly et al. 2004) (Kelly et al. 2004) U.S.A. “binge drinking (drinking six 
or more drinks at a time) 
None 
(Kim et al. 2007) (Kim et al. 2007) U.S.A. “Binge drinking defined as 
consuming 5 or more drinks 
in a single day” 
 
“alcohol containing” 
320 
Reference of Paper Reference for 
Definition 
Country of 
Study 
Definition Definition of Drink 
(King and Epstein 
2005) 
(King and Epstein 
2005) 
U.S.A. “Binge is defined as five or 
more drinks/occasion for 
males and four or more 
drinks/occasions for 
females” 
 
None 
(Kishikawa et al. 2005) (Malyutina et al. 
2002) 
Japan “”Binge drinking” is defined 
as the consumption of 160 
g/day or more or pure 
ethanol usually lasting for a 
week and over” 
The term “drink” not used in the 
definition of binge 
(Kokotailo et al. 2004) (Kokotailo et al. 
2004) 
U.S.A. “4 or more occasions when 5 
or more drinks were 
consumed in 1 sitting (binge 
drinking)” 
 
 
 
 
“one standard drink was 12 ounces 
of beer, 5 ounces of wine, or 1.5 
ounces of hard liquor” 
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Reference of Paper Reference for 
Definition 
Country of 
Study 
Definition Definition of Drink 
(Kristjanson et al. 
2007) 
(Kristjanson et al. 
2007) 
Russia “they were asked how many 
times they had consumed 5 
or more drinks (of any type 
or combination of types of 
alcoholic beverages) on an 
occasion during the past 30 
days” 
“One glass of vodka was assumed 
to contain 50 ml, 1 glass of dry wine 
150 ml, 1 glass of fortified wine 90 
ml, and 1 can of beer 330 ml” 
(Kushner et al. 2005) (Kushner et al. 
2005) 
U.S.A. “drinking binge (i.e. four 
standard drinks for women 
and five for men in a single 
drinking episode” 
“Standard” 
(Lange et al. 2004) (Murray et al. 2002) The 
Netherlands 
“rapid intake of large 
quantities of alcohol in a 
short period of time (binge 
drinking)” 
“66 g of alcohol in the Bacardi 
Breezer group and 69 g of alcohol in 
the red wine group” 
(Louise Floyd et al. 
2006) 
(Louise Floyd et al. 
2006) 
U.S.A. “binge drinking (5 or more 
drinks per drinking 
occasion)” 
 
None 
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Reference of Paper Reference for 
Definition 
Country of 
Study 
Definition Definition of Drink 
(Lukas et al. 2005) (Lukas et al. 2005) U.S.A.. “binge drinking that often 
exceeds 10 to 12 beers per 
episode” 
 
 
“10-12 beers” 
(May et al. 2006) (May et al. 2006) Italy “heavy episodic drinking 
(e.g. “binge drinking”)” 
“Standard” 
(Miller and Spear 2006) (Johnston et al. 
2005) 
U.S.A. “Binge drinkers (defined in 
this survey as the 
consumption of 5 or more 
drinks in a single episode” 
None 
(Molina et al. 2007) (Molina et al. 2007) U.S.A. “5 or more drinks consumed 
per drinking occasion 
(sometimes referred to 
“binge drinking”) 
None 
(Monti et al. 2004) (Wechsler et al. 
1994) 
U.S.A. “Binges are sometimes 
defined as drinking five or 
more alcoholic drinks on an 
occasion” 
None 
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Reference of Paper Reference for 
Definition 
Country of 
Study 
Definition Definition of Drink 
(Parks and Fals-
Stewart 2004) 
(Wechsler et al. 
1994) 
U.S.A. “binge drinking (four or more 
drinks/occasion)” 
 
None 
(Pelc et al. 2002) (Pelc et al. 2002) Belgium, 
Austria, UK, 
Portugal and 
Switzerland 
“binge (an episode of 
drinking limited to 2 to 4 
days between two 
consecutive visits)” 
None 
(Reinert and Allen 
2007) 
(Reinert and Allen 
2007) 
U.S.A. “Binge drinking ≥ 8 units 
alcohol/d” 
 
 
 
 
Drink defined in units 
(Reynaud et al. 2005) (National 
Household Survey 
on Drug Abuse 
(NHSDA) 2002) 
U.S.A. “”binge drinking” (i.e., 
consuming five or more 
drinks at a single setting for 
men and four or more drinks 
at a single setting for 
women)” 
None 
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Reference of Paper Reference for 
Definition 
Country of 
Study 
Definition Definition of Drink 
(Riley et al. 2003) 
 
 
 
(Riley et al. 2003) U.S.A. “binge drinking (5 or more 
drinks per occasion)” 
1.0 oz of absolute alcohol (AA) per 
day 
(Ristuccia et al. 2007) (Johnston et al. 
2003) 
U.S.A. “binge ethanol use (the 
consumption of 5 or more 
drinks in a row)” 
None 
(Russell et al. 2004) Russell et al. 
(2004)  
U.S.A. “heavy drinking rates (days 
of 5+ drinks/drinking days x 
100) 
“standard drinks are defined as 
containing approximately 0.6 
ounces or 14 g of ethanol” 
(Selin 2003) (Selin 2003) Sweden “frequency of binge drinking 
(drinking at least one bottle 
of wine or a corresponding 
quantity of other alcoholic 
beverages on one occasion)” 
“One bottle of wine or a 
corresponding quantity of other 
alcoholic beverages on one 
occasion” 
(Silvers et al. 2003) (National 
Household Survey 
on Drug Abuse 
(NHSDA) 2001) 
U.S.A. “binge drinking (consumption 
of five or more drinks on one 
occasion)” 
None 
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Reference of Paper Reference for 
Definition 
Country of 
Study 
Definition Definition of Drink 
(Slawecki and Ehlers 
2005) 
(Substance Abuse 
and Mental Health 
Services 
Administration 
2004) 
U.S.A. “binge drinkers; that is they 
consumed more than five 
drinks in a single drinking 
episode within the past 30 
days.” 
None 
(Stein et al. 2005) (National Institute 
on Alcohol Abuse 
and Alcoholism 
1995) 
U.S.A. “Hazardous drinking was 
scored 1 if the participant 
reported 1 or more binge 
drinking episodes or if the 
participant exceeded an 
average of 14 drinks (7 
drinks for women) per week” 
None 
(Stewart et al. 2005) (Stewart et al. 
2005) 
U.S.A. “binge drinking (drinking five 
or more alcoholic beverages 
per occasion for boys and 
four or more for girls)” 
“one drink equals one 12 oz 
bottle/can of beer, or one small 4 oz 
glass of wine, or one 1 oz shot of 
hard liquor, either straight or with a 
mixer” 
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Reference of Paper Reference for 
Definition 
Country of 
Study 
Definition Definition of Drink 
(Tokunaga et al. 2006) (National 
Household Survey 
on Drug Abuse 
(NHSDA) 2002) 
U.S.A. “binge alcohol drinking (5 or 
more drinks on 1 occasion)” 
None 
(Townshend and Duka 
2005) 
(Townshend and 
Duka 2005) 
U.K. “binge drinking behaviour is 
the consumption of large 
amounts of alcohol within a 
limited time period followed 
by a period of abstinence” 
“Unit” 
(Valencia-Martin et al. 
2007) 
(Strategy Unit 
Alcohol Harm 
Reduction Project 
2003) 
Spain “Binge drinking was defined 
as the intake of 8 or more 
standard units of alcohol in 
men, and 6 or more in 
women, during any drinking 
session (1 evening or 1 
night)” 
 
 
 
“standard unit has been estimated 
as 10 g of pure alcohol; thus, binge 
drinking amounts to an intake of  
≥80 g of alcohol in men and ≥60 g of 
alcohol in women” 
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Reference of Paper Reference for 
Definition 
Country of 
Study 
Definition Definition of Drink 
(van den Wildenberg et 
al. 2006) 
(van den 
Wildenberg et al. 
2006) 
The 
Netherlands 
“binges (defined as 5 drinks 
or more in a drinking 
episode)” 
Standard 
(van den Wildenberg et 
al. 2007) 
(van den 
Wildenberg et al. 
2007) 
The 
Netherlands 
“binges (6 drinks or more on 
1 occasion)” 
“A standard drink contains 10 g 
alcohol/U” 
(Varlinskaya and Spear 
2004) 
(Varlinskaya and 
Spear 2004) 
U.S.A. “binge drinking patterns (i.e. 
five drinks or more in a row)” 
None 
(Wechsler and Nelson 
2006) 
(Johnston et al. 
2005) 
U.S.A. “binge drinking as a pattern 
of alcohol consumption 
characterized by 5 or more 
drinks in a row for males 
(and 4 or more drinks in a 
row for females” during the 
past 2 weeks” 
 
 
 
 
None 
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Reference of Paper Reference for 
Definition 
Country of 
Study 
Definition Definition of Drink 
(White et al. 2005) (Wechsler and 
Nelson 2001) 
U.S.A. “Harvard School of Public 
Health determined that four 
drinks per session for a 
woman and five drinks per 
session for a man serve as 
thresholds for risky, or binge, 
drinking” 
“standard drink as a 12 oz beer, a 4 
oz glass of wine, or 1.25 oz of liquor 
in a shot or mixed drink” 
(White et al. 2006) (Wechsler et al. 
1994) 
U.S.A. “binge drinking implies 
consuming large amounts of 
alcohol in a relatively short 
period of time.  In studies of 
college drinking, the term 
refers to a dichotomous 
variable defined by meeting 
or exceeding a threshold, 
such as 4 or more drinks 
(4+) for females and 5 or 
more drinks (5+) for males” 
 
“a drink was defined as a 12 oz of 
5% beer, 5 oz of 12% wine, or 1.5 
oz of 40% liquor in a shot or mixed 
drink” 
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Reference of Paper Reference for 
Definition 
Country of 
Study 
Definition Definition of Drink 
(Wilhelmsen et al. 
2005) 
(Wilhelmsen et al. 
2005) 
U.S.A. “binge drinking (consuming 
five or more drinks on the 
same occasion)” 
“beer (number of 12 oz. cans), wine 
(number of 6 oz. glasses), or liquor 
(number or shots)” 
(Windle 2004) (Windle 2004) U.S.A. “Binge drinking was 
measured with a survey 
question requesting how 
many times the adolescent 
has consumed six or more 
drinks in a single sitting over 
the past 6 months” 
“Questions were asked separately 
for beer, wine, and hard liquor and 
were then summed to form single 
measure of binge drinking” 
(Woerle et al. 2007) (Woerle et al. 2007)  U.S.A. “Binge drinkers were defined 
as those who reported 
having ≥ 5 drinks on at least 
1 occasion” 
 
 
 
 
 
None 
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Reference of Paper Reference for 
Definition 
Country of 
Study 
Definition Definition of Drink 
(Wood et al. 2007) (Wechsler et al. 
1994) 
U.S.A. ““binge” drinking for that day 
(operationalized for men as 
consuming 5 or more drinks 
and for women as 
consuming 4 or more drinks 
in a single sitting)” 
Standard 
(Yuan et al. 2004) (Yuan et al. 2004) Denmark “Binge drinking was defined 
as an intake of eight or more 
drinks on one occasion” 
“standard quantities of alcoholic 
beverages in Denmark (12 g per 
unit, equal to 0.42 oz of absolute 
alcohol)l” 
 
 
 
 
 
 
 
 
 
 
331 
B. Table of 2008-2009 Studies Investigating the Relationship between Alcohol Consumption and Homocysteine  
Reference 
& Country 
Aim Participants Methodology Results Conclusion 
(Devika et 
al. 2008) 
India 
Investigate serum 
homocysteine in 
individuals 
undergoing 
alcohol 
withdrawal.   
N=50.  Patients with 
existing liver disease not 
included.  Patients 
abused alcohol for 8-10 
years.  Undergoing 8 
week detoxification 
program.  Group 1 
completed 8 week 
detoxification (N=39).  
Group 2 did not complete 
detoxification (N=11). 
Patient’s diet supplemented 
with folic acid, vitamin B6 and 
B12.  Blood samples taken an 
admission and at end of 8 
week detoxification. 
Homocysteine analysed by 
ELISA.  Other markers 
analysed by an auto-analyser.    
 
 
Homocysteine levels 
significantly decreased 
(p<0.002) to normal 
levels;   GGT (p<0.02) 
and ALT (p<0.03) levels 
also decreased at end of 
8 week detoxification.  
Homocysteine at 
admission 26 ±13.36 
µmol/l.  Homocysteine 
after detoxification 14.31 
± 5.7µmol/l.  
 
 
 
 
 
 
Study suggests that after 8 
week abstinence program 
and vitamin B 
supplementation, 
homocysteine can be 
lowered in an alcoholic 
patient group.   
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Reference 
& Country 
Aim Participants Methodology Results Conclusion 
(Gibson et 
al. 2008) 
Northern 
Ireland 
Investigate the 
effect of a 2 week 
intervention of red 
wine and vodka 
on levels of total 
homocysteine. 
Participants consumed 
no alcohol for 1st two 
weeks.  Healthy male 
volunteers n=85.  Aged 
between 21-70 years.  
Participants did not drink 
more than 21 units/week, 
have abnormal liver 
profiles and did not take 
vitamin supplements 
For two weeks, participants 
consumed either 240 ml of 
12% red wine or 80 ml of 
37.5% Smirnoff vodka (24 g or 
3 units/day).  Participants 
finished study with a two week 
alcohol free period.  Vodka 
drinkers were told not to use 
fruit juices as mixers.  Blood 
sampling taken at baseline 
and at end of 2 week alcohol 
drinking period.   
Plasma homocysteine 
analysed using HPLC-FD.  
Folate and Vitamin B12 
analysed using 
radioimmunoassay.  MTHFR 
polymorphism identified using 
PCR and HinFl digest.    
Homocysteine increased 
after 2 week red wine 
intervention by 5% 
(p=0.03), but no 
significant increases in 
homocysteine after 
vodka intervention 
(p=0.09).  Folate and B12 
did not differ significantly 
between interventions.   
After 2-week intervention 
folate and vitamin B12 
decreased, but 
homocysteine increased.  
There was no difference in 
the levels of homocysteine, 
folate or B12 between vodka 
and red wine drinkers.  
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C. Table of 2008-2009 Studies Investigating the Relationship between Folate, Vitamin B12 and Homocysteine  
Reference & 
Country  
Aim Participants Methodology Results Conclusion 
(Stea et al. 
2008) 
Norway 
Investigate the 
effects of 
homocysteine, folate 
and vitamin B12 by 
increasing vegetable 
content of diet. 
N=541 males 
aged 18-26 
years.  
Intervention 
group = 416 
males. Control 
group of 105 
males.  
Intervention 
length 5 months.   
Participants were asked to 
keep food diaries.   
Homocysteine and 
riboflavin were analysed by 
HPLC.  Vitamin B12 and 
folate analysed by 
immunoenzymatic assay.    
Intervention reduced 
homocysteine levels by 10% 
(p=0.002).  Decrease of 
homocysteine was positively 
related to change in cysteine 
and inversely related to change 
in concentration of folate 
(p=0.021). 
Study showed intervention 
which increased 
vegetables, fruit and bread 
intake, had positive effect 
on reduction of 
homocysteine levels.  Also 
change in cysteine folate 
and flavo-coenzymes are a 
predictor of change in 
homocysteine levels.     
(Dangour et 
al. 2008) 
UK 
Investigate 
association of folate, 
vitamin B12 and 
homocysteine in 
relation to death from 
all causes and CVD 
in older individuals. 
N=853 males and 
females aged >75 
years 
Homocysteine analysed by 
fluorescence polarization 
immunoassay.  Vitamin B12 
and folate analysed by 
Becton Dickinson 
Simultrac kit.     
Individuals with plasma 
homocysteine levels in top one 
third had 2 times higher risk of 
all cause mortality in comparison 
with the individuals in the bottom 
one third.  No association in 
folate, vitamin B12 and mortality.   
Results extend previously 
published findings of 
homocysteine and 
mortality rate and the 
absence of any link 
between folate and vitamin 
B12 and mortality. 
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Reference & 
Country  
Aim Participants Methodology Results Conclusion 
(Wotherspoon 
et al. 2008) 
UK 
Investigate the 
impact of oral folic 
acid supplementation 
upon plasma 
homocysteine levels, 
endothelial function 
and oxidative stress 
in patients with type 2 
diabetes and 
microalbuminuria. 
N=16 patients.  2 
months of oral 
supplementation.  
Patients 
randomised to 
either group 1 
receiving 5 mg of 
folic acid or group 
2 received 
placebo. 
Baseline sampling and 
sampling after intervention. 
HbAic measured using 
HPLC.  Urine creatinine by 
Jaffe reaction.  
Homocysteine by LC. 
Plasma homocysteine fell by 
25% in the folic acid group but 
there was no difference in 
endothelial function or markers 
of oxidant stress in the treatment 
group. 
Study concluded that oral 
folic acid supplementation 
successfully lowered 
plasma homocysteine 
levels; however this was 
not associated with 
improvements in 
endothelial function or 
markers of oxidative 
stress. 
(Pfeiffer et al. 
2008) 
USA 
Investigate the total 
homocysteine data in 
the pre-fortification 
NHANES III and the 
in 3 post-fortification 
survey period in a 
national sample of 
the US population. 
Data adjusted 
from original 
survey.   
Homocysteine in plasma 
analysed at the DCD 
nutrition laboratory using a 
commercial florescence 
polarization immunoassay 
reagent set.  
Mean plasma total 
homocysteine decreased by 8, 9 
and 10% for adolescent, adult 
and older men by 6, 3 and 13%.  
Plasma total homocysteine 
concentrations (>13 µmol/l) for 
older men and women 
decreased from pre-fortification 
(14% and 5% respectively).   
After adjusting for method 
changes, pre-fortification to 
post-fortification decreases 
in circulating total 
homocysteine 
concentrations of 
approximately 10%.  
Similar effects seen in 
smaller intervention trials.  
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Reference & 
Country  
Aim Participants Methodology Results Conclusion 
(Al-Tahan et 
al. 2008) 
Spain 
To investigate and 
assess the status of 
folate, Cobalamin 
and homocysteine in 
health Spanish 
adolescents 
N=165 (84 
females; 81 
males; range 13-
18.5 years). 
Serum Cobalamin and 
folate determined using 
Abboy Imx auto analyser.  
Total homocysteine 
measured using fully 
automated fluorescence 
polarization immunoassay. 
MTHFR detected using 
PCR and allele specific 
restriction digestion of the 
amplified products with the 
restriction enzyme Hinfl 
Males had markedly higher 
homocysteine (males 8.92 5.51-
22.94) µmol/l; females 7.91 
(5.09-13.86) µmol/l); whereas 
females showed higher serum 
cobalamin concentration (males 
540.00 (268.00-946.47) pmol/l; 
females 594.82 (280.63-
1,559.64) pmol/l).  Adolescents 
with the homozygous carrier of 
MTHFR displayed significantly 
higher homocysteine and lower 
serum folate; normal 5.73 (3.09-
10.73) ng/ml serum folate, 7.57 
(4.94-12.94) µmol/l 
homocysteine; homozygous 
4.10 (2.75-7.88) ng/ml serum 
folate, 10.83 (7.00-22.82) µmol/l 
homocysteine.   
The study provides data on 
levels of folate, coablaim 
and homocysteine in 
Spanish adolescents.   
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Reference & 
Country  
Aim Participants Methodology Results Conclusion 
(Tanaka et al. 
2009) 
USA 
To investigate 
genetic factors that 
affect circulating 
vitamin B6, vitamin 
B12, folate and 
homocysteine, a 
genome-wide 
association analysis. 
InCHIANTI 
N=1175, 
SardiNIA 
N=1115, BLSA 
N=640.  Meta 
analysis 
Not stated. The association of MTHFR, a 
gene consistently associated 
with homocysteine was 
confirmed in this meta-analysis. 
The ALPL gene likely includes 
the catabolism of vitamin B6 
while FUT2 interferes with 
absorption of vitamin B12. 
The study findings 
highlight the mechanisms 
that affect vitamin B6, 
vitamin B12 and 
homocysteine serum 
levels. 
(Mitchell et al. 
2009) 
USA 
Evaluate a method 
based on stable 
isotope dilution liquid 
chromatography-
multiple reaction 
monitoring/mass 
spectrometry (LC-
MRM/MS ) for the 
detection of folate 
and homocysteine 
phenotype 
No sample 
number of 
participants 
given.  Blood 
samples taken 
from 
premenopausal 
women.  
LC-MRM/MS used to 
quantify RBS folate 
derivatives 5-
methyltetrahydrofolate (5-
CH3-THF), tetrahydrofolate 
(THF) and 5,10-
methenyltetrahydrofolate 
(5,10-methenylTHF). 
RBS 5-CH3-THF had a 
reciprocal relationship with total 
homocysteine (p=0.0003), 
whereas RBC THF and RBS, 
5,10-MTHF had direct 
relationships (p=0.01, 0.04 
respectively).  In combination 
these three variables accounted 
for 42% of the variation in total 
homocysteine levels. 
Study concluded that a 
robust method for the 
detection of RBC 5-CH3-
THF will improve the 
folate/homocysteine 
phenotyping in patient 
management.  This 
method will provide less 
error and provide more 
powerful statistical 
evidence. 
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D. Table of 2008-2009 Studies Investigating the Relationship between the MTHFR(C677T) polymorphism and Homocysteine  
Reference 
& Country 
Aim Participants Methodology Results Conclusion 
(Nagele et 
al. 2008) 
Austria 
To investigate if 
individuals with 
MTHFR(C677T) 
polymorphism 
develop higher 
plasma 
homocysteine 
concentrations 
after nitrous oxide 
anaesthesia 
compared with 
wild type 
individuals. 
N=140 healthy 
participants.  Aged 
over 18 years.  
All patients were given 
nitrous oxide (N2O) as 
a general anaesthetic 
for a surgical 
procedure.  
Homocysteine analysed 
by microparticle 
immunoassay (Abbott).  
Folate and Vitamin B12 
were analysed by 
radioassay.   MTHFR 
polymorphism analysis 
by PCR and restriction 
enzymes. 
Patients with homozygous 
MTHFR (C677T or A1298C) 
(N=25) developed plasma 
concentrations of 14.9 (10-
26.4) µm compared to the 
wild-type and heterozygous 
(N=115) of 9.3 (7.5-15.5) 
µm.  After dose of NO 
homocysteine concentration 
tripled in individuals who 
were homozygous for 
MTHFR. 
 
 
 
 
 
 
Study found that patients with 
the MTHFR polymorphism, 
either C677T or A1298A were 
at risk of developing higher 
plasma homocysteine 
concentration after undergoing 
nitrous oxide anaesthesia.  .   
Individuals who possessed the 
MTHFR polymorphism were 
the only patients who’s 
homocysteine concentration 
reached abnormal levels of 
>15 µm. 
338 
Reference 
& Country 
Aim Participants Methodology Results Conclusion 
(Alessio et 
al. 2008) 
Brazil 
Investigate the 
polymorphism in 
the gene  
cystathionine ß-
synthase (CBS) 
and the 
prevalence in 
Brazilian children 
in relation to 
homocysteine, 
vitamin B12 and 
folate, who have 
been previously 
genotyped for 
MTHFR, 
methionine 
synthase 
recductase 
(MTRR) 
N=220 healthy 
children. 129 females 
and 91 males.  Age 
range 1-8 years (mean 
= 4.8 years).   
Homocysteine analysed 
by HPLC-FD.  Folate and 
vitamin B12 analysed by 
elctrochemiluminescence 
immunoassay.  CBS 
gene polymorphism 
detected by PCR and 
restriction enzymes.   
 
19.5% of population were 
heterozygote for the 
844ins68 polymorphism.  In 
children who had the 
insertion, also carried the 
CBS T833C mutation. 
Mutations 677TT, 1298AA 
and 68WW are associated 
with an increase in 
homocysteine concentration.  
Folate and Vitamin B12 were 
not significantly different in 
these groups. 
 
Study suggests a genetic 
influence in the concentration 
of homocysteine that is not 
dependent on folate or vitamin 
B12.   
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Reference 
& Country 
Aim Participants Methodology Results Conclusion 
(Yang et al. 
2008) 
USA 
Assess the 
prevalence of 
genetic 
polymorphisms 
which have a 
relation to serum 
folate and 
homocysteine 
levels. 
DNA samples from 
6793 participants who 
participated in the 3rd 
National Health and 
Nutrition Examination 
Survey (NHANES III).  
The samples were 
genotyped for the 
following: MTHFR 
C677T, A1298C, 
MTRR 66AG, cys 
844ins68. 
 
The influences of the 
above genotypes on 
folate and homocysteine 
levels were analysed by 
age, sex, folate intake 
and 3 specific race-
ethnicity groups. Folate 
and vitamin B12 analysed 
using a radioprotein 
binding assay.  
Homocysteine 
determined using HPLC. 
All race-ethnicity groups, 
serum folate and 
homocysteine concentration 
were significantly related to 
the MTHFR(C677T) genotypes.  
Participants who posses the 
MTHFR(C677T) polymorphism 
had a 22.1% lower serum 
folate and a 25.7% higher 
homocysteine than the 
individuals with the CC 
genotype.  Moderate daily 
folic acid intake (mean 
150µg/d; 95%CI:138,162) 
significantly reduced the 
difference in mean 
homocysteine levels 
between the MTHFR
 
CC and 
TT genotypes.   
Study concludes that the 
MTHFR(C677T) polymorphism 
was associated with significant 
differences in serum folate and 
homocysteine concentrations 
in the US population before 
folic acid fortification.  The 
effect of MTHFR 677CT on 
homocysteine concentrations 
was reduced by moderate 
daily folic acid intake.   
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& Country 
Aim Participants Methodology Results Conclusion 
(Naess et 
al. 2008) 
Norway 
Investigated the 
homocysteine 
levels and the 
MTHFR 
polymorphisms 
before the event 
of first venous 
thrombosis in the 
general 
population. 
Case-cohort designed 
study.  N=66,140 from 
the Norwegian Health 
Study of 
NorsTrondelag 
(HUNT2).  Samples 
were analysed at 33 
month before the VT 
event. 
Serum homocysteine 
and MTHFR genotyping.  
Serum homocysteine 
was analysed using 
automated HPLC with 
reverse phase separation 
and fluorescence 
detection.  MTHFR 
polymorphism was 
detected using RFLP, 
PCR and restriction 
enzyme digestion 
enzyme HinFl. 
Folate was determined 
within a hospital 
laboratory using the 
Architect Folic Acid 
assay. 
 
There was no graded 
association with VT over 
quintiles of homocysteine.  In 
men the OR was 2.17 (95% 
CI 1.20-3.91) for levels 
above versus below the 95th 
percentile, but no 
association was found in 
women (OR 1.00). 
The MTHFR C677T 
genotype was not related to 
risk for VT. 
In conclusion elevated 
homocysteine levels in the 
general population did predict 
subsequent first VT in men but 
no in women. 
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Reference 
& Country 
Aim Participants Methodology Results Conclusion 
(Grassi et 
al. 2008) 
Italy 
Investigate the 
novel genetic 
factors on plasma 
levels of total 
homocysteine 
and fibrinogen 
N=302, comprised of a 
complex segmental 
analysis of a highly 
selected group of 44 
families.  Each family 
included at least one 
member with fatal 
premature (<50yrs) 
IHD. 
HPLC measured using 
HPLC.  FIB measured 
suing prothrombin time 
derived method using an 
automated centrifugal 
coagulometer.  MTHFR 
genotyping using PCR 
and restriction digestion 
with HINfI. 
Total homocysteine and FIB 
levels were influenced by 
two major genes.  A 
significant total 
homocysteine latent class-MI 
association (OR=3.24; 95% 
CI, 1.37 to 7.68) and non-
significant total 
homocysteine level MI-
association (OR=1.65 per 1-
log 10 µmol/l, 95% CI, 0.56 
to 4.81) were estimated 
suggesting a direct influence 
of the homocysteine major 
gene as a supressor plasma 
total homocysteine levels.  
 
 
 
Concluded evidence for a 
major latent gene effect 
influencing variation in total 
homocysteine plasma levels, 
which is independent on 
C677T MTHFR polymorphism 
and significantly affecting the 
risk of MI.  
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Reference 
& Country 
Aim Participants Methodology Results Conclusion 
(Barbosa et 
al. 2008) 
Brzail 
Investigate the 
association 
between MTHFR 
(C677T and 
A1298C), MTR 
A2756G and 
MTRR A66G 
gene 
polymorphism 
and total 
homocysteine, 
methymalonic 
acid, and 
SAM/SAH levels 
and the potential 
interactions with 
folate and 
cobalamin. 
N=275 females, 
sampled at labour and 
gave birth to health 
babies.   
All markers measured in 
serum.  Polymorphism 
determined using PCR 
and RFLP. 
Folate determined using 
ion capture method and 
by chemiluminscnet 
method.  Cobalamin 
concentrations were 
measured using the 
Immuliet kite. 
Total homocysteine was 
determined using the 
GCMS. 
Serum folate, MTHFR 
C677T allele and MTR 
2756AA genotypes were the 
predictors of total 
homocysteine levels in 
pregnant women.  Low 
levels of serum folate were 
associated with elevated 
total homocysteine in 
pregnant women, 
independently of the gene 
polymorphism.  In pregnant 
women carrying MTHFR 
677T allele, or MTHFR 
1298AA or MTRR 66AA 
genotypes, lower cobalamin 
levels were associated with 
higher levels of total 
homocysteine.   
Serum folate and MTHFR 
C677T and MTR A25576G 
gene polymorphisms were the 
determinants of total 
homocysteine levels.  The 
interactions between low 
levels of serum cobalamin and 
MTHFR or MTRR A66G gene 
polymorphism was associated 
with increased total 
homocysteine.  
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Reference & 
Country 
Aim Participants Methodology Results Conclusion 
(Keles et al. 
2009) 
Turkey 
Investigate 
plasma 
homocysteine 
levels in patients 
with early 
formation of 
angiographically 
visible collaterals 
after acute 
myocardial 
infarction. 
N=60 participants (47 
males and 13 females).  
Age range 32-77 years.  
All patients had ST-
segment elevation 
myocardial infarction 
and underwent 
coronary angiography.    
Total homocysteine 
levels determined 
using HPLC with 
Fluorescence 
detection.   
 
  
No statistical difference between 
participants in relation to gender, 
age, lipid profile, prevalence of 
hypertension, diabetes mellitus and 
smoking.  Plasma homocysteine 
concentration in patients with poor 
collateral formation was 18.2±8.6 
µmol/l.  Patients with good collateral 
formation had homocysteine level of 
12.7±2.4 µmol/l.  24 participants had 
a plasma concentration that was 
above normal range of >15 µmol/l, of 
which 20 had poor collateral 
formation.  Homocysteine levels 
were the only independent variable 
that affected the development of 
collaterals (p=0.003). 
Inverse relationship 
between plasma 
homocysteine levels and 
the formation of collateral 
development after MI. 
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Country 
Aim Participants Methodology Results Conclusion 
(Vaya et al. 
2008) 
Spain 
Investigate 
homocysteine 
levels in patients 
with confirmed 
DVT. 
DVT group (N=155). 
Control group (N=153). 
Healthy subjects with 
no previous history of 
thrombotic events.  All 
Caucasians. Sampling 
took place 6-months 
after thrombotic event.   
Homocysteine 
measured by 
fluorescence 
polarization 
immunoassay 
(FPIA).  
No significant different between 
control and DVT group in relation to 
homocysteine levels (p= 0.233).  
DVT group homocysteine = 10.1±3.7 
µM.  Control homocysteine 10.2±2.8 
µM.   
Study suggests 
hyperhomocysteinema is 
not an independent risk 
factor for DVT.  Also the 
Mediterranean diet can 
impact on homocysteine 
levels, due to a diet large 
in fish, fruit and 
vegetables.   
(Cui et al. 
2008) 
Japan 
Investigate the 
association of 
serum 
homocysteine and 
cardiovascular 
disease in an 
Asian population. 
N=38158 (13382 
males, 24776 females).  
Participants had no 
cardiovascular disease 
histories.    
Homocysteine 
analysed using 
HPLC.  Serum total 
and high density 
lipoprotein 
cholesterol was 
measured using 
enzymatic 
methods.   
 
At 10 year follow-up there were 444 
cardiovascular related deaths.  
Participants within the highest total 
homocysteine quartile (>15.3 µmol/l) 
had higher mortality, in comparison 
with the lower quartile (<10.5 µmol/l) 
High serum total 
homocysteine level were 
associated with increased 
mortality from ischemic 
stoke, coronary heart 
disease and total 
cardiovascular disease 
among a Japanese 
population. 
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Country 
Aim Participants Methodology Results Conclusion 
(Shammas et 
al. 2009) 
USA 
Evaluation of the 
biomarkers of 
combined non-
fatal myocardial 
infraction and end 
point death, 2 
years after 
coronary artery 
bypass grafting. 
N=121. Patients 
included who were 
undergoing bypass 
surgery for coronary 
artery disease.  Two 
groups: no symptoms 
after surgery; 
asymptomatic after 
surgery including non-
fatal MI.   
No laboratory 
methodology 
stated.  The 
patients had blood 
sampling taken 1 
week before 
surgery and at 2 
year follow up. 
90 patients remaining of original 
cohort after 2 years.  Univariate 
analysis showed significantly higher 
homocysteine level in patients who 
met the combined end point versus 
those that did not (11.0 ng/mol vs 9.7 
ng/mol) p<0.05.  Logistic regression 
analysis modelling indicated 
homocysteine is an independent 
predictor of primary combined end 
point (p=0.016). 
Study suggests 
homocysteine is an 
independent predictor of 
the combined end point of 
cardiovascular death, 
non-fatal MI and vein 
graft disease 2 years after 
bypass surgery.   
(Albert et al. 
2008) 
USA 
Investigate 
intervention of 
vitamins B6, B12 
and folic acid 
supplementation 
in high risk women 
with and without 
CVD.  
N=5442 females.  
Aged 42 years and 
over with history of 
CVD or 3 or more 
coronary risk factors.  
Daily dose of 2.5 mg 
folic acid, 50 mg B6 and 
1 mg vitamin B12. 
RCT of 
combination pill or 
placebo. 
Homocysteine 
analysed by 
enzymatic assay 
and folate analysed 
by immunoassay. 
Intervention group plasma 
homocysteine was decreased by 
18.5% (p<.001), by a difference of 
2.27 µmol/l in comparison with 
placebo group.  
 
After the 7.3 year 
intervention, the 
combination pill did not 
decrease the risk of CVD 
events in high risk 
females, despite a 
significant decrease in 
homocysteine. 
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Country 
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(Freitas et al. 
2008) 
Portugal 
Investigate 
prevalence of 
MTHFR 
polymorphism in 
population of 
individuals with 
CVD. 
N=510 healthy 
individuals with no 
history of CVD as 
control group. N=298 
individuals in CVD 
group. CVD confirmed 
using angiography. 
MTHFR 
polymorphisms 
identified using 
PCR and restriction 
enzymes.  
Homocysteine in 
plasma analysed 
using HPLC.   
Homocysteine was independently 
correlated with CVD.  Homocysteine 
was significantly higher in individuals 
who had MTHFR polymorphism 
C677T and 1298AA.  The presence 
of both polymorphic genotypes 
suggests an increase in the risk of 
developing CVD.  In study population 
there was a higher presence of the 
1298AA genotype and CVD.   
Study suggests that the 
presence of the 1298AA 
and combination of 
C677T and 1298AA 
polymorphism within the 
MTHFR enzyme, have a 
1.6 fold increased risk of 
developing CVD in 
Madeira.   
(Onat et al. 
2008) 
Turkey 
Investigate serum 
homocysteine 
levels in 
association with 
coronary artery 
disease and 
metabolic disease 
in a Turkish 
population. 
N=338 men, N=342 
females, with median 
age 55 years.   
Homocysteine was 
measured using 
nephelometry. 
Vitamin B12 and 
folate analysed 
using 
chemiluminscent 
immunometric 
methods.   
Serum homocysteine concentration 
was 12.7 ± 1.5 µmol/l in men and 9.6 
± 1.4 µmol/l in women.  
Homocysteine levels in men were 
independently associated with CHD.  
Folate levels in men were shown to 
have a significant inverse 
association with CHD.  
Study suggests in Turkish 
men, high folate and high 
serum homocysteine 
levels are independently 
associated with CHD.  In 
Turkish women, vitamin 
B12 concentrations are 
significantly associated 
with metabolic syndrome.   
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Country 
Aim Participants Methodology Results Conclusion 
(Foussas et 
al. 2008) 
Greece 
Investigate 
homocysteine 
levels on the long-
term 
cardiovascular 
mortality in 
patients with ST-
segment elevation 
myocardial 
infarction (STEMI) 
or non-ST-
segment elevation 
acute coronary 
syndromes 
(NSTE-ACS). 
N=458 STEMI group 
and N=476 NSTE-ACS 
group.  Patients who 
presented within the 
first 12 to 24 hours of 
index pain were 
studied.   
Homocysteine and 
cardiac troponin I 
(cTnI) were 
measured using 
enzyme based 
immunoassay.  C-
reactive protein 
was measured 
using 
nephelometric 
method. 
No difference in the risk of 30 day 
cardiovascular death among the 
tertiles of total homocysteine in 
patients with STEMI (7.2%, 8.5%, 
and 12.4% for the first second and 
third tertiles respectively; ptrend=0.3.  
Patients in the upper total 
homocysteine tertile were at a 
significantly higher unadjusted risk of 
late (from 31 days through 5 years) 
cardiovascular death than those in 
the other two tertiles in STEMI 
(23.4%, 27.9% and 41.8% for the 
first, second and third tertiles 
respectively; ptrend<0.001). 
 
 
 
 
Data from the study 
indicates that total 
homocysteine levels 
which were determined 
on admission do not 
serve as an independent 
predictor of long term 
cardiovascular mortality in 
patients who have STEMI 
or NSTE-ACS. 
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Country 
Aim Participants Methodology Results Conclusion 
(Sosin et al. 
2008) 
UK 
Study 
hypothesised that 
ethnic differences 
in homocysteine 
are present in 
patients with 
systolic heart 
failure.    
N=112, UK multiethnic 
individuals with systolic 
heart failure.  Control 
matched subjects, 
N=131. 
Homocysteine, 
folate, and vitamin 
B12 measured using 
the ADVIA Centaur 
automated 
immunochemistry 
system.  
Plasma homocysteine levels were 
significantly higher in heart failure 
patients compared to controls 
(p<0.001), which was consistent 
across all ethnic groups.  No 
significant different in levels of folate 
and vitamin B12 in patients and 
controls. A stepwise linear 
regression model showed 
homocysteine levels in patients and 
controls were independently 
associated with age (p<0.001), 
vitamin B12 (p<0.001); folate 
(p<0.001) and health control status 
(p<0.001), but not with gender, 
ethnicity, diabetes status, smoking 
status or BNP levels.       
Study suggests that there 
is no evidence of ethnic 
differences in 
homocysteine levels 
between the following 
ethnic groups: White 
European, south Asian 
and African Caribbean 
patients who have 
systolic heart failure. The 
study showed that there 
no difference between 
levels of folate and 
vitamin B12 in patients 
and control groups which 
indicates that the level of 
homocysteine could be 
driven by dietary factors.   
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Aim Participants Methodology Results Conclusion 
(Ebbing et al. 
2008) 
Norway 
Investigate the 
dosing of folic 
acid, vitamins B12 
and B6 on patients 
with coronary 
artery disease and 
aortic valve 
stenosis. 
Randomised double-
blind controlled trial.  
N=3096 adult 
participants who were 
undergoing coronary 
angiography.  20.5% of 
study population 
female, mean age 
61.7% were 
randomised.   
Participants 
randomised into 4 
groups: group 1 
received folic acid 
0.8 mg, vitamin B12 
0.4 mg, vitamin B6 
40 mg (N=772).  
Group 2 received 
folic acid plus 
vitamin B12 
(N=772).  Group 3 
received vitamin B6 
(N=772).  Placebo 
(N=780). 
All laboratory 
markers analysed 
within hospital 
laboratories.  No 
techniques stated.   
Mean plasma total homocysteine 
concentrations were reduced by 30% 
after 1 year of treatment in the 
groups receiving folic acid and 
vitamin B12.  The trial was terminated 
early because of concern among 
participants due to preliminary 
results from a contemporaneous 
Norwegian trial suggesting adverse 
reactions from the intervention.   
The trial did not find any 
effective results for the 
treatment of folic 
acid/vitamin B12 or vitamin 
B6 on total mortality or 
cardiovascular events.  
The findings gathered 
before termination did not 
suggest the use of 
vitamin B as a secondary 
prevention of patients 
with coronary artery 
disease.      
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(Collings et al. 
2008) 
Finland 
Investigate 
whether common 
risk variables 
interact with the 
Connexin (Cx37) 
polymorphism 
causing possible 
interactions with 
early markers of 
atherosclerosis  
N=1440 population 
from the cardiovascular 
risk in young Finn’s 
study. Young adult 
sample.    
Homocysteine was 
determined using 
mircoparticle 
enzyme 
immunoassay kit. 
Homocysteine in subjects with the 
TT genotype were found to be 
associated with higher flow mediated 
dilation (FMD) values (p for 
interaction 0.038). 
Study concluded the 
effect of smoking and 
homocysteine levels on 
arterial endothelial 
functions and elasticity 
were modified by the 
allelic variation of the 
Cx37 gene.   
(Rassoul et 
al. 2008) 
Germany 
Aim to investigate 
the relationship 
between the 
severity of CAD 
and the MTHFR 
polymorphism. 
N=113 male patients 
undergoing coronary 
artery bypass surgery.  
Mean age 63±11 
years. 
Serum 
homocysteine was 
measured by 
HPLC-FD.  MTHFR 
identified using 
PCR. Serum folate/ 
vitamin B12 by 
chemiluninscene.  
Patients with CAD showed a 
significantly higher serum 
concentration of homocysteine than 
control subject (p<0.01).  The serum 
homocysteine level was significantly 
higher in patients’ with increased 
scores than in patients with mild 
CAD, with and without the MTHFR 
polymorphism. 
Study has shown that 
hyperhomocystemia was 
significantly related to the 
severity of CAD 
independently of MTHFR 
polymorphism.   
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(Yeter et al. 
2008) 
Turkey 
Investigate the 
relationship 
between plasma 
homocysteine 
levels and ST 
segment 
resolution (STR) 
after fibrinolytic 
therapy. 
N=49 patients, all 
administered fibrinolytic 
therapy for ST-
segment elevation 
myocardial infarction 
(STEMI).  Group 1 
N=15, group 2 N=34.  
Group 1= STR less 
than 50%; group 2 = 
maximum STR ≥ 50%. 
Total homocysteine 
was analysed using 
HPLC-FD. 
Plasma homocysteine levels were 
22.5±10 µmol/l in group 1 and 
14.1±4 µmol/l in group 2 (p<0.001). 
Studied concluded that 
plasma homocysteine 
levels are associated with 
impaired STR after 
fibrinolytic therapy in 
acute STEMI. 
(Ghosh, 
Khare and 
Shetty 2009) 
India 
Observe the 
prevalence of 
plasma 
hyperhomocystein
emia in a patient 
cohort with MI 
after a 2 week 
folic acid 
intervention 
N=120 patients with 
acute MI.  Age <40yrs. 
Control group N=500 
age and sex matched.  
Patients given 2 week 
intervention of 5 mg 
folic acid/daily. 
 
Tested for 
homocysteine 8-10 
weeks after MI. 
Plasma 
homocysteine 
measured using a 
microplate enzyme 
immunoassay kit. 
63 out of 120 patients presented with 
hyperhomocysteinaemia compared 
with 9% of the age and sex matched 
controls.  57% of patients with 
hyperhomocysteineamias responded 
to the oral folic acid therapy.  The 
cyanoco-balamin therapy only 
normalised homocysteine level in 2 
out of 12 patients 
Study concluded that 
hyperhomocysteinaemia 
is common amongst 
young acute myocardial 
infarction patients from 
western India. 
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(Yoldas et al. 
2008) 
Turkey 
Investigate the 
change in hsCRP 
and homocysteine 
during the acute 
period of ischemic 
stroke and 
evaluate the 
relationship 
between these 
two biomarkers. 
N=40 patients admitted 
with ischemic stroke.  
hsCRP and 
homocysteine 
measured at the 2nd, 
5thand 10th day post 
stroke.  N=40 controls, 
age and sex matched.  
Mean age 70±9 years.   
Homocysteine 
determined using 
HPLC with 
fluoresce detection, 
using the Clin Rep 
Kit. 
   
Patients mean homocysteine levels 
were 40.6±9.6 µmol/l on the 2nd day, 
21.7±11.1 µmol/l on the 5th day and 
20.7±9.2 µmol/l on the 10th day.  The 
mean homocysteine level on the 
control subjects was 11±1.1 µmol/l.  
The homocysteine levels of the 
patients were higher than the control 
subjects at all times (p<0.01).  
Study concluded that 
patients with stroke have 
higher circulating serum 
hsCRP and homocysteine 
levels.  However although 
homocysteine was found 
to be higher, it does not 
seem to be related to 
prognosis.   
(Kalita et al. 
2009) 
India 
Comparison of the 
risk factors, nature 
of stroke and 
outcome of 
patients with and 
without hyper-
homocysteinemia.   
N=198 patents with 
ischemic stroke (36 
female with median 
age 56 yrs).  N=200 
healthy controls.   
Biomarkers measured 
1 month after stroke. 
Serum B12, folate 
and homocysteine 
were determined 
using ADVIA direct 
chemiluminscence 
assay.  
Serum homocysteine was elevated 
in 60.6% and serum B12 low in 
25.7% and folic acid in 42.1%.  
Homocysteine levels correlated with 
serum vitamin B12.   Homocysteine 
levels in stroke patients did not 
significantly differ from controls.  
Study concluded that 
hyperhomocysteinemia 
was present in 60.6% of 
stroke patients which is 
related to low serum 
vitamin B12 levels.  
Patients with hyper-
homocysteinemia had a 
better 3-month outcome.   
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(Saposnik et 
al. 2009) 
USA 
To determine if 
vitamin therapy 
reduced the risk of 
ischemic and 
hemorrhagic 
stroke as well as 
stroke disability.   
N=5522 adults (aged 
55 years or older) with 
known CVD; 
randomised to receive 
daily combination of 
2.5mg folic acid, 50 mg 
vitamin B6 and 1 mg of 
vitamin B12 or placebo 
for 5 years.   
Homocysteine was 
measured using the 
fluorescence 
polarization 
immunoassay.  
The mean homocysteine 
concentration decreased by 2.2 
µmol/l in the vitamin therapy group 
and increased by 0.80 µmol/l in the 
placebo group. 
Lowering of 
homocysteine with folic 
acid, vitamins B6 and B12 
did reduce the risk of 
overall stroke, but not the 
severity of the stroke or 
disability. 
(Osorio et al.  
2008) 
Spain 
Investigate the 
levels of 
homocysteine 
during post MI 
follow-up. 
N=127 male patients 
with acute MI.  N= 90 
health controls.  Bloods 
taken on day 0, 2, 5, 7, 
9 and 11 post MI and 
compared. 
Homocysteine, 
folate and vitamin 
B12 determined 
using a competitive 
chemilusncent 
immunoassay.   
MI patients had higher homocysteine 
levels on day 0 versus controls.  
Patients with similar homocysteine 
levels to controls on day 0 showed 
significantly higher levels at each 
time-point post infraction.  Patients 
with significantly higher (p<0.001) 
homocysteine levels than controls on 
day 0 showed significantly lower 
levels at time-points post infraction. 
Study concluded that 
different behaviours of 
homocysteine levels in MI 
patients might correspond 
to a history or absence of 
asymptomatic myocardial 
ischemia.  Further 
research is required. 
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Reference & 
Country 
Aim Participants Methodology Results Conclusion 
(Puttonen et 
al. 2009) 
Finland 
Investigate the 
association 
between shift work 
and 
cardiovascular 
disease risk. 
N=1543 (712 men and 
831 females) young 
adults recruited as part 
of Cardiovascular Risk 
in Young Finns study. 
Homocysteine was 
measured using the 
microparticle 
enzyme 
immunoassay kit. 
Mean (SD) homocysteine in males 
day shift 9.14 (3.27); shift work 8.74 
(2.70), p=0.126.  Mean 
homocysteine females day shift 
10.84 (4.08), night shift 10.83 (4.48), 
p=0.955.  These relationships 
persisted after adjustment for age 
and risk factors such as low socio-
economic positions, job strain, 
smoking, diet, family history of CHD, 
physical inactivity, alcohol 
consumption, obesity, homocysteine, 
C-reactive protein, blood pressure 
and lipids.  In women, no association 
was found between shift work and 
carotid atherosclerosis indicators. 
 
 
 
Study concludes that the 
results suggest that shift 
work accelerates the 
atherosclerotic process 
and that the effects of 
shift work on subclinical 
atherosclerosis are 
observed in men already 
before the age of 40. 
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Reference & 
Country 
Aim Participants Methodology Results Conclusion 
(Nevado Jr 
and Imasa 
2008) 
Philippine 
To determine the 
effects of clinical 
risk factors that 
are responsible for 
the occurrence of 
mortality in 
myocardial 
infarction.  
N=124 Filipino 
patients.  Composite 
outcomes of mortality 
and nonfatal 
myocardial infarction 
were measured after 6 
months.   
Homocysteine 
levels were 
determined using 
the Abbott Imx 
assay. 
Homocysteinemia (>16 µmol/l) is 
associated with increased mortality 
and composite outcomes (mortality, 
nonfatal re-infarction and serious 
rehospitalisation). No association 
was detected for the conventional 
risk factor. 
Increased homocysteine 
levels are associated with 
mortality and serious 
nonfatal outcomes in 
patients with unstable 
angina and NSTEMI. 
(Ranucci et 
al. 2009) 
Italy 
To investigate 
whether elevated 
homocysteine 
further increases 
the morbidity and 
mortality in 
patients 
undergoing 
cardiac surgery on 
cardiopulmonary 
bypass (CPB). 
N=531 undergoing 
cardiac operations on 
CPB.   
Total homocysteine 
was determined 
using an immuno-
fluorescence 
method.  
Elevated homocysteine levels (>15 
µmol/l) were observed in 209 
patients.  Homocysteinaemia was 
associated with higher mortality and 
preoperative morbitity (major 
morbidity, low cardiac output, acute 
renal failure, mesenteric infarction 
and thrombo-embolic events).  Pre-
operative homocysteine levels 
remained independently associated 
with hospital mortality.  
Study concluded that 
elevated pre-operative 
homocysteine levels are 
independently associated 
with increased morbidity 
and mortality particularly 
in patients undergoing 
CPB. 
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Reference & 
Country 
Aim Participants Methodology Results Conclusion 
(Min et al. 
2009) 
Korea 
Evaluate the 
usefulness of 
baseline 
homocysteine 
levels for 
predicting the risk 
of short or long-
term 
cardiovascular 
events after 
successful 
coronary stenting. 
N=2019 patients with 
clinical events and 
normal preprocedural 
creatine kinase (CK)-
MB levels. 
Poster-abstract.  
Methodology not 
stated.  
After multi-variate logistic analysis, 
homocysteine levels (OR 1.03; 95% 
CI 1.01-1.05), female sex (OR 1.86; 
95% CI 1.31-2.65), hypertension 
(OR 2.49; 95% CI 1.06-2.10), 
multivessel diseases (OR 2.21; 95% 
CI 1.40-3.47), American Heart 
Association lesion type B2/C (OR 
2.53; 95% CI 1.32-4.85) and stent 
length (OR 2.53; 95% CI 1.32-4.85) 
were independently associated with 
peroiprocediral MI. 
 
 
 
 
 
 
 
Study concluded that 
preprocedural levels of 
homocysteine were an 
independent predictor for 
preprocedural MI and 
death or MI after 
successful coronary 
stenting. 
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Reference & 
Country 
Aim Participants Methodology Results Conclusion 
(Orhan et al. 
2009) 
Turkey 
To evaluate the 
relationship 
between 
homocysteine 
levels and the 
development of 
left ventricular 
thrombus in acute 
anterior 
myocardial 
infarction patients 
directed to 
thrombolytic 
therapy. 
 
 
 
 
 
N=95 patients 
presenting with ST 
elevated acute anterior 
MI. Two groups N=14 
of thrombosis in the left 
ventricle following MI or 
N=65 with no 
thrombosis. 
Total (free plus 
bound) 
homocysteine level 
was determined 
using HPLC. 
Total fasting homocysteine levels 
(18.24±5.67 mmol/l versus 
12.31±3.52 mmol/l p<0.001) were 
significantly higher in patients with 
left ventricular thrombosis.   Higher 
homocysteine levels (p=0.04) were 
independent predictors of left 
ventricular thrombus formation. 
Study concluded that 
diabetes mellitus, higher 
wall motion score index 
and 
hyperhomocysteinemia 
independently increases 
the risk for the 
development of left 
ventricular thrombus 
formation in patients with 
acute anterior myocardial 
infarction following 
thrombolytic therapy. 
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Reference & 
Country 
Aim Participants Methodology Results Conclusion 
(Sternic et al. 
2009) 
Serbia 
Investigate hyper-
homocysteinemia 
in individuals with 
established 
ischemic 
cerebrovascular 
disease. 
N=55 males and N= 40 
females.  Mean age 
55.6±14.9 years.  
Established ischemic 
cerebrovascular 
disease. 
Limited 
methodology as 
only published 
abstract.  
Homocysteine 
analysed in 
plasma. 
Mean group homocysteine level 
14.3±5.03 µmol/l.  Univariate 
analysis showed higher 
homocysteine level was associated 
with increased risk of cognitive 
decline. 
Study indicated 
association between high 
plasma homocysteine 
levels and cognitive 
decline in patients with 
established ischemic 
cerebrovascular disease. 
(Hyun et al. 
2009) 
Korea 
Investigate 
association of total 
plasma 
homocysteine with 
arterial stiffness, 
brachial-artery 
pulse wave 
velocity (baPWV), 
LDL 
atherogenecity 
and inflammation. 
N=612 healthy men; 
age range 31-79 years. 
Methodology not 
stated as study is 
published as a 
conference 
abstract. 
In all patients total homocysteine 
concentrations showed positive 
correlation with age.  Negative 
correlation with folate and vitamin 
B12.   Total homocysteine was 
associated with baPWV in men with 
high total homocysteine level (≥13.1 
µmol/l, N=153; R=0.258, p=0.001) 
after adjustments for age, BMI, 
smoking, drinking, folate and B12.  
This was not found in patients with 
low total homocysteine (p=0.478). 
Study concluded that 
enhanced arterial 
stiffness in 
hyperhomocysteinemia 
could be attributed in part 
to homocysteine related 
LDL atherogenecity.   
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Reference & 
Country 
Aim Participants Methodology Results Conclusion 
(Krstevska et 
al. 2009) 
Macedonia 
Study investigated 
the levels of 
homocysteine in 
healthy subjects 
and patients with 
arterial occlusive 
disease (AOD) 
and the 
prevalence of 
MTHFR, with an 
aim to show a link.  
Healthy controls and 
patients with AOD.  No 
numbers given as 
study published as a 
conference abstract.   
Homocysteine 
methodology not 
stated.   
MTHFR 
polymorphism 
indentified using 
PCR with CVD 
StripAssay as a 
segment of 12 
mutations of the 
cardiovascular 
system. 
Total homocysteine levels were 
significantly higher in patients with 
AOD.  Within the Macedonian 
healthy population, frequency of C 
allele was dominant then in T allele 
and was similar in patients.  The 
greatest gene mutations, 45% had 
the heterozygote gene CT, the 
homozygote for the wild genotype 
CC, 42% and genotype TT 13%.  
There was no significant difference 
of gene mutations as risk factor for 
AOD.  Homocysteine levels of 
healthy subjects with different 
genotypes of MTHFR(C677T) showed 
significantly higher values of TT and 
CT genotype compared to CC 
genotype. 
 
Study concluded that 
there was no correlation 
of MTHFR(C677T) 
polymorphism with AOD. 
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Reference & 
Country 
Aim Participants Methodology Results Conclusion 
(Agoston-
Coldea et al. 
2009) 
France 
Investigated the 
relationship 
between 
homocysteine and 
apolipoproteins A-
1 and B 
concentrations in 
patients with prior 
myocardial 
infractions (MI).   
N=208 patients (100 
men and 108 women); 
aged 60.08±10.43 
years.  2 groups: 104 
patients with prior MI 
and 104 without CAD. 
Methodology not 
stated as study is 
published as a 
conference abstract 
Patients with prior MI had higher 
mean values of plasma 
homocysteine than the control 
patients (18.98±4.72 versus 
14.09±3.32 µmol/l, p≤0.001).  Study 
results showed a positive correlation 
between plasma homocysteine 
levels and the severity of coronary 
lesions (R=0.765, p<0.05). 
Study concluded that 
plasma homocysteine is 
positively correlated with 
the number of injured 
coronary vessels.  Study 
suggests homocysteine 
and apoB/apoA-1 could 
be used as biomarkers of 
cardiovascular risk. 
(Naono et al. 
2009) 
Japan 
Investigated the 
association 
plasma 
homocysteine 
levels with long-
term major 
adverse 
cardiovascular 
events (MACEs).  
N=231 patients with 
previous percutaneous 
coronary intervention 
(PCI). 
Homocysteine in 
plasma measured 
using HPLC.   
An univariate analyses by a Cox 
proportional hazards regression 
model showed that plasma 
homocysteine level was not 
associated with the primary (hazard 
ratio [HR] 1.13, 95% CI 0.41-3.08, 
p=0.82) and secondary (HR 1.60, 
95% CI 0.75-3.42, p=0.23) end 
points.   
Study concluded that 
plasma homocysteine 
levels appear to be 
unrelated to recurrent 
angina, new MI and long-
term MACE within 
coronary artery disease 
patients with previous 
PCI.  
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F. HI Study Email and Poster Advertisement 
THIS PROJECT HAS ETHICAL APPROVAL 
 
 
 
!!!!!!!!ME!!!!!! 
 
 
WHAT KIND OF DRINKER ARE 
YOU????? 
 
Would you like to be part of the biomedical 
PhD research project: "The effect of 
alcohol toxicology in the form of different 
alcohol drinking patterns on biomarkers of 
cardiovascular disease (CVD) risk" 
 
DRINKERS & NON-DRINKERS WELCOME 
MALE & FEMALES AGED 18-50 YRS 
 
If you would like to take part and get more information on 
this project, please contact me on the numbers/e-mail 
below. 
 
Julie Murdoch  
Tel: (0131) 474 0000 
Mobile: 07796947611 
E-mail: jmurdoch@qmu.ac.uk 
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G. HI Study Information Sheet - Version 1 
 
 
Information Sheet 
 
My name is Julie Murdoch and I am a PhD student from the School of Health 
Sciences at Queen Margaret University in Edinburgh. As part of my PhD 
degree, I am undertaking a research project entitled: “The effect of alcohol 
toxicology in the form of different alcohol drinking patterns on 
biomarkers of cardiovascular disease (CVD)  risk”. 
 
This study will investigate the levels of a naturally occurring compound in 
blood, known as homocysteine (Hcy).  Increasing levels of homocysteine 
have been linked to increasing CVD risk.  Different alcohol drinking patterns 
may also be relevant and for this reason the study will also measure; an 
alcohol consumption biomarker; two vitamins from the B-vitamin family and 
identify the presence of two forms of a gene which influences Hcy 
metabolism in blood. 
The findings of the project will be valuable because levels of Hcy have not 
been analysed in individuals who consume alcohol in a non-chronic pattern.  
The data from this study will be compared to data gathered within an alcohol 
rehabilitation unit. 
I am looking for volunteers to participate in the project. Please see table 1 
which details the inclusion (people who can take part) and exclusion (people 
who can not take part) criteria.  
Table 1: Inclusion and Exclusion Criteria 
Inclusion Criteria Exclusion Criteria 
Men and women aged 18-50yrs Pregnant 
In good health Trying to become pregnant 
 Breast-feeding 
History of cardiovascular disease 
History of cancer 
Diabetes mellitus 
Gastric or duodenal ulcers 
Liver or gallbladder disease 
Known history of blood borne viruses 
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If you agree to participate in the study, you will be asked to follow the 
timetable which is shown in table 2. Female volunteers will be asked to take 
a section of the questionnaire home, to answer questions relating to their 
menstrual history, in private and return it in the pre-paid envelope provided.  
 
Table 2: Study Timetable for Participants 
Timetable What is required of participant 
Questionnaire and Introduction Meeting 
at a place and time most convenient to 
the participant. 
You will be asked to complete a 
questionnaire and will be given a urine 
sample container and a 7-day alcohol 
and diet diary. 
Female participants will be asked to 
return the questionnaire in a pre-paid 
envelope. 
Day 1 (Baseline) at QMU You will be asked to bring to the 
meeting a waking urine sample, and the 
completed alcohol and diet diary. 
Fasting* blood sample will be taken. 
You will be given another 7-day diet and 
alcohol diary. 
Appointment for 3 months time will be 
made to return to QMU for blood and 
urine sampling. 
Day 2 (Three months from date of 
baseline sampling) at QMU 
You will be asked to bring to the 
meeting a waking urine sample, and the 
completed alcohol and diet diary. 
Fasting* blood sample will be taken. 
You will be given another 7-day diet and 
alcohol diary. 
Appointment for 3 months time will be 
made to return to QMU for blood and 
urine sampling. 
Day 3 (Six Months from date of baseline 
sampling) at QMU 
You will be asked to bring to the 
meeting a waking urine sample, and the 
completed alcohol and diet diary. 
Final fasting* blood sample will be 
taken. 
* You should not eat 12 hours before the time of your blood sampling appointment, 
for example if your appointment is at 8am you should eat nothing after 8pm the 
previous night.  Once the blood sample has been taken you will be offered a soft 
drink and biscuits before you leave QMU. 
The blood that you provide will be analysed using various scientific 
techniques for the levels of Hcy; an alcohol consumption biomarker; vitamins 
and 2 forms of a gene which is important to Hcy metabolism.  The urine that 
you provide will be used to develop an analytical method for identifying Hcy 
in urine, thus hopefully providing a less invasive method for use in future 
studies. 
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If you are found to have the second form of the gene which influences Hcy 
metabolism, you will be informed of this result and will not be included in the 
study.  This is because the second form of this gene can affect the way the 
body metabolises Hcy, which will result in anomalies within the data.  I will 
provide you with a letter of this finding to take to your general practioner, who 
will advise you of the medical aspects of this finding, and he/she may advise 
that you increase your folate intake.  All information regarding participant’s 
genetic information will be destroyed when the study is finished.
 
Since your participation will involve you travelling to Queen Margaret 
University, you will be reimbursed for out-of-pocket travel expenses. 
All data will be confidential and be anonymised. Your name will be replaced 
with a participant number, and it will not be possible for you to be identified in 
any reporting of the data gathered.  Once my thesis has been published all 
original questionnaires will be destroyed. 
The results of this study will be included in my PhD thesis and may be 
published in a scientific journal or presented at a scientific conference. 
If you would like to contact an independent person, who knows about this 
project but is not involved in it, you are welcome to contact Dr Mary Warnock. 
Her contact details are given in table 3. 
If you have read and understood this information sheet, any questions you 
had have been answered, and you would like to be a participant in the study, 
please read and sign the consent form. 
Table 3: Contact details of Researcher and Independent Advisor 
 Contact detail of the 
Researcher 
Contact details of the 
Independent Advisor 
Name Julie Murdoch Dr. Mary Warnock 
Address PhD Student, 
Nursing 
School of Health Sciences 
Queen Margaret University 
Queen Margaret University 
Drive 
Edinburgh 
EH21 6UU 
Lecturer 
Dietetics, Nutrition & Biological 
Sciences 
School of Health Sciences 
Queen Margaret University  
Queen Margaret University Drive 
Edinburgh EH21 6UU 
E-mail jmurdoch@qmu.ac.uk mwarnock@qmu.ac.uk 
Telephone 0131 474 0000 0131 474 0000 
Mobile/Fax 07796947611 0131 474 0001 
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H. HI Study Information Sheet - Version 2 
 
 
Information Sheet 
 
My name is Julie Murdoch and I am a PhD student from the School of Health 
Sciences at Queen Margaret University in Edinburgh. As part of my PhD 
degree, I am undertaking a research project entitled: “The effect of alcohol 
toxicology in the form of different alcohol drinking patterns on 
biomarkers of cardiovascular disease (CVD)  risk”. 
 
This study will investigate the levels of a naturally occurring compound in 
blood, known as homocysteine (Hcy).  Increasing levels of homocysteine 
have been linked to increasing CVD risk.  Different alcohol drinking patterns 
may also be relevant and for this reason the study will also measure; an 
alcohol consumption biomarker; two vitamins from the B-vitamin family and 
identify the presence of two forms of a gene which influences Hcy 
metabolism in blood. 
The findings of the project will be valuable because levels of Hcy have not 
been analysed in individuals who consume alcohol in a non-chronic pattern.  
The data from this study will be compared to data gathered within an alcohol 
rehabilitation unit. 
I am looking for volunteers to participate in the project. Please see table 1 
which details the inclusion (people who can take part) and exclusion (people 
who can not take part) criteria.  
Table 1: Inclusion and Exclusion Criteria 
Inclusion Criteria Exclusion Criteria 
Men and women aged 18-50yrs Pregnant 
In good health Trying to become pregnant 
 Breast-feeding 
History of cardiovascular disease 
History of cancer 
Diabetes mellitus 
Gastric or duodenal ulcers 
Liver or gallbladder disease 
Known history of blood borne viruses 
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If you agree to participate in the study, you will be asked to follow the 
timetable which is shown in table 2. Female volunteers will be asked to take 
a section of the questionnaire home, to answer questions relating to their 
menstrual history, in private and return it in the pre-paid envelope provided.  
Table 2: Study Timetable for Participants 
Timetable What is required of participant 
Questionnaire and Introduction Meeting 
at a place and time most convenient to 
the participant. 
You will be asked to complete a 
questionnaire and will be given a urine 
sample container and a 7-day alcohol 
and diet diary. 
Female participants will be asked to 
return the questionnaire in a pre-paid 
envelope. 
Day 1 (Baseline) at QMU You will be asked to bring to the 
meeting a waking urine sample, and the 
completed alcohol and diet diary. 
Fasting* blood sample will be taken. 
You will be given another 7-day diet and 
alcohol diary. 
Appointment for 3 months time will be 
made to return to QMU for blood and 
urine sampling. 
Day 2 (Three months from date of 
baseline sampling) at QMU 
You will be asked to bring to the 
meeting a waking urine sample, and the 
completed alcohol and diet diary. 
Fasting* blood sample will be taken. 
You will be given another 7-day diet and 
alcohol diary. 
Appointment for 3 months time will be 
made to return to QMU for blood and 
urine sampling. 
Day 3 (Six Months from date of baseline 
sampling) at QMU 
You will be asked to bring to the 
meeting a waking urine sample, and the 
completed alcohol and diet diary. 
Final fasting* blood sample will be 
taken. 
* You should not eat 12 hours before the time of your blood sampling appointment, 
for example if your appointment is at 8am you should eat nothing after 8pm the 
previous night.  Once the blood sample has been taken you will be offered a soft 
drink and biscuits before you leave QMU. 
The blood that you provide will be analysed using various scientific 
techniques for the levels of Hcy; an alcohol consumption biomarker; vitamins 
and 2 forms of a gene which is important to Hcy metabolism.  The urine that 
you provide will be used to develop an analytical method for identifying Hcy 
in urine, thus hopefully providing a less invasive method for use in future 
studies. 
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If you are found to have the second form of the gene which influences Hcy 
metabolism, you will be informed of this result by letter and you will be asked 
to sign a consent form, if you would still like your data to be analysed.  I will 
provide you with a letter of this finding to take to your general practioner, who 
will advise you of the medical aspects of this finding, and he/she may advise 
that you increase your folate intake.  All information regarding participant’s 
genetic information will be destroyed when the study is finished.
 
Since your participation will involve you travelling to Queen Margaret 
University, you will be reimbursed for out-of-pocket travel expenses. 
All data will be confidential and be anonymised. Your name will be replaced 
with a participant number, and it will not be possible for you to be identified in 
any reporting of the data gathered.  Once my thesis has been published all 
original questionnaires will be destroyed. 
The results of this study will be included in my PhD thesis and may be 
published in a scientific journal or presented at a scientific conference. 
If you would like to contact an independent person, who knows about this 
project but is not involved in it, you are welcome to contact Dr Mary Warnock. 
Her contact details are given in table 3. 
If you have read and understood this information sheet, any questions you 
had have been answered, and you would like to be a participant in the study, 
please read and sign the consent form. 
Table 3: Contact details of Researcher and Independent Advisor 
 Contact detail of the 
Researcher 
Contact details of the 
Independent Advisor 
Name Julie Murdoch Dr. Mary Warnock 
Address PhD Student, 
Nursing 
School of Health Sciences 
Queen Margaret University 
Queen Margaret University 
Drive 
Edinburgh 
EH21 6UU 
Lecturer 
Dietetics, Nutrition & Biological 
Sciences 
School of Health Sciences 
Queen Margaret University  
Queen Margaret University Drive 
Edinburgh EH21 6UU 
E-mail jmurdoch@qmu.ac.uk mwarnock@qmu.ac.uk 
Telephone 0131 474 0000 0131 474 0000 
Mobile/Fax 07796947611 0131 474 0001 
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I. HI Study Consent Form 
 
 
Consent Form 
 
“The effect of alcohol toxicology in the form of different alcohol drinking 
patterns on biomarkers of cardiovascular disease risk”.   
 
I have read and understood the information sheet and this consent form. I 
have had an opportunity to ask questions about my participation. 
I understand that I am under no obligation to take part in this study. 
I understand that I have the right to withdraw from this study at any stage 
without giving any reason. 
I agree to participate in this study. 
Name of participant: _____________________________________ 
Signature of participant: _____________________________________ 
Signature of researcher: _____________________________________ 
Date: _________________ 
 
Contact details of the researcher 
Name of researcher: Julie Murdoch 
Address: PhD Student, Nursing, School of Health Sciences 
Queen Margaret University 
Queen Margaret University Drive, Edinburgh, EH21  6UU 
Email: jmurdoch@qmuc.ac.uk 
Telephone: 0131 474 0000 
Mobile: 07796947611 
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J. ADI Study Information Sheet 
 
 
Patient Information Sheet 
 
Study Title: “The effect of alcohol toxicology in the form of different 
alcohol drinking patterns on biomarkers of cardiovascular disease 
(CVD) risk”. 
 
 
My name is Julie Murdoch and I am a PhD student from the School of Health 
Sciences at Queen Margaret University in Edinburgh. As part of my PhD 
degree, I am undertaking a research project.  I would like to invite you to take 
part in the above research study.  Before you decide you need to understand 
why the research is being done and what it would involve for you.  Please 
take time to read the following information carefully.  Talk to other people 
about the study if you  wish.   
 
Part 1 tells you the purpose of this study and what will happen to you if you 
take part.  Part 2 gives you more detailed information about the conduct of 
the study.  Please ask me or the independent advisor or the medical staff of 
the Alcohol Problems Unit (APU) if there is anything that is not clear or if you 
would like more information.  Please take time to decide whether or not you 
wish to take part. 
 
 
Part 1 
 
This study will investigate the levels of a naturally occurring compound in 
blood, known as homocysteine (Hcy).  Increasing levels of homocysteine 
have been linked to increasing CVD risk.  Different alcohol drinking patterns 
may also be relevant and for this reason the study will also measure; an 
alcohol consumption biomarker; two vitamins from the B-vitamin family and 
identify the presence of two forms of a gene which influences Hcy 
metabolism in blood.  This research project will form a chapter within my PhD 
thesis. 
 
The finding of the project will be valuable as the results from this study will be 
compared to results from another study I am running which looks at levels of 
the above biomarker’s within abstainers, binge drinkers and occasional 
drinkers. 
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You are being invited to take part in this study as you are: male or female 
aged 18-50 years, are an in-patient of the Alcohol Problems Unit (APU) 
within the Royal Edinburgh Hospital or an out-patient of the Alcohol Problem 
Service and are taking the prescribed medication chlordiazepoxide. 
 
It is up to you to decide to take part.  I will describe the study and go through 
this information sheet which I will then give to you.  I will then ask you to sign 
a consent form to show you have agreed to take part.  You are free to 
withdraw at any time, without giving a reason.  This would not affect the 
standard of care you receive. 
 
If you agree to participate in the study, you will be asked to follow the 
timetable which is shown in table 2. Female volunteers will be asked to 
complete a section of the questionnaire in private, relating to questions about 
their menstrual history.   It is necessary to ask female participants questions 
regarding their menstrual, contraceptive and menopausal history as they 
have an effect on the level of Hcy in the blood. 
Table 2: Study Timetable for Participants 
Timetable What is required of participant 
Questionnaire and Introduction Meeting 
at the  Ritson Clinic or 35 Morningside 
Park  
 
You will be asked to complete a 
questionnaire. 
Female participants will be asked to 
complete a section of the questionnaire 
in private. 
Day 1 (Baseline) at APU or 35 
Morningside Park 
Fasting* blood sample will be taken. 
Waking urine sample 
Day 3 at Ritson Clinic or 35 Morningside 
Park  
Fasting* blood sample will be taken. 
Waking urine sample 
* You should not eat 12 hours before the time of your blood sampling appointment, 
for example if your appointment is at 8am you should eat nothing after 8pm the 
previous night.  Once the blood sample has been taken you will be offered a soft 
drink and biscuits. 
On the day of your admission to the APU routine blood tests were carried 
out, one of these tests was for the level of folate and vitamin B12 within your 
body.  The results of that specific test will be made available to me, the 
researcher to include with the other data you have provided for this study.  
Also if you are being prescribed B vitamin supplements orally or 
intravenously as part of your clinical care package then the dose of the 
supplements will also be made available to the researcher.  
The blood that you provide will be analysed using various scientific 
techniques for the levels of Hcy; an alcohol consumption biomarker; vitamins 
and 2 forms of a gene which is important to Hcy metabolism.  The urine that 
you provide will be used to develop an analytical method for identifying Hcy 
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in urine, thus hopefully providing a less invasive method for use in future 
studies. 
If you are found to have the second form of the gene which influences Hcy 
metabolism, you will be informed of this result and will not be included in the 
study analysis.  I will provide you with a letter of this finding to take to your 
general practitioner (GP), who will advise you of the medical aspects of this 
finding, and he/she may advise that you increase your folate intake, such as 
increasing your fruit and vegetable intake.  All information regarding 
participant’s genetic information will be destroyed when the study is finished. 
I cannot promise that your participation in this study will help you, but the 
information I get from this study may help improve people’s awareness of 
alcohol related health problems. 
Any complaint about the way you have been dealt with during the study or 
any possible harm you might suffer will be addressed.  The detailed 
information on this is given in Part 2. 
 
Your participation in this study will be kept confidential and I will follow ethical 
and legal practise and all information about you will be handled confidentially.  
The details are included in Part 2. 
If the information in Part 1 has interested you and you are considering 
participation, please read the additional information in Part 2 before making 
any decision. 
Part 2 
Sometimes new information becomes available.  If this happens the 
researcher will tell you and discuss whether you should continue in the study.  
If you decide not to carry on, the researcher will make arrangements for your 
care to continue.  If you decide to continue in the study the researcher may 
ask you to sign an updated consent form.  Also if new information becomes 
available the researcher might consider that you should withdraw from the 
study.  The researcher will explain the reasons and arrange for your care to 
continue.  If the study is stopped for any reason the researcher will inform 
you and arrange for your care to continue. 
If you decide to withdraw from the study for any reason, all information and 
samples that you provide will be destroyed and will be not used in any data 
analysis. 
If you have a concern about any aspect of this study, you should ask to 
speak to the researcher or independent advisor who will do their best to 
answer your questions (please see table 3 for contact details).  If you remain 
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unhappy and wish to complain formally, you can do this through the NHS 
Complaints Procedure.  Details can be obtained from the hospital. 
Table 3: Contact details of Researcher and Independent Advisor 
 Contact detail of the 
Researcher 
Contact details of the 
Independent Advisor 
Name Julie Murdoch Dr. Mary Warnock 
Address PhD Student, Nursing,  
School of Health Sciences 
Queen Margaret University  
Queen Margaret University 
Drive 
Musselburgh 
EDINBURGH 
EH21 6UU 
Lecturer, Dietetics, Nutrition & 
Biological Sciences 
School of Health Sciences 
Queen Margaret University 
Queen Margaret University Drive 
Musselburgh 
EDINBURGH 
EH21 6UU 
E-mail jmurdoch@qmu.ac.uk mwarnock@qmu.ac.uk 
Telephone (0131) 474 0000 (0131) 474 0000 
Mobile/Fax 07796947611/(0131) 474 
0001 
(0131) 474 0001 
In the event that something goes wrong and you are harmed during the 
research and this is due to the researcher’s negligence then you may have 
grounds for a legal action for compensation against Queen Margaret 
University, but you may have to pay your legal costs.  The normal NHS 
complaints mechanisms will still be available to you. 
All information which is collected about you during the course of the research 
will be kept strictly confidential and any information about you which leaves 
the hospital will have your name removed so that you cannot be identified. 
Your General Practitioner (GP) will be informed via letter of your participation 
within this study.  Your GP will also be sent a copy of this information sheet. 
The biological samples that you provide will be new samples, in excess of 
clinical care samples and will be stored under participant numbers, which will 
only be identifiable to the researcher.  The samples will be analysed within 
QMU laboratories and biochemistry laboratories at the Edinburgh Royal 
Infirmary.  All biological samples will be destroyed at the end of the study. 
The data that you provide will be secured within a locked cabinet which is 
only accessible by the researcher.  All data will be identifiable by a unique 
participant number.  All data will be destroyed when the study is complete.  
You will be contacted via letter if you are found to carry the 2nd form of the 
gene which affects Hcy metabolism, which you are advised to take to your 
GP.  None of the biological samples or data that you provide will be 
transferred out of the UK.     
The results of this study be included in my PhD thesis and may be published 
in a scientific journal or presented at a scientific conference. 
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Queen Margaret University is funding this PhD research study.  The doctor in 
charge of your care is not being paid for including you in this study. 
All research in the NHS is looked at by an independent group of people, 
called a Research Ethics Committee to protect your safety, rights wellbeing 
and dignity.  This study has been reviewed and given favourable opinion by 
Lothian Research Ethics Committee. 
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K. ADI Study Consent Form  
 
Centre Number: APU-1 
Study Number: 07/S1102/23 
Patient Identification Number for this Study: 
 
CONSENT FORM 
 
Title of Project: Effect of alcohol toxicology in the form of different alcohol 
drinking patterns on biomarkers of cardiovascular disease (CVD) risk 
 
Name of Researcher: Julie M. Murdoch 
 
Please Initial Box 
 
1. I confirm that I have read and understood the information sheet dated 
………….. (version 2) for the above study.  I have had the opportunity to 
consider the information, ask questions and have had these answered 
satisfactorily. 
 
2. I understand that my participation is voluntary and that I am free to withdraw 
at any time without giving any reason, without my medical care or legal rights 
being affected. 
 
3. I understand that relevant sections of my medical notes and data collected 
during the study, may be looked at by individuals from Queen Margaret 
University, from regulatory authorities or from the NHS trust where it is 
relevant to my taking part in this research,  I give the permission for these 
individuals to have access to my records. 
 
4. I agree to my GP being informed of my participation in the study. 
 
5. I agree for genetic analysis to be undertaken on the blood samples which I 
provide as part of the above study. 
 
6. I agree to take part in the above study. 
 
 
 
 
 
Name of Patient  Date  Signature 
 
 
 
 
 
Name of Person   Date  Signature 
taking consent 
 
When completed, 1 for patient; 1 for researcher site file 1 (original) to be kept in 
medical notes. 
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L. HI Study Questionnaire 
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M. Diet Diary 
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N. ADI Study Questionnaire 
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O. Alcohol Manufacturers (AM) Method Spreadsheet 
 
Name of Drink 
Type of 
Drink 
% 
ABV 
Volume 
(ml) Measurement 
No 
of 
Units 
UK Standard Alcohol 
Content (g)/Unit 
Alcohol content 
(g)/Drink 
Smirnoff Ice & Bliss 
Ready to 
Drink 
(RTD) 5.5 275 Bottle 1.5 8 12 
WKD; Bacardi Breezer; Diet Bacardi; Reef;  
Archers Aqua & Other Average RTD 
Ready to 
Drink 
(RTD) 5 275 Bottle 1.4 8 11.2 
Red Square 
Ready to 
Drink 
(RTD) 5.1 275 Bottle 1.4 8 11.2 
Mudshake; Chekov; Bailey's Glide &  VK 
Vodka Kick 
Ready to 
Drink 
(RTD) 4 275 Bottle 1.1 8 8.8 
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Name of Drink 
Type of 
Drink 
% 
ABV 
Volume 
(ml) Measurement 
No of 
Units 
UK Standard Alcohol 
Content (g)/Unit 
Alcohol Content 
(g)/Drink 
Bailey's Liqueur 17 50 Glass 0.9 8 7.2 
Southern Comfort Liqueur 37 50 Glass 1.9 8 15.2 
Tia Maria Liqueur 26.5 50 Glass 1.3 8 10.4 
Pimms No1 Liqueur 25 50 Glass 1.3 8 10.4 
Archers Aqua Liqueur 23 50 Glass 1.2 8 9.6 
Malibu Liqueur 21 50 Glass 1.1 8 8.8 
Contreau & Drambuie Liqueur 40 50 Glass 2.0 8 16 
Tia Lusso Liqueur 17 50 Glass 0.9 8 7.2 
Tequila Liqueur 38 25 Shot Glass 1.0 8 7.6 
Sambuca Liqueur 42 25 Shot Glass 1.1 8 8.4 
Jagermeister Liqueur 35 25 Shot Glass 0.9 8 7 
Apple Sourz Liqueur 15 25 Shot Glass 0.4 8 3 
After-Shock Liqueur 40 25 Shot Glass 1.0 8 8 
Absinthe Liqueur 60 25 Shot Glass 1.5 8 12 
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Name of Drink Type of Drink % ABV 
Volume 
(ml) Measurement 
No of 
Units 
UK 
Standard 
Alcohol 
Content 
(g)/Unit 
Alcohol 
content 
(g)/Drink 
Smirnoff Red Vodka; Gordon's Gin; Bacardi; Glen 
Vodka;  London Gin Distiller's Vodka; Vladivar 
Classic Vodka;  Chekov & Other Average Light 
Spirit Light Spirit 37.5 25 Small Single 0.9 8 7.2 
Smirnoff Red Vodka; Gordon's Gin; Bacardi; Glen 
Vodka;  London Gin Distiller's Vodka; Vladivar 
Classic Vodka;  Chekov & Other Average Light 
Spirit Light Spirit 37.5 35 Large Single 1.3 8 10.4 
Smirnoff Red Vodka; Gordon's Gin; Bacardi; Glen 
Vodka;  London Gin Distiller's Vodka; Vladivar 
Classic Vodka;  Chekov & Other Average Light 
Spirit Light Spirit 37.5 50 Small Double 1.9 8 15.2 
Smirnoff Red Vodka; Gordon's Gin; Bacardi; Glen 
Vodka;  London Gin Distiller's Vodka; Vladivar 
Classic Vodka;  Chekov & Other Average Light 
Spirit Light Spirit 37.5 70 Large Double 2.6 8 20.8 
Smirnoff Red Vodka; Gordon's Gin; Bacardi; Glen 
Vodka;  London Gin Distiller's Vodka; Vladivar 
Classic Vodka;  Chekov & Other Average Light 
Spirit Light Spirit 37.5 1000 1 Litre Bottle 37.5 8 300 
Smirnoff Red Vodka; Gordon's Gin; Bacardi; Glen 
Vodka;  London Gin Distiller's Vodka; Vladivar 
Classic Vodka;  Chekov & Other Average Light 
Spirit Light Spirit 37.5 700 Bottle 26.3 8 210.4 
Smirnoff Red Vodka; Gordon's Gin; Bacardi; Glen 
Vodka;  London Gin Distiller's Vodka; Vladivar 
Classic Vodka;  Chekov & Other Average Light 
Spirit Light Spirit 37.5 350 Half Bottle 13.1 8 104.8 
Captain Morgan; Bombay Sapphire Gin; Captain 
Morgans Spiced & Absolut Vodka Light Spirit 40 25 Small Single 1 8 8 
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Name of Drink Type of Drink % ABV 
Volume 
(ml) Measurement 
No of 
Units 
UK 
Standard 
Alcohol 
Content 
(g)/Unit 
Alcohol 
content 
(g)/Drink 
Captain Morgan; Bombay Sapphire Gin; Captain 
Morgans Spiced & Absolut Vodka Light Spirit 40 35 Large Single 1.4 8 11.2 
Captain Morgan; Bombay Sapphire Gin; Captain 
Morgans Spiced & Absolut Vodka Light Spirit 40 50 Small Double 2 8 16 
Captain Morgan; Bombay Sapphire Gin; Captain 
Morgans Spiced & Absolut Vodka Light Spirit 40 70 Large Double 2.8 8 22.4 
Captain Morgan; Bombay Sapphire Gin; Captain 
Morgans Spiced & Absolut Vodka Light Spirit 40 1000 1 Litre Bottle 40 8 320 
Captain Morgan; Bombay Sapphire Gin; Captain 
Morgans Spiced & Absolut Vodka Light Spirit 40 700 Bottle 28 8 224 
Captain Morgan; Bombay Sapphire Gin; Captain 
Morgans Spiced & Absolut Vodka Light Spirit 40 350 Half Bottle 14 8 112 
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Name of Drink 
Type 
of 
Drink 
% 
ABV 
Volume 
(ml) Measurement 
No 
of 
Units 
UK 
Standard 
Alcohol 
Content 
(g)/Unit 
Alcohol content 
(g)/Drink 
Bells; Famous Grouse; Teachers; William Grants; Jack Daniels; 
Martell VS; Courvoisier; Three Barrels; Whyte & Mackay; 
Glenfiddich SR & Other Average Dark Spirit 
Dark 
Spirit 40 25 Small Single 1 8 8 
Bells; Famous Grouse; Teachers; William Grants; Jack Daniels; 
Martell VS; Courvoisier; Three Barrels; Whyte & Mackay; 
Glenfiddich SR & Other Average Dark Spirit 
Dark 
Spirit 40 35 Large Single 1.4 8 11 
Bells; Famous Grouse; Teachers; William Grants; Jack Daniels; 
Martell VS; Courvoisier; Three Barrels; Whyte & Mackay; 
Glenfiddich SR & Other Average Dark Spirit 
Dark 
Spirit 40 50 Small Double 2 8 16 
Bells; Famous Grouse; Teachers; William Grants; Jack Daniels; 
Martell VS; Courvoisier; Three Barrels; Whyte & Mackay; 
Glenfiddich SR & Other Average Dark Spirit 
Dark 
Spirit 40 70 Large Double 2.8 8 22 
Bells; Famous Grouse; Teachers; William Grants; Jack Daniels; 
Martell VS; Courvoisier; Three Barrels; Whyte & Mackay; 
Glenfiddich SR & Other Average Dark Spirit 
Dark 
Spirit 40 1000 1 Litre Bottle 40 8 320 
Bells; Famous Grouse; Teachers; William Grants; Jack Daniels; 
Martell VS; Courvoisier; Three Barrels; Whyte & Mackay; 
Glenfiddich SR & Other Average Dark Spirit 
Dark 
Spirit 40 700 Bottle 28 8 224 
Bells; Famous Grouse; Teachers; William Grants; Jack Daniels; 
Martell VS; Courvoisier; Three Barrels; Whyte & Mackay; 
Glenfiddich SR & Other Average Dark Spirit 
Dark 
Spirit 40 350 Half Bottle 14 8 112 
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Name of Drink 
Type of 
Drink 
% 
ABV 
Volume 
(ml) Measurement No of Units 
UK Standard 
Alcohol Content 
(g)/Unit 
Alcohol 
content 
(g)/Drink 
Other Average Fortified Wine 
Fortified 
Wine 18 50 Glass 0.9 8 7.2 
Other Average Fortified Wine 
Fortified 
Wine 18 750 Bottle 14 8 108 
Harveys Bristol Cream & Croft 
Fortified 
Wine 17.5 50 Glass 0.9 8 7.2 
Harveys Bristol Cream & Croft 
Fortified 
Wine 17.5 750 Bottle 13 8 105 
Martinin Rosso; Martinin Rosso; Martini 
Extra Dry & QC 
Fortified 
Wine 15 50 Glass 0.8 8 6.4 
Martinin Rosso; Martinin Rosso; Martini 
Extra Dry & QC 
Fortified 
Wine 15 750 Bottle 11 8 90 
Cockburns Reserve; Grahams LBV; 
Dows LBV & Taylors LBV 
Fortified 
Wine 20 50 Glass 1 8 8 
Cockburns Reserve; Grahams LBV; 
Dows LBV & Taylors LBV 
Fortified 
Wine 20 750 Bottle 15 8 120 
Buckfast Tonic Wine 15 750 Bottle 11 8 90 
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Name of Drink 
Type of 
Drink 
% 
ABV 
Volume 
(ml) Measurement 
No 
of 
Units 
UK 
Standard 
Alcohol 
Content 
(g)/Unit 
Alcohol content 
(g)/Drink 
Moet; Veuve Cliquot; Jacobs Creek Sparkling; Mumm; 
Bollingner; Piper Heidsieck; Heidieck Monopole & Other 
Average Champagne & Sparkling Wine 
Champagne 
& Sparkling 
Wine 12 125 Small Glass 1.5 8 12 
Moet; Veuve Cliquot; Jacobs Creek Sparkling; Mumm; 
Bollingner; Piper Heidsieck; Heidieck Monopole & Other 
Average Champagne & Sparkling Wine 
Champagne 
& Sparkling 
Wine 12 175 
Standard 
Glass 2.1 8 16.8 
Moet; Veuve Cliquot; Jacobs Creek Sparkling; Mumm; 
Bollingner; Piper Heidsieck; Heidieck Monopole & Other 
Average Champagne & Sparkling Wine 
Champagne 
& Sparkling 
Wine 12 250 Large Glass 3 8 24 
Moet; Veuve Cliquot; Jacobs Creek Sparkling; Mumm; 
Bollingner; Piper Heidsieck; Heidieck Monopole & Other 
Average Champagne & Sparkling Wine 
Champagne 
& Sparkling 
Wine 12 375 Half Bottle 4.5 8 36 
Moet; Veuve Cliquot; Jacobs Creek Sparkling; Mumm; 
Bollingner; Piper Heidsieck; Heidieck Monopole & Other 
Average Champagne & Sparkling Wine 
Champagne 
& Sparkling 
Wine 12 750 Bottle 9 8 72 
Lanson 
Champagne 
& Sparkling 
Wine 12.5 125 Small Glass 1.6 8 12.8 
Lanson 
Champagne 
& Sparkling 
Wine 12.5 175 
Standard 
Glass 2.2 8 17.6 
Lanson 
Champagne 
& Sparkling 
Wine 12.5 250 Large Glass 3.1 8 24.8 
Lanson 
Champagne 
& Sparkling 
Wine 12.5 375 Half Bottle 4.7 8 37.6 
Lanson 
Champagne 
& Sparkling 
Wine 12.5 750 Bottle 9.4 8 75.2 
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Name of Drink 
Type of 
Drink 
% 
ABV 
Volume 
(ml) Measurement 
No 
of 
Units 
UK 
Standard 
Alcohol 
Content 
(g)/Unit 
Alcohol content 
(g)/Drink 
Freixnet 
Champagne 
& Sparkling 
Wine 11.5 125 Small Glass 1.4 8 11.2 
Freixnet 
Champagne 
& Sparkling 
Wine 11.5 175 
Standard 
Glass 2 8 16 
Freixnet 
Champagne 
& Sparkling 
Wine 11.5 250 Large Glass 2.9 8 23.2 
Freixnet 
Champagne 
& Sparkling 
Wine 11.5 375 Half Bottle 4.3 8 34.4 
Freixnet 
Champagne 
& Sparkling 
Wine 11.5 750 Bottle 8.6 8 68.8 
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Name of Drink 
Type 
of 
Drink 
% 
ABV 
Volume 
(ml) Measurement 
No 
of 
Units 
UK 
Standard 
Alcohol 
Content 
(g)/Unit 
Alcohol 
content 
(g)/Drink 
Nottage Hill Chardonnay; Trulli (Pinot Grigio); Banrock Station 
Colombard Chardonnay; Blossom Hill (Californian White) & Other 
Average White Wine  
White 
Wine 12 125 Small Glass 1.5 8 12 
Nottage Hill Chardonnay; Trulli (Pinot Grigio); Banrock Station 
Colombard Chardonnay; Blossom Hill (Californian White) & Other 
Average White Wine  
White 
Wine 12 175 
Standard 
Glass 2.1 8 16.8 
Nottage Hill Chardonnay; Trulli (Pinot Grigio); Banrock Station 
Colombard Chardonnay; Blossom Hill (Californian White) & Other 
Average White Wine  
White 
Wine 12 250 Large Glass 3 8 24 
Nottage Hill Chardonnay; Trulli (Pinot Grigio); Banrock Station 
Colombard Chardonnay; Blossom Hill (Californian White) & Other 
Average White Wine  
White 
Wine 12 375 Half Bottle 4.5 8 36 
Nottage Hill Chardonnay; Trulli (Pinot Grigio); Banrock Station 
Colombard Chardonnay; Blossom Hill (Californian White) & Other 
Average White Wine  
White 
Wine 12 750 Bottle 9 8 72 
Wolf Blass Chardonnay 
White 
Wine 13.5 125 Small Glass 1.7 8 13.6 
Wolf Blass Chardonnay 
White 
Wine 13.5 175 
Standard 
Glass 2.4 8 19.2 
Wolf Blass Chardonnay 
White 
Wine 13.5 250 Large Glass 3.4 8 27.2 
Wolf Blass Chardonnay 
White 
Wine 13.5 375 Half Bottle 5.1 8 40.8 
Wolf Blass Chardonnay 
White 
Wine 13.5 750 Bottle 10.1 8 80.8 
Jacobs Creek Chardonnay & Average 13% White Wine 
White 
Wine 13 125 Small Glass 1.6 8 12.8 
Jacobs Creek Chardonnay & Average 13% White Wine 
White 
Wine 13 175 
Standard 
Glass 2.3 8 18.4 
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Name of Drink 
Type 
of 
Drink 
% 
ABV 
Volume 
(ml) Measurement 
No 
of 
Units 
UK 
Standard 
Alcohol 
Content 
(g)/Unit 
Alcohol 
content 
(g)/Drink 
Jacobs Creek Chardonnay & Average 13% White Wine 
White 
Wine 13 250 Large Glass 3.3 8 26.4 
Jacobs Creek Chardonnay & Average 13% White Wine 
White 
Wine 13 375 Half Bottle 4.9 8 39.2 
Jacobs Creek Chardonnay & Average 13% White Wine 
White 
Wine 13 750 Bottle 9.8 8 78.4 
Jacobs Creek Semillion Chardonnay 
White 
Wine 11.5 125 Small Glass 1.4 8 11.2 
Jacobs Creek Semillion Chardonnay 
White 
Wine 11.5 175 
Standard 
Glass 2 8 16 
Jacobs Creek Semillion Chardonnay 
White 
Wine 11.5 250 Large Glass 2.9 8 23.2 
Jacobs Creek Semillion Chardonnay 
White 
Wine 11.5 375 Half Bottle 4.3 8 34.4 
Jacobs Creek Semillion Chardonnay 
White 
Wine 11.5 750 Bottle 8.6 8 68.8 
Montana (Sauvingon Blanc) 
White 
Wine 12.9 125 Small Glass 1.6 8 12.8 
Montana (Sauvingon Blanc) 
White 
Wine 12.9 175 
Standard 
Glass 2.3 8 18.4 
Montana (Sauvingon Blanc) 
White 
Wine 12.9 250 Large Glass 3.2 8 25.6 
Montana (Sauvingon Blanc) 
White 
Wine 12.9 375 Half Bottle 4.8 8 38.4 
Montana (Sauvingon Blanc) 
White 
Wine 12.9 750 Bottle 9.7 8 77.6 
Average 9% White Wine 
White 
Wine 9 125 Small Glass 1.1 8 8.8 
Average 9% White Wine 
White 
Wine 9 175 
Standard 
Glass 1.6 8 12.8 
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Name of Drink 
Type 
of 
Drink 
% 
ABV 
Volume 
(ml) Measurement 
No 
of 
Units 
UK 
Standard 
Alcohol 
Content 
(g)/Unit 
Alcohol 
content 
(g)/Drink 
Average 9% White Wine 
White 
Wine 9 250 Large Glass 2.3 8 18.4 
Average 9% White Wine 
White 
Wine 9 375 Half Bottle 3.4 8 27.2 
Average 9% White Wine 
White 
Wine 9 750 Bottle 6.8 8 54.4 
Average 10% White Wine 
White 
Wine 10 125 Small Glass 1.3 8 10.4 
Average 10% White Wine 
White 
Wine 10 175 
Standard 
Glass 1.8 8 14.4 
Average 10% White Wine 
White 
Wine 10 250 Large Glass 2.5 8 20 
Average 10% White Wine 
White 
Wine 10 375 Half Bottle 3.8 8 30.4 
Average 10% White Wine 
White 
Wine 10 750 Bottle 7.5 8 60 
Average 11% White Wine 
White 
Wine 11 125 Small Glass 1.4 8 11.2 
Average 11% White Wine 
White 
Wine 11 175 
Standard 
Glass 1.9 8 15.2 
Average 11% White Wine 
White 
Wine 11 250 Large Glass 2.8 8 22.4 
Average 11% White Wine 
White 
Wine 11 375 Half Bottle 4.1 8 32.8 
Average 11% White Wine 
White 
Wine 11 750 Bottle 8.3 8 66.4 
Average 14% White Wine 
White 
Wine 14 125 Small Glass 1.8 8 14.4 
Average 14% White Wine 
White 
Wine 14 175 
Standard 
Glass 2.5 8 20 
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Name of Drink 
Type 
of 
Drink 
% 
ABV 
Volume 
(ml) Measurement 
No 
of 
Units 
UK 
Standard 
Alcohol 
Content 
(g)/Unit 
Alcohol 
content 
(g)/Drink 
Average 14% White Wine 
White 
Wine 14 250 Large Glass 3.5 8 28 
Average 14% White Wine 
White 
Wine 14 375 Half Bottle 5.3 8 42.4 
Average 14% White Wine 
White 
Wine 14 750 Bottle 9 8 72 
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Name of Drink Type of Drink 
% 
ABV 
Volume 
(ml) Measurement 
No 
of 
Units 
UK 
Standard 
Alcohol 
Content 
(g)/Unit 
Alcohol 
content 
(g)/Drink 
Ernest & Julio Gallo Merlot Red Wine 12.5 125 Small Glass 1.6 8 13 
Ernest & Julio Gallo Merlot Red Wine 12.5 175 
Standard 
Glass 2.2 8 18 
Ernest & Julio Gallo Merlot Red Wine 12.5 250 Large Glass 3.1 8 25 
Ernest & Julio Gallo Merlot Red Wine 12.5 375 Half Bottle 4.7 8 38 
Ernest & Julio Gallo Merlot Red Wine 12.5 750 Bottle 9.4 8 75 
Campo Viejo (Rioja); Jacobs Creek (Shiraz Cabernet) & 
Wolf Blass (Shiraz Cabernet) Red Wine 13 125 Small Glass 1.6 8 13 
Campo Viejo (Rioja); Jacobs Creek (Shiraz Cabernet) & 
Wolf Blass (Shiraz Cabernet) Red Wine 13 175 
Standard 
Glass 2.3 8 18 
Campo Viejo (Rioja); Jacobs Creek (Shiraz Cabernet) & 
Wolf Blass (Shiraz Cabernet) Red Wine 13 250 Large Glass 3.3 8 26 
Campo Viejo (Rioja); Jacobs Creek (Shiraz Cabernet) & 
Wolf Blass (Shiraz Cabernet) Red Wine 13 375 Half Bottle 4.9 8 39 
Campo Viejo (Rioja); Jacobs Creek (Shiraz Cabernet) & 
Wolf Blass (Shiraz Cabernet) Red Wine 13 750 Bottle 9.8 8 78 
9% Red/Rose Wine Red/Rose Wine 9 125 Small Glass 1.1 8 8.8 
9% Red/Rose Wine Red/Rose Wine 9 175 
Standard 
Glass 1.6 8 13 
9% Red/Rose Wine Red/Rose Wine 9 250 Large Glass 2.3 8 18 
9% Red/Rose Wine Red/Rose Wine 9 375 Half Bottle 3.4 8 27 
9% Red/Rose Wine Red/Rose Wine 9 750 Bottle 6.8 8 54 
10% Red/Rose Wine Red/Rose Wine 10 125 Small Glass 1.3 8 10 
10% Red/Rose Wine Red/Rose Wine 10 175 
Standard 
Glass 1.8 8 14 
10% Red/Rose Wine Red/Rose Wine 10 250 Large Glass 2.5 8 20 
10% Red/Rose Wine Red/Rose Wine 10 375 Half Bottle 3.8 8 30 
10% Red/Rose Wine Red/Rose Wine 10 750 Bottle 7.5 8 60 
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Name of Drink Type of Drink 
% 
ABV 
Volume 
(ml) Measurement 
No 
of 
Units 
UK 
Standard 
Alcohol 
Content 
(g)/Unit 
Alcohol 
content 
(g)/Drink 
        
11% Red/Rose Wine Red/Rose Wine 11 125 Small Glass 1.4 8 11 
11% Red/Rose Wine Red/Rose Wine 11 175 
Standard 
Glass 1.9 8 15 
11% Red/Rose Wine Red/Rose Wine 11 250 Large Glass 2.8 8 22 
11% Red/Rose Wine Red/Rose Wine 11 375 Half Bottle 4.1 8 33 
11% Red/Rose Wine Red/Rose Wine 11 750 Bottle 8.3 8 66 
12% Red/Rose Wine Red/Rose Wine 12 125 Small Glass 1.5 8 12 
12% Red/Rose Wine Red/Rose Wine 12 175 
Standard 
Glass 2.1 8 17 
12% Red/Rose Wine Red/Rose Wine 12 250 Large Glass 3 8 24 
12% Red/Rose Wine Red/Rose Wine 12 375 Half Bottle 4.5 8 36 
12% Red/Rose Wine Red/Rose Wine 12 750 Bottle 9 8 72 
14% Red/Rose Wine Red/Rose Wine 14 125 Small Glass 1.8 8 14 
14% Red/Rose Wine Red/Rose Wine 14 175 
Standard 
Glass 2.5 8 20 
14% Red/Rose Wine Red/Rose Wine 14 250 Large Glass 3.5 8 28 
14% Red/Rose Wine Red/Rose Wine 14 375 Half Bottle 5.3 8 42 
14% Red/Rose Wine Red/Rose Wine 14 750 Bottle 10.5 8 84 
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Name of Drink Type of Drink % ABV 
Volume 
(ml) Measurement 
No of 
Units 
UK 
Standard 
Alcohol 
Content 
(g)/Unit 
Alcohol 
content 
(g)/Drink 
Strongbow Cider/Perry 5.3 330 Bottle 1.7 8 13.6 
Strongbow Cider/Perry 5.3 440 Can 2.3 8 18.4 
Strongbow Cider/Perry 5.3 284 Half Pint 1.5 8 12.0 
Strongbow Cider/Perry 5.3 568 Pint 3.0 8 24.0 
Lambrini; White Lightening; Diamond White & Frosty 
Jack Cider/Perry 7.5 330 Bottle 2.5 8 20.0 
Lambrini; White Lightening; Diamond White & Frosty 
Jack Cider/Perry 7.5 440 Can 3.3 8 26.4 
Lambrini; White Lightening; Diamond White & Frosty 
Jack Cider/Perry 7.5 284 Half Pint 2.1 8 16.8 
Lambrini; White Lightening; Diamond White & Frosty 
Jack Cider/Perry 7.5 568 Pint 3.4 8 27.2 
Scrumpy Jack & Blackthorn  Cider/Perry 6 330 Bottle 2.0 8 16.0 
Scrumpy Jack & Blackthorn  Cider/Perry 6 440 Can 2.6 8 20.8 
Scrumpy Jack & Blackthorn  Cider/Perry 6 284 Half Pint 1.7 8 13.6 
Scrumpy Jack & Blackthorn  Cider/Perry 6 568 Pint 3.4 8 27.2 
Gaymer Olde English and Jacques Cider/Perry 5.5 330 Bottle 1.8 8 14.4 
Gaymer Olde English and Jacques Cider/Perry 5.5 440 Can 2.4 8 19.2 
Gaymer Olde English and Jacques Cider/Perry 5.5 284 Half Pint 1.6 8 12.8 
Gaymer Olde English and Jacques Cider/Perry 5.5 568 Pint 3.1 8 24.8 
Woodpecker  Cider/Perry 3.5 330 Bottle 1.2 8 9.6 
Woodpecker  Cider/Perry 3.5 440 Can 1.5 8 12.0 
Woodpecker  Cider/Perry 3.5 284 Half Pint 1.0 8 8.0 
Woodpecker  Cider/Perry 3.5 568 Pint 2.0 8 16.0 
St Heliers Pear Cider and Other Average Cider/Perry Cider/Perry 5 330 Bottle 1.7 8 13.6 
St Heliers Pear Cider and Other Average Cider/Perry 
 Cider/Perry 5 440 Can 2.2 8 17.6 
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St Heliers Pear Cider and Other Average Cider/Perry Cider/Perry 5 284 Half Pint 1.4 8 11.2 
St Heliers Pear Cider and Other Average Cider/Perry Cider/Perry 5 568 Pint 2.8 8 22.4 
Magners, Bulmers, Kopparberg Pear Cider/Perry 4.5 330 Bottle 1.5 8 12.0 
Magners, Bulmers, Kopparberg Pear Cider/Perry 4.5 440 Can 2.0 8 15.8 
Magners, Bulmers, Kopparberg Pear Cider/Perry 4.5 284 Half Pint 1.3 8 10.4 
Magners, Bulmers, Kopparberg Pear Cider/Perry 4.5 568 Pint 2.6 8 20.5 
Thatcher's Katy Cider Cider/Perry 7.4 330 Bottle 2.4 8 19.2 
Thatcher's Katy Cider Cider/Perry 7.4 440 Can 3.3 8 26.0 
Thatcher's Katy Cider Cider/Perry 7.4 284 Half Pint 2.1 8 16.8 
Thatcher's Katy Cider Cider/Perry 7.4 568 Pint 4.2 8 33.6 
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Carlsberg Special Brew Lager 9 330 Bottle 3.0 8 24 
Carlsberg Special Brew Lager 9 440 Can 4.0 8 32 
Carlsberg Special Brew Lager 9 284 Half Pint 2.6 8 20.8 
Carlsberg Special Brew Lager 9 568 Pint 5.1 8 40.8 
Stella Lager 5.2 330 Bottle 1.7 8 13.6 
Stella Lager 5.2 440 Can 2.3 8 18.4 
Stella Lager 5.2 284 Half Pint 1.5 8 12 
Stella Lager 5.2 568 Pint 3.0 8 24 
Carling Lager 4.1 330 Bottle 1.4 8 11.2 
Carling Lager 4.1 440 Can 1.8 8 14.4 
Carling Lager 4.1 284 Half Pint 1.2 8 9.6 
Carling Lager 4.1 568 Pint 2.3 8 18.4 
Fosters, Carlsberg and Tennants Lager 4 330 Bottle 1.3 8 10.4 
Fosters, Carlsberg and Tennants Lager 4 440 Can 1.8 8 14.4 
Fosters, Carlsberg and Tennants Lager 4 284 Half Pint 1.1 8 8.8 
Fosters, Carlsberg and Tennants Lager 4 568 Pint 2.3 8 18.4 
Budweiser; Kronenbourg; Grolsch; Becks; Carlsberg Export; 
Heineken, Asahi, Cobra and Straropramen & Other Average Lager Lager 5 330 Bottle 1.7 8 13.6 
Budweiser; Kronenbourg; Grolsch; Becks; Carlsberg Export; 
Heineken, Asahi, Cobra and Straropramen & Other Average Lager Lager 5 440 Can 2.2 8 17.6 
Budweiser; Kronenbourg; Grolsch; Becks; Carlsberg Export; 
Heineken, Asahi, Cobra and Straropramen & Other Average Lager Lager 5 284 Half Pint 1.4 8 11.2 
Budweiser; Kronenbourg; Grolsch; Becks; Carlsberg Export; 
Heineken, Asahi, Cobra and Straropramen & Other Average Lager Lager 5 568 Pint 2.8 8 22.4 
Corona Lager 4.6 330 Bottle 1.5 8 12 
Corona Lager 4.6 440 Can 2.0 8 16 
Corona Lager 4.6 284 Half Pint 1.3 8 10.4 
Corona Lager 4.6 568 Pint 2.6 8 20.8 
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Pilsner Lager 4.4 330 Bottle 1.5 8 11.6 
Pilsner Lager 4.4 440 Can 1.9 8 15.2 
Pilsner Lager 4.4 284 Half Pint 1.2 8 9.6 
Pilsner Lager 4.4 568 Pint 2.5 8 20 
Peroni Lager 5.3 330 Bottle 1.7 8 13.6 
Peroni Lager 5.3 440 Can 2.3 8 18.4 
Peroni Lager 5.3 284 Half Pint 1.5 8 12 
Peroni Lager 5.3 568 Pint 3.0 8 24 
Baltika Lager 5.1 330 Bottle 1.7 8 13.6 
Baltika Lager 5.1 440 Can 2.2 8 17.6 
Baltika Lager 5.1 284 Half Pint 1.4 8 11.2 
Baltika Lager 5.1 568 Pint 2.9 8 23.2 
Miller Lager 4.7 330 Bottle 1.6 8 12.4 
Miller Lager 4.7 440 Can 2.1 8 16.8 
Miller Lager 4.7 284 Half Pint 1.3 8 10.4 
Miller Lager 4.7 568 Pint 2.7 8 21.6 
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John Smiths; Stones & Other Average 
Beer/Ale Beer/Ale 4 330 Bottle 1.3 8 10.4 
John Smiths; Stones & Other Average 
Beer/Ale Beer/Ale 4 440 Can 1.8 8 14.4 
John Smiths; Stones & Other Average 
Beer/Ale Beer/Ale 4 284 Half Pint 1.1 8 8.8 
John Smiths; Stones & Other Average 
Beer/Ale Beer/Ale 4 568 Pint 2.3 8 18.4 
Guinness & Caffreys Beer/Ale 4.2 330 Bottle 1.4 8 11.2 
Guinness & Caffreys Beer/Ale 4.2 440 Can 1.8 8 14.4 
Guinness & Caffreys Beer/Ale 4.2 284 Half Pint 1.2 8 9.6 
Guinness & Caffreys Beer/Ale 4.2 568 Pint 2.4 8 19.2 
Boddingtons & Tetleys Beer/Ale 3.8 330 Bottle 1.3 8 10.4 
Boddingtons & Tetleys Beer/Ale 3.8 440 Can 1.7 8 13.6 
Boddingtons & Tetleys Beer/Ale 3.8 284 Half Pint 1.1 8 8.8 
Boddingtons & Tetleys Beer/Ale 3.8 568 Pint 2.2 8 17.6 
McEwans Export & Old Speckled Hen Beer/Ale 4.5 330 Bottle 1.5 8 12.0 
McEwans Export & Old Speckled Hen Beer/Ale 4.5 440 Can 2.0 8 16.0 
McEwans Export & Old Speckled Hen Beer/Ale 4.5 284 Half Pint 1.3 8 10.4 
McEwans Export & Old Speckled Hen Beer/Ale 4.5 568 Pint 2.7 8 21.6 
Newcastle Brown Beer/Ale 4.7 330 Bottle 1.6 8 12.8 
Newcastle Brown Beer/Ale 4.7 440 Can 2.1 8 16.8 
Newcastle Brown Beer/Ale 4.7 284 Half Pint 1.3 8 10.4 
Newcastle Brown Beer/Ale 4.7 568 Pint 2.7 8 21.6 
Worthington Beer/Ale 3.6 330 Bottle 1.2 8 9.6 
Worthington Beer/Ale 3.6 440 Can 1.6 8 12.8 
Worthington Beer/Ale 3.6 284 Half Pint 1.0 8 8.0 
Worthington Beer/Ale 3.6 568 Pint 2.0 8 16.0 
Belhaven Best and Tennents Special Beer/Ale 3.5 330 Bottle 1.2 8 9.2 
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Belhaven Best and Tennents Special Beer/Ale 3.5 440 Can 1.5 8 12.0 
Belhaven Best and Tennents Special Beer/Ale 3.5 284 Half Pint 1.0 8 7.9 
Belhaven Best and Tennents Special Beer/Ale 3.5 568 Pint 2.0 8 15.8 
Caledonian -80/ Beer/Ale 4.1 330 Bottle 1.4 8 10.8 
Caledonian -80/ Beer/Ale 4.1 440 Can 1.8 8 14.4 
Caledonian -80/ Beer/Ale 4.1 284 Half Pint 1.2 8 9.6 
Caledonian -80/ Beer/Ale 4.1 568 Pint 2.3 8 18.4 
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A. Table of Participants Mean Alcohol Consumption (g) During Drinking Days 
(N=26) 
 
Mean Alcohol Consumption During Drinking Days (g) 
by Analysis Method 
Participant 
No. 
No. of Drinking 
Days ONS WinDiets Alcohol Manufacturer 
2 6 66.7 81.9 92.5 
4 5 11.2 32.8 31.7 
7 3 13.3 40.0 27.3 
8 4 28.0 59.4 57.9 
10 7 60.6 115.9 84.4 
12 5 16.0 25.6 30.5 
13 5 62.4 76.7 75.1 
14 3 10.7 15.0 15.4 
15 6 10.7 20.8 20.9 
17 6 14.7 32.4 30.0 
19 6 18.7 33.2 33.3 
21 4 40.0 41.1 51.0 
22 3 64.0 63.7 65.3 
23 1 8.0 16.8 17.0 
24 5 43.2 66.1 65.2 
25 2 16.0 31.8 30.0 
26 6 41.3 60.4 60.8 
27 5 22.4 31.1 30.5 
28 3 29.3 38.4 41.3 
30 5 9.6 14.6 17.9 
31 1 48.0 47.5 48.0 
32 6 73.3 67.3 153.0 
33 1 64.0 130.2 139.0 
34 2 24.0 28.4 30.8 
35 3 13.3 24.0 20.0 
36 1 72.0 69.5 117.0 
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B. Bar graph of HI study drinkers (N=26) mean alcohol consumption during drinking days calculated by three differing 
procedures.   
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A. Published Abstract: Alcohol Consumption And Cardiovascular Disease 
Risk – Depends How You Measure It? 
 J.M. Murdoch, J.S. Gill and H.I.M. Davidson, School of Health Sciences, Queen 
Margaret University, Edinburgh, Scotland, EH21 6UU 
 
Introduction 
The abuse of alcohol is a major public health concern within the U.K. and has been 
linked to a wide range of health conditions including increased risk of cardiovascular 
disease (CVD).  The U.K. Department of Health recommends limiting daily alcohol 
consumption to 24-32g (male) and 16-24g (female).  Any attempt to provide a 
reliable and credible estimate of the disease risk associated with intake of alcohol is 
critically dependent on the accuracy of the method employed to record consumption. 
The aim of the present work was to compare the accuracy of three analytical 
methods of assessing alcohol consumption in a population sample who recorded 
their drinking prospectively in a 7 day diary.   
 
Methods 
Data (derived from the first author’s PhD study) from 26 participants (18 female and 
8 male), who consumed alcohol were analysed.  Mean alcohol consumption during 
drinking days was calculated in grams using the following three analytical methods: 
alcohol drink unit measurements from the Office of National Statistics (ONS) 
questionnaire; WinDiets dietary software (WD) and Alcohol Manufacturer’s (AM) 
information.  Female participants data were further categorised according to the 
following drinking guidelines: “sensible” (<24g); “exceeding daily limits” (24-47g) and 
“binge” (>48g) at one session using AM.  Female participants daily alcohol 
consumption was categorised using WD and ONS and compared to AM. 
 
Results  
The total sample had a mean alcohol consumption during drinking days of: 
AM=53.3g (SD 37.5); WD=48.6g (SD 29.6); ONS=33.9g (SD 22.8).  The 
consideration of %ABV and drink sizes will produce the most accurate estimate of 
alcohol intake; the AM method.  WD underestimates average consumption by 8.8%, 
ONS by 36.4%.  Student T-test was significant (p=<0.001) for ONS compared to 
AM, but was not significant for WD comparison (p=0.258).  Female participant’s 
416 
daily alcohol consumption was categorised according to UK daily limits.  WD and 
ONS miscategorised 11% and 55% of participants, respectively.   
 
Discussion 
The present findings indicate that in studies dependent on participant recall of 
alcohol intake, a failure to account for individual drink sizes and %ABV, may 
seriously underestimate intake and the proportion of drinkers exceeding safe 
guidelines. Investigations which explore the relationship between alcohol intake and 
CVD disease risk will benefit from measures which improve the accuracy of the 
quantification of alcohol intake. 
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B. Poster Presented at the 32nd Annual Scientific Meeting of the Research 
Society on Alcoholism, June 2009, San Diego, California, USA. 
 
 
 
